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Abstract 
 
This thesis is composed of two separate projects: Kinetic Template-Guided Tethering of Fragments and Design and 
Synthesis of a Chemical Probe to Dissect the Cellular Signalling Cascade leading to Cyclin D1 Degradation after 
DNA Damage.   
 
Kinetic Template-Guided Tethering of Fragments 
The development of a novel methodology for the site-directed discovery of small molecule, protein-binding ligands is 
described. The protein of interest, with a cysteine thiol (either native or engineered) adjacent to the desired binding 
pocket, is incubated with mixtures of low molecular weight compounds (fragments) modified with either an 
acrylamide or a vinyl sulfonamide capture group. Any ligand within the mixture that binds within the pocket brings 
the capture group into close proximity with the cysteine thiol, promoting a conjugate addition reaction at an increased 
rate over the background reaction. The capture reaction is designed to be slow, such that during the time course of an 
experiment, no adduct formation is observed unless the reaction is templated by the protein. By this method, binding 
ligands are rapidly identified by mass spectrometry analysis of the crude reaction mixtures. The methodology has 
been termed ‘kinetic template-guided tethering’. 
 
 
 
Design and Synthesis of a Chemical Probe to Dissect the Cellular Signalling Cascade leading to Cyclin D1 
Degradation after DNA Damage  
An inhibitor described within the literature was found to attenuate the reduction of cyclin D1 after DNA damage to 
cells. In order to implement a two-step chemical proteomics strategy to find the molecular target of this inhibitor, a 
synthesis of the compound with an alkyne appendage was required. The alkyne acts as a functional handle for 
attachment of  a reporter molecule in cells via the Huisgen cycloaddition (‘Click’) reaction. The design and synthesis 
of this inhibitor with the alkyne appendage is described. 
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Kinetic Template-Guided Tethering of Fragments 
1. Introduction 
1.1. High-throughput screening and chemical space 
Central to both drug discovery and chemical biology is the search for new small molecule, protein-binding ligands. In 
the early 1990s, the number of molecules contained within ‘drug discovery chemical space’ was estimated to be in 
excess of 1050.[1] Attempts to search this vast chemical arena led to the advent of high-throughput screening (HTS) and 
combinatorial chemistry. Large libraries of compounds were generated by the pharmaceutical industry, containing 
molecular structures of high complexity, with physicochemical properties that were later identified as unsuitable for 
medicinal chemistry optimisation. Such large libraries were expensive to produce, maintain and screen, and it became 
evident at the start of the 21st century that this approach was failing in the discovery of new drugs. 
 A simple model to describe protein-ligand molecular complimentarity was proposed by Hann and colleagues in 2001, 
where the interaction between a ligand and a protein was modelled as a series of interaction types (+/-).[2] In this 
model, an interaction occurs only if all features between ligand and protein match exactly. This model predicted a 
rapid decrease in the probability of successful binding upon increase in ligand molecular complexity, due to the 
decreasing number of ways to generate a match in comparison to the increasing number of ways to generate a 
mismatch. This ‘complexity model’ has been used to explain why hit compounds generated via HTS tend to be of low 
quality, with many suboptimal interactions and mismatches, and low affinity (usually micromolar) considering their 
high molecular weight and lipophilicity. A set of empirical rules to describe the physicochemical properties of orally 
bioavailable drugs was  suggested by Lipinski in 1997, now referred to as Lipinski’s rule of 5 (Ro5).[3] Lipinski’s rules 
state that MW < 500, cLogP < 5, number of H-bond donors < 5, number of H-bond acceptors < 10 and number of 
rotable bonds (NROT) < 10. Compounds detected as hits in HTS were difficult to optimise in potency without 
increasing molecular weight and lipophilicity, pushing them outside of the suggested limits set by Lipinski. In support 
of Lipinksi, compounds of higher lipophilicity and MW have been found to suffer higher attrition rates in the clinic.[4, 
5] The compounds generated by HTS were suggested as not ‘lead-like’, and publications in the late 1990s suggested a 
revision in the design of libraries, to move towards lower molecular complexity, lower MW and lower lipophilicity to 
improve the lead-optimisation process.[4-7]  
1.2. Fragment-based drug discovery 
Fragment-based drug discovery (FBDD), developed as a means to overcome the difficulties encountered during 
optimisation of HTS lead compounds, involves screening low molecular weight (ca. 110-350 Da) compounds 
(‘fragments’) against the biological target. As initially proposed by Congreve et al., fragments are generally designed 
to conform to a rule-of-three; MW ≤	 300, H-bond donors ≤ 3, H-bond acceptors ≤ 3, NROT ≤ 3, cLogP ≤	 3 and PSA 
≤ 60.[8] The low MW and lipophilicity of fragment starting points allows significant increases in both physicochemical 
profiles upon optimisation of potency, without breaching the limits set by Lipinski for orally bioavailable drugs. The 
hits generated by FBDD also tend to be of higher quality that those identified from HTS. This is measured by ligand 
efficiency, a concept designed to identify the  binding affinity conferred by each heavy atom (non-hydrogen) within 
the molecule.[9, 10] All small molecules must overcome a binding entropic barrier, which is approximately independent 
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of molecular weight.[11] Therefore, fragments must form high quality binding interactions in order to have a 
measurable affinity, and are highly ligand efficient. Fragments are unlikely to be identified as hits if any of the 
interactions made between protein and ligand are suboptimal. By their nature, fragments bind only very weakly to 
proteins, usually with low millimolar or high micromolar binding affinities. Specialised biophysical screens are 
usually adopted to measure these weak interactions, which cannot generally be detected using functional enzyme 
assays. As discussed by Hann et al. the molecular weight and complexity of fragments must not be so low that an 
unambiguous binding mode cannot be identified.[2] A simplified protein-ligand interaction model predicted that 
ligands of very low complexity would bind in multiple orientations. In addition, a basal level of complexity was 
required in order to be able to detect the interaction at all.  
Fragment library size 
An advantage conferred by FBDD is that only small libraries of compounds need to be screened against the target 
protein in comparison to HTS approaches. Reymond et al. calculated the number of possible chemical structures per 
number of heavy atoms, and found this number to increase approximately exponentially.[12] For each heavy atom 
added, the number of possible structures increased approximately 8-fold. A library of 1000 molecules, which contain 
12 or fewer heavy atoms, samples ca. 0.001 % of the total theoretical number of chemical structures of this size.[13] 
However, if the number of heavy atoms is increased to ≤	 25, a library of 1000 compounds only samples a meagre 10-
14 %.[13] Fragment libraries tend to include between 1000-20000 ligands; Astex Therapeutics screened a library of 
1600 fragments, with an average molecular weight ca. 170 Da against HSP90, whereas Plexxikon screened 20,000 
compounds against B-RAF with fragments which had a slightly higher molecular weight range of 150-350 Da.[13] 
These small libraries of fragments are easier to characterise and maintain than larger HTS libraries. In addition, 
fragments are often synthetically more accessible than the larger, more complex molecules employed in HTS 
campaigns.  
Fragment optimisation: linking and growing  
The pioneering work of Fesik, Hajduk and colleagues, published in the mid-1990s, was key in the development of 
fragment-based drug discovery.[14, 15] They noted the low probability of generating a hit compound, which contained 
all the required functional groups in the proper spatial arrangement for tight binding, by screening lead-like molecules 
against a biological target. This led them to develop a methodology they termed structure-activity relationships by 
NMR or ‘SAR by NMR’, where small fragments of lead-like compounds were screened against a protein. These 
fragments were then linked or grown to form high affinity binders at a later point during optimisation. They detected 
the binding of fragments to the protein surface by measuring peturbations in amide 15N shifts using NMR and 15N-
labelled protein. Such NMR techniques allow the detection of very weak millimolar binding, and are therefore ideal 
for fragment screening. In this early work, fragment screening against a matrix metalloproteinase (MMP), Stromelysin 
(MMP3), using SAR by NMR led to the identification of two weak binding fragments, acetohydroxamic acid (Kd = 17 
µM) and (4’-hydroxybiphenyl-3-yl)-acetonitrile (Kd = 20 µM), which were linked by a methylene unit to generate a 
highly potent inhibitor with Kd = 15 nM.[14] The potency of the linked compound was higher than the sum of the two 
individual fragment affinities (termed ‘superadditivity’), originating from the high energy penalty paid by fragments 
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upon binding due to the loss of both translational and rotational entropy.[11] This early example of fragment linking is 
highly impressive considering the challenges which have since been encountered by others to optimise fragments in 
this way. Howard et al. reported that during the course of their work to develop an inhibitor of the protease enzyme 
thrombin, linking two optimally bound fragments together compromised the original fragment orientations.[16] Huth et 
al. failed to observe the desired increase in potency upon linking of two HSP90-binding fragments, potentially due to 
a suboptimal linker strategy, which introduced an unfavorable energy penalty.[17] Both the length and the chemical 
nature of the linker influence fragment binding.[18]  
‘Fragment growing’, where structure-guided drug design is used to form additional interactions by growing out from 
the original fragment, has generally been the most successful strategy for fragment-to-lead optimisation. Hajduk has 
shown that it is possible to optimise fragments to lead compounds whilst keeping the ligand efficiency constant using 
a retrospective study of 18  drug leads from 15 different internal projects at Abbott Laboratories.[19] In this study, the 
drug leads were systematically reduced in size until the smallest compound with reported potency was reached, with 
the ligand efficiency reported at each stage.  
Fragment-based drug discovery (FBDD) is now considered a validated approach for the discovery of new inhibitors, 
and a large number of reviews have been published[13, 20-22] in addition to a number of books.[23] There are now several 
compounds in clinical trials that have emerged from fragment-based approaches.[24] In addition, Vemurafenib, 
developed by Plexxicon using a fragment-based approach,[25] was approved by the FDA in 2011 for the treatment of 
late stage melanoma.  
Challenges for FBDD: fragment screening 
A crucial challenge for FBDD is the identification of weak binding fragments, and over the past decade considerable 
effort has been put into the development of specialised screening technologies.[26] Fragments cannot usually be 
detected using biochemical assays, but require biophysical screening technologies such as NMR,[27] X-ray 
crystallography,[28] surface plasmon resonance (SPR),[29] isothermal titration calorimetry (ITC)[30] and 
Thermofluor®,[31] Figure 1. Despite significant progress in this area, fragments often need to be screened at high 
concentrations, leading to additional problems. Screening at high concentrations can lead to the generation of false 
positives, where inhibition is not caused by one-to-one protein-ligand binding.[32]  
Usually a combination of biophysical techniques is applied during the search for a hit fragment, where a tradeoff 
between throughput and structural information is made.[33] For Thermofluor® and SPR, high throughput can be 
achieved (≥100,000 compounds is routine), but no information on the binding location is gained and fragment 
solubility is crucial due to the high screening concentrations required. Ligand-based NMR techniques such as 
saturation transfer difference (STD) experiments involve measurement of the 1D chemical shift of the ligand in the 
presence of a stoichiometric amount of protein, with and without selective irradiation of the protein resonances.[34] 
Irradiation of the spectrum is usually carried out between 1-2 ppm, which is highly populated with protein signals and 
not usually ligand signals. If the relaxation rate of the ligand protons is longer than the protein-ligand dissociation rate 
(koff), usually true for high micromolar to low millimolar binders, an accumulation of saturated ligand occurs and a 
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difference between the irradiated and non-irradiated spectrum is observed. Such ligand-based NMR techniques are 
still amenable to high-throughput, but give no information on the binding site. At best, the part of the ligand in contact 
with the protein surface (binding epitope) can be identified.  
Perhaps the most utilised approach for hit identification and validation by NMR identifies chemical shift changes 
upon binding of free protein to ligand using 2D 15N/1H and/or 13C/1H heteronuclear single quantum coherence (HSQC) 
correlation spectroscopy.[35] The initial challenge in the use of such an NMR technique is the expression of milligram 
quantities of isotopically enriched protein. A significant advantage of this technique is that compounds that bind to the 
protein can be characterised without knowledge of the protein function. Additionally, ligand binding can be detected 
over an unlimited binding affinity range. However, in order gain structural information about the binding site, the 
NMR spectrum must be assigned, a process usually only possible for proteins with a molecular weight of less than 40 
kDa. Nuclear Overhauser Effect (NOE) experiments can be used to provide a more precise determination of the ligand 
binding mode.[36] The chemical shift approach is thought to be one of the most reliable, robust and reproducible 
methods to monitor ligand binding. One of the major disadvantages of this technique is that the protein must be stable 
over the long data acquisition process.[37] Wang et al. screened a 10,000-member custom made fragment library 
against 15N-labelled BACE-1, a target currently thought to be important for the treatment of Alzheimers disease, using 
HSQC NMR.[38] They identified a thiourea fragment with a Kd of 550 µM, which was rapidly optimised using a 
combination of HSQC NMR and a functional assay to improve affinity by a factor of 36, to give a Kd of 15 µM. An 
X-ray crystal structure, in addition to NMR structural data, allowed the characterisation of the binding mode and 
further optimisation studies.  
Screening by X-ray crystallography yields the highest degree of structural information, but represents the lowest in 
terms of throughput.[33] A robust method for obtaining high quality protein crystals is required.  
 
Figure 1 Comparison of screening techniques and the potency ranges they are suitable to identify. 
Whilst biophysical methods for FBDD have been highly successful against certain target classes, they do not provide 
the means to target a specific site on  a protein surface. Such site-directed drug discovery becomes important in the 
field of protein-protein interaction (PPI) inhibition. PPIs are thought to be crucial therapeutic targets in a number of 
diseases.[39, 40] PPI interfaces tend to be large, flat and featureless, and many were initially labelled as undruggable by 
small molecules. However, a report by Clackson and Wells in 1995 changed this perception.[41] They discovered that 
only a few key residues were responsible for a large proportion of the energetics of the hGH-hGHbp PPI by the 
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generation of a series of alanine scanning mutants. Such ‘hotspots’ have not only been discovered as a feature of 
many PPIs, but there are now a number of examples of small molecules able to disrupt a PPI by binding to a hotspot 
pocket.[42-44] Despite some successes, the search for selective small molecule inhibitors of PPIs remains challenging. 
The development of methods to target them in a site-directed manner with fragments would be of high importance, 
allowing access to this class of therapeutics.  
1.3. Site-directed drug discovery 
1.3.1. Protein-directed dynamic combinatorial chemistry 
In accordance with the law of mass action, a dynamic equilibrium of compounds generated by a reversible reaction is 
shifted upon addition of a protein, which binds certain combinations, towards the best binding components.[45] This 
protein-directed dynamic combinatorial chemistry (DCC) offers an opportunity to combine synthesis and screening all 
in one step, in addition to a providing a potential solution to the fragment-linking problem. Furthermore, if one of the 
components of the mixture is a known binder, the selection of a higher-affinity binding combination is site-directed. 
Protein-directed DCC was first demonstrated by Huc and Lehn, who incubated a mixure of 3 aromatic aldehydes with 
a 15-fold excess of 4 aliphatic amines under physiological conditions in the presence and absence of carbonic 
anhydrase (CA) II.[46] The virtual combinatorial library generated by the freely reversible amine-aldehyde 
condensation was affected by the presence of CAII, which directly assembles binding combinations. The position of 
equilibrium was fixed by reduction of the resulting imines with sodium cyanoborohydride, and the resulting mixtures 
analysed by HPLC. Amplification of one aldehyde-amine pair at the expense of others suggested a binding 
combination, which was consistent with previous inhibitors of CAII.  
Eliseev et al. identified that deconvolution of DCLs becomes very difficult, and sometimes impossible, as the number 
of molecular components increases.[47] They used the reversible reaction between aldehydes and a core amine scaffold 
1, to probe a hydrophobic pocket on influenza virus A neuraminidase. Amine 1 is based on the commercial 
neuraminidase inhibitor Tamiflu 2, which binds adjacent to the hydrophobic 
pocket of interest, Figure 2. In a major advance on the previous work, they 
carried out the screening under conditions in which coupled products were 
only present in trace quantities, except for stabilised protein-binding 
combinations, which biased the equilibrium. The reactions were carried out in 
the presence of a very slow acting reductant such that significant coupled 
amine products were only observed for binding species. An important 
consideration was that whilst the reduced amine products are the observed 
amplified species, it is the transient imine which is the protein-binding 
species. The authors comment that whilst the amplified coupled amines 
tended to be higher affinity binders than combinations not amplified, there 
were occasional exceptions where amines not selected had higher affinity that those selected. In an extension of their 
original work, Eliseev et al. carried out similar DCC experiments with ketones rather than aldehydes.[48]  
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Figure 2 (Top) active component of 
Tamiflu. (Bottom) reaction between core 
amine scaffold and series of aldehydes to 
probe the adjacent hydrophobic pocket. 
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Scott et al. probed the pantoate binding pocket of pantothenate synthetase using 5’-deoxy-5’-thioadenosine 3 as a non-
covalent anchor fragment.[49] The DCL was composed of fragment 3 in addition to a number of other thiols, and the 
subsequent thiol-disulfide exchange monitored by HPLC. Comparison of the resulting protein-induced 
thermodynamic distribution to that in the absence of the template identified disulfide 4 as a favorable binding 
combination, Figure 3. Disulfide 4 was subsequently confirmed to bind to pantothenate synthetase with a Kd = 210 
µM. Crystal structures of thioadenosine 3 and disulfide 4 indicated identical binding modes for the adenosine moiety 
in the pantoate pocket, as expected.    
 
Figure 3 Thioadenosine 3 was incubated with a number of thiols in the presence and absence of pantothenate synthetase. Disulfide 4 was 
identified from the DCL as a thermodynamically stablised combination in the presence of the protein and demonstrated a moderate Kd of 
210 µM.  
In an impressive extension of protein DCC, Congreve et al. incubated DCLs with protein crystals and identified 
binding combinations by the resulting electron density maps after x-ray diffraction of the crystals.[50] They used this 
‘dynamic combinatorial crystallography’ (DCX) to identify inhibitors of cdk2 with DCLs composed of hydrazines and 
isatins to generate the corresponding hydrazones. The major advantage of this compared to standard protein DCC is 
firstly that identification of the binding ligand is facile, and secondly that a detailed ligand binding mode is 
immediately obtained.  
To use protein templated DCC as a method of site directed ligand discovery, a ligand adjacent to the pocket of interest 
must already be known. In addition, this ligand must be amenable to modification with a reactive group to allow 
reversible reaction with other fragments in the mixture. An elegant solution to this problem was discovered by 
Erlanson et al. as discussed in the following section.  
1.3.2. Disulfide tethering 
Pioneering work was carried out by Erlanson, Wells and colleagues, as part of Sunesis Pharmaceuticals, to develop a 
methodology for the site-directed discovery of protein-binding ligands. This methodology is an extension of protein 
DCC and has been termed disulfide tethering. A solvent exposed cysteine thiol (either native or engineered) on the 
surface of the protein of interest, in the vicinity (5-10 Å) of the target pocket, is allowed to react reversibly with a 
mixture of disulfide-modified fragments as an active consituent of the DCL. A thiol-disulfide equilibrium of protein-
fragment adducts is generated. Any fragment within the mixture, which makes favourable interactions with the 
protein, is stabilised within the thermodynamic equilibrium at the expense of other protein-fragment adducts. Analysis 
of crude reaction mixtures by mass spectrometry allows the identification of favorable adducts, which can be 
deconvoluted to identify fragments with the highest binding affinity. The overall level of protein modification can be 
tuned by the addition of a reductant.  
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As an initial proof-of-concept for disulfide tethering, Erlanson et al. incubated a library of  ca. 1200 disulfide-
modified fragments in cocktails of up to 100 with the enzyme thymidylate synthase (TS).[51] Within this initial library, 
an N-tosyl D-proline fragment was observed to form a significant adduct with TS. Removal of the disulfide bond 
identified N-tosyl D-proline as a millimolar binder, and this initial hit was subjected to medicinal chemistry 
optimisation to increase affinity to the low micromolar region. Since this initial proof-of-concept work, tethering has 
been applied to a range of biological targets, as discussed in the following section.  
Tethering with extenders - caspase-3 
Cysteine aspartyl proteases (caspases) play key roles in cytokine maturation and apoptosis.[52] Caspase-3 has been 
suggested as a point for therapeutic investigation in a wide range of diseases such as Alzheimers, Parkinsons, sepsis 
and myocardial infarction. Caspase-3 was considered by Sunesis to provide an ideal starting point for their tethering 
based drug discovery as it has a nucleophilic cysteine (catalytic) in the active site pocket. Many inhibitors for caspase-
3 are tetrapeptides, which contain an aspartyl residue that binds in a conserved aspartyl pocket within the active site. 
To probe the pocket from this aspartyl binding-site, Sunesis designed inhibitor 5 containing an 
arylacyloxymethylketone-modified aspartyl thioester.[53] Alkylation of the protein with arylacyloxymethylketone 5 
and subsequent removal of the thioester to reveal the free thiol was successful, Figure 4.  
 
Figure 4 (Top) Caspase-3 was covalently modified with inhibitor 5, and the thioacetate protecting group removed to reveal a free thiol 
for tethering experiments. Salicyclic acid derivative 6 was identified as a favourable binding combination. (Bottom) Replacement of the 
arylacyloxymethylketone with an aldehyde yielded low micromolar inhibitor 7. Rigidification and functionalisation of the linker 
improved potency to 20 nM.  
This modifed caspase-3 was then subjected to tethering experiments from which salicyclic acid derivative 6 was 
selected as the most prominent fragment hit. Replacement of the labile disulfide bond with an alkane and the 
arylacyloxymethylketone with an aldehyde warhead generated sulfonamide 7 as a low 
micromolar inhibitor. Rigidification of the linker to give benzylsulfonamide 8 yielded a 10-
fold improvement in affinity, and further functionalisation improved affinity by another 10-
fold, yielding a 20 nM inhibitor, pyrimidine 9. Presumably the aldehyde would have been 
replaced had the programme advanced towards the development of a caspase-3 clinical 
candidate. Fragment 10 could not be detected as an inhibitor of capsase-3 in a conventional enzyme activity assay, 
even when screened at high millimolar concentrations, indicating that it would probably not have been detected in a 
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conventional fragment screen, Figure 5. The same approach was applied to caspase-1 to identify a single digit 
nanomolar inhibitor.[54]  
An allosteric pocket was identified in both caspase-3 and caspase-7 by screening 10,000 thiol-containing compounds 
against the native enzymes (which contain 5 cysteine residues).[55] Indole 11 and dichloroaryl 12 selectively modified 
cys264 (caspase-3) and cys290 (caspase-7), as identified by screening against a panel of cysteine mutants, Figure 6. 
These cysteine residues sit at the bottom of a deep cavity, 14 Å from the active site cysteine, and when modified with 
either indole 11 or dichloroaryl 12 inactivate the proteases. This work demonstrates the power of site directed drug 
discovery for the identification of novel allosteric pockets.  
 
Figure 6 Thiols 11 and 12 identified as allosteric inhibitors of caspase-3 and caspase-7 via tethering. 
Probing an adaptive binding site - interleukin 2   
The cytokine interleukin-2 (IL-2) is a critical factor in the immune response, and has been linked to a number of 
immunodisorders.[56] IL-2 interacts with its heterotrimeric receptor (composed of three subunits α, β, and γ) to induce 
T-cell proliferation. Alkyne 13 was discovered by Hoffman La-Roche in 1997 to bind specifically and reversibly to 
IL-2 with an IC50 of 3 µM, Figure 7.[57]  Alkyne 13 binds to IL-2 at the IL-2/IL-2Rα interface and disrupts the PPI. A 
crystal structure of alkyne 13 bound to IL-2, obtained by Sunesis, 
indicated that part of the IL-2/13 binding pocket undergoes a 
striking transformation upon binding, where the flat unliganded 
surface in the apo structure undergoes significant side chain and 
loop movements to create a hydrophobic binding pocket.[58] To 
probe both the adaptive and rigid subsites of the IL-2/13 binding 
interaction, Sunesis constructed a panel of 11 cysteine mutants of 
IL-2 in the vicinity of both pockets and screened a library of 7000 
disulfide-modified fragments against each.[58] Mutants with a 
poor hit rate were found to target the rigid pocket, whereas 
mutants which demonstrated a high hit rate mapped fragments to 
the adaptive pocket. This adaptive site may therefore be more 
amenable to bind small drug-like molecules, although it would 
not have been identified from a crystal structure of the apo 
protein form. The adaptive site, which binds the biaryl alkyne motif in compound 13, was found to have a high 
propensity for aromatic groups, and in accordance with this, indole glyoxylate 14 was observed to bind in this region 
when tethered to Y31C as identified by a crystal structure. Merging alkyne 13 and glyoxylate 14 to yield compound 
15 led to a two-fold improvement in affinity from alkyne 13, providing an early demonstration that tethering was able 
to discover fragments suitable for merging with a lead molecule to improve affinity.[59] 
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Figure 7 Compound 13 was discovered by Roche in 1997 
to bind to IL-2 in a pocket with two subsites, one highly 
adaptive and one rigid. Indole glyoxylate 14 was selected 
by mutant Y13C during disulfide tethering experiments, 
where the indole ring sits in the adaptive binding pocket 
occupied by the terminal phenyl ring in alkyne 13. 
Merging the two compounds gave inhibitor 15, which has 
a 2-fold improvement in binding affinity over alkyne 13. 
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Tethering with breakaway extenders – protein tyrosine phosphatase 1B  
Protein tyrosine phosphatase (PTP) enzymes remove a phosphate group from phosphotyrosine (pTyr) protein and 
peptide substrates, and are recognised as a challenging, but important target class in drug discovery.[60] Many PTP 
enzymes have a small, hydrophilic active site pocket designed to accommodate bisanionic pTyr, and tend not to bind 
drug-like molecules. PTP1B has been implicated as a target for the treatment of obesity and type II diabetes, but the 
associated challenges have prevented a pharmaceutically acceptable compound reaching clinical trials. Erlanson et al. 
applied disulfide tethering to identify a weak active site fragment binder of PTP1B. [61] The catalytic cysteine, at the 
bottom of the narrow active site channel in PTP1B, was considered inappropriate for disulfide tethering. The residues 
surrounding the active site pocket were considered crucial to maintain the finely tuned, delicate catalytic machinery. 
This tethering problem led to the development by Sunesis of ‘tethering 
with breakaway extenders’.[61] A cysteine was introduced far from the 
active site and subsequently modified with breakaway extender 16, 
composed of a reactive bromoacetamide and a pTyr mimic, Figure 8. The 
pTyr mimic binds to the active site pocket protecting the active site 
cysteine from alkylation and positioning the bromoacetamide close to the 
mutant cysteine for covalent modification, Figure 9. Cleavage of the thioester with hydroxylamine places the thiol 
over the active site pocket for tethering screens. A library of ca. 15,000  disulfide-modified fragments were screened 
against the modified PTP1B to identify a pyrazine fragment as a millimolar inhibitor.  
 
Figure 9 Tethering with ‘breakaway extenders’ developed by Sunesis to find fragments for PTP1B.  
Aurora kinase – tethering with dynamic extenders 
In an impressive extension of their previous work, Erlanson and colleagues developed ‘tethering with dynamic 
extenders’ to identify a low micromolar inhibitor of Aurora A kinase.[62] Aurora A plays a critical role in the 
regulation of mitosis and is thought to be an important target for drug development.[63] Tethering with dynamic 
extenders was developed as a means to probe both the purine binding site, and an adjacent adaptive binding pocket. 
Diaminopyrimidine, a known binder of the purine binding pocket, was modified with two disulfide appendages to 
give compound 17, and incubated with a library of ca. 4500 disulfide-modified fragments under partially reducing 
conditions, Figure 10. The authors comment that due to the the stringent requirement for two disulfides to exist 
simultaneously, only very few hits were identified overall. Fragment 18 was identified as a hit, and upon replacement 
of the labile disulfide with a flexible alkyl chain, generated a diaminopyrimidine-18 inhibitor with an IC50 of 17 µM. 
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Figure 8 Breakaway extender 16. 
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This impressive methodology has the potential to probe adaptive pockets to generate novel fragments once an 
inhibitor for an adjacent site is known. It also demonstrates potential to link fragments together, a non-trivial task.[64]  
 
 
Figure 10 Tethering with dynamic extenders. Diaminopyrimidine 17 was incubated with mixtures of disulfides, of which disulfide 18 is 
an example, under partially reducing conditions in the presence of aurora A kinase. Favorable combinations were identified by mass 
spectrometry analysis of the crude mixtures. Aurora A kinase is represented by the cyan shape in the schematic, whilst the red circle 
represents the diaminopyrimidine and the purple square/yellow star represent disulfide-modified fragments.  
Disadvantages of reversible covalent capture  
Whilst the pioneering work reported by Sunesis led them to discover a number of active compounds, the practical 
difficulties in the implementation of disulfide tethering has prevented the use of the this methodology by others for the 
discovery of fragments. One of the biggest hurdles is perhaps the custom synthesis of unsymmetrical disulfides, which 
can rapidly disproportionate under certain conditions.[65] Published work by Sunesis describes the use of 
unsymmetrical disulfides with one side modified with a group to increase aqueous solubility and the other with a 
fragment. Additionally, high resolution mass spectrometry is needed to detect and resolve bound fragments, where 
care must be taken upon analysis not to peturb the rapidly equilibrating DCL. Furthermore, disulfide linked fragments 
identified by tethering must be resynthesised with a stable linker – an operation that may abrogate affinity due to the 
loss of the characteristic 90° disulfide dihedral bond angle.  
Work was carried out previously* in an attempt to use disulfide tethering to identify an inhibitor of cdc25 phosphatase. 
Cdc25 phosphatases drive the cell cycle by dephosphorylation of substrate proteins, and have been identified as 
overexpressed in a significant number of cancers.[66-68] They are therefore considered as viable therapeutic targets, but 
despite a significant effort in the literature, only one pharmaceutical entity has entered clinical trials.[69] This is 
potentially due to the very small and narrow, hydrophilic active site pocket, which is particularly unsuitable to bind 
drug-like molecules.[70, 71] However, a hotspot over 20 Å from the active site pocket was reported for cdc25B as 
crucial for binding to cdk substrates, and may potentially represent a new pocket to target for cdc25-cdk inhibition.[72-
74] Disulfide tethering was initially chosen as a means to target this pocket in a site specific manner, but difficulties 
were encountered. During the synthesis of unsymmetrical disulfides, it was noted that a significant number of 
compounds were highly labile, and rapidly led to statistical mixtures of products whilst as a solution in organic 
                                                        
* Carried out by RHN as part of MRes degree.  
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solvent, even in the absence of any additive such as acid or base, Equation 1. Synthesis of fragments for screening was 
therefore highly time-consuming. 
 
Equation 1 disulfide disproportionation.  
Additionally, MALDI was the only mass spectrometry technique available at the time the experiments were 
conducted, but at the working MW of the protein (ca. 23kDa) significant isotopic broadening prevented the accurate 
deconvolution of protein adducts, Figure 11. It was desirable for the DCL to be enzymatically digested to allow 
MALDI analysis of the resulting peptide-adducts, which would concomitantly identify the position of modification. 
However, this would have required an acidic quench of the DCL, which would have made the sample unsuitable for 
digestion by most proteolytic enzymes. An impressive desulfurisation reaction reported by Davis et al. to generate a 
stable thioether from a disulfide was considered as a means to overcome this problem.[75] In their work, a thioether 
glycoprotein was generated from a disulfide glycoprotein by treatment with a phosphine in buffer. However, this was 
not pursued as the proposed mechanism for this reaction would require the protein to be severed from the fragment, 
rendering the final thioether mixture as an untrue representation of the original disulfide distribution.  
 
Figure 11 Representative spectrum obtained using MALDI for analysis of adducts by disulfide tethering.* The proportion of the protein 
present as an adduct was tuned by addition of a reductant. ‘High’ and ‘low’ indicate the concentration of βME in the sample. Red trace = 
20 mM βME; blue trace = 0.2 mM βME; black trace = no βME.  Catalytic domain of cdc25A Y386C is represented by CD-cdc25A-
Y386C.  
The work presented within this thesis describes a proof-of-concept for an irreversible fragment-capture methodology 
for the site-directed identification of fragments. This methodology will be referred to as ‘kinetic template-guided 
tethering’ (KTGT), and was initially designed to overcome the difficulties encountered during disulfide tethering. The 
                                                        
* Image generated and work carried out by R. H. Nonoo as part of MRes degree, 2008.[129] 
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concept is similar to that previously described for reversible tethering except that in KTGT, fragments are modified 
with a reactive electrophilic capture group for irreversible reaction with cysteine. In KTGT the capture group must be 
sufficiently unreactive that over the time course of the experiment, an adduct is only observed to form if the fragment 
binds to the protein and thereby increases the reaction rate by increased proximity. If the protein templates the 
reaction in this way, a stable adduct is formed and subsequently identified by mass spectrometry analysis. A suitable 
functional group should be stable to enzymatic digestion, to allow the use of MALDI to identify the location of 
binding adducts. The capture group should be easy to install synthetically, compatible with the aqueous screening 
conditions and highly selective for reaction with cysteine. After the identification of a hit fragment using KTGT, the 
capture group can be removed and the remaining fragment optimised using conventional medicinal chemistry. As an 
alternative, KTGT could be envisaged as a method for the discovery of irreversible covalent inhibitors. Such covalent 
inhibitors have traditionally been avoided by the pharmaceutical industry due to the potential for off-target effects, 
resulting in high toxicity. However, many drugs do act via  an irreversible mechanism, and there has been a recent 
interest in covalent drugs.[76-78]  
 
1.4. Evidence in support of a KTGT hypothesis  
1.4.1. Activity based protein profiling and affinity labelling 
KTGT can be considered to form a continuum with activity-based protein profiling (ABPP) and affinity labelling 
(AL), two techniques that are widely used to identify proteins that bind to a particular ligand. ABPP and AL both 
involve the design of a chemical probe to target specifically a particular enzyme family, but whereas ABPP uses the 
nucleophilic residue fundamental to the catalytic mechanism of action of an enzyme, AL targets non-catalytic 
residues. Chemical probes generally consist of three distinct functional parts: a reactive group for irreversible covalent 
modification of the protein of interest; a ligand to bind to the binding site of the required enzyme family; a tag for 
purification or identification of labelled enzymes. The chemical probe is added to a mixture of proteins, such as a 
crude cell extract, and those which are labelled are subsequently identified. As for KTGT, the warhead in both AL and 
ABPP must be sufficiently unreactive that selectivity for a particular enzyme class is high. The reaction only occurs 
upon binding of the ligand, bringing the reactive group into close proximity with the reactive site on the protein 
(usually a nucleophilic residue) and accelerating the reaction rate by increased proximity.  
 
An interesting functional proteomic strategy was reported by Cravatt et al. in 2007, which made use of an ABPP 
probe specific for the serine hydrolases (SH) to identify selective SH carbamate inhibitors.[79] SHs are almost 
universally susceptible to active site serine modification by fluorophosphonate (FP) compounds. Such compounds 
have been conjugated to reporter molecules for use as ABPP probes of the serine hydrolases in a range of proteomes. 
Cravatt et al. preincubated the proteome from COS-7 cells expressing high levels of active SH ABHD6 individually 
with 55 carbamate ligands as potential SH inhibitors.  This was followed by addition of a rhodamine tagged FP (FP-
R) and subsequent analysis by in-gel fluorescence in comparison to control with no added inhibitor. This not only 
indicated which carbamates inhibited the desired ABHD6 SH, but also indicated for each inhibitor the degree of 
selectivity for inhibition between the different SHs.  
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The validity of KTGT was alluded to by D.A. Erlanson and S.K Hansen in 2008,[80] after Sames and colleagues 
demonstrated an epoxide as a suitable electrophile during work to develop a selective affinity probe.[81] 
Benzenesulfonamide, a potent nanomolar inhibitor of carbonic anhydrase II (CAII), was separately modified with  
twelve electrophiles including an epoxide, in addition to a fluorescent tag, to yield 12 chemical probes. These were 
individually incubated with a selection of proteins and subsequently analysed by in-gel fluoresence. Whereas 
promiscuous electrophiles such as a vinyl sulfone reacted non-selectively, the epoxide probe demonstrated a high 
selectivity for CAII over other proteins. Labelling by the epoxide probe was abolished in the presence of 
ethoxzolamide, a potent CAII inhibitor, indicating that modification by the epoxide probe was promoted by a 
molecular recognition event. Further studies indicated that the epoxide was modified by a histidine residue situated 
adjacent to the pocket.  
1.4.2. Thermodynamic vs kinetic drug discovery: receptor accelerated synthesis 
In receptor-accelerated synthesis (RAS), a protein brings two binding fragments, each decorated with complementary 
reactive functionality, into close proximity causing them to undergo an irreversible reaction that would not have 
occurred in solution. The two complementary functional groups are designed to react only slowly in the absence of a 
template, but upon binding to the receptor a significant increase in effective molarity makes the reaction pseudo 
intramolecular, causing it to proceed rapidly. Analysis of reaction mixtures in the presence and absence of the 
template, usually by LC-MS based techniques, quickly identifies binding combinations. In this way, the protein 
effectively assembles its own inhibitor from smaller building blocks, Figure 12. The irreversibility of the reaction in 
RAS is a key and fundamental difference that distinguishes it from DCC. Whereas protein templated DCC results in 
the amplification of the most thermodynamically stable species, RAS relies on chemistry for which a high kinetic 
barrier prevents covalent bond formation in solution in the absence of a template. By bringing the components 
together, the protein lowers the energetic barrier for reaction by stabilising the transition state. This necessitates a 
product-like transition state if the accelerated products are to be successful inhibitors.[82] Significant work has been 
carried out to determine that this kinetic rate acceleration corresponds to binding affinity in a number of cases, as will 
be discussed in the following section.  
 
Figure 12 Schematic to illustrate receptor accelerated synthesis. The red and blue spheres represent functional groups able to react with 
one another once brought into close proximity by the ‘template’, represented in cyan. Reactive functional groups are brought into close 
proximity by the binding of ligands to the receptor.  
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Carnitine acetyltransferase – SN2 reaction 
RAS was conceptually proposed in the 1980s by Jencks who rationalised that enzymes generate a significant rate 
acceleration, relative to the untemplated reaction in solution, by decreasing the entropy of bound reactants.[83, 84] 
However, the very first example of RAS was reported in 1969 by Chase and Tubbs, who were interested in the 
enzyme carnitine acetyltransferase.[85, 86] They wanted to modify amino acids in the vicinity of the active site with 
either coenzyme A (CoA) or carnitine-based alkylating agents. However, they found that carnitine acetyltransferase 
was rapidly inhibited by bromoacetyl carnitine only after CoA was added to the reaction mixture, and analogously, by 
bromoacetyl-CoA only after the addition of carnitine, Figure 13. Based on a series of biochemical experiments, the 
authors were able to elucidate that, rather than modification of the protein, both carnitine and CoA formed a ternary 
complex with the enzyme. The bromoacetyl group was then rapidly transferred to carnitine, which subsequently 
reacted with the CoA thiol in a nucleophilic substitution reaction. The rate acceleration by the template was 
determined to be significant, such that formation of a CoA-carnitine adduct took more than 90 minutes in solution, but 
only seconds in the presence of the protein.  
 
Figure 13 First reported example of RAS. CoA = Coenzyme A. C = carnitine. Carnitine acetyltransferase represented by the cyan ellipse.  
Glycinamide ribonucleotide transformylase – SN2 reaction 
 In 1991, Benkovic and colleagues reported the formation of a multisubstrate adduct inhibitor, synthesised in situ by a 
protein template.[87] They found that incubation of glycinamide ribonucleotide transformylase (GAR TFase) with its 
substrate glycinamide ribonucleotide (GAR) 19 and a folate-
derived cofactor affinity label, N-10-(bromoacetyl)-
dideazafolate 20, led to the generation of a new inhibitor by a 
templated alkylation reaction, Figure 14. Although the natural 
cofactors for the protein have only micromolar affinities for 
GAR TFase, the adduct formed by reaction of GAR 19 and N-
10-(bromoacetyl)-dideazafolate 20 demonstrates an 
impressive picomaolar affinity. In 1981, Jencks rationalised 
that the binding of a molecule A-B is often much greater than 
Figure 14 Templated reaction between β-GAR 19 and affinity 
label 20. Green line schematically represents the protein 
pocket. 
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the sum of the individual binding energies A and B.[84] This originates from an entropic penalty (ΔGs), approximately 
independent of molecular size, which both A, B and A-B must overcome in order to bind to the protein. As the 
intrinsic binding energies of A (ΔGiA), and B (ΔGiB), are smaller than A-B (ΔGiAB), the binding of A-B is more 
favourable than the sum of A and B individually by an amount which corresponds to the entropic term, Figure 15.   
 
Figure 15 A simplified view of the balance of Gibbs free energies for binding of A, B and A-B to a protein. 1 and 2: No binding is 
observed for ligands A or B (in this schematic) as the intrinsic binding energy (ΔGi) is equal to the entropic penalty (ΔGS), a term which is 
approximately independent of molecular weight. 3: The intrinsic binding energy of A-B to the protein equals the sum of the intrisic 
binding energy of A and that of B. However, as the entropic penalty is approximately independent of molecular weight, a binding energy 
(ΔG0AB) is observed (orange arrow), which is equal to ΔGS.  
Whilst the GAR TFase inhibitor formed by reaction of GAR 19 and N-10-(bromoacetyl)-dideazafolate 20 had 
excellent binding affinity, the presence of the charged phosphate group prevented cellular uptake, resulting in poor 
bioavailability and preventing clinical development. As GAR TFase has the ability to assemble the drug in situ in the 
presence of the natural substrate GAR 19, Benkovic and colleagues investigated the potential for folate analogues to 
act as prodrugs.[88, 89] N-10-(bromoacetyl)-dideazafolate 20 was found to be too reactive to be adopted for this purpose, 
prompting a search for a suitable replacement folate analogue. Substitution of the α-
bromo-amide with a dibromide functionality generated a compound which formed a 
high affinity adduct with natural substrate GAR 19 in the presence of enzyme, Figure 
16. This was initially presumed to proceed via SN2 bromide displacement, but upon 
generation of a crystal structure, a hydroxy group was observed in the place of the tertiary bromide. The authors 
proposed that fast generation of the bromonium ion, ring opening with water to form the bromohydrin, and subsequent 
displacement of the second bromide generated the epoxide as the active species for RAS. 
Bovine carbonic anhydrase II – SN2 reaction 
Huc and Lehn utilised the displacement of an α-halogen by a thiol for their RAS approach, three decades after the 
initial report by Chase and Tubbs.[90] Sulfonamide 21, a known inhibitor of bovine carbonic anhydrase (CA II), was 
incubated with binary mixtures of chlorides in the presence and absence of CA II. It was observed that the protein 
consistently accelerated the synthesis of the higher affinity inhibitor, an observation later confirmed by Kolb.[91] As an 
example, incubation of CA II with a binary mixture of chlorides 22 and 23 resulted in a 92 % yield of sulfide 24  and 
only an 8 %  yield of sulfide 25. However, in the absence of CA II, a 50 % yield of each sulfide was observed. The 
increase in the yield of sulfide 24 from 50 to 92 % is consistent with its affinity for CAII, which is 9-fold higher than 
sulfide 23, Figure 17. This gives rise to a selectivity of ca. 0.2, i.e. the relative quantity of a binder to its closest 
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competing compound divided by the relative difference in binding constants.[92] This selectivity value is similar to that 
achieved with DCL chemistry.[92]   
 
Figure 17 Receptor accelerated synthesis using carbonic anhydrase and known sulfonamide inhibitor 21. 
Kallikrein – nucleophilic aromatic substitution 
The use of electrophilic aromatic substitution as the irreversible reaction in RAS, was demonstrated by Mosbach et 
al.[93] The protease kallikrein was incubated with a selection of four amines in addition to a substituted 4,6-
dichlorotriazine. This led to the templated synthesis of the expected four products, with the rate acceleration of each 
product closely linked to its binding affinity. The amplification of each binder, relative to its closest competing 
compound, was ca. 1.5 times higher than their relative binding constants, giving rise to a selectivity of 1.5.  
Preincubation of kallikrein with high affinity inhibitor aprotinin significantly reduced the formation of SNAr product. 
Interestingly, the templated reaction resulted in the formation of twice as much triazine 26 as its enantiomer triazine 
27, reflecting their binding constants of 33 and 47 µM respectively, Figure 18.   
 
Figure 18 Enantiomeric inhibitors 26 and 27 synthesised using kallikrein as a template. 
SIRT enzymes – SN2 reaction 
The catalytic mechanism of lysine deacetylation by the sirtuin (SIRT) enzymes was utilised by Suzuki and colleagues 
in the design of sirtuin-selective inhibitors.[94] The SIRT enzymes catalyse NAD+-dependent deacetylation of lysine 
residues, resulting in the release of nicotinamide and O-acetyl-ADP-ribose, Figure 19.[94] Attack from the lysine amide 
oxygen onto the 1’-carbon of the ribose ring of NAD+ displaces nicotinamide and results in the formation of an imido 
ester conjugate. The enzyme subsequently catalyses imido ester hydrolysis, releasing the free amine lysine residue. 
Coumarin-based inhibitor 28 was reported by Jung et al. to be deacetylated by SIRT1, and can be used as a substrate 
for fluorescence-based assays.[95] Introducing an electron withdrawing group into the α-position of the acetamide led 
to inhibitor 29, an analogue of 28. The electron withdrawing group was rationalised by Suzuki et al. to stabilise an 
anion at this position, and thereby increase the nucleophilicity of the α-carbon. Attack onto the NAD+ ribose ring from 
the α-carbon then results in the formation of a highly thermodynamically stable C-C bond, generating in situ a stable, 
high affinity inhibitor which occupies both the NAD+ and the acetylated lysine pockets. A number of anion stabilising 
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groups were investigated, including esters, ketones and sulfones amongst others. Use of an ethyl ester generated the 
highest affinity inhibitor, with IC50 of 3.9 µM and selectivity for SIRT1 over other SIRT enzymes.  
 
Figure 19 Comparison of the mechanism of NAD+-dependent SIRT catalysed lysine deacetylation, and the approach to develop SIRT 
inhibitors by a receptor-accelerated synthesis. 
Bcl-XL – sulfo-click reaction 
Manetsch et al. developed a PPI inhibitor targeting Bcl-XL in an impressive demonstration of RAS.[96] Interuption of 
the interaction between anti-apoptotic Bcl-XL with pro-apoptotic protein partners is thought to induce apoptosis via  
initiation of a signalling cascade. Bcl-XL has therefore become an attractive target for the development of anticancer 
agents. In their work, Manetsch et al. utilise the reaction of a thioacid and sulfonyl azide to generate an amide, a 
reaction that they proposed as particularly suitable for RAS, Figure 20.[97, 98]  
 
Figure 20 Mechanism for reaction of a sulfonyl azide with a thioacid to generate an amide, termed the ‘sulfo-click’ reaction. 
Incubation of Bcl-XL with 6 sulfonyl azides and 3 thioacids in all possible 18 binary combinations led to the 
acceleration of only known inhibitor 30, reported previously by Abbott to have a Ki of 19 nM, Figure 21.[99, 100] This 
rate accelerlation was dramatically reduced in the presence of BH3 peptides bak or bim, both known to interact with 
Bcl-XL at the PPI interface. Simultaneous incubation of Bcl-XL with all 6 azides and 1 thioacid impressively led to 
only the amplification of compound 30, highlighting the potential for RAS approaches to be used in a high-throughput 
manner.  
 
Figure 21  
In an extension of this work, Manetsch et al. synthesised a larger library of thioacids and sulfonyl azides, and 
incubated them as previously in the presence and absence of Bcl-XL in 81 parallel binary experiments.[101] This 
identified three new acylsulfonamide inhibitors in addition to sulfonamide 30. Mutagenesis of Bcl-XL residues 
predicted to be key for binding led to reduced amplification of the acylsulfonamide products. Including the 4 hit 
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compounds, 37 acylsulfonamides were synthesised and tested for their ability to disrupt the Bcl-XL/Bak BH3 PPI. 
Strikingly, the 4 compounds identified during RAS experiments were the most potent compounds by a significant 
degree. Additionally, all thioacid and sulfonylazide building blocks were determined to be very weak inhibitors, 
indicating RAS as a powerful technique to build potent inhibitors from weakly binding building blocks. Both the 
reliability and the bioorthogonality of the reaction between thioacids and sulfonylazides led Liskamp to term it the 
‘sulfo-click’* reaction.[103]  
Huisgen cycloaddition 
A new strategy for RAS was introduced by Sharpless, who realised the potential of the azide-alkyne Huisgen 
cycloaddition as a bioorthogonal ligation reaction for use in RAS.[104] Whilst the work developed by Huc and Lehn 
could be envisaged to suffer from side reactions, such as a cysteine thiol reacting with one of the chloride substrates, a 
bioorgthogonal ligation reaction reacts independently of the myriad chemistry found in a biological system. Previous 
work that inspired Sharpless included that by Mock and colleagues, who elegantly demonstrated that cucurbituril, a 
nonadecacyclic cage, acted as an entropic trap for the azide and alkyne and kinetically enhanced the rate of the 
cycloaddition by 105-fold.[105] In addition, work by Bertozzi demonstrated the power of bioorthogonal reactions to 
probe biological systems.[106, 107]  
The first biological target explored by Sharpless and colleagues in their investigation of RAS was acetylcholine 
esterase (AChE), which has two distinct binding pockets in close proximity to one another.[108-110] The catalytic pocket 
sits at the bottom of a 20 Å deep, narrow ‘gorge’ with a perhipheral pocket located adjacent to the rim. A number of 
ligands had previously been determined as site-specific inhibitors of AChE; tacrine specifically targets the catalytic 
pocket with a Kd of 18 nM and propidium specifically binds at the peripheral pocket with a Kd of 1.1 µM. The enzyme 
was incubated with a selection of 8 azide and alkyne-modified tacrine-based ligands, and 50 propidium-based ligands, 
also decorated with either azide or alkyne functionality in 189 parallel experiments. From this virtual library of 378 
bivalent ligands (syn and anti products), AChE accelerated the rate of only six combinations. Interestingly, 
comparison with authentic samples revealed that the protein selectively accelerated the synthesis of only the syn-
triazoles, which exhibited very low Kd values between 33 fM to 3 pM. These were found to be 10-1000 times stronger 
than the corresponding anti-congeners, which have a more elongated form and a significantly compromised fit within 
the active site gorge. In addition, analysis of crystal structures of the bound ligands identified AChE to be in a 
previously unobserved conformation, suggesting that the RAS methodology has the potential to trap enzymes in 
unexpected low abundance conformations that may be missed by more conventional screening approaches, in addition 
to the identification of novel building block combinations.  
Detailed studies were carried out by Sharpless and Kolb to determine the propensity of RAS to generate false negative 
and positive results.[91] 24 anti-substituted triazoles were synthesised, and their Kd values against bovine carbonic 
anhydrase II (bCAII) determined. Those triazoles which were previously found to be generated by a templated bCAII 
                                                        
* Click reactions were introduced as a chemical philosophy by K. Barry Sharpless in 2001. Click reactions “must be modular, wide 
in scope, give very high yields, generate only inoffensive byproducts that can be removed by nonchromatographic methods, and be 
stereospecific (but not necessarily enantioselective)”.[102]   
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synthesis were determined as potent subnanomolar inhibitors, whereas those from non-templated building block 
combinations were found to be poor inhibitors. This indicated that RAS is not susceptble to the generation of false 
positive results. However, there were a few bCAII inhibiting combinations which were not detected by RAS, 
indicating that this technique is susceptible to false negatives.   
Work carried out with HIV-1 protease demonstrated that the building blocks used in RAS do not need to be high 
affinity binders.[111] Alkyne 31, with an IC50 > 100 µM and azide 32 with an IC50 of 4 µM were incubated with the 
HIV protease as a template, Figure 22. This led to a 10-fold increase in the overall product formation over the 
background reaction, in addition to an increased regioisomeric ratio of 18:1 in favour of the anti-triazole 33 from the 
2:1 background ratio. Anti-triazole 33 was determined to be an inhibitor of HIV-1 protease with an IC50 = 6 nM (Ki = 
1.7 nM). During the course of this work, the authors also demonstrated the feasibility of multicomponent incubations, 
extending the scope of RAS as a useful tool in the development of protein inhibitors. Incubation of the HIV-1 protease 
with 5 alkynes and 1 azide led to the amplification of only one triazole product, which was detected by HPLC and 
mass spectrometry in single ion mode (LC-MS SIM).  
 
Figure 22 Alkyne 31 and azide 32 react in the presence of HIV-1 protease to generate anti-triazole 33 in an increased rate over the 
background reaction, and in increased selectivity.   
RAS is a valuable addition to the arsenal of tools available for  drug discovery. The suitability of the technique to 
identify potent inhibitors from weak binding building blocks suggests it may be valuable for fragment linking, which 
although conceptually simple, has proven extremely difficult in practice. The main disadvantage is that, in the absence 
of a known binder, RAS is not suitable for site-directed drug discovery.  
1.5. The capture group in KTGT 
The fundamental requirement for a suitable KTGT capture group was considered to be its rate of reaction with 
cysteine, which must be slow in the absence of a template, but amenable to a proximity induced rate acceleration. In 
addition, the reaction must be completely irreversible, compatible with aqueous solvent, selective for cysteine and 
inert to the myriad other functionality present under the screening conditions, and the capture group must be 
synthetically facile to install.  Two functional groups, the acrylamide and the vinyl sulfonamide, were considered for 
use in KTGT as outlined in the following section.  
1.5.1. Acrylamide 
The suitability of the acrylamide functional group for KTGT is perhaps best illustrated by its presence in a number of 
kinase inhibitors which are currently in clinical trials.[112] Optimised inhibitors have been shown as rapid inactivators 
of the target kinase, whilst exhibiting impressive selectivity with respect to other kinases, other proteins more 
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generally and small molecule thiols such as glutathione and DTT. Such irreversible inhibitors have been shown to 
outperform their reversible counterparts both in vitro and in animal models.[113]  
In work carried out by Meares et al. a known chelate ligand of the antibody CHA255 was modified with an 
acrylamide function group.[114] This was carried out in conjunction with a co-crystal structure, allowing the acrylamide 
to be added to a position on the ligand adjacent to a suitable cysteine thiol on the antibody. Addition of the acrylamide 
modified-ligand to raw tissue culture medium from cells expressing the recombinant antibody led to 50 % 
modification of CHA255 within 10 minutes, whereas modification of other protein thiols was negligible over a 2 h 
time period. This suggests the reactivity of the acrylamide is sufficiently low for the background reaction with 
endogenous nucleophiles to be negligible. In the presence of a protein template, a rapid reaction ensues.  
An acrylamide functional group was also used by Belshaw et al. who engineered a mutant cysteine residue adjacent to 
the cyclosporin A binding site in cyclophilin A, in addition to modification of cyclosporin A with an acrylamide.[115] 
As for the antibody CHA255, this was also carried out with the guidance of receptor-ligand co-crystal structures to 
ensure the nucleophile and electrophile were suitably positioned for reaction acceleration. Impressively, the modified 
cyclosporin A was able to selectively modify mutant cyclophilin A in complex media such as Jurkat T-cell cytosolic 
extract. Addition of excess unmodified cyclosporin A completely abrogated affinity labelling, indicating that the 
acrylamide required the binding pocket to template the reaction.  
Singh et al. reported an inhibitor of the viral protease HCV NS3/4A, which contained an acrylamide group to 
covalently modify a non catalytic cysteine residue.[116] The inhibitor demonstrated an IC50 against HCV NS3/4A of 2 
nM whilst an analogue with the acrylamide Michael acceptor saturated was almost 1000 times less potent (IC50 = 1.1 
µM). The acrylamide-inhibitor demonstated high selectivity for HCV NS3/4A over a panel of other proteases and in 
addition, demonstrated no nonspecific reactivity towards the small molecule thiol glutathione. Mass spectrometry 
analysis confirmed the formation of a single adduct between HCV NS3/4A and the inhibitor, suggesting the 
acrylamide was resistant to the other nucleophiles on the protein surface.  
Fry et al. reported a novel class of acrylamide-modified quinazoline inhibitors against the epidermal growth factor 
receptor (EGFR).[113] Modification of a previously reported inhibitor 34,[117] yielded acrylamide 35 and analogue 
acrylamide 36 as potent and selective, irreversible inhibitors of the EGFR, active both in vivo  and in vitro, Figure 23.  
 
Figure 23 
Alkylation by inhibitor 35 was selective for cys773 within the ATP pocket, despite the presence of four other cysteine 
residues. Both inhibitors 35 and 36 were found to be inactive against insulin, PDGF and basic FGF receptor tyrosine 
kinases, in addition to protein kinase C, with approximately 105-fold selectivities for EGFR. Docking studies indicated 
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that acrylamide 35 bound in the EGFR ATP pocket, bringing the β-carbon atom of the acrylamide to within a distance 
of 2.8 Å of the nucleophilic cys773 thiol atom. Interestingly, inhibitor 36 placed the acrylamide β-carbon atom at least 
7 Å away according to the docking model, perhaps explaining why this inhibitor modifies the cysteine thiol with 
slower reaction kinetics.  The authors suggest that the Michael addition to the acrylamide group in inhibitors 35 and 
36 only occurs because of the increased proximity for the reaction, induced by binding in the ATP pocket.  
1.5.2. Vinyl sulfonamide 
In 2003, Roush et al. reported a study of the Michael addition rate of 2’-(phenylethyl)thiol to a range of Michael 
acceptors, including the vinyl sulfonamide*.[118] The vinyl sulfonamide was found to be the least reactive, with the rate 
of thiol addition to phenyl vinyl sulfonate esters proceeding approximately 3000 times faster. This suggested the vinyl 
sulfonamide as a potential group for use in KTGT, as it is less likely to react non-selectively than other Michael 
acceptors. In addition to this work, vinyl sulfonamides have been reported to react 390 times faster with cysteine than 
with lysine at pH 8.1 in a phosphate buffer.[119]  
Qiao et al. have demonstrated vinyl sulfonamides as mechanism-based affinity probes.[120] The adenylating enzyme 
MbtA selectively transfers the acyl group from acyladenylate intermediates 37 to aryl carrier proteins (ArCP), with 
loss of AMP, Figure 24. A vinyl sulfonamide acyladenylate analogue 38 was unreactive to Michael addition with the 
ArCP thiol in the absence of the MbtA enzyme. In the presence of MbtA, electrophile 38 binds to the enzyme, which 
templates the irreversible conjugate addition of the ArCP thiol.  
 
Figure 24. 1. Adenylating enzyme MbtA catalyses the transfer of the acyl group from acyladenylate 37 to aryl carrier protein (ArCP). 2. 
Conjugate addition of ArCP to vinyl sulfonamide-adenylate 38 only occurs in the presence of MbtA.  
Vinyl sulfonamides have been described as providing a polarised and yet inert unsaturated bond, and are unreactive 
towards serine proteases, metalloproteases, non-active site cysteines and circulating thiols such as glutathione,[121] 
whilst being potent inhibitors of the cysteine proteases when embedded within a scaffold which confers affinity for 
the active site pocket.[122] 
                                                        
* This study did not include the acrylamide Michael acceptor.  
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1.6. Aim 
The overall aim for this research was the development of a site-directed methodology for the discovery of low 
molecular weight protein-binding ligands. By screening mixtures of fragments with a reactive appendage against the 
protein target, binding ligands should be rapidly identified using mass spectrometry techniques. Covalent adducts 
formed should be stable to proteolytic digestion allowing the position of modification to be identified by analysis of 
the resulting peptides. Libraries of modified fragments should be amenable to rapid synthesis. Both the acrylamide 
and vinyl sulfonamide functional groups will be investigated for use in this methodology.  
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2. Preliminary work towards kinetic template-guided tethering 
2.1. HPLC studies to determine reaction irreversibility 
The instantaneous reaction between simple thiols and 2-cyanoacrylates at physiological pH was reported in the 1960s, 
but at this time the products could not be isolated or characterised.[123] This suggested that the conjugate addition to 
such electrophiles was reversible, and this was conclusively demonstrated by Serafimova et al. in 2012.[124] This 
reversibility was thought to arise from the increased acidity of the αC-H protons, and in accordance with this the 
Michael addition to acrylates, acrylonitriles and acrylamides was found to be irreversible, resulting in the generation 
of stable thioether bonds.[124] Surprisingly, the reaction between enones and thiols was found to be freely reversible 
under physiological conditions and was used by Greaney et al. to probe glutathione S-transferases using a dynamic 
combinatorial approach.[125, 126] The irreversibility of the Michael addition of thiols to vinyl sulfonamides and 
acrylamides is largely assumed within the literature. As discussed, acrylamides have been utilised as irreversible 
covalent warheads in kinase and non-kinase inhibitors,[127] five of which are currently in clincal trials, and vinyl 
sulfonamides have similarly been used as reactive functional groups to irreversibly inhibit the cysteine proteases.[120] 
However, a systematic study has not been reported that conclusively demonstrates the irreversibility of these reactions 
over the pH 8-11 range. This was considered important for their use in KTGT; An irreversible reaction ensures that 
the observed results represent a kinetic rate enhancement due to reduction of the reaction energy barrier upon 
fragment binding to protein, as opposed to a thermodynamic distribution as would be observed for DCC.  
For both reactions, HPLC studies were undertaken using model thiols to investigate reaction irreversibility. A small 
collection of vinyl sulfonamides 39-45 and acrylamides 46-55 were synthesised to carry out proof-of-concept work, 
Figure 25.  
 
 
Figure 25 Synthesis of vinyl sulfonamides from the corresponding amine and 2-chloroethanesulfonyl chloride (A) and acrylamides from 
the corresponding amine and acryloyl chloride (B). 
A subset of the collection included five benzylamines, four with para modifications. These were included on the basis 
that they should all demonstrate equivalent conjugate addition reactivity with the electrophilic moiety insulated from 
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the varying portion of the molecule by the benzylic methylene. Although these acrylamides/vinyl sulfonamides were 
synthesised for use in proof-concept studies, the amine fragments were chosen to be rule-of-three compliant such that 
the collection could be incorporated at a later time into a larger library.[8] The vinyl sulfonamides were synthesised 
from 2-chloroethanesulfonyl chloride and available amines in the presence of triethylamine base to effect the chloride 
displacement and elimination in one step. The acrylamides were synthesised, also in one step, from acryloyl chloride 
and available amines in the presence of triethylamine base.    
To determine reaction irreversibility a procedure was employed as illustrated in Figure 26, whereby two different 
electrophiles (either vinyl sulfonamides or acrylamides) were reacted separately with a nucleophilic thiol and the 
reaction allowed to proceed until no futher changes were observed. A second electrophile was then added to each 
reaction and any further changes monitored over time. An irreversible reaction should yield two different reactant-
product distributions whereas a reversible reaction should converge to a single thermodynamic distribution.  
 
Figure 26 Schematic to illustrate the procedure adopted to test reaction irreversibility. Two electrophiles (either vinyl sulfonamide or 
acrylamide) were reacted separately with a nucleophile (model thiol) and the reaction allowed to proceed until no further changes were 
observed by HPLC. To each reaction was then added the second elecrophile. If the reaction is reversible (top) then both reactions should 
converge to the same thermodynamic distribution over time. If the reactions are irreversible then two separate distributions are generated.  
Benzylmercaptan was initially chosen as the model thiol, due to its strong UV chromophore which allows it to be 
monitored by HPLC in addition to the electrophile. However, due to poor aqueous solubility at the concentrations 
required to generate reliable HPLC data, other thiols such as N-acetyl L-cysteine, glutathione and mercaptosuccinic 
acid were adopted. Whilst N-acetyl L-cysteine-vinyl sulfonamide conjugation addition products were facile to 
separate from starting vinyl sulfonamides by HPLC, many of the analogous acrylamide adducts were inseparable from 
their starting acrylamides despite extensive efforts to optimise solvent gradients. Mercaptosuccinic acid generated 
acrylamide-conjugate addition products which were significantly more polar than the starting acrylamides, 
presumably due to the additional polar carboxylic acid functionality. These mixtures were therefore more readily 
separated (see appendix I, p213, Figure 119). However, the reaction between acrylamides and mercaptosuccinic acid 
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was prohibitively slow. Reaction between acrylamides and glutathione proceeded at a more reasonable reaction rate 
and also gave separable products by HPLC. The gradual formation of disulfide over time using N-acetyl L-cysteine, 
glutathione or mercaptosuccinic acid cannot be measured by HPLC as neither compound has a suitable UV 
chromophore. Authentic samples of a selection of the conjugate addition products were synthesised, Scheme 1 and 
analysed by HPLC to confirm retention times. 
 
Scheme 1 Synthesis of vinyl sulfonamide and acrylamide conjugate addition products. 
One equivalent of N-acetyl L-cysteine was added separately to both vinyl sulfonamides 40 (vial one) and 41 (vial two) 
in aqueous buffer, pH 8, and the reactions monitored by HPLC, Figure 27 and Figure 28. Both reactions were 
observed to proceed directly to products (confirmed using authentic samples of conjugate addition products) with no 
side-product formation. Neither reaction went to completion, presumably due to competing thiol oxidation to 
disulfide. After 460 min (vial one) or 320 min (vial two), one equivalent of vinyl sulfonamides 41 and 40 respectively 
were added to the mixtures and both reactions monitored for a further 850 min. Formation of a second conjugate 
addition product was not observed in either reaction, indicating complete irreversibility on this time scale. Two sets of 
acrylamide pairs 55/46 and 49/46 were used with glutathione as the model thiol to demonstrate the irreversibility of 
conjugate addition to acrylamide at pH 8, (data shown in appendix I, p213, Figure 120 and Figure 121). Irreversibility 
for both vinyl sulfonamide and acrylamide conjugate additions was also confirmed at pH 11. Using acrylamides 46 
and 51, the reaction with both glutathione and N-acetyl L-cysteine at pH 11 was determined to be irreversible over a 
12 h time period (see appendix I, p214, Figure 122 and Figure 123). Vinyl sulfonamides 39 and 41 were used to 
determine reaction irreversibility between vinyl sulfonamide and N-acetyl L-cysteine at pH 11 (see appendix I, p215, 
Figure 124). Furthermore, an authentic sample of conjugate addition product 59 was added to vinyl sulfonamide 39 at 
pH 11, and irreversibility confirmed by the lack of formation of a second conjugate addition product or second 
acrylamide (see appendix I, p216, Figure 125). 
It was noted during the course of these studies that acrylamides 51 and 52, the only compounds conjugated to 
aromatic systems, both reacted very rapidly with glutathione compared to other acrylamides, with reactions gone to 
completion in approximately 5 min. The greater electron withdrawing nature of the ArN substituent, compared to 
ArCH2N, increases the reactivity of the acrylamide towards Michael addition. This was assumed to render these 
acrylamides unsuitable for KTGT experiments due to the high expected background reaction.  
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Figure 27 (Left hand side) Overlay of HPLC traces for the addition of vinyl sulfonamide 41 to N-acetyl L-cysteine. As expected, the 
peak due to vinyl sulfonamide 41 diminishes over time, and a new peak for the conjugate addition product 59 appears. (Right hand side) 
Overlay of HPLC trace just before addition of vinyl sulfonamide 40 and the HPLC traces 10 and 850 minutes after addition. Reactions 
were carried out in ammonium bicarbonate buffer (100 mM) pH 8. Time for each measurement is indicated in minutes.  
 
Figure 28 (Left hand side) Overlay of HPLC traces for the addition of vinyl sulfonamide 40 to N-acetyl L-cysteine. As expected, the 
peak due to vinyl sulfonamide 40 diminishes over time, and a new peak for the conjugate addition product 58 appears. (Right hand side) 
Overlay of the HPLC trace just before addition of vinyl sulfonamide 41 and the HPLC traces 10 and 850 minutes after addition. Reactions 
were carried out in ammonium bicarbonate buffer (100 mM) pH 8. Time for each measurement is indicated in minutes.  
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To summarise, HPLC studies confirmed the thiol-acrylamide and thiol-vinyl sulfonamide conjugate addition reactions 
to be irreversible at both pH 8 and pH 11 over the time scales monitored. Both electrophiles were converted smoothly 
to products with no side-product formation.  
It was noted during the irreversibility studies that the acrylamides were generally significantly less reactive towards 
conjugate addition than the vinyl sulfonamides. This was conclusively shown for one vinyl sulfonamide/acrylamide 
pair, Figure 29. Vinyl sulfonamide 45 and acrylamide 55 were mixed separately with reduced glutathione and the 
reactions monitored by HPLC over time. The vinyl sulfonamide was observed to be significantly more reactive than 
the acrylamide.   
 
 
Figure 29 Comparison of the reactivity of the vinyl sulfonamide and acrylamide functional groups towards conjugate addition of reduced 
glutathione (GSH). Glutathione and electrophile were mixed at equimolar concentrations in an ammonium bicarbonate buffer (pH 8) and 
the reaction monitored by reverse phase HPLC. The area under the peak of the unreacted electrophile, normalised to the value at t = 0 min 
is plotted against time. Black trace represents reaction of acrylamide 55, red trace represents reaction of vinyl sulfonamide 45.  
2.2. Initial attempts to develop KTGT using cdc25A 
With the Michael addition of small molecule thiols to acrylamides and vinyl sulfonamides determined as irreversible 
under aqueous conditions, initial work in the use of these functional groups to identify inhibitors of cdc25 
phosphatases was undertaken. Cdc25A has five native cysteine residues; cys430 
(active site cysteine), cys441, cys476, cys384 and cys480, Figure 30. Examination 
of the cdc25A crystal structure (PDB code 1C25) indicated that cys430, cys441 and 
cys476 were solvent exposed and may therefore compromise tethering specificity. 
Of the residues surrounding the active site, tyr386 was well placed to tether 
fragments into the active site pocket, Figure 31. 
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Figure 30 Crystal structure of native cdc25A (PDB 1C25) with all 5 cysteines highlighted. In 
cdc25A’ cys430, cys441and cys476 have been mutated to serine. Cys384 and cys480 appear 
buried within the interior of the protein. 
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Figure 31 Active site pocket of cdc25A (green) with tyr386 highlighted. PDB code 1C25. 
A quadruple cdc25A mutant of the catalytic domain was therefore required (cdc25A’), with the solvent exposed 
cysteines mutated to non-nucleophilic residues and with tyr386 mutated to cysteine. Such extensive mutation of native 
cysteine residues can cause disruption to the tertiary structure of the protein if key structural disulfide bridges are 
removed. In cdc25A, cys430 resides in close proximity to cys384, termed the ‘backdoor cysteine’, which functions to 
protect the active cys430 during oxidative stress by formation of a disulfide bond. This disulfide bond was therefore 
assumed to have no structural function, as the enzyme is active in its absence. Cys480 resides in close proximity to 
cys476 but these residues do not appear to form a disulfide bond in the cdc25A crystal structure. Disruption of 
disulfide bridges was therefore hypothesised not to cause a major structural change to cdc25A. There is no consensus 
amino acid substitution for cysteine;[128] alanine is thought to be the closest match in terms of hydrophobicity (for non-
charged cysteine residues), whereas serine provides a closer size match. Serine residues were chosen to replace the 
solvent exposed cysteine groups.   
The quadruple mutant DNA cdc25A’ was generated by PCR from an available construct (pGEX-KG vector containing 
wild type cdc25A*) and cloned into a pET21a expression vector (pET21a-cdc25A’).[129]† Expression of the protein was 
carried out using E. coli BL21 (DE3) cells which were transformed with the plasmid by electroporation. After the 
required growth of the cells (usually to a volume of 2 L), expression was induced by addition of IPTG. Specifically, 
this induces expression of the T7 RNA polymerase, which begins rapid and extensive translation of the cdc25A’ gene 
within the pET21a plasmid, which contains a T7 promoter region. Extremely high yields of the desired mutant 
cdc25A’ protein were obtained using this expression system.  
The cells were lysed by sonication and the desired protein extracted from the lysate using anionic beads composed of 
an insoluble resin with attached sulfopropyl groups. The protein was gradually eluted from the beads using an 
increasing linear NaCl gradient which disrupts protein-bead electrostatic interactions. As this protein is an inactive 
mutant with the active site cysteine mutated to serine, an activity assay could not be used to detect the cdc25A’ in the 
fractions. Each fraction was therefore subjected to SDS PAGE, and the elution of cdc25A’ visualised by staining for 
total protein with Coomassie blue, Figure 32. Fractions which contained cdc25A’ were combined and concentrated 
using a 10 kDa centrifugal filter and the retentate centrifuged to remove the significant quantity of precipitation 
                                                        
* Generated by coworker J. C. Collins.  
† Work previously carried out by R. H. Nonoo as part of MRes degree.  
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generated during the concentration process. The filtrate was subjected to further purification by gel filtration 
generating cdc25A’ of reasonably high purity, Figure 32. The cdc25A’ precipitate was re-dissolved in a TRIS-HCl 
buffer containing 6 M urea and dialysed into buffer with a gradually decreased concentration of urea over a 24 h 
period in accordance with standard literature protocols to re-fold precipitated protein. The protein obtained by this 
method was of higher purity than that obtained by gel filtration, Figure 32.  
 
Figure 32 Purification of cdc25A’ by ion exchange and either gel filtration (GF) or precipitation (P). 
A thermal shift assay was used to determine whether the cdc25A’ generated by precipitation was folded. This 
involved incubating the protein with a fluorescent reporter dye, Sypro Orange, which is effectively quenched in 
aqueous solution but upon interaction with the hydrophobic interior of protein begins to fluoresce with high quantum 
yield. This generates a ‘melt curve’, shown schematically in Figure 33, from which the protein TM can be calculated 
from the first derivative. Cdc25A’ (isolated by precipitation) generated a melt curve upon heating, although the TM 
was observed to be ca. 5 °C lower than for active cdc25A triple cysteine mutant,[129]* Figure 34.  
 
Figure 33 Depiction of a typical melt curve. The blue sphere represents a folded protein, the orange spheres represent the dye Sypro 
Orange and the dark blue patches represent hydrophobic regions exposed upon protein unfolding.  
                                                        
* Worked carried out by R. H. Nonoo as part of MRes degree.  
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Figure 34 LHS Melt curve and its first derivative for cdc25A’ (purified by the precipitation method) using 8 wells heated at a rate of 0.5 
°C/min in the presence of the fluorescent dye Sypro Orange. As the protein is heated and begins to unfold, buried hydrophobic residues 
become solvent exposed and interact with the dye, which begins to fluoresce. The point at which the protein is half folded and half 
unfolded is represented by the melting temperature (TM), which is calculated as the lowest point of the first derivative of the melt curve. 
RHS Bar chart to illustrate the TM values for cdc25B-WT, cdc25A triple cys mutant and cdc25A Y386C.*  
As previously discussed, the signal observed using MALDI spectroscopy for the catalytic domain of cdc25A Y386C 
(approximately 23,500 Da) was subject to significant isotopic broadening, and due to this effect, protein and protein-
adduct peaks could not be resolved.[129]*  A general protocol was therefore developed for digestion of the protein into 
low MW peptides prior to MS analysis, Figure 35. After incubation of the protein with acrylamide(s) or vinyl 
sulfonamide(s), excess electrophile was quenched by the addition of βME to prevent non-specific tethering during the 
digestion period. Digestion of the protein by the action of a proteolytic enzyme then generated a mixture of peptides 
with the retention of thioether bonds. Trypsin was chosen as the proteolytic enzyme for this work as it was 
commercially available in an autolytic-resistant form, thereby limiting contamination of spectra with non-cdc25A’ 
enyzme fragments. Additionally, as tryspin is most efficient at pH 8 it was added directly to the protein-vinyl 
sulfonamide/acrylamide mixtures. 
 
Figure 35 Schematic to illustrate the MALDI screening protocol. Cdc25A’ was incubated with mixtures of either vinyl sulfonamides or 
acrylamides in an ammonium bicarbonate buffer (pH 8), to allow KTGT to occur. A large excess of βME was subsequently added to the 
mixture to quench the reaction. Trypsin was finally added to digest the protein into low MW peptides and the solvent was removed from 
the mixture. The peptide mixture was then analysed by MALDI MS.  
                                                        
* Work previously carried out by R. H. Nonoo as part of MRes thesis.  
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Trypsin cleaves proteins at the carboxyl side of arginine and lysine residues except when followed by proline. 
Digestion of cdc25A’ by trypsin conveniently divides the three cysteine residues in the protein into three distinct 
peptides; peptide-994 (cys384), peptide-1296 (cys386) and peptide-2339 (cys480) where the peptide number refers to 
its mass in daltons. Using trypsin it was therefore possible not only to detect covalent adduct formation, but also to 
determine the tethering location. All tethering experiments were carried out in an ammonium bicarbonate buffer at pH 
8 with the protein at a concentration of approximately 10 µM, as estimated using a Bradford assay. The volatility of 
ammonium bicarbonate allows its removal in vacuo prior to MS analysis. This was found to be a key criteria for the 
aqueous reaction medium as the presence of buffer molecules in samples for MS analysis has a highly detrimental 
effect on the quality of mass spectra.[130]  
A typical MALDI spectrum obtained upon digestion of cdc25A’ with the high MW peptides identified is shown in 
appendix III, p217, Figure 126. Initially cdc25A’ (isolated by gel filtration rather than precipitation) was incubated 
with one vinyl sulfonamide (39, 40, 41, 43 or 45) at 1.0, 0.5 or 0.1 mM for 10 min at room temperature, and quenched 
for 10 min at room temperature with 10 equivalents of βME before addition of tryspin. For all sulfonamides at all 
concentrations, large adducts were seen to both the 994 and 1296 peptides. No adducts were seen to the 2339 peptide, 
but for all cases, including the control with no added vinyl sulfonamide, the parent 2339 peptide was not observed 
either. When all 5 sulfonamides, 39, 40, 41, 43 and 45 were incubated with the protein in the same mixture, with each 
sulfonamide at either 0.1 or 0.2 mM, with the same quench procedure, adducts to both the 994 and 1296 peptides were 
observed for all sulfonamides, Figure 36.  
 
Figure 36 MALDI spectrum obtained after trypsin digestion of cdc25A’(gel filtration) preincubated with vinyl sulfonamides 39, 40, 41, 
43 and 45 each at 100 µM and quenched with 10 equivalents of βME.  
All further experiments were carried out using the cdc25A’ protein purified by precipitation, as this gave a strong 
peak for the peptide at 2339 and tethering at the third cysteine was therefore observed. This protein sample was also 
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significantly less contaminated, as indicated by SDS PAGE, and the obtained mass spectra were of higher quality. 
Experiments with five vinyl sulfonamides 39, 40, 41, 43 and 45 incubated with the protein in one-pot were repeated 
with each vinyl sulfonamide at 1 and 20 µM, and with the same quench procedure. With each sulfonamide at 1 µM, 
no tethering to any cysteine was observed. However, with each sulfonamide at 20 µM, tethering was seen to all three 
cysteines, Figure 37.   
 
Figure 37 MALDI spectrum of cdc25A’ incubated with 5 vinyl sulfonamides, 39, 40, 41, 43 and 45 each at 20 µM and the mixture 
digested with tryspin. Adducts are seen to all three cysteines.  
As Cys384 and Cys480 were hypothesised to be buried within the protein interior, tethering at these cysteine residues 
indicated that either the βME quench was not effective or that in fact these residues were solvent exposed in cdc25A’. 
Cdc25A’ was incubated with sulfonamide 40  at 20 µM for 10 min at 4 °C and subsequently quenched with a large 
excess of βME (either 100, 500 or 1000 equivalents) at 4 °C for 16 h. Thermal shift 2 h after βME addition indicated 
that samples with 100 equivalents of βME contained folded protein, but those with either 500 or 1000 equivalents 
gave undefined melt curves indicating various degrees of protein unfolding, Figure 38. The samples were analysed by 
thermal shift again after 16 h, but all samples were completely unfolded (no melt curve). MALDI analysis of the 
digested samples indicated tethering to all three cysteines with 100 equivalents of βME, tethering to only the 994 and 
1297 peptides with 500 equivalents of βME and tethering to only the 1297 peptide with 1000 equivalents of βME 
(although the adduct formed to the 1297 peptide after treatment with 1000 equivalents of βME was in very low yield), 
Figure 39. These results suggested that almost no tethering to the protein occurred within the allotted 10 min pre-
quench incubation time due the lack of any significant adduct to the sample quenched with 1000 equivalents of βME. 
These experiments also indicated that under these conditions, 100-500 equivalents of βME was insufficient to 
effectively quench the remaining electrophile before background reaction with protein.   
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Figure 38 Left hand side: Thermal shift melt curves for cdc25A’ incubated with sulfonamide 40 (20 µM) and either 100 equivalents of 
βME (black trace), 500 equivalents of βME (green trace) or 1000 equivalents of βME (blue trace). Right hand side: First derivative of 
the melt curves. All tests were run in duplicate.  
 
Figure 39 Tethering of vinyl sulfonamide 40 to cdc25A’ at various concentrations of βME. Red sphere = peptide 994, purple sphere = 
peptide 1296, green sphere = peptide 2339.  
2.3. Preliminary results for acrylamide tethering 
When cdc25A’ (isolated by precipitation) was incubated with acrylamide 47 (20 µM, 30 minutes, rt) and subsequently 
quenched with βME (1000 equivalents, 2h, rt), no significant adduct formation was seen with any of the three 
cysteine-containing peptides. However, when the same acrylamide was screened at 100 µM with the same quench 
procedure, low abundance adducts were seen to form with all three cysteines. This presumbly indicates that the 
addition of acrylamide 47 is not templated by the protein, such that upon increasing the acrylamide concentration, the 
background reaction at all three cysteines is increased.  
2.4. Summary and conclusions  
In this section of work, cdc25A’ was incubated with vinyl sulfonamides and acrylamides and mixtures were digested 
proteolytically. Analysis of the resulting peptide mixtures by MALDI MS indicated that thioether bonds generated by 
conjugate addition reactions were stable to the proteolytic enzyme trypsin. Furthermore, up to five covalent adducts 
were resolved to three distinct peptides from the same sample, highlighting the powerful resolution obtained by 
MALDI at these low molecular weights. Extensive modification of all three cysteine residues indicated that either the 
quench with βME was ineffective or that the cysteine residues hypothesised to be buried were actually solvent 
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exposed, potentially due to the fluxional nature of the protein in solution. In either case, the observed modification of 
protein thiols with all electrophiles in the mixture, to approximately equal extents, indicated a non-templated 
background reaction and a lack of KTGT. It was decided that a model system with a positive control was required to 
validate the KTGT technique. This model system should be composed of a biomolecule with a known ligand to act as 
a positive control. If the biomolecule selects the known ligand from a pool of compounds using KTGT, this firstly 
provides a validation of the technique and secondly a set of conditions to use with the therapeutically useful target 
cdc25A’. 
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3. Thymidylate synthase as a model system for proof-of-concept studies 
3.1. Introduction 
Thymidylate synthase (TS) was chosen as the model system with which to validate KTGT. TS is a small (ca. 30 kDa), 
highly conserved enzyme which has been extensively studied within the literature. TS has been isolated from highly 
varied sources including bacteria, yeast, viruses, bacteriophage and vertebrates,[131] but much of the work to elucidate 
the structure and function of this enzyme has utilised either Lactobacillus casei or Escherichia  coli TS, which share 
82 % homology over the active site region.[132] TS catalyses the reductive methylation of deoxyuridine 
monophosphate (dUMP) by cofactor 5,10-methylenetetrahydrofolate (mTHF) to deoxythymidine monophosphate 
(dTMP), providing the sole de novo source of dTMP for DNA synthesis and repair in the cell, Figure 40 (A).[133] E. 
coli TS has five native cysteine residues, of which only the active site residue has been reported to be solvent exposed, 
Figure 40 (B).[51]  
 
Figure 40 (A) Reductive methylation of dUMP to dTMP by TS. The new bond formed is shown in red. 
Native TS exists as a symmetric obligate dimer, where each monomer contains a 
deep active site cavity lined by the side chains of 25 residues, four of which are 
contibuted by the other subunit.[131] Of the 25 residues which line the active site 
pocket, 16 are invariant across 8 TS sequences.[131] Within the family of folate-
utilising enzymes, TS is particularly unique due to the dual role played by its 
folate cofactor as both a one-carbon donor and a reductant. The catalytic 
mechanism for dTMP synthesis involves the initial formation of a ternary TS-
dUMP-mTHF complex before attack of the TS active site cysteine (C146 in E. 
coli, C198 in L. casei) onto C6 of the dUMP pyrimidine ring, Scheme 2. The 
resulting enol(ate) attacks through the α-carbon onto mTHF which has been 
activated by formation of an imminium ion from the 1,1-diamine. Regeneration of 
the enolate and E1CB elimination of THF generates an exocyclic α,β-unsaturated 
alkene. This is reduced in situ by the already bound THF, which donates a 
hydride by pushing from the N5 lone pair, resulting in formation of the imine 
dihydrofolate (DHF). Conjugate addition of hydride onto the substrate generates the saturated system, from which a 
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final E1CB elimination of the enzyme releases dTMP. Structures of TS bound to mechanism based inhibitors, which 
mimic reaction intermediates[134-137] in addition to site directed mutagenesis studies to trap reaction intermediates[138, 
139] have validated the described catalytic mode of action, which was initially proposed through a series of kinetic 
analyses and spectroscopic data.[140]  
 
Scheme 2 Catalytic mechanism of action for TS.  
The active site cysteine in TS has been postulated to have a surprisingly high pKa value of approximately 8.[141] Many 
catalytic cysteine residues have pKa values considerably lower than that of isolated cysteine, and are therefore often 
present as the more nucleophilic thiolate.[142] Such acidity is usually conferred by the environment set up by residues 
in the active site pocket. The high pKa of the active site cysteine in the apo TS enzyme is thought to act as a protective 
mechanism to guard the thiol from oxidation.[143] Generation of the thiolate is thought to occur upon dUMP substrate 
binding, which triggers a sequence of proton transfers resulting in thiol deprotonation by His207.[143] Before substrate 
binding, the basicity of His207 is reduced by neighbouring Arg126 whose cationic guanidinium moiety is stacked 
against the imidazole ring. Upon dUMP binding, the guanadinium moiety in Arg126 forms a hydrogen bond with the 
phosphate group of dUMP, neutralising the charge and raising the basicity of the local His residue, which then 
abstracts a proton from the catalytic cysteine to activate it as the thiolate for Michael addition to dUMP. It is thought 
that Ser167 is involved in this proton transfer, although the exact role this residue plays is currently unclear.[143, 144] 
Additionally, a role for Arg218 has been proposed in the activation of the active site cysteine.[131, 140, 145]  
As TS provides the only intracellular de novo source of dTMP, it is crucial for DNA synthesis and repair. Selective 
inhibition of TS has been achieved by a number of compounds, many of which are substrate (e.g. 5-fluoro 
deoxyuridine monophosphate) or folate analogues (e.g. Raltitrexed), and lead to toxicity in actively dividing cells.[146] 
As such, TS is a critical target in the treatment of cancers such as ovarian, colorectal, breast, head and neck, pancreatic 
and gastric with significant achievements in the clinic to date.[146, 147] The substantial success of TS as a target in the 
development of anticancer therapeutics has led to a very thorough exploration of this protein within the literature. The 
availability of protocols for enzyme expression, purification, crystallisation and the wealth of available crystal 
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structure data encouraged the use of TS as a model system. In addition, TS has been used a number of times to 
validate other methods of drug discovery.[148-151]  
Significantly, E. coli TS was used to generate an initial proof-of-concept for disulfide tethering by Erlanson et al.[51] 
and was therefore considered to provide an excellent 
platform for proof-of-concept KTGT studies. Although TS 
has 5 native cysteine residues, in agreement with previous 
studies,[152] Erlanson et al. demonstrated that only the 
catalytic cysteine (C146) is solvent exposed.[51] Treatment 
of the native enzyme with the disulfide cystamine yielded 
complete, single modification, whereas no reaction at all was observed with TS 
mutant C146S. In their proof-of-concept, Erlanson et al. incubated TS with 
mixtures of up to 100 disulfides from a custom synthesised library and analysed 
the resulting distributions by mass spectrometry. They reported the selection of 
proline analogue 63 by TS, as identified by the high intensity disulfide adduct 
formed to this ligand at the expense of other protein-ligand adducts, Figure 41. 
Removal of the labile disulfide bond generated N-tosyl D-proline 64, a millimolar 
inhibitor of TS enzyme activity. Interestingly, proline-disulfide analogue 63 was found by the authors to be selected 
both by native TS and by a C146S L143S mutant but not by a C146S H147C mutant. This suggested that whilst there 
was some flexibility in the tethering location for this ligand, Figure 42, there was also some dependence on cysteine 
placement.  
A total of 1200 disulfides were screened against TS using the mass spectrometry-based tethering assay, leading to the 
identification of some significant positive and negative SAR. The authors disclosed a selection of disulfide-modified 
ligands from this study, including N-methyl D-proline disulfide 65, which was not selected by the enzyme. The 
original N-tosyl D-proline ligand 64 was optimised to give higher affinity ligand 66 by the replacement of the tosyl 
CH3 with L-glutamic acid to incorporate part of the natural cofactor, improving affinity almost 50-fold.  
In this work, the ligands originally reported by Erlanson et al. were modified for use as positive and negative controls 
in KTGT by the appendage of either acrylamide or vinyl sulfonamide functional groups, Figure 43  
 
Figure 43 Ligands selected and not-selected by disulfide tethering[51] and their adaption for use as positive and negative controls 
respectively in KTGT by addition of either a vinyl sulfonamide or acrylamide group. Only acrylamide indicated in schematic.  
Disulfide 
Tethering
N
SO
N
H
SRS
O
O
Selected
Not 
selectedN
O
N
H
SRS
KTGT N
S
N
H
O
O
ON
N
H
O
Negative control Positive control
6365
68 67
Figure 41 
N
SO O
N
H
O
S
63
Figure 42 Overlaid crystal structures of 
proline analogue 63 tethered within the 
active site pocket of TS from mutant 
cysteine 143 (blue) (PDB code 1F4D ) 
and wild type cysteine 146 (yellow) 
(PDB code 1F4C ). 
 
Kinetic Template-Guided Tethering of Fragments                                                                                       Chapter Three 
  48 
The ligands were designed such that the electrophilic atom marking the point of covalent modification was kept 
consistent between both tethering types. The carbonyl adjacent to the pyrrolidine ring in disulfides 63 and 65 was 
moved to a new position two atoms further from the ring in positive control 67 and negative control 68 in order to 
place the acrylamide in the correct location. The proline-carbonyl in optimised ligand 66 was also moved in the same 
manner to yield higher affinity positive control 69 for KTGT, Figure 44. It was predicted that, due to the flexibility 
observed in the tethering location, these small molecular changes would not affect the ability of the compounds to act 
as appropriate controls.   
 
Figure 44 Optimisation of N-tosyl D-proline 64 to D-proline derivative 66 by Erlanson et al. improved affinity towards TS by almost 50-
fold.[51] This micromolar inhibitor was modified for use in KTGT as a high affinity tethering control by the addition of a vinyl 
sulfonamide or acrylamide group. Only acrylamide 69 indicated in schematic.  
The overall aim for work described within this chapter is to use E. coli TS to obtain a proof-of-concept for KTGT. 
This includes the following:  
1. Cloning, expression and purification of E. coli TS.  
2. The synthesis of appropriate positive and negative control ligands.  
3. Demonstration that from a mixture of acrylamides or vinyl sulfonamides, TS selects only the positive and not 
the negative control ligand.  
4. Digestion of TS-acrylamide/vinylsulfonamide adducts and MALDI MS analysis of the resulting peptide 
mixtures to identify the position of modification.  
3. 2. Cloning, expression and purification of wild type E. coli thymidylate synthase 
3.2.1. Cloning strategy 
To generate high quantities of active TS enzyme, a pET/E. coli expression system was adopted. The pET vectors are 
particularly suitable for rapid, high level expression in bacteria due to the viral T7 promotor, which, along with a lac 
operator, flanks the gene of interest within the cloning region of the plasmid, Figure 45. The T7 promotor does not 
occur anywhere else within the prokaryotic genome and is highly specific for only the T7 RNA polymerase.[153] The 
lacI gene, also encoded within the pET plasmid, codes for the lac repressor protein which binds to the lac operator 
sequence, preventing transcription of the gene of interest. Expression of a desired recombinant protein using the pET 
vector must be carried out using a strain of E. coli which has been engineered to contain the gene for the T7 RNA 
polymerase. This is most often E. coli BL21 (DE3) in which the T7 RNA polymerase gene is flanked by a lac 
promotor and a lac operator sequence. Protein expression is only activated by the addition of IPTG which displaces 
the lac repressor protein from the lac operator and activates transcription of T7 RNA polymerase. T7 RNA 
polymerase then rapidly and profusely transcribes the gene inserted into the cloning region of the pET vector. The 
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strong, constitutively active T7 promotor ensures that transcription continues as long as the T7 RNA polymerase is 
present. Expression of this gene increases rapidly as the quantity of mRNA increases, often until the protein of interest 
is the most dominant component of the cell, comprising more than 50 % of the total cell protein a few hours post-
induction.  
 
Figure 45 The pET21a vector which contains a multiple cloning region (see Appendix V) (cloning) preceded by the lac operator (LacO) 
and the T7 promotor (T7). The plasmid also contains a gene to confer ampicillin resistance (amp R) and lacI which codes for the lac 
repressor protein.  
To clone the TS gene into the pET21a expression vector, a two-step cloning stratgy was adopted. Difficulties were 
previously encountered cloning a DNA insert obtained by PCR 
directly into the pET21a plasmid, but were overcome using a ‘t-tailing’ 
strategy.* This involved the addition of a deoxyadenosine (dA) to the 
3’ end of the original DNA insert and cloning into a pGEM-T vector, 
which has a single terminal deoxythymidine on each 3’ end. The 
overhanging bases make this method more efficient than cloning with 
‘blunt ends’ and subcloning from pGEM-T to pET21a is more efficient 
than from the PCR insert. The TS gene was amplified from whole E. 
coli BL21 (DE3) cells, which contain the sequence within their 
genome, using PCR, Figure 46. The insert generated by PCR was 
heated in the presence of a Taq DNA polymerase and dATP to effect 
the addition of an A base to the 3’ ends. The t-tail insert was ligated 
into the pGEM-T vector using a T4 DNA ligase enzyme, Figure 47, but problems were encountered at this stage in the 
selection of colonies containing the insert. This is presumably as a small percentage of the commercial pGEM-T 
contains the non t-tailed vector, which can ligate itself to generate an empty vector.  
 
Figure 47 The desired successful ligation reaction between pGEM-T and the insert with overhanging A-bases.  
A blue/white selection procedure was adopted to increase the probability of selecting transformants containing an 
insert. The transformed cells were grown in the presence of IPTG to induce gene transcription and 5-bromo-4-chloro-
                                                        
* Work previously carried out by R. H. Nonoo during MRes.  
Figure 46 Schematic illustration of PCR. 
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3-indolyl-[β]-D-galactopyranoside (Xgal), which is converted to a bright blue product by the enzyme β-galactosidase, 
the product from the LacZ gene. β-Galactosidase functions as a homotetramer with tetramerisation dependent on the 
N-terminal 50 amino acids. E. coli DH5α cells used for cloning are only able to express a truncated form of β-
galactosidase, which fails to tetramerise. The missing N-terminal sequence can be provided in trans from plasmids 
such as pGEM, leading to blue colonies after ampicillin selection. However, if the plasmid contains an insert, 
production of the N-terminal peptide is disrupted, tetramerisation of the LacZ gene product does not occur, and a 
white colony results. White colonies were selected, grown on a small scale, and the DNA isolated and digested to 
identify correct transformants. These were then grown on a larger scale and the DNA extracted, purified and 
sequenced to yield the desired pGEM-T-TS plasmid.  
The cloning sites EcoRI and NdeI were used to subclone the insert from the pGEM-T vector to the pET21a expression 
vector. This cloning strategy was complicated by the presence of two further NdeI sites within the TS insert, Figure 
48. A partial digest strategy was adopted in an effort to obtain the TS insert cut at only the desired NdeI site. The 
plasmid was fully digested with EcoRI over a one hour period in ten separate aliquots. Successively more dilute NdeI 
enzyme was subsequently titrated into each sample, and the digest allowed to proceed for 15 minutes. A fully digested 
NdeI/EcoRI sample was prepared as a control. The sample which contained NdeI at 5 x dilution gave a band at just 
above the 700 bases DNA ladder band as required for the correct insert. This digest was therefore repeated with four 
further samples of the pGEM-TS plasmid DNA in order to obtain a reasonable quantity of the digested insert. The 
insert was ligated into the cloning region of pET21a pre-digested with NdeI/EcoRI, and transformed into E. coli 
(DH5α) cells. Colonies were selected and grown overnight on a small scale and the DNA isolated and digested to 
identify correct transformants. These were then grown on a larger scale and the DNA isolated, purified and sequenced. 
However, the sequence indicated that the insert had been cut at two consecutive NdeI points (indicated in Figure 48 by 
asterisks), rather than the desired NdeI and EcoRI sites to give an insert of 563 bases rather than the desired 802 bases 
in a plasmid termed pET21a-TSNdeI.  
 
Figure 48 DNA sequence for the catalytic domain of TS with sites for selected restriction enzymes highlighted. The insert 
was found to be cut at two consecutive NdeI sites (indicated by an asterix) rather than the desired NdeI and EcoRI sites.  
To complete the cloning, the pGEM-T-TS plasmid was cut with EcoRI and AscI whilst the pET21a plasmid 
containing the partial TS sequence was cut with EcoRI and AscI. The insert from the pGEM-TS digest was ligated 
into the EcoRI/AscI cut pET21a plasmid to give the full TS catalytic domain cloned into the pET21a expression vector 
(pET21a-TS), Figure 49, which was isolated, purified and sequenced.  
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Figure 49 Schematic to illustrate the final TS cloning steps. pET21a-TSNdeI and pGEM-TS were both cut with AscI and EcoRI restriction 
enzymes and the insert from pGEM-TS ligated into the cut pET21a to generate the final desired pET21a-TS construct. The blue part of 
the circle represents the vector sequence and the black part of the circle represents the insert sequence.  
3.2.2. Expression and purification 
E. coli BL21-DE3 cells were transformed with the pET21a-TS vector by electroporation, grown and subsequently 
induced with IPTG. It was found that incubation at 37 °C rather than 18 °C after IPTG induction was optimal. After 
the induction period, analysis of the cells by SDS PAGE indicated a strong band for TS, Figure 50 (A). The 
purification was largely carried out in accordance with a literature protocol.[154] The cells were lysed by sonication and 
the nucleic acid removed by precipitation with streptomycin sulfate. Addition of ammonium sulfate to 50 % saturation 
yielded a precipitate which was mainly composed of other contaminant proteins, although some TS was evident (B). 
This precipitate was removed by centrifugation and the supernatant saturated to 80 % with ammonium sulfate. This 
yielded a second precipitate which contained the desired TS protein (B). The precipitate was dialysed into a potassium 
phosphate buffer and then bound to anion exchange cellulose beads (DE-52) pre-equilibrated in a potassium 
phosphate  buffer. TS was eluted by increasing the concentration of NaCl in the buffer by stepwise increments. As the 
protein has a theoretical pI of 5.5 it harbours an overall negative charge during the purifcation procedure which is 
carried out in buffers of pH 7.5-8.0. The negatively charged protein binds strongly to the positively charged diethyl 
ammonium beads until displaced by salt ions. Fractions containing TS by SDS PAGE were combined and the protein 
precipitated by addition of ammonium sulfate to 80 % saturation. The precipitated protein was collected by 
centrifugation and stored at – 70 °C. The purity of the TS was increased by eluting the protein from the DE-52 beads 
through a thin walled glass column equipped with a frit. Application of buffer with increasing concentrations of salt 
generated more of a continous salt gradient, Figure 51.  
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Figure 50 SDS PAGE of E. coli TS samples taken from various stages during purification. A. BL21 (DE3) cells transformed with 
pET21a-TS and induced with IPTG. B. Ammonium sulfate precipitation of crude extract to 50 % and 80 % as indicated. C. Ion exchange 
chromatography of dialysed 80 % ammonium sulfate extract. Wash NaCl concentrations (M) are indicated above each lane. D. Combined 
ion exchange extracts at 0.25 M NaCl after precipitation with ammonium sulfate to 80 % saturation, collection of the precipitate by 
centrifugation and resuspension in potassium phosphate buffer.   
 
Figure 51 Elution of TS from beads through a thin glass walled column, generating more of a continous salt gradient. A band is seen for 
TS in the first fraction due to saturation of the resin.  
A spectrophotometric assay was used to confirm that the purified TS had retained enzymatic activity. This assay, first 
reported by Wahba and Friedkin in 1961, is based on a marked spectral change at 340 nm which is observed when 
mTHF is converted to DHF.[155] mTHF is unstable and was therefore generated from tetrahydrofolate and 
formaldehyde in situ by a non-enzymatic reaction in accordance with the published procedure, Scheme 3. In the 
presence of a high concentration βME and an excess of formaldehyde, mTHF is reported to be stable for an hour at 
rt.[155] dUMP was added to a mixture of tetrahydrofolate, formaldehyde, magnesium chloride and purified TS and the 
absorbance measured over time at 340 nm. Absorbance at 340 nm was also measured for a reference sample, which 
was identical except for the absence of dUMP. The absorbance difference was calculated and plotted as a function of 
time to indicate that the TS enzyme was active, Figure 52.  
 
Scheme 3 Active TS catalyses the reductive methylation of dUMP to dTMP with concomitant conversion of 5,10-
methylenetetrahydrofolate to dihydrofolate. 5,10-Methylenetetrahydrofolate was generated in situ from tetrahydrofolate and 
formaldehyde. 
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Figure 52 Absorbance difference measured at 340 nm as a function of time between two samples containing tetrahydrofolate, 
formaldehyde, magnesium chloride, purified TS and either dUMP or no dUMP (reference sample). Values are the average of 3 runs with 
error bars representing the standard devation. Conditions: 40 mM TRIS-HCl pH 7.5, 100 mM βME, 0.75 mM EDTA, 12 mM HCHO, 20 
mM MgCl2, 1 mM dUMP, 150 µM mTHF, 0.2 µM TS.  
3.3. Ligand synthesis 
To obtain a proof-of-concept for KTGT, a number of acrylamide and vinyl sulfonamide-modified control ligands 
were required, as summarised in Figure 53. These novel compounds were synthesised from chiral pool starting 
material D-proline, as discussed in the following section.  
 
Figure 53  Both positive controls and the negative control were synthesised from D-proline.  
3.3.1. Lower affinity positive control 
It was envisaged that D-proline was a suitable chiral pool starting material to generate the desired positive control 
acrylamide 67 and vinyl sulfonamide 70. As shown retrosynthetically in Scheme 4, reaction of primary amine 72 with 
acryloyl chloride or 2-chloroethanesulfonyl chloride generates the desired acrylamide 67 and vinyl sulfonamide 70 
respectively in the final step. As divergence from the linear sequence occurs in the last step, the total number of steps 
to form both the vinyl sulfonamide and the acrylamide is minimised. Amine 72 is generated from tosylate 73 by 
displacement with azide and subsequent reduction. Bis-tosylation on both the N and O atoms after reduction of D-
-0.02	

0	

0.02	

0.04	

0.06	

0.08	

0.1	

0.12	

0	
 50	
 100	
 150	
 200	
 250	
 300	
 350	

Ab
so
rb
an
ce
 di
ffe
re
nc
e a
t 3
40
 nm
	

time (s)	

H
N
HO
ON
N
H
N
N
H
SO
O
N
N
H
SO
O O
HN
O
OH
O
OH
X
X
O
68
67     X = CO
70     X = SO2
69     X = CO
71     X = SO2
Kinetic Template-Guided Tethering of Fragments                                                                                       Chapter Three 
  54 
proline to D-prolinol generates the desired N substitution and concomitantly modifies the alcohol for SN2 
displacement.   
 
Scheme 4 Retrosynthesis from desired lower affinity positive control ligands acrylamide 67 and vinyl sulfonamide 70.  
The synthesis commenced with a one-step reduction of D-proline to D-prolinol using LiAlH4 and bis-tosylation of the 
crude reduction product with p-toluenesulfonyl chloride. The use of triethylamine as the base and dichloromethane as 
the solvent for the tosylation step gave mainly the N-tosyl D-prolinol 74 with only a trace quantity of the required 
N,O-bis-tosyl 73. Submitting this crude mono/bis mixture to tosylation with neat pyridine to act as a nucleophilic 
catalyst gave smooth conversion to the the desired D-pyrrolidine 73, but in a poor 21 % isolated yield over the three 
steps, Table 1 (entry 1). The bis-tosylation reaction was improved with the use of neat pyridine as the solvent, 
generating the desired D-pyrrolidine 73 in a 49 % yield from D-proline over two steps (entry 2). It was considered that 
perhaps the yield for the reaction could be improved by tosylation in two separate steps, and treatment of the 
intermediate D-prolinol with only one equivalent of tosyl chloride and excess triethylamine in dichloromethane gave 
complete selectivity for N tosylation, although the yield was still moderate at 58 % from D-proline (entry 3).* The low 
isolated yield for the tosylation of the pyrrolidine N suggested that the LiAlH4 reduction was sub-optimal, and as such, 
any future work should include an optimisation of this step.  
 
Table 1 Reduction  and tosylation of D-proline. 
In agreement with this, the route was also started from the commercially available D-prolinol, which was treated with 
neat pyridine and tosyl chloride (3 equivalents) to furnish the desired bis-tosyl pyrrolidine 73 in quantitative yield, 
Table 2 (entry 1). Reducing the equivalents of tosyl chloride to 2.2 led to a significant reduction in isolated yield 
(entry 2). 
                                                        
* Selectivity for N was confirmed by oxidation of alcohol 74 to aldehyde 75 using Dess-Martin periodinane (yield 36 %).  
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Table 2 Tosylation of D-prolinol.  
An SN2 displacement of the tosylate with azide took the bis-tosylpyrrolidine 73 to the azide 76 in 75 % yield. A 
subsequent Staudinger reduction of the azide was used to generate the amine 72, which was initially taken straight on 
to reaction with acryloyl chloride without complete separation of the triphenylphosphine oxide impurity. This 
generated the desired acrylamide 67, although in a poor 13 % yield over the two steps. Purification of the intermediate 
amine on silica led to a 49% isolated yield from the Staudinger reduction, but using a more successful alternative 
route, the azide 76 was hydrogenated to the amine using a Pd/C catalyst and H2 (g) at atmospheric pressure. This 
proceeded in quantitative yield with facile isolation of the pure amine 72. The amine was subsequently reacted with 
acryloyl chloride to generate the desired acrylamide 67 in a moderate 74 % yield or 2-chloroethanesulfonyl chloride to 
generate the vinyl sulfonamide 70 in a 42 % yield via displacement of the sulfonyl chloride and E1CB elimination of 
the second chloride. The overall route is summarised in Scheme 5.  
 
Scheme 5 Synthesis of the lower affinity positive controls acrylamide 67 and vinyl sulfonamide 70.  
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3.3.2. Higher affinity positive control 
To synthesise the higher affinity positive controls, a similar route to that described for the lower affinity postitive 
controls was envisaged, except that a functional handle was required at the para position of the N-substituted 
phenylsulfonamide for installation of the L-glutamic acid functionality at a later stage in the route, Equation 2.  
 
Equation 2  
An initial attempt was made to bis-sulfonylate D-prolinol with 4-(chlorosulfonyl)benzoic acid, but difficulties were 
encountered during extraction from the aqueous layer after work up due to the polar nature of the product. It was 
anticipated that this would be a recurring problem with this route, and as such, the carboxylic acid was protected as 
the methyl ester 77, Scheme 6. It was expected that an excess of the 4-(chlorosulfonyl)benzoic acid methyl ester 77 
would react with D-prolinol to generate the bis-sulfonylated compound 78. This reaction was carried out with Et3N 
rather than pyridine as the base to prevent potential addition of the nucleophilic groups to the ester via nucleophilic 
pyridine catalysis. However, as previously observed, this caused the reaction at O to be significantly slower than at the 
more nucleophilic N, with the isolated yield of the bis-sulfonylated pyrrolidine 78 only 30 % in the presence of three 
equivalents of sulfonylchloride and triethylamine base after 16 h at rt. Reaction of D-prolinol with only one equivalent 
of sulfonyl chloride 77 gave complete selectivity for reaction at N, with isolated yields of 93-94 % of the N-sulfonyl 
prolinol 79 after 1 h at rt. The selectivity for N was confirmed by Dess-Martin oxidation of the alcohol 79 to the 
aldehyde 80, Scheme 6.  
 
Scheme 6 
Tosylation of sulfonamide 79 with 1.2 equivalents of both tosyl chloride and triethylamine went only partially to 
completion by TLC after 18 h at rt. Addition of a second equivalent of both tosyl chloride and triethylamine in an 
attempt to push the reaction to completion gave an 83 % isolated yield of pyrrolidine 81 after an additional 27 h, 
Table 3 (entry 1). Increasing the number of equivalents of both tosyl chloride and triethylamine to 3.0 led to 
completion of the reaction by TLC after 6 h and isolated yields for pyrrolidine 81 of 89-94 % (entry 2). This two-step 
sulfonylation reaction sequence allowed selective formation of sulfonamide 79 using the more expensive sulfonyl 
chloride 77 and subsequent formation of the sulfonyl ester with tosyl chloride to generate pyrrolidine 81.   
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Table 3 Conditions for the tosylation of pyrrolidine 79.  
SN2 displacement of tosylate 81 with azide could not be effected using the conditions employed to generate azide 76, 
Table 4 (entry 1). However, by switching the solvent from diethylene glycol to DMF, the azide 82 was isolated in  
yields of 93-100 % (entry 2).  
 
Table 4 Conditions for the synthesis of azide 82.  
A Staudinger reduction of the azide using PPh3 and THF/H2O generated the desired amine 83 although in a poor 48 % 
yield, Table 5 (entry 1). The low yield for this transformation may be due to the resistance of the intermediate 
iminophosphorane 84, isolated as a side-product from this reaction, to hydrolysis. As hydrogenation of the azide 82 
with a Pd/C catalyst generated the desired primary amine 83 reproducibly with yields between 96-100 % (entry 2), the 
Staudinger reduction was not further pursued.  
 
Table 5 Conditions for the reduction of azide 82 to amine 83.  
Primary amine 83 was reacted with acryloyl chloride to give the desired acrylamide 85 in yields between 71-72 %, 
Scheme 7. Hydrolysis of the methyl ester using LiOH generated the desired carboxylic acid 86, as a functional handle 
for installation of the L-glutamic acid, in excellent yields between 93-97 %.  
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Scheme 7 
An attempt was made to generate the acid chloride from carboxylic acid 86 using thionyl chloride. Quenching a drop 
of the reaction mixture with MeOH and subsequent TLC analysis indicated a mixture of products which did not 
include the desired ester. The crude reaction mixture was nevertheless added to a solution of L-glutamic acid in 
aqueous sodium bicarbonate in an attempt to form the desired amide using Schotten-Baumann conditions. Problems 
were encountered during the work up of this reaction, with no product extracted from the acidic aqueous layer, and it 
was therefore unknown at which stage this reaction had failed. Double-protection of the L-glutamic acid carboxylic 
acid groups as tert-butyl esters was desired to allow use of a carbodiimide coupling strategy, which would avoid 
generation of the acid chloride. The protected L-glutamic acid di-tert-butyl ester 87 was commercially available but 
expensive, and therefore attempts were made to synthesise it.  
The protection of L-glutamic acid 88 to the di-tert-butyl ester 87 has been reported using isobutylene gas.[156] As this 
was unavailable at the time of synthesis, attempts were made to carry out this transformation using available reagents. 
Protection of amine 88 with a carbobenzyloxy (Z) group was initially carried out to add a UV chromophore for TLC 
analysis, to reduce any side-product formation and to aid with extraction from aqueous solvents. In addition, removal 
of the Z protecting group can be carried out orthogonally to the tert-butyl ester groups by hydrogenation. Z-L-glutamic 
acid 89 was generated in a 98 % yield, Scheme 8.   
Z-L-glutamic acid 89 was treated with trifluoroacetic anhydride in THF at 0 °C for 30 min to activate the acid groups 
as mixed anhydrides. Subsequent addition of tert-butanol was expected to generate the desired esters but 1H NMR of 
the crude reaction mixture indicated no conversion to the desired product. Treatment of Z-L-glutamic acid 89 with 
diisopropylcarbodiimide in the presence of DMAP resulted in the generation of only the mono-protected ester (20 % 
isolated yield) after 16 h reaction at rt. Reaction of Z-L-glutamic acid 89 with oxalyl chloride and subsequent addition 
of tert-butanol yielded none of the desired product, potentially due to unsuccessful generation of the acid chlorides as 
observed by methanol quench TLC analysis. It was decided that in order to progress more quickly with the synthesis, 
the L-glutamic acid di-tert-butyl ester 87 would be purchased.  
 
Scheme 8 
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The L-glutamic acid di-tert-butyl ester 87 was purchased as the HCl salt and reacted with carboxylic acid 86 using 
EDCI.HCl as the coupling reagent. Excess Et3N was added to generate the free primary amine from the HCl salt in 
situ. However, under these conditions only a 4 % yield of the desired product 91 was obtained, Scheme 9. It was 
thought that this might be due to use of the HCl salt of the amine rather than the free amine. A literature reaction to 
couple para-nitrobenzoic acid with L-glutamic acid di-tert-butyl ester in the presence of EDC.HCl, HOBt and 
DCM/H2O was carried out using L-glutamic acid di-tert-butyl ester HCl salt and an additional equivalent of 
triethylamine to determine whether the reported yield could be reproduced.[157] However, as only a 45 % yield of the 
desired product 92 was obtained in comparison to the 98 % reported yield, it was decided that the free amine as 
opposed to the salt should be used. The free amine was generated by a basic wash with NaHCO3 and taken on to 
reaction with carboxylic acid 86 in the presence of EDC.HCl, HOBt and CH2Cl2/H2O to achieve the amide 91 in a 
moderate yields of 53-74 %, Scheme 9. Intermediate 91 was deprotected with TFA in chloroform to give the final 
desired product 69 in 53 % yield (25 mg). 
 
Scheme 9 
The overall route reached the desired compound in only 9 steps, each in moderate-to-excellent yields. The vinyl 
sulfonamide higher affinity positive control ligand 71 was also synthesised from primary amine 83 as an common 
intermediate, Scheme 10. Treatment of amine 83 with 2-chloroethanesulfonyl chloride and triethylamine generated 
vinyl sulfonamide 93 in a modest 58 % yield. Hydrolysis of the ester with lithium hydroxide was facile, with isolation 
of the acid 94 achieved in quantitative yield. The coupling reaction between carboxylic acid 94 and di-tbutyl L-
glutamic acid 87 to yield di-ester 95 and the final deprotection step were both effected in high yields of 85 % and 94 
% respectively to generate the final desired vinyl sulfonamide 71 (500 mg).  
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Scheme 10 Overall synthetic route to both acrylamide and vinyl sulfonamide-modified higher affinity positive control compounds. 
Amine 83, a common intermediate in both routes, is highlighted.  
Unfortunately, severe solubility problems were encountered with both final compounds acrylamide 69 and vinyl 
sulfonamide 71. Both were found to be insoluble in all solvents tested, including DMSO, despite extended sonication 
and gentle heating. Attempts to generate salts from the corresponding acids in order to increase aqueous solubility 
were unsuccessful.  
3.3.3. Negative control 
A route to the desired negative control ligand 68 was designed as shown retrosynthetically in Scheme 11. In this route, 
the acrylamide is installed last, allowing divergence at the lastest point in the synthesis for the potential addition of 
other capture groups at a later point. The primary amine 96 is generated from N-methyl D-prolinol 97 in the three step 
tosylation-azide displacement-reduction sequence previously applied to positive controls. The N-methyl D-prolinol 97 
is generated by a reductive amination of D-prolinol.   
 
Scheme 11 Retrosynthetic analysis of negative control ligand 68.  
Eschweiler-Clarke reductive amination of D-prolinol using 37 % aqueous formaldehyde and formic acid furnished the 
desired N-methyl D-prolinol 97 in a moderate 66 % isolated yield after reflux for 20 h, Scheme 12. Although 
tosylation of N-methyl D-prolinol was successful, with the desired product 98 identified by 1H NMR of the crude 
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reaction mixture, the mass recovery for the reaction was poor due to the difficulty in extraction of the product from 
the basic aqueous layer during reaction work up. In addition, the product was observed to undergo decomposition on 
silica during purification. It was considered at this point that taking the basic N-methyl pyrrolidine functionality 
through the synthesis would result in significant mass loss due to high aqueous solubility. To overcome this, it was 
decided that the synthesis would commence with a Boc protection of the pyrrolidine N, with the protecting group 
removed and the N methylated in the final two steps.  
 
Scheme 12 
Boc protection of D-prolinol was successful, generating the desired pyrrolidine 99 in a 73 % isolated yield. The 
synthetic route was also started from D-proline with a LiAlH4 reduction and Boc-protection to yield intermediate 99. 
Treatment of D-proline with LiAlH4 for 1 h at 0 °C and subsequent Boc protection led to a 56 % isolated yield of 99, 
Table 6 (entry 1). Increasing the LiAlH4 reaction time to 1 h at 0 °C and 1 h at rt led to an increase of the the isolated 
yield of 99 to 68 % over the two steps (entry 2).  
 
Table 6 Boc protection conditions.  
The desired pyrrolidine 100 was generated in 89 % yield by tosylation of alcohol 99 with 1.2 equivalents of tosyl 
chloride in pyridine, Table 7 (entry 1). Changing the tosylation conditions to 3 equivalents of both tosyl chloride and 
triethylamine led to a quantitative yield of pyrrolidine 100 (entry 2).  
 
Table 7 Conditions for the tosylation of pyrrolidine 99.  
SN2 displacement of the tosylate was unsuccessful with 2.15 equivalents of azide in DMF, Table 8 (entry 1). Changing 
the solvent to DMSO and increasing the number of equivalents of azide to 6 led to the desired azide 101 in moderate 
yields of between 78-81 % (entry 2).  
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Table 8 Conditions for the synthesis of azide 101.  
Hydrogenation of azide 101 using a Pd/C catalyst under an atmosphere of H2 gas led to the desired amine 102 in high 
yields of between 75-100 %, Scheme 13. Reaction of the primary amine with acryloyl chloride generated N-Boc 
protected acrylamide 103 in moderate yields between 67-72 %, ready for the final Boc-group removal and reductive 
amination.  
 
Scheme 13 
Following treatment of N-Boc acrylamide 103 with TFA, 1H NMR indicated a mixture of two acrylamides. However, 
column chromatography on silica to separate these compounds resulted in the isolation of only one compound, which 
had no olefinic protons by 1H NMR. 13C NMR and 1H NMR were consistent with this product as the 5,7 fused bicyclic 
ring 104 resulting from a 7-endo-trig intramolecular conjugate addition of the free secondary amine at the acrylamide 
β-carbon, Scheme 14.  
 
Scheme 14 
The most intense peak obtained during electrospray mass spectrometry analysis had a mass consistent with dimer 
104a [2M + H]+, with a small peak with the mass of the 5,7 bicyclic ring 104. The appearance of the dimer peak is 
likely to be explained by the formation of intermolecular H-bond bridges which are stable enough to stay intact during 
ionisation in the mass spectrometer, Figure 54. The observation of such intermolecular H-bond bridges by MS has 
been previously reported for similar structures.[158] If the presence of peak [2M + H]+ in the mass spectrum had been 
due to covalent dimer 104b, then a peak for 104 [M + H]+ would probably not have been observed.  
 
Figure 54 
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Protection strategy 
With a gram quantity of the N-Boc protected pyrrolidine 103 in hand, a protecting group strategy to mask the 
acrylamide during the deprotection and reductive amination steps starting from this intermediate 103 was desired. It 
was considered that conjugate addition of a latent leaving group to the α,β-unsaturated amide would protect the 
acrylamide during the Boc-removal and reductive amination steps, before ‘activation’ of the of the leaving group and 
regeneration of the acrylamide. Substituted selenides and sulfides are obvious choices for this chemistry due to their 
high propensity for conjugate addition, and ease of removal by elimination after oxidation to the selenoxide or 
sulfoxide respectively. Both sulfoxide and selenoxide 2,3-syn eliminations proceed through planar 5-membered 
transition states, but the rate of this reaction is significantly higher for selenoxides which often fragment 
spontaneously at room temperature.[159] Sulfoxides often require heating to effect the desired elimination, the rate of 
which increases with increasing degree of double bond substitution.[160] Elimination from β-phenylsulfinyl carbonyls 
is favoured relative to the analogous α-phenylsulfinyl derivatives due to the increased acidity of the proton which is 
abstracted in the transition state. In addition, β-phenylsulfinyl carbonyl elimination does not lead to the development 
of  positive charge adjacent to the carbonyl as the C-S bond breaks, an unfavorable situation which does occur in the 
analogous α-phenylsulfinyl elimination, Figure 55.[160]  
 
Figure 55 A comparison of the 2,3-syn elimination of α- and β-phenylsulfinyl carbonyls to generate the α,β-unsaturated carbonyls. 
Murphy et al. used thiophenol to protect acrylamide 105 during the synthesis of Coerulescine and Horsfiline, Scheme 
15.[161, 162] Thioether 106 was stable under the DIBAL-H reduction conditions to generate alcohol 107, and oxidation 
to the sulfoxide and subsequent elimination regenerated the acrylamide 108.  
 
Scheme 15 Use of thiophenol as an acrylamide protecting group reported by Murphy et al. in their synthesis of Horsfiline and 
Coerulescine.  
This thiophenol protecting group strategy was adopted to protect acrylamide 103 in the synthesis of negative control 
ligand 68. A model acrylamide 47 was initially adopted to test the suitability of this strategy, Scheme 16. As the rate 
of sulfoxide 2,3-syn elimination can vary considerably depending on the degree of alkene substitution, it was 
important to establish conditions for elimination to generate the monosubstituted acrylamide. It was also crucial to 
establish the stability of the thioether to the acidic reductive amination conditions. 1,4-Addition of thiophenol to 
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acrylamide 47 generated the desired thioether 109 in a 41 % isolated yield. To test the stability of this to the 
Eschweiler-Clarke reductive amination conditions, thioether 109 was subjected to 24 h reflux in formic acid and 37 % 
aqueous formaldehyde, and whilst a few side-products were observed to form by TLC, the starting material was still 
the main component of the reaction mixture. Oxidation of the thioether to the sulfoxide 110 was effected in high 
yields using either mCPBA (89 %) in chloroform or sodium meta-periodate (85 %) in MeOH but not sodium meta-
periodate in a mixture of MeOH and H2O which returned only starting material, possibly due to its insolubility in the 
MeOH/H2O mixture, Table 9. The sulfoxide was heated to reflux in chloroform in an attempt to effect the desired 2,3-
syn elimination. However, even after 120 h the sulfoxide 110 remained as the major product by TLC although with a 
number of minor side-products. Pleasingly, treatment of thioether 109 with potassium tert-butoxide in THF gave 
complete conversion to the acrylamide 47 by elimination of thiophenolate with formation of no other side-product. A 
1H NMR yield of 74 % was obtained for this reaction after aqueous work up. As base treatment of thioether 109 led 
directly to the desired product in high yield and concomitantly removed one step from the linear sequence, the 
sulfoxide elimination was not further pursued.  
 
Scheme 16 Protecting group strategy using test substrate acrylamide 47. *Yield estimated by 1H NMR with tetramethylsilane as the 
internal standard. 
 
Table 9 Conditions for the oxidation of sulfide 109 to sulfoxide 110.  
Treatment of the N-Boc pyrrolidine intermediate 103 with 2 equivalents of thiophenol and 1 equivalent of 
triethylamine in dichloromethane generated the desired thioether 111 in a poor 23 % isolated yield, Table 10 (entry 1). 
This was improved to 65 % by changing the solvent to THF and increasing both the equivalents of thiophenol and 
triethylamine to 3.2 and 4.5 respectively (entry 2). The Boc group was successfully removed in an excellent 97 % 
yield using 4 M HCl in dioxane to yield the desired amine 112 as the HCl salt.  
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Table 10 Conditions for the conjugate addition of thiophenol to acrylamide 103.  
An Eschweiler-Clarke reductive amination reaction to methylate the pyrrolidine N was unsuccessful, and resulted in 
decomposition, Table 11 (entry 1). The reductive amination was successfully carried out by refluxing the free amine 
in methanol and paraformaldehyde followed by reduction with sodium cyanoborohydride to generate N-methyl 
pyrrolidine 113 in a 97 % isolated yield (entry 2). Finally, the N-Me pyrrolidine thioether 113 was treated with 
potassium tert-butoxide to funish the final negative control ligand 68 in a moderate 52 % isolated yield.  
 
Table 11 Reductive amination conditions.  
The Boc-deprotection of acrylamide intermediate 103, which led to the formation of 5,7-bicyclic 104 as previously 
discussed, was thought to be an interesting reaction for further investigation. To test the effect of different Boc-
deprotection reagents on this reaction, acrylamide 103 was treated with 2 M HCl in ether for 3 h. Analysis of the 
crude reaction mixture by 1H NMR indicated that the reaction had gone to two products, consistent with the desired 
acrylamide and the 5,7-bicyclic system 104 in approximately a 1:1.25 ratio. This mixture was subjected to reductive 
amination conditions, Scheme 17, which surprisingly led to the isolation of dimer 114. Formation of dimer 114 
presumably results from successful reductive amination followed by intermolecular attack from the tertiary N onto the 
α,β-unsaturated bond of a second acrylamide. It is surprising that this occurs in preference to the intramolecular 
reaction. It may be the case that the intramolecular reaction is readily reversible, but then it is again surprising that this 
reversibility is not seen for the intermolecular reaction. Furthermore, it is curious that no further polymerisation 
occurred during this reaction, although this may account for the lost mass. It was hypothesised that treatment of 
intermediate 114 with strong base would effect the elimination of the tertiary amine leaving group, generating two 
molecules of the desired product. Indeed, addition of potassium tert-butoxide to dimer 114 generated the desired 
acrylamide 68 in yields between 58-82 %, providing a second route to the desired negative control ligand.  
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Scheme 17 
In summary, the desired negative control ligand with an acrylamide appendage 68 was successfully synthesised using 
two synthetic routes, Scheme 18. The first route utilised a sulfide protecting group strategy, whereby addition of 
thiophenol to the acrylamide masked the reactive functionality during Boc-deprotection and reductive amination. This 
route reached the desired product in 9 steps from either D-proline or D-prolinol, with all steps achieved in moderate-to-
high yields. The second route reached the desired product in 7 steps via generation of the unusual dimer intermediate 
114.  
 
Scheme 18 Synthesis of negative control acrylamide 68.  
3.4. Acrylamides and kinetic template-guided tethering 
3.4.1. Intrinsic ligand reactivity 
An HPLC study was carried out to compare the intrinsic reactivity of positive control acrylamide 67 with a number of 
the ‘dummy’ acrylamides before protein screening. It was crucial that selection of the positive control from a mixture 
of acrylamides by the protein was due to a template-based rate enhancement rather than a high intrinsic reactivity. 
Binary mixtures of acrylamides, composed of the positive control with one dummy ligand, were incubated with an 
excess of reduced glutathione. Reactions were carried out in an aqueous ammonium bicarbonate buffer at pH 8, to 
mimic the conditions later used for protein screening, and aliquots taken for HPLC analysis at various time points. 
The concentrations of both acrylamides within the binary mixture were measured at these time points and the ratio 
plotted against time, Figure 56. Interestingly, the data identified the positive control acrylamide as the least 
intrinsically reactive in the mixture, although acrylamides 48, 54 and 55 were observed to react only very slightly 
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faster. N-phenyl piperazine acrylamide 49 was identified to react significantly faster than the positive control and was 
expected to react promiscuously during protein screening. Conjugate addition of glutathione to acrylamide 51 was 
exceptionally fast with the reaction complete in less than one minute. Acrylamide 51 was therefore excluded from 
protein screening experiments on this basis. Acrylamide 49 was not excluded from protein screens as it was hoped to 
qualitatively indicate the degree of selection conferred by KTGT. 
 
 
 
 
Figure 56 Relative Michael addition rates between the positive control and a series of ‘dummy’acrylamides with reduced glutathione (G). 
Binary mixtures of acrylamides as indicated were incubated with an excess of reduced glutathione and the concentration of each 
remaining electrophile monitored over time by HPLC. The chart indicates [acrylamide]/[positive control 67] against time.  
3.4.2. Mass spectrometry analysis  
Analysis of the complete thymidylate synthase catalytic domain (TS) by MALDI confirmed the unsuitability of this 
mass spectrometry technique for KTGT screening, Figure 57. The base of the singly charged protein peak spans a 
mass range of ca. 2000 Da, 10 times the mass of acrylamide-fragments. As discussed (Chapter two) attempts were 
previously made to develop a three-stage screening protocol for KTGT including incubation of protein with 
acrylamides, trypsin digestion of the crude mixture and subsequent analysis by MALDI. It was identified as crucial to 
fully quench the acrylamide before the addition of trypsin to prevent nonspecific untemplated tethering to peptide 
fragments during proteolysis. In order to develop such a procedure and to validate KTGT, TS was adopted as a model 
system due to the significant difficulties encountered with cdc25 which lacks a positive control. Before the use of TS 
in the development of a proteolytic procedure for analysis of KTGT using MALDI, a significant effort was applied to 
develop an electrospray ionisation (ESI) mass spectrometry protocol for analysis of full molecular weight TS. ESI 
would eliminate the additional variables conferred by the quench and proteolytic digestion, and would allow KTGT to 
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be observed in situ. The facilty for analysis of proteins by ESI had not been available during the previous studies 
conducted in chapter two.* 
 
Figure 57 MALDI analysis of TS. The singly charged peak has a base width of approximately 2000 Da as indicated by the red arrow. The 
doubly and triply charged peaks are also evident from the spectrum.  
Electrospray Ionisation MS and Matrix-Assisted Laser Desorption Ionisation MS  
In general, mass spectrometers are composed of an ionisation source, a mass analyser and a detector. During 
ionisation, gas phase ions are generated from the analyte and are subsequently separated based on their m/z ratio by 
the mass analyser. Before the development of MALDI and ESI MS, there were a number of available methods for 
analyte ionisation (including electron ionisation (EI) and chemical ionisation (CI)), but none that were able to cause 
ionisation without analyte fragmentation. Both MALDI and ESI are soft ionisation methods – with ESI described as 
the most gentle ionisation technique available for MS[163] – in that minimum internal energy is transferred to the 
analyte, overcoming the propensity of the analyte to fragment.[164] Both methods are suitable for the analysis of high 
molecular weight biomolecules, including DNA, proteins, lipids and glycoconjugates.  
In ESI MS, the sample is continuously sprayed into the ionisation source via a thin needle at which a high electrical 
potential is applied. This results in the formation of electrically charged droplets, a process which is termed 
nebulisation. The solvent evaporates from the charged droplets until the repulsive forces between the ions at the 
droplet surface exceed surface tension and the ions desorb into the gas phase. Generally, the ions generated by the ESI 
process remain intact (i.e. no fragmentation) and are multiply charged by protonation (in positive ion mode) or 
deprotonation (in negative ion mode). The peaks generated for the analyte therefore form an envelope along the m/z-
axis where each peak represents the intact molecular species with particular charge. The molecular mass of the analyte 
can be determined from two adjacent peaks within this envelope by a technique termed ‘mathematical charge 
deconvolution’. If the molecular mass of the analyte is termed M and the m/z ratios for two adjacent peaks 
                                                        
*Both MALDI and ESI ionisation sources were coupled time-of-flight (ToF) mass analysers for the work carried out in this 
thesis. 
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representing charge states (n)+ and (n-1)+ are termed m1 and m2 respectively then two simultaneous equations are 
generated, where m1 = (M + n)/n and m2 = [M + (n - 1)]/(n - 1) which can be solved for M and n. An accurate mass for 
the analyte is usually generated from the average mass calculated for each set of two adjacent peaks within an 
envelope. This manual interpretation of ESI spectra is challenging when mixtures of analytes are used, with each 
different species generating a distinct envelope of multiply charged peaks which interlace with each other and are 
difficult to distinguish. Deconvolution software, such as ‘MaxEnt’ developed by Waters, is usually required to 
deconvolute such spectra. ESI has no theoretical limit for the molecular weight of the analyte due to this multiple 
charging effect which lowers the m/z ratio to within the detection limit.  
The observed charge state distribution (CSD) for analytes is affected by many factors and is a topic which has been 
intensely debated over the past two decades. Somewhat counterintuitively it has been shown that the analyte charge 
state (CS) observed in the gas phase does not correspond to that in the bulk solution.[165] In addition, the maximum CS 
in positive mode does not necessarily correspond to the number of basic sites (for proteins Lys, His, Arg and N-
terminus) and in negative mode, acidic sites (Glu, Asp, Asn, Gln and C-terminus). Whitesides et al. suggest that this is 
due to a fundamental difference between solution and gas phase acidity/basicity.[166] In solution, the net charge of a 
protein depends on the number of ionisable groups, their pKa values and the pH of the solution. In the gas phase, the 
net charge depends on physical properties such as the molecular surface area and the Coulombic repulsion between 
charged sites on the protein surface.[166] A critical determinant of the CSD is the geometry and size of the analyte in 
question. For example, the CSD is narrower and the average CS is lower for a native protein in comparison to the 
same protein after denaturation. Upon denaturation, the spatially compact, native protein becomes extended and 
solvent exposed leading to the change in average CS and CSD, shown schematically for cytochrome C in Figure 
58.[167] At pH 6.4, cytochrome C adopts its native, tightly folded conformation leading to a narrow CSD with the 
average CS as +8 observed in the positive ESI mass spectrum. Under denaturing conditions (pH 2.4), the protein is 
mainly in an unfolded state, leading to an increase in the average CS from +8 to +17 and an increase in the number of 
total charges present within the CSD. Folded and non-folded states can also be observed to co-exist in equilibrium 
with one another, Figure 58 pH 2.6. Similar observations were made by LeBlanc et al. upon heat denaturation of 
proteins,[168] whilst Loo et al. found the CSD to vary with the denaturing capacity of the solvent.[169] Covey et al. 
proposed that the maximum CS for a protein or peptide corresponds to the number of basic sites,[170] but although this 
often correlates reasonably well with observed  results, there are also significant anomalies. For example, both actin 
and S4 ribosomal protein contain 46 basic sites.[171, 172] S4 ribosomal protein demonstrates a maximum CS of +30, 
which correlates well with the theories of both Covey and Whitesides. Actin, however, demonstrates a maximum 
charge state of +56 indicating that it can retain significantly more protons than it has basic sites.  
 
Figure 58 ESI mass spectra of cytochrome C at pH 6.4, pH 4.2, pH 2.6, and pH 2.3. pH adjusted by addition of hydrochloric acid to the 
protein in 0.5 mM ammonium acetate with 3 % MeOH. Image reproduced from work published by Konermann et al.[167]  
Kinetic Template-Guided Tethering of Fragments                                                                                       Chapter Three 
  70 
In constrast to ESI, MALDI-MS usually results in the generation of only the singly charged molecular ion. Peaks due to the 
doubly and triply charged analyte may be observed in low intensity. The resolution achieved using MALDI usually 
decreases as the molecular weight of the analyte increases, due to isotopic broadening of the peak.  
Both MALDI and ESI sources were coupled to time-of-flight mass analysers for the work carried out in this thesis. 
The purpose of the mass analyser within a mass spectrometer is to separate the gaseous ions based on their m/z values. 
There are currently four main mass analysers in use: Quadruple (Q), Quadruple ion trap (QIT), Time of Flight (ToF) 
and Fourier Transform Ion Cyclotron Resonance (FT-ICR).[164] The ToF mass analyser accelerates ions using an 
electric field of known strength. The kinetic energy transferred to ions with a particular charge is constant, resulting in 
a slower passage through the analyser for ions with higher mass.    
Method development for ESI  
The initial challenge in the development of a KTGT ESI screening procedure was to find conditions that would allow 
the ionisation of protein in the mass spectrometer. The protein must be in a solution of buffer with reducing agent 
during the incubation with acrylamide fragments. The buffer ensures that the pH is kept constant, irrespective of the 
acrylamide-fragments added, whilst also stabilising the folded state of the protein and the reducing agent prevents 
oxidation of the active site cysteine thiol. Such conditions require careful consideration, as buffers, salts and metal 
ions have the potential to interfere significantly with the quality of ESI spectra.[130]  
In the initial protocol adopted, the TS pellet obtained from the protein purification was resuspended in TRIS-HCl 
buffer (20 mM), and dialysed for 48 h against the same buffer to remove any bound sulfate ions. The concentration of 
the resultant protein solution was then adjusted as required for KTGT experiments, and incubated with acrylamides. 
After the incubation period was complete, the aqueous solvent was removed in vacuo and the pellet redissolved in 
MeCN/H2O (0.1 % TFA) (1:1) for MS analysis. As TRIS-HCl buffer is usually acceptable at, or below, 
concentrations of 100 mM,* it was the buffer of choice initially used to test this procedure. However, despite the low 
concentrations of TRIS-HCl buffer present, no multiply charged peaks to indicate protein were obtained. Use of the 
volatile buffer ammonium bicarbonate (50 mM) in this procedure rather than TRIS-HCl also failed to generate a 
protein electrospray spectrum.  
To overcome this, a new strategy was adopted to remove the buffer ions. The protein was precipitated from a 
phosphate buffer by addition of ice-cold methanol, on the premise that whilst the protein precipitates, buffer and other 
organic molecules remain in solution. This method assumes that covalent attachment of a fragment to the active site 
cysteine does not affect the precipitation efficiency of the protein. To develop a protocol for this, some preliminary 
experiments were carried out. To analyse qualitatively how much protein from the original sample was precipitated 
over time, methanol was added to three identical samples. From one of the samples (lane 1, Figure 59) the protein 
precipitate was collected after 2 minutes on ice, whereas both the second and third samples (lanes 2, 3) were kept at -
80 °C overnight after methanol addition with one (lane 2) washed with ice-cold methanol after the pellet was 
collected. Retention of protein after incubation overnight at -80 °C appeared to be almost quantitative, with only a 
                                                        
* Personal communication with J. Barton, Imperial College Mass Spectrometry Technician.   
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small loss when a methanol wash was applied. However, precipitation of TS (using lane 3 conditions) and submission 
of the protein pellet to the ESI conditions* resulted in no multiply charged peaks.  
Figure 59 Qualitative analysis of the retention of protein during the precipitation protocol. Lane 1 precipitation of 
protein by addition of 200 µL methanol (at -20 °C) to 20 µL TS in potassium phosphate for 2 minutes. Precipitate 
collected and dissolved in 20 µL phosphate buffer. Lane 2 As for lane 1, but sample allowed to precipitate 
overnight at -80 °C, and subsequently washed with methanol (200 µL, -20 °C) before addition of phosphate 
buffer. Lane 3 As for lane 2 but no methanol wash. Lane 4 TS with no precipitation.  
Adopting a third strategy, the buffer was changed to 10 mM ammonium bicarbonate, the ESI conditions were changed 
to MeOH/0.5 % aq. formic acid (1:1) rather than MeCN/0.1 % aq. TFA (1:1), and the solution was manually injected 
onto the spectrometer using a syringe pump, with data collected over a 3 minute period. This finally resulted in the 
generation of multiply charged peaks, which could be deconvoluted using MaxEnt to give the mass of the protein as 
30410 Da as expected, Figure 60.  
 
Figure 60 A typical spectrum obtained by positive mode ESI MS of thymidylate synthase. A. Raw data clearly demonstrates the expected 
envelope of multiply charged peaks. The charges have been labelled and range from + 37 to + 14 as calculated from the molecular mass 
(30409 Da) using m = (M - n)/n as previously described. B. Deconvoluted spectrum (MaxEnt) in the mass range of interest (30400-30800 
Da where tethered adducts are expected) and over the full range. The peak for singly charged thymidylate synthase is labelled (30409 Da) 
along with the peak for the doubly charged protein (15205 Da).  
Conveniently, it was found that the 1:1 MeOH/0.1% aq. formic acid solvent mixture for MS could be added straight to 
the protein/ammonium bicarbonate solution [MeOH/0.1% formic acid/protein solution, 2:2:1 by volume] to achieve 
the same mass spectrum. The step to remove the buffer in vacuo was therefore removed from the protocol.  
The final optimised protocol used for KTGT screening, Figure 61, was as follows. After purification of TS, 
ammonium sulfate was used to precipitate the protein, which was stored at -80 °C as a pellet until required. The pellet 
was then dissolved in ammonium bicarbonate (10 mM) and DTT (1 mM)† and dialysed for 48 h against 4 x 2 L 
changes of the same buffer. This very thorough dialysis was required to remove all bound sulfate ions.‡ After dialysis 
the protein concentration was adjusted to 10 µM using a Bradford assay or Nanodrop, and stored at 4 °C for up to one 
month. Ligands were added to aliquots of the protein stock solution and after the set incubation time quenched with 
                                                        
* Pellet re-dissolved in acetonitrile:aqueous TFA (0.1 %).  
† See appendix III, p219 for rationale behind DTT concentration.  
‡ See appendix III, Figure 129, p218 for spectrum obtained if dialysis is not thorough enough.  
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0.5 % formic acid and MeOH and the sample injected on to the electrospray mass spectrometer. Mass spectrometry 
results presented herein were obtained using this protocol.  
 
Figure 61 Optimised protocol for KTGT using ESI MS analysis. Before use, TS protein was dialysed thoroughly into an ammonium 
bicarbonate (10 mM) buffer to remove non-volatile buffer ions. The protein was then incubated with acrylamides/vinyl sulfonamides for a 
specific time at rt. A 1:1 formic acid (0.5 % aqueous)/MeOH mixture was subsequently added to prepare the solution for MS analysis and 
concomitantly to quench the reaction. The resulting mixture was injected onto the mass spectrometer at a rate of 20 µL/min, and data 
recorded for at least 3 min. The resulting envelope of multiply charged peaks was deconvoluted using Waters MaxEnt software.  
Mass spectrometry experiments 
Treatment of TS with an excess of iodoacetamide resulted in single and complete modification of the apo protein to 
the protein-acetamide adduct (protein + 57 Da) indicating only one surface exposed cysteine residue in agreement 
with reported experiments,[51] Figure 62.  
 
Figure 62 Front MS trace: apo TS. Back MS trace: TS (10 µM) after treatment with iodoacetamide (4 mM) for 10 min at rt. TS is 
shown as a grey sphere. 
Treatment of TS with positive control acrylamide-fragment 67 led to single modification of the protein after 30 min at 
room temperature. The yield of the adduct formed within this time period was dependent on the concentration of 
acrylamide 67 applied, Figure 63. At 100 µM acrylamide 67, only a low yielding adduct was observed to form during 
the 30 min incubation time, but on increasing the concentration to 200 and 400 µM, the yield of this adduct increased 
significantly. When TS was incubated with a mixture of acrylamide 67 and acrylamide 47 (in a 1:1 molar ratio), only 
positive control 67 was selected by the protein, even when both were applied at 400 µM (appendix III, p218, Figure 
127). 
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Figure 63 Overlaid mass spectra of TS incubated for 30 minutes with acrylamide ligand 67 at increasing final concentrations of 0, 100, 
200 and 400 µM. The peak for TS is seen to diminish in favour of the TS-67 adduct as the concentration of fragment 67 is increased.  
The protein was subsequently incubated with mixtures of acrylamides, as indicated in Figure 64. Incubation of TS 
with mixture I at room temperature, with each acrylamide at 400 μM, resulted in modification of the apo protein with 
only acrylamide 67, Figure 65. Complete modification of the apo protein with this positive control compound 
occurred before the formation of any other adduct, despite the presence of the more intrinsically reactive N-phenyl 
piperazine fragment 49.  
 
Figure 64 Acrylamide mixtures used in MS studies.  
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Figure 65 TS incubated with library of acrylamide-fragments, mixture I, each library member present at 400 μM and protein at 10 μM. 
Aliquots taken at the times indicated and analysed by electrospray MS. This indicated an increase in the concentration of the TS-67 
adduct at the expense of the apo protein, with no other TS adduct formed. Peaks corresponding to the protein and to the protein-67 adduct 
are highlighted in orange.  
Complete modification of TS with 
acrylamide 67, enzymatic digestion 
with trypsin and analysis of the 
peptide mixture using MALDI, 
localised the position of modification 
to the peptide containing the active 
site cysteine, Figure 66. Full 
modification of TS with 
iodoacetamide and incubation of the 
TS-acetamide adduct with 
acrylamide 67 resulted in no further 
modification of the protein. These 
experiments strongly suggested that 
modification of the protein had 
occurred at the expected surface 
exposed cysteine. The adduct formed 
between TS and positive control 67 
was confirmed to be through a stable covalent bond; TS was fully modified with positive control 67 and subsequently 
washed thoroughly with an ammonium bicarbonate solution using a centrifuge filter to remove low molecular weight 
Figure 66 Trypsin digest and MALDI analysis of apo TS (left) and TS-67 (right).  
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entities but retain protein. Analysis of the resulting mixture by ESI MS indicated that the TS-67 adduct had remained 
intact.  
Fragment 47 was incubated with TS at 2.4 mM for 4 h and peaks corresponding to TS-47 and the apo protein were 
observed (appendix III, p218, Figure 128). This indicated that other TS-fragment adducts were able to form under 
more forcing conditions and furthermore, that these were able to ionise in the ESI MS. Incubation of mixture II with 
papain and p97 resulted in the formation of no adduct, consistent with no kinetic-template-guided tethering, although 
both papain and p97 underwent full and single modification with iodoacetamide under the same conditions as TS, 
indicating the presence of a reactive solvent exposed cysteine thiol. As papain is a cysteine protease, and therefore 
designed to attack amide bonds, some tests were carried out to check the stability of the acrylamides in the presence of 
the enzyme. To a solution of papain in ammonium bicarbonate (pH 8), three acrylamides (49, 55 and 67) were 
separately added from MeOH stock solutions. The stability of the acrylamides was monitored by TLC, indicating only 
a trace of side-product formation after 7 h. The experiment with 67 was repeated on a larger scale and analysed by 1H 
NMR after 16 h, confirming the presence of only a trace of a side-product.  
Surprisingly, when TS was incubated with mixture II, which contains negative control 68 in addition to the 
acrylamides in mixture I, formation of an adduct to both the positive and negative control compounds was observed. 
The TS-negative control adduct formed to a greater extent than the TS-positive control adduct, Figure 67.  
 
Figure 67 TS incubated with Mixture II (each acrylamide at a final concentration of 343 µM) in ammonium bicarbonate buffer (10 mM) 
at pH 8. Adducts to both the positive (yellow) and negative (orange) control are observed to form with the peak due to apo TS highlighted 
in red.  
Unlike the positive control adduct, Figure 69, formation of the negative control adduct was strongly dependent on pH, 
Figure 68, with adduct formation at pH 8.1, but almost no formation at pH 7.2. Incubation of TS with mixture II at pH 
7.2 for 60 minutes resulted in formation of an adduct only to the positive control 67, with formation of an adduct to 
the negative control only visible after 120 minutes, Figure 70. When mixture II was incubated with papain at pH 8.1, 
no adduct was observed to form to any acrylamide, including the negative control compound 68, suggesting that 
modification of TS by acrylamide 68 did not occur on the basis of a high intrinsic reactivity. The position of 
modification by negative control ligand 68 was confirmed at the catalytic cysteine in the same way as for the positive 
Kinetic Template-Guided Tethering of Fragments                                                                                       Chapter Three 
  76 
control ligand. This included MALDI analysis after trypsin digestion and addition of acrylamide 68 to a solution of 
TS fully modified with one equivalent of iodoacetamide, which led to no further reaction.  
 
Figure 68 TS incubated with negative control compound 68 at 400 µM for 60 minutes at rt in the presence of formic acid, giving the pH 
values indicated.  
 
Figure 69 TS incubated with positive control compound 67 at 400 µM for 60 minutes at rt in the presence of formic acid, giving the pH 
values indicated. 
 
Figure 70 TS incubated with mixture II, each acrylamide at 300 µM, at pH 7.2. Aliquots taken for MS analysis at 2, 30, 60 and 120 
minutes.  
Disulfide tethering studies carried out by Erlanson et al., whereby disulfide 65 was identified not to bind to TS, were 
carried out in aqueous solutions of pH 7.5.[51] It was considered that the basicity of the N-pyrrolidine in acrylamide 
Kinetic Template-Guided Tethering of Fragments                                                                                       Chapter Three 
  77 
ligand 68 may have accounted for its selection by TS. The pKa of N-pyrrolidine is reported as 10.46 in aqueous 
solution,[173, 174] but the effect of the acrylamide moiety in 68, or the amide in 65 on this value was unknown. 
Interestingly, the aqueous pKa values for a series of cyanoamines were available, Figure 71.[175] The tertiary amine in 
1,5-substituted 115 has a basicity comparable to N-pyrrolidine, with pKa = 10.46. However, as the cyano group was 
brought closer to the amine in 1,2-substituted 116, the effect on the basicity of the N was significant, bringing the pKa 
value down to 7.5 due to the destabilising electron withdrawing effect of the nitrile on the cationic charge at the 
protonated N. A further significant shift in basicity was observed for 1,1-substituted 117 with pKa = 4.5, although 
overlap between the N lone pair and the C-CN σ* orbital may contribute towards this. By comparison with this series 
of cyanoamines, the pKa of tertiary amine 68 was predicted to be ca. 7-8. Continuing this estimation, tertiary amine 
65 was expected have a pKa value of ca. 4-5, although the validity of this particular estimate may be compromised by 
the lack of orbital overlap of the N lone pair with a low energy σ* orbital. On these assumptions, however, decreasing 
the pH from 8.1 to 7.2 leads to significant protonation of tertiary amine 68, suggesting that it was the deprotonated 
form of this ligand which is selected by TS.  
 
Figure 71 Reported pKa values (black), [173-175]  and estimated pKa values (red).  
Several mechanisms were considered to account for these observations as outlined below and summarised in Figure 
72. 
1. At ca. pH 8 and in a deprotonated state, pyrrolidine 68 may undergo an intramolecular cyclisation from the teriary 
N onto the acrylamide to form a 5,7-bicyclic ring system. This could in itself be a fragment binder, whilst also 
providing a site of electrophilic attack. As the pH is lowered, the tertiary amine becomes protonated and this 
cyclisation is prevented.  
2. In its deprotonated state, ligand 68 may form hydrogen bonding interactions to residues within the protein pocket, 
an interaction which would  not occur upon protonation.  
3. The tertiary amine moiety within 68 may catalyse the addition of the catalytic thiol to the acrylamide by acting as a 
base to generate the thiolate. This seems highly plausible given that the active site cysteine, with a pKa of 8,[141] would 
be only partly deprotonated at pH 8.1 and the reaction would therefore be particularly susceptible to base-mediated 
acceleration. Similar rate-accelerated cysteine thiol-acrylamide Michael additions using a built-in tertiary amine have 
previously been previously reported.[112, 176]  
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Figure 72 Three possible mechanistic explanations for the pH-dependent selection of negative control ligand 68 by TS. 1. At pH 8 an 
intramolecular cyclisation occurs to form 5,7-bicyclic compound 104 which in itself is an electrophilic TS fragment binder. 2. 
Deprotonated ligand 68 makes favourable interactions with a residue in the pocket of TS at pH 8, which are disrupted at pH 7 as the 
pyrrolidine becomes protonated. Image shows PDB file 1F4C altered using WebLabViewer to replace the N-tosyl with an N-methyl. 
Residues within 4 Å of the pyrrolidine ligand are highlighted, with the protein secondary structure in grey. Image generated using PyMol. 
3. At pH 8, the deprotonated pyrrolidine 68 is able to accelerate the addition of the catalytic cysteine to the acrylamide by intramolecular 
base-catalysis. Upon lowering the pH the pyrrolidine becomes protonated and therefore unable to catalyse the addition. Shown 
highlighted in the blue box: intramolecular base-catalysed addition of an acrylamide to a cysteine thiol reported by Wissner et al.[176]  
3.4.3. Synthesis of a second negative control ligand 
In their original disulfide tethering proof-of-concept, Erlanson et al. reported that, in addition to disulfide 65, disulfide 
118 was not selected by TS.[51] Ligand 119 was therefore designed and synthesized to replace acrylamide 68 as a 
negative control for KTGT, based on the disulfide-modified ligand originally reported, Figure 73.  
 
Figure 73 Design of an alternative negative control ligand by comparison with a ligand reported not to be selected by TS by Erlanson et 
al.[51] Dotted arrow compares the position of electrophilic attack for both ligands.  
The synthetic route to novel compound 119 commenced with a Sharpless aziridination of allyl benzene using 
chloramine-T.3H2O and catalytic trimethylphenyl ammonium tribromide (PTAB), Scheme 19.[177] The aziridine 120 
was isolated as an inseparable mixture with an unidentified impurity and was taken straight on to the next step. The 
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ring opening was carried out using TMSN3 to yield an inseparable mixture of both ring-opened regioisomers 
121a/121b in an 8:1 ratio in favour of the desired isomer 121a. This mixture was hydrogenated using Pd\C catalyst 
and H2 to give the mixture of amines 122a/122b and subsequently treated with acryloyl chloride to give, after 
purification, the desired negative control ligand 119 in a 27 % yield over two steps. An unexpected side-product 123 
was isolated in a 19 % yield from the final step of this reaction sequence, which was tentatively assigned as shown in 
Figure 74.  
 
Scheme 19 Synthesis of negative control ligand 119.  
 
Figure 74 Isolated as a side-product after the treatment of amines 122a/122b with acryloyl chloride.  
Both compounds 119 and 123 have very similar Rf values, leading to a close separation during purification on silica 
gel. The desired compound 119 was isolated in complete purity by 1H NMR and TLC (with none of the side-product 
123 observed), but this was not sufficient for KTGT experiments. Incubation of TS (10 µM) with 400 µM of 
acrylamide 119 for 20 min led to the formation of a significant adduct between TS and the impurity 123, in addition to 
an unassigned adduct with a molecular weight 27 Da higher than than the TS-123 adduct, Figure 75. The N-
(sulfonamide)-acrylamide Michael acceptor within ligand 123 was likely to be highly reactive towards conjugate 
addition, such that contamination of the sample of acrylamide 119 with only a trace quantity of this reactive 
compound was significant enough to react with the catalytic cysteine. The contaminated sample of acrylamide 119 
was subjected to further purification using a preparatory LC-MS to remove traces of reactive ligand 123. Incubation 
of TS with pure negative control compound 
119 at 400 µM led to no modification of the 
protein, even after a 60 minute incubation 
period. 
Figure 75 Deconvoluted ESI mass spectrum of a 
sample of TS (10 µM) incubated with acrylamide 
119 (purified by column chromatography on silica) 
(400 µM) in an ammonium bicarbonate buffer (10 
mM) with DTT (1 mM), pH 8, after 20 min 
incubation. A adduct to side-product 123 was 
observed as indicated. 	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Incubation of cdc25A with mixture IV with each acrylamide at 100 µM led to the formation of a low yielding adduct 
to negative control compound 119, but not to any other acrylamide in the mixture, including the positive control 67. 
Cdc25A was incubated with iodoacetamide to generate a cdc25A-acetamide adduct over time. The reaction was noted 
to be slower than with TS, papain or p97, which all went to completion within 10 min. The reaction between cdc25A 
and iodoacetamide went only to 25 % completion within 10 min, and to 65% after 60 min. This may be due to the 
very small and narrow active site pocket shielding the active site cysteine residue from the bulk solvent.  
When TS was incubated with mixture III with each acrylamide at  final concentration of 100 µM, no adduct was 
identified to form to negative control ligand 119 and an adduct was formed, as expected, to positive control compound 
67. However, a further adduct was also observed to form with N-benzylpiperidine acrylamide 54, Figure 76. When TS 
was incubated with a slightly larger library, mixture IV, still only adducts to positive control 67 and N-
benzylpiperidine acrylamide 54 were formed. The adduct to N-benzylpiperidine acrylamide 54 was localised to the 
active site cysteine, as was previously carried out for positive control 67 and negative control 68, using MALDI after 
trypsin digest and addition to TS after full modification with iodoacetamide. TS and N-benzylpiperidine acrylamide 
54 were identified to form a stable covalent bond in the same manner as was carried out for positive control 67. TS 
was fully modified with N-benzylpiperidine acrylamide 54 and the mixture subjected to thorough washing through a 
centrifuge filter. Subsequent analysis by ESI MS indicated that the TS-54 adduct was still intact.  
 
Figure 76 TS (10 µM) in ammonium bicarbonate (10 mM), DTT (1mM), pH 8, incubated with mixture III, each acrylamide at 100 µM, 
and analysis at 270 min.   
As this fragment contains a basic amine, with a pKa value of approximately the same value as for negative control 
68,[178, 179] it was considered that it may act via a similar base-catalysed intramolecular thiol deprotonation mechanism, 
Figure 77. Whilst this could not be ruled out, this ligand did not show a tethering dependence on pH between 8.1 – 7.2 
as was observed for negative control 68. The molecular similarity between positive control 67 and piperidine ligand 
54 suggested that perhaps N-benzylpiperidine acrylamide 54 was actually a fragment binder of TS. Additionally, the 
N-benzyl piperidine motif was found embedded within a series of ligands reported as TS inhibitors.[180] The 
spectrophotometric assay, originally reported by Wahba and Friedkin, and previously used to confirm TS activity, was 
used to measure the binding affinity for the fragments used in the acrylamide-tethering studies. The aim of this work 
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was to confirm acrylamide 67 as a positive control and to elucidate the binding affinity of the N-benzyl piperidine 
fragment 54 in addition to a selection of the other ligands.  
 
Figure 77 Acrylamide 54 may react with TS via an intramolecular deprotonation of the cysteine thiol.   
3.4.4. Synthesis of non-tethering control ligands and spectrophotometric assay 
A series of non-tethering ligands was required to quantify binding to the active site pocket. These were synthesised 
from the respective amine and either acetyl chloride or acetic anhydride, Figure 78. N-tosyl D-proline 64, synthesised 
from D-proline and tosyl chloride (Equation 3), was used as a control with a known Ki value.[51]  
 
Figure 78 a. AcCl, Et3N, Et2O b. AcCl, Et3N, CH2Cl2 c. Ac2O, CH2Cl2 d. AcCl, Et3N, THF.  
 
Equation 3 
Thymidylate synthase (TS) catalyses the methylation and subsequent reduction of dUMP using mTHF as a cofactor 
for both steps, resulting in the production of dTMP and DHF as previously discussed. The sequential mechanism 
proposed for this reaction involves the initial binding of the substrate dUMP before binding of the cofactor mTHF. 
Once substrate and cofactor are bound, methylation and reduction reactions occur sequentially before the release of 
dihydrofolate and subsequently thymidylate. N-tosyl D-proline inhibitor 64 was determined as competitive with only 
dUMP by Erlanson et al.[51] This is perhaps initially counterintuitive when the crystal structure of this ligand bound to 
TS is examined, as the ligand clearly overlaps with both the dUMP and mTHF binding sites, Figure 79. This is 
presumably due to the sequential order of TS catalysis, in which if dUMP is unable to bind then mTHF is also unable 
to bind. In steady state Michaelis Menten enzyme kinetics, the KM value equals the concentration of substrate required 
to generate an initial velocity equal to half the maximum velocity (Vmax). Ideally, when using an assay to measure IC50 
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values for competitive inhibitors, substrate concentrations equal to their KM values are used to ensure that the inhibitor 
is not out-competed by the enzyme substrate. If higher substrate concentrations are used, higher inhibitor 
concentrations are required in order to be able to monitor inhibition. The KM values for dUMP and mTHF from the 
literature vary from 0.2-5.0 μM and 14-15 μM respectively. Ideally, therefore, in this assay the concentration of 
dUMP used would be ca. 2 μM.  
 
Figure 79 Overlay of two crystal structures: N-tosyl D-proline (carbons in yellow) bound in the active site of TS (PDB code 1F4C) and 
mTHF (carbons in cyan) and dUMP (carbons in green) bound in the active site of TS (PDB code 3BHL).  
Unfortunately, due to technical limitations, sensitivity at the required 340 nm wavelength was too low to screen at 
dUMP KM concentrations. To get an accurate and reliable measure of the initial enzyme velocity, a 0.1 unit change in 
absorbance over time was required, which meant a minimum dUMP concentration of 20 µM. Below 20 µM dUMP, 
the quantity of DHF formed during the course of the reaction was too low to detect. Using the Cheng-Prussoff 
equation to relate IC50 to Ki, a dUMP concentration of approximately 10 x KM yields IC50 values that are ca. 10 x Ki 
values. Using fragment inhibitors with intrinsically low affinity (high Ki values) led to practical difficulties using the 
spectrophotometric assay.  
To generate an IC50 curve for N-tosyl D-proline 64, a range of log[inhibitor] concentrations between 0.5 - 1.2 were 
screened against the enzyme (0.1 μM) with mTHF (150 μM) and dUMP (20 μM) at 25 °C. The enzyme was 
preincubated with the inhibitor for 15 min prior to addition of substrates. Initial velocities were calculated by fitting a 
linear trendline to the initial portion of the curve and taking the gradient as a fraction of the initial velocity of the 
uninhibited reaction. This generated a sigmoidal dose-response curve with an IC50 value of 10.4 ± 0.1 mM, which is 
an order of magnitude higher than the reported Ki value (1.1 mM ± 0.25 mM) as expected, Figure 80. Using the 
Cheng-Prussoff equation and an experimentally determined KM value for dUMP,[181] the IC50  was converted into a Ki 
value of 0.59 ± 0.06 mM, in reasonable agreement with the literature.[51]  
 
Figure 80 IC50 curve for N-tosyl D-proline 64. Points are the average of three repeats and error bars represent the standard deviation. 
Sigmoidal curve generated using OriginPro 8.5 software.  
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Applying the same method to generate an IC50 value for positive control acetamide 128 failed due to poor solubility at 
the high concentrations required. In an attempt to overcome this, the percentage of DMSO was increased from 4 to 8 
% and samples were both pre-incubated and assayed at 30 °C rather than 25 °C. These conditions conferred sufficient 
aqueous solubility that acetamide 128 could be dissolved at all the required concentrations. Unfortunately, even under 
these conditions, acetamide 128 crystallised from the solution during the course of the assay leading to an unexpected, 
rapid increase in absorbance at 340 nm over time, Figure 81. All other compounds retained greater than 70 % enzyme 
activity at 40 mM, except for N-benzyl piperidine acetamide 127, which only retained 66 % activity at 30 mM. An 
IC50 value for inhibitor 127 greater than 30 mM implies that this compound is a very weak TS fragment binder with a 
Ki > 3 mM. The weak affinity of acetamide 127 for TS may suggest that tethering to acrylamide fragment 54 occurs 
by an intramolecular base-mediated rate acceleration rather than a template-based effect.  
 
Figure 81 Screening of positive control acetamide 128 at 15.8 mM. Red data points show the absorbance difference at 340 nm over time 
in the presence of acetamide 128 at 15.8 mM, grey data points show absorbance difference at 340 nm over time for the protein in the 
absence of the inhibitor. Assay carried out at 30 °C. Samples preincubated at 30 °C for 8 minutes prior to assay. 
3.4.5. Thermofluor® 
It was considered that a qualitative measure of binding affinity for positive control acetamide 128 to TS might be 
obtainable through a more sensitive biophysical screen such as Thermofluor®. This fluorescence-based thermal shift 
assay is a general method to measure ligand-induced stabilisation of protein. The protein is heated in the presence of a 
dye such as Sypro Orange, as previously described (p39), 
resulting in the generation of a melt curve. The melting 
temperature (Tm) for the protein is calculated as the minimum 
point in the first derivative of the melt curve, and is expected 
to increase in the presence of a binding ligand. Reported Tm 
stabilisations for binding fragments are usually expected to be 
about 0.5 °C.[182] TS was heated in the presence of Sypro 
Orange to generate a melt curve, Figure 82. Unfortunately, no 
increase in Tm value was achieved in the presence of known 
fragment inhibitor N-tosyl D-proline 64, even up to fragment 
concentrations of 10 mM. Thermofluor was therefore 
concluded not to be suitable for the identification of fragment binders to TS.  
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Figure 82 Melt curve for thymidylate synthase.  
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3.4.5. Competition studies 
To determine whether the observed adduct formation with N-benzyl piperidine acrylamide 54 and positive control 67 
was a template-dependent effect or not, a series of competition studies were carried out, Figure 83. Pre-incubation of 
TS with N-tosyl D-proline 64 before addition of acrylamides was expected to block the active site pocket, slowing 
down the rate of adduct formation relative to a control tethering experiment. TS was preincubated with either 4 mM 
N-tosyl D-proline 64 or 4 mM formic acid as a pH control. After a 15 minute preincubation period, acrylamides 54 or 
67 were added to the sample and aliquots taken for MS analysis over a 20 minute period. Acrylamide 67 demonstrated 
no tethering to TS after preincubation with N-tosyl D-proline 64, whereas tethering did occur after preincubation with 
formic acid. Likewise for N-benzyl piperidine acrylamide 54, the tethering observed after preincubation with formic 
acid was significantly reduced after preincubation with N-tosyl D-proline 64, Figure 84. These results indicated that 
the active site pocket was indeed required to template the Michael addition reaction. 
 
Figure 83 Schematic to illustrate competition tethering experiments. 
 
Figure 84 (Left hand side) TS preincubated with either 4 mM formic acid (blue graph) or 4 mM N-tosyl D-proline 64 (black graph) for 
15 minutes before addition of N-benzyl piperidine acrylamide 54 at 400 µM. (Right hand side) TS incubated with 4 mM formic acid for 
15 minutes before addition of positive control acrylamide 67 at 400 µM. When TS was preincubated with N-tosyl D-proline 64 there was 
no reaction with acrylamide 67 within the 20 minute incubation period. Each graph is an average of 3 repeats where the error bars 
represent the standard deviation. The average pH values for the different solutions: pH(TS/formic acid/54) = 7.05; pH(TS/formic acid/67) 
= 6.94; pH(TS/64/54) = 7.17; pH(TS/64/67) = 7.12. 
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A crystal structure of N-tosyl D-proline bound to the protein obtained by Erlanson et al.[51] indicated that whilst the 
pocket was blocked, the active site cysteine was available and still solvent exposed, Figure 85. This was a necessary 
requirement for the competition study to be able to differentiate between the non-templated and the templated 
reaction. In an attempt to show that the pocket was blocked whilst the cysteine was solvent exposed, the protein was 
incubated with iodoacetamide in the presence of either N-tosyl D-proline 64 or formic acid. A low concentration of 
iodoacetamide (100 µM) was used in this study to ensure a slow enough rate of reaction for measurements to be taken 
over a 20 min period. In the presence of formic acid, the iodoacetamide modified the protein to approximately 50 % 
conversion over the 20 min analysis time as expected. Interestingly however, in the presence of N-tosyl D-proline 64 
no reaction with iodoacetamide was observed. It was considered initially that this might be due to a reaction between 
the iodoacetamide and the N-tosyl D-proline, but after 300 minutes, the protein was completely present as an 
acetamide adduct. It was also considered that upon binding of the N-tosyl D-proline 64, the protein adopts a different 
conformation where the cysteine is blocked. A comparison of the apo (1F4B) and bound (1F4C) crystal structures 
indicated that this was not the case, although this did not give any information about the tertiary protein structure in 
solution. Unfortunately, the significant reduction in rate of acetamide-adduct formation rendered by the pre-incubation 
with N-tosyl D-proline 64 suggested that no meaningful result could be gained from competition studies of this nature 
with this protein.    
 
Figure 85 N-tosyl D-proline bound to TS. Active site cys146 is highlighted. PDB code 1F4C. Image generated using AstexViewer. 
3.4.6. Reaction irreversiblility 
Although extensive HPLC studies had been carried out to demonstrate the irreversibility of the thiol-acrylamide/vinyl 
sulfonamide Michael addition reaction using small molecule 
thiols, an ESI MS study was carried out using the protein to 
confirm irreversibility under the TS-tethering conditions. The 
method used in this study is illustrated schematically in Figure 86. 
TS was fully modified separately with two acrylamides 54 and 67, 
by treatment with each acrylamide at 400 µM for 3.5 h at room 
temperature under the standard screening conditions. After this 
time, acrylamide 54 was added to the TS-67 sample and 
acrylamide 67 was added to the TS-54 sample, with both new 
acrylamides added to 400 µM final concentration. After 1 h the 
samples were analysed by ESI MS, which indicated complete Figure 86 Schematic to illustrate the irreversibility method.  
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reaction irreversibility by the formation of no new TS-acrylamide adduct, Figure 87.  
 
Figure 87 Left hand side: Incubation of TS (10 µM) with acrylamide 54 (400 µM) for 3.5 h and analysis by ESI MS indicated complete 
modification of the protein. Addition of acrylamide 67 (400 µM) to the TS-54 adduct and analysis by ESI MS after 1 h indicated no 
formation of a second adduct. Right hand side: Incubation of TS (10 µM) with acrylamide 67 (400 µM) for 3.5 h and analysis by ESI 
MS indicated complete modification of the protein. Addition of acrylamide 54 (400 µM) to the TS-67 adduct and analysis by ESI MS 
after 1 h indicated no formation of a second adduct.   
3.5. Vinyl sulfonamides and kinetic template-guided tethering 
As the vinyl sulfonamides were identified as significantly more reactive than the acrylamides towards conjugate 
addition (Chapter Two), it was assumed that the level of background reaction would be too high for the use of this 
functional group in KTGT. Work was carried out in an attempt to either prove or disprove this hypothesis. To account 
for this higher intrinsic reactivity of the vinyl sulfonamides, screening was carried out at 10 µM rather than 400 µM. 
TS was incubated with a mixture of 4 vinyl sulfonamides, 41, 43, 44 and 70 each at 10 µM and the sample analysed 
after 2, 10, 30 and 120 min, Figure 88. Interestingly this resulted in the selection of only positive control 70, with no 
adduct formed to the N-benzyl piperidine fragment previously identified. The reversibility of vinyl sulfonamide 
addition to TS was examined using the same method as for the acrylamides. TS was fully modified with either vinyl 
sulfonamide 44 or 70, and subsequently incubated with the second sulfonamide, indicating that the reaction was 
completely irreversible over the 120 minute time period examined.  
 
Figure 88 TS incubated with 4 vinyl sulfonamides, each at 10 µM, and analysis by ESI MS carried out at 2, 10, 30 and 120 minutes. 
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3.5. Summary and conclusions 
TS was adopted as a model protein to develop a proof-of-concept for KTGT. A number of positive and negative 
control ligands were designed and synthesised and TS was cloned, expressed and purified. A reliable, robust and 
facile method was developed for the incubation of ligands with protein prior to analysis by ESI MS. Using 
iodoacetamide, TS was shown to have only one surface exposed cysteine thiol in agreement with that previously 
reported. Using the developed method, TS was incubated with a mixture of acrylamides including the positive control 
67 and piperazine acrylamide 49 with a high intrinsic reactivity. Analysis by ESI MS indicated modification of the 
protein by only the positive control ligand 67 and not the more reactive ligand 49, providing an initial proof-of-
concept for KTGT. Incubation with N-methyl pyrrolidine negative control compound 68 led to unexpected 
modification of the protein, which may be due to intramolecular base-catalysis by the tertiary amine. Ligand 54, 
containing a tertiary amine functionality, was also unexpectedly found to modify the protein, an effect which may also 
be due to a similar base catalysis. Ligand 54 was identified as a weak fragment binder of TS using an enzymatic 
spectrophotometric assay. Incubation of TS with a mixture of vinyl sulfonamides led to modification of the protein 
with only the positive control 70, suggesting that this functionality is also potentially suitable for KTGT experiments. 
Protein-acrylamide adducts were stable to proteolytic digestion, allowing the position of modification to be identified 
by MALDI MS of the crude peptide mixtures. Reaction of the protein with both acrylamides and vinyl sulfonamides 
was found to be completely irreversible as expected. No further work is carried out with the vinyl sulfonamides in this 
thesis, but this certainly represents an area with scope for future studies. The acrylamide KTGT work described in this 
chapter was published in 2012.[183]   
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4. Design of a linker for acrylamide-based KTGT 
4.1. Introduction and aim  
To develop KTGT into a general strategy for the discovery of protein-binding ligands, an important consideration was 
the design of a structural element to separate the acrylamide from the fragment. The purpose of this linker was 
twofold: to isolate the acrylamide from the fragment to ensure identical kinetic reactivity across the library members 
and to allow the acrylamide some flexibility to find the local cysteine thiol after fragment binding, Figure 89. The key 
challenge during this work was the design of such a linker without loss of the effective molarity induced by the 
template.  
 
Figure 89 Schematic to illustrate KTGT with a flexible linker.  
Work published by Whitesides et al. in 2007 examined the change in effective molarity (Meff) with linker length for 
intramolecular protein-ligand binding in a related system.[184] Adopting human carbonic anhydrase (hCA) as a model 
system, a benzene sulfonamide ligand was covalently tethered to the protein surface, in the vicinity of the binding 
pocket, by linkers of various lengths comprised of oligo(ethylene glycol) units (n = 0, 2, 5, 10 and 20), Figure 90. 
 
 
Figure 90 Human carbonic anhydrase (hCA) was modified covalently with a known aryl sulfonamide binder via oligo(ethyleneglycol) 
tethers of various lengths n = 0, 2, 5, 10 and 20.  
Whitesides et al. calculated the effective molarity for binding of the ligand to the protein according to Equation 4, 
where Kdinter represents the affinity of the untethered ligand for the protein, and Kdintra represents the affinity of the 
tethered ligand for the protein.  
Meff = Kdinter/Kdintra 
Equation 4 
Kdintra was calculated according to Equation 5, which was derived from the thermodynamic cycle shown in Figure 91.  
Kdintra = KdEthox/Kdcomp, Ethox 
Equation 5 
Ethoxzolamide (Ethox), Figure 92, binds to hCA and quenches intrinsic protein fluorescence, which derives from 
tryptophan residues, offering a spectrophotometric method to follow binding. Incubation of hCA (modified with the 
benzene sulfonamide ligand via various linker lengths) with varying concentrations of Ethox allowed calculation of 
the dissociation constant for the competing Ethox ligand (Kdcomp, Ethox).    
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Figure 91 Thermodynamic cycle used by whitesides et al. to calculate Kdintra, utilising the observed dissociation constant (Kdcomp, Ethox) for 
competing ligand Ethox (shown as a white square). Kdintra = KdEthox/ Kdcomp, Ethox.  
 
Figure 92 Ethoxzolamide (Ethox).  
Whitesides et al. previously argued that flexible oligomers should not be suitable as linkers in multivalent ligands due 
to the severe loss of conformational entropy when the linker becomes bound at both ends.[185] The results obtained 
using hCA as a model system contradicted this hypothesis. With the number (n) of oligo(ethyleneglycol) units n = 2, 
the linker was at an optimal length and the effective molarity was highest, Figure 93 scenario 2. Surprisingly, as the 
linker length was increased beyond the optimal value, only a weak dependency on length was observed with an 8-fold 
decrease in Meff from n = 2 to n = 20, scenario 3. When n = 0, the linker was too short to allow unconstrained ligand 
binding and the effective molarity was < 1, scenario 1. The authors proposed this to be qualitatively in accordance 
with a model that treats the linker as a random-coil polymer, which retains significant conformational mobility once 
bound, and only contributes entropically to the thermodynamics of the system. The weak dependence on linker length 
led the authors to suggest that the most effective strategy for the design of multivalent ligands is to connect the two 
moieties by a flexible linker, which is significantly longer than the distance between the two sites. This was in 
agreement with a thermodynamic analysis published by Kane in 2010.[186]  
 
Figure 93 Three scenarios observed by Whitesides et al. 1. The linker length is too short to allow the ligand to reach the binding pocket 
and the effective molarity is < 1. 2. The linker is exactly the right length to allow the ligand to reach the pocket and the effective molarity 
is highest. 3. The linker is longer than the distance between the tether point and the pocket, but the effective molarity is only moderately 
reduced.  
In a very interesting report, Blaustein et al. tethered triethylamine to Shaker K+ channels via flexible linkers of various 
lengths.[187] A maleimde group was used as a functional handle to attach the linker to the channel by reaction with a 
solvent exposed cysteine residue. The variant of Shaker channel used in these experiments had a high affinity external 
triethylamine pocket, which caused block of the channel upon binding, Figure 94. When the linker was too short to 
allow the triethylamine ligand to reach the pore, no significant block of the channel was observed as expected. A 
OEt
N
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O
O
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significant jump in ion channel block was observed when the linker length was increased from 11 to 12 Å, with the 
quaternary ammonium now able to reach the pore. Surprisingly however, as the linker length was further increased, 
blockage of the ion channel also continued to increase. The authors suggest that longer linkers are able to adopt a 
greater number of conformations that result in binding, whereas the shorter linker must adopt the improbable, fully 
extended conformation to achieve this. 
 
Figure 94 Schematic to illustrate the Shaker K+ channel with a tethered triethylamine ligand. 
A thorough kinetic analysis of this work was later published by Blaustein.[188] Interestingly, he reported that not only 
did tethered blockers of longer length achieve greater block of the ion channel, but that these linkers also covalently 
modified the solvent exposed cysteine at a faster rate. Blaustein proposed that, just as the longer linkers result in a 
higher concentration of triethylamine at the pore, and therefore greater block of the channel, the same longer linkers 
(before covalent attachment) bind the triethylamine pocket and result in a higher concentration of maleimide near the 
reactive cysteine. Interestingly, longer linkers were observed to react with the channel via biphasic kinetics when there 
was more than one reactive cysteine in the vicinity of the pore. Reaction with the first cysteine was observed to be 
much faster due to binding of the triethylamine group and resultant increase in maleimide concentration at the first 
cysteine. With the triethylamine moiety now efficiently blocking the pore, all further reactions proceed at the slower 
rate of background reaction. Shorter linkers that demonstrated only a partial block of the pore reacted with single 
phase kinetics. 
 
Although the papers published by Whitesides and Blaustein reported different observed changes in effective molarity 
with linker length, both sets of results suggest that the use of a long and flexible linker is a justifiable strategy for 
multivalent ligands. This was thought to be particularly suitable for KTGT where a library of compounds would 
ideally be screened against a range of proteins where the distance between the nucleophilic protein capture atom and 
the fragment pocket would vary slightly. For each system, the linker would confer the required flexibility for the 
acrylamide to react with the cysteine thiol after fragment binding, Figure 95 scenario 3,  in addition to normalising the 
intrinsic kinetic reactivity across the fragment library. Without the incorporation of a linker into fragments for KTGT, 
it was considered that a significant number of false negatives might result, due to fragment binding in a conformation 
with the acrylamide unable to reach the reactive cysteine thiol, Figure 95 scenario 1.    
 
Thymidylate synthase was used once again as the model system for this work. The overall aim was to design and 
synthesise a library of acrylamide-linker-fragments, including the positive and negative controls, and to demonstrate 
selection of only the positive control fragment by the protein.  
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Figure 95 Three scenarios for KTGT which vary by linker length. 1. The linker length is too short to reach the cysteine such that the 
effective molarity is 0. 2. When the linker length is exactly right the effective molarity is highest. 3. Multivalent systems with long 
flexible linkers lose effective molarity with length only slowly.    
4.2. Linker design 
The distance between the carboxylic acid oxygen atom in N-tosyl D-proline fragment 64 and the sulfur atom from 
C146 in TS is 0.37 nm, as determined using an available crystal structure (PDB code 1F4E), Figure 96.* When this 
fragment is tethered to C146 via a disulfide linkage (PDB code 1F4C), the distance between the amide NH and the 
sulfur atom is 0.47 nm,* suggesting the linker as almost exactly the right length. In order to probe the importance of 
linker length for KTGT, a linker in excess of the approximately ideal 0.4 nm length was required. A linker spanning a 
maximum length of ca. 3.5 times this distance was therefore designed, Figure 96. The linker was comprised of 2.5 
ethylene glycol units, with the amine fragment attached to the linker via a carboxylic acid handle, Figure 97. 
Oligo(ethylene glycol) units were chosen to constitute the linker as these confer a solubility advantage over a 
hydrocarbon chain, have been found not to interact non-selectively with protein surfaces[189] and are a common moiety 
in multivalent ligands.[23]  
 
Figure 96 Design of a linker for KTGT. Left hand side: Crystal structure (PDB code 1F4E) of WT-TS with N-tosyl D-proline bound in 
the active site pocket. The distance between the active site cysteine sulfur atom and the oxygen atom from the carboxyl group in the 
proline ligand is highlighted (0.37 nm). Middle: Crystal structure (PDB code 1F4C) of WT-TS covalently modified with N-tosyl D-
proline via  a disulfide linkage. The distance between the cysteine sulfur and the oxygen atom in the ligand is highlighted (0.47 nm). 
Images were generated using AstexViewer. Right hand side: Comparison of KTGT and KTGT with a linker. The linker spans a 
maximum distance of approximately 1.26 nm, calculated using ChemBio3D Ultra.  
 
Figure 97 Acrylamide-linker-fragment design.  
                                                        
* Measured using AstexViewer software.  
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4.3. Synthetic route one 
The initial strategy developed to synthesise a PEG-modified acrylamide library was based on a retrosynthetic analysis 
shown in Scheme 20. The amide bond forming reaction to couple amine fragments to the common intermediate 
carboxylic acid 131 is carried out in the ultimate step to diversify the synthesis at the latest possible point. The 
carboxylic acid required for this final step was thought to be obtainable from alcohol 132 by reaction with a haloacetic 
acid. It was considered at this step that the haloacetic acid may require protection, firstly due to the requirement for 
the use of strong base to effect the SN2 reaction, and secondly as the carboxylic acid 131 was anticipated to be highly 
polar and therefore potentially problematic to isolate. Disconnection of the acrylamide C-N bond gives commercially 
available 2-(2-aminoethoxy)ethane 133 as the starting point for the synthesis.    
 
Scheme 20 Retrosynthetic analysis to reach library of acrylamide-linker-fragments.  
It was initially anticipated that only poor chemoselectivity for the N over the O in the acetylation of 2-(2-
aminoethoxy)ethane 133 would be possible, and this amino-alcohol was therefore reacted with an excess of acryloyl 
chloride to acetylate both nucleophilic atoms. Basic cleavage of the ester bond with aqueous LiOH during work up 
then generated the desired carboxylic acid. Unfortunately, the acid was highly water soluble and could not be 
extracted in a reasonable yield from the aqueous layer. This was overcome by reacting 2-(2-aminoethoxy)ethane with 
one equivalent of acryloyl chloride, which pleasingly gave reasonable selectively for the more nucleophilic nitrogen. 
By omitting an aqueous workup and passing the crude reaction mixture straight through a silica column, the desired 
acrylamide 132 was isolated in a moderate 67 % yield.   
Tert-butyl protected chloroacetic acid was initially chosen as the electrophile for the alkylation of acrylamide 132. 
Protection as an ester was chosen to aid isolation by decreasing the polarity of the final compound. A tert-butyl group 
was chosen as the ester substituent to prevent transesterification with the nucleophilic alcohol rather than the desired 
alkylation. Triethylamine was initially chosen as the base in the alkylation step to avoid generation of the alkoxide, 
which was anticipated to attack the acrylamide either intra- or intermolecularly. With triethylamine as the base, there 
was no reaction with chloroacetic acid tert-butyl ester after 3 h at 70 °C, Table 12 (entry 1). Using a stronger base, 
potassium butoxide, a 6 % isolated yield of the desired product 134 was obtained after reaction for 12 h at rt, with a 
significant quantity of starting material left as indicated by TLC (entry 2). Use of a stronger base (NaH) and 12 h 
reflux in THF led to the generation of none of the desired product by TLC (entry 3). Treatment of alcohol 132 with 
the α-bromo rather than α-chloro ester in the presence of potassium tert-butoxide and THF increased the yield of this 
reaction to 20 %, presumably due to the increased ability of the α-haloester to undergo SN2 displacement. Repeating 
this reaction, but reversing the order of addition such that the α-bromo ester was added to the reaction mixture before 
the potassium tert-butoxide base, increased the yield of this reaction to 28 % (entry 4). Reaction of α-bromo acetic 
acid with alcohol 132 in the presence of potassium tert-butoxide led to none of the alkylated product 131 (entry 5). A 
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large batch of acrylamide 132 was synthesised to further optimise these reactions, but this was observed to polymerise 
under vacuum. The low yields encountered throughout this synthesis may be due to polymerisation side reactions.  
 
Table 12 Conditions for the alkylation of alcohol 132. An asterix indicates reversed order of addition such that the base is added to the 
mixture of the alcohol and the alkylating agent.  
An attempt was made to selectively alkylate alcohol 133 to ether 135 in the presence of the primary amine by full 
deprotonation using one equivalent of NaH and subsequent addition of the chloroacetic acid tert-butyl ester, Equation 
6. After reaction with chloroacetic acid tert-butyl ester at 70 °C for 1 h, a new product was evident by TLC analysis 
although significant quantities of both starting materials were still present. An attempt was made to isolate this new 
product but it could not be extracted from the aqueous layer during work up.   
 
Equation 6 
As a new protection strategy, a literature synthesis was adopted to dibenzylate 2-(2-aminoethoxy)ethanol, alkylate the 
free alcohol with α-bromoacetic acid, and remove the N-benzyl groups using hydrogenolysis with a palladium on 
charcoal catalyst, Scheme 21.[190] At this point, reaction of the resulting amine 138 with acryloyl chloride did not yield 
any of the desired acrylamide 131. The carboxylic acid was thought to be problematic here due to potential reaction 
with acryloyl chloride to generate an anhydride, leading to a number of other side reactions.  
 
Scheme 21 
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To overcome this, it was desirable for the carboxylic acid to be protected as the tert-butyl ester. N-dibenzyl 2-(2-
aminoethoxy)ethane 136 was treated with chloroacetic acid tert-butyl ester and NaH and refluxed in THF, but this 
failed to generate any of the desired ester 139, Table 13 (entry 1). Repeating this reaction at room temperature led to 
the isolation of carboxylic acid 137 (47 % yield) rather than the desired ester (entry 2). The use of bromoacetic acid 
tert-butyl ester with NaH base led to the disappearance of the starting material by TLC after 2 h, but gave only a 21 % 
isolated yield of ester 139 (entry 3). The presence of significant material on the baseline for this reaction suggested 
formation of the carboxylic acid. However, upon repeating this reaction with a 12 h rather than 2 h stirring time, a 57 
% isolated yield of the desired product 139 was obtained (entry 4). The yield for this reaction was significantly 
improved by stirring at 0 °C rather than room temperature, leading to a 68 % isolated yield for ester 139 after 2.5 h 
(entry 5) and a 75 % yield after 3 h (entry 6).  
 
Table 13 Conditions for the alkylation of alcohol 136.  
Using the hydrogenolysis conditions which worked almost quantitatively to take dibenzyl amine 137 to the free amine 
138 resulted in the removal of only one benzyl group from ester 139, Table 14 (entry 1). This was initially a surprising 
result as the two hydrogenolysis substrates, carboxylic acid 137 and ester 139, differ only at the end of the molecule 
furthest from the reacting centre. However, it is well documented that the product amine from N-debenzylation 
reactions can poison the palladium catalyst, an effect which can be minimised by the addition of acid.[191] The absence 
of the carboxylic acid in ester 139 leads to poisoning of the catalyst by the di-debenzylated amine product, effectively 
halting the reaction. Addition of an acid such as acetic acid may have provided a simple solution to convert ester 139 
directly to primary amine 135. However, treatment of the mono-benzylamine 140 with Pearlman’s catalyst Pd(OH)2 
under an atmosphere of H2 (g) for 3 days resulted in generation of the desired primary amine 135 in 100 % yield 
(entry 2). It was also found that primary amine 135 could be generated straight from the dibenzylated amine 139 with 
Pearlman’s catalyst and ammonium formate as the hydrogen transfer agent in refluxing methanol for 24 h (entry 3).    
 
Table 14 Hydrogenolysis conditions.  
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The resulting amine was reacted with acryloyl chloride to generate the acrylamide 134, albeit in a disappointing 22 % 
yield, Scheme 22. Attempted deprotection of tert-butyl protected carboxylic acid 134 in 4M HCl in dioxane was 
unsuccessful.  
 
Scheme 22 
4.4. Summary of attempts to use route one 
2-(2-Aminoethoxy)ethane 133 was reacted selectively at N to generate acrylamide 132 in moderate 67 % yield, 
Scheme 23. Attempts to react this with chloroacetic acid tert-butyl ester to generate the desired tert-butyl protected 
library synthesis precursor 134 were unsuccessful. Use of the α-bromoacetic acid tert-butyl ester led to the successful 
alkylation of alcohol 132 to ether 134, albeit in poor 28 % yield. The reaction between alcohol 132 and α-bromoacetic 
acid was unsuccessful. The intermediate acrylamide 132 was found to polymerise under vacuum, precluding large 
scale synthesis of this compound. Polymerisation was considered a potential problem in the alkyation reactions due to 
the presence of the nucleophilic alcohol and the electrophilic acrylamide within the same molecule. Direct alkylation 
of the alcohol 133 to generate amine 135, in an attempt to overcome this problem, was unsuccessful. Protection of 
amine 133 as the dibenzyl amine, alkylation with bromoacetic acid to generate carboxylic acid 137 and facile 
hydrogenation of the benzyl groups led to intermediate amine 138. At this point, generation of the desired acrylamide 
from amine 138 was unsuccessful, potentially due to generation of an anhydride and other side reactions. It was 
thought that this could be overcome by protection of the carboxylic acid as the ester, and generation of the tert-butyl 
ester 135 was successful, although optimised deprotection conditions were then required to remove the benzyl groups. 
Amine 135 was taken onto the acrylamide 134, albeit in low 22 % yield, but it was found that the tert-butyl ester 
group in acrylamide 134 could not be removed. The acrylamide was considered to be highly problematic within this 
synthetic route, and a protecting strategy to overcome this was therefore investigated.  
 
Scheme 23 Summary of attempts to reach the desired carboxylic acid 131. Intermediate 132 highlighted in red was found to polymerise 
under vacuum.  
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4.5. Synthetic route two  
It was decided that a protection strategy was required with the electrophilic acrylamide generated in a late step to 
avoid polymerisation. Furthermore, the final deprotection reaction should avoid strongly basic or acidic conditions to 
prevent side reactions. Finally, the protecting group should confer some degree of hydrophobicity to help with 
purification and isolation. An α-phenylselenide was chosen for this purpose, and a retrosynthesis to reach the desired 
compounds using this protecting group is shown in Scheme 24. The acrylamide is generated in the final step by 
oxidation of the selenium and in situ retro-ene to eliminate phenyl selenenic acid. It was envisaged that the α-
phenylselanyl amide would be stable through the amide bond formation and alkylation steps. A literature method was 
available for the preparation of 2-phenylselanyl-propionic acid 142 from ethyl 2-bromopropionate 141, which is 
commercially available.  
 
Scheme 24 Second generation retrosynthetic analysis to reach desired acrylamide-PEG linker-fragments for KTGT.  
Starting from the commercially available α-bromoethyl ester 141, the α-phenylseleno acid 142 was generated by an 
SN2 displacement of the bromide by phenyl selenide, generated by an in situ reduction of diphenyl diselenide, in 
excellent yields between 87-94 %, Scheme 25. Basic hydrolysis of the ester in aqueous KOH furnished the carboxylic 
acid 145 in yields between 72-81 %. Treatment of carboxylic acid 145 with oxalyl chloride and catalytic DMF 
generated the acid chloride, which was quenched in situ with 1.5 equivalents of 2-(2-aminoethoxy)ethane 133 to yield 
the desired amide 143 in a moderate 63 % yield, in addition to the di-acetylated side-product 146 in 14 % yield.  
 
Scheme 25 
The yield of 143 was improved to 79 % by treatment of the crude reaction mixture with aqueous KOH in EtOH to 
hydrolyse the ester, Scheme 25. Extraction of the basic aqueous layer during work up furnished alcohol 143 in high 
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purity, removing the need for column chromatography. Additionally, carboxylic acid 145 was recovered from the 
reaction in high purity by acidification of the aqueous layer and further extraction.  
 
Reaction of the N-acetylated alcohol 143 with tert-butyl bromoacetate and KOtBu in THF, conditions which were 
previously successful for this type of alkylation, led to degradation by TLC and isolation of none of the desired 
product 147, Table 15 (entry 1). The reaction was attempted with benzyl bromoacetate, KOtBu and THF as a 
hydrogenation deprotection step was thought to be favourable over an acidic hydrolysis step, which previously caused 
problems. However, only starting material was recovered from the reaction with none of the desired product 148 
(entry 2). Refluxing the N-acetylated alcohol 143 in THF with α-bromoacetic acid and NaH for 3 days also gave no 
reaction, with analysis of the crude reaction mixture by 1H NMR indicating mainly starting material (entry 3).  
 
Table 15 Conditions for the alkylation of intermediate 143. 
The quality of the NaH used in this reaction, in addition to two other sources, was checked using a literature allylation 
of benzyl alcohol with allyl bromide, reported to go to 99 % yield.[192] The three sources of NaH gave conversions of 
60, 60 and 61 % to the desired ether 149, Equation 7, indicating that the quality of the NaH was almost certainly not 
responsible for the 0 % yield achieved for the alkylation of alcohol 143. Changing α-bromoacetic acid to α-iodoacetic 
acid led to a trace of the desired product 144 using NaH as the base, Table 15 (entry 4). Recrystallisation of the 
iodoacetic acid immediately prior to reaction increased the yield of carboxylic acid 144 significantly to a moderate 62 
% (entry 5). Increasing the reaction time from 30 min to 16 h did not significantly improve the yield (entry 6).  
 
Equation 7 Test allylation reaction. Conversions to ether 149 of 60, 60 and 61 % were achieved using three different sources of NaH. 
With the desired intermediate 144 in hand, the next stage in the synthetic sequence involved the derivatisation of the 
carboxylic acid with amine fragments. As this step forms the point of divergence in the sequence and therefore has to 
be repeated for each fragment, high yielding reactions with minimal byproducts were desired. Treatment of carboxylic 
144 with oxalyl chloride and DMF (cat.) in THF at rt led to degradation as observed by methanol quench TLC 
analysis, which indicated 4 products. The mixture was nevertheless treated with benzylamine and triethylamine, but 
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only diphenyl diselenide was isolated from the reaction mixture (31 % yield). Lowering the temperature for the 
formation of the acid chloride to 0 °C still indicated the same degradation by MeOH quench and subsequent TLC 
analysis. As an alternative to acid chloride formation, a series of N,N’-dicyclohexylcarbodiimide (DCC) coupling 
reactions were attempted. Although removal of the N,N’-dicyclohexylurea byproduct is often tricky by column 
chromatography, the insolubility of the urea in acetonitrile reported by a coworker allows separation from products, 
which are freely soluble. It was found in practice, however, that the urea was sparingly soluble in acetonitrile such that 
significant numbers of washings were required to gain complete purity, even though this step was often carried out 
after column chromatography. Both amides 150 and 151 were extensively purified, but were still contaminated by the 
urea 152, with molar ratios (product:152) of 3:2 and 2:1 respectively, as calculated by 1H NMR, Table 16 (entries 1-
2).  Amides 153-155 were successfully separated from the urea byproduct to give the desired products in moderate-to-
good yields between 54 - 91% (entries 3 – 5).  
 
Table 16 Coupling carboxylic acid 144 to amine fragments.  
A novel amide-bond forming method recently published by Allen et al. was adopted to form the desired amides 
without the requirement for extensive purification.[193] The acid and the amine were refluxed in toluene overnight with 
a ZrCp2Cl2 Lewis acid catalyst to yield, in most cases, the desired amide as the only product in 100 % conversion. 
Purification often required only a filtration to remove solid impurities. To illustrate the superiority of the zirconocene 
dichloride method, the synthesis of amide 155 was carried out using both methods. The DCC-coupling reaction and 
the zirconocene dichloride reflux, gave yields of 54 % and 94 % respectively. The DCC-coupling method required 
two purifications using silica gel chromatography and three acetonitrile washes to remove the contaminating urea, 
whereas the zirconocene method required only filtration of the crude reaction mixture to remove solid impurities, and 
led to the isolation of amide 155 in high purity. Oxidation of the selenium with sodium meta-periodate led to in situ 
elimination, yielding the final desired compounds and the phenyl selenenic acid by-product. An overall summary of 
the route is shown in Scheme 26.   
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Scheme 26 Overall synthetic route to desired acrylamide-PEG linker-fragments for KTGT. *Using the HCl salt of the amine.  
4.6. Mass spectrometry screening and intrinsic reactivity 
Incubation of TS with positive control PEG-linked acrylamide 164 at a final concentration of 400 µM led to very slow 
generation of a TS-164 adduct, Figure 98. Modification of TS with positive control PEG-linked acrylamide 164 
proceeded at a rate approximately 20 times slower than with initial positive control acrylamide 67. Incubation of TS 
with a mixture of 6 PEG-linked acrylamide fragments (158-160 and 162-164)*, each at 400 µM final concentration for 
180 min, led to slow adduct formation with each acrylamide, with no enhanced binding to the positive control 164, 
Figure 99. This slow rate of modification probably represents the rate of background reaction.  
 
Figure 98 TS (10 µM) in ammonium bicarbonate (10 mM) and DTT (1 mM) at pH 8 incubated at rt with positive control PEG-linked 
acrylamide 164 at 400 µM final concentration from a stock solution in MeOH. Aliquots taken for ESI MS analysis at 1, 2, 5 and 9 h.  
                                                        
* Acrylamide 161  had to be excluded on the basis of poor aqueous solubility.  
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Figure 99 TS (10 µM) in ammonium bicarbonate (10 mM) and DTT (1 mM) at pH 8 incubated at rt with a mixture of 6 acrylamides 158, 
159, 160, 162, 163, 164 each at 400 µM for 180 min. All major adduct peaks are assigned by mass (Da). LHS chart indicates the intensity 
for each peak, integrated using MaxEnt. The intensity for the peak at 30771/30774 Da was divided in half, as the contribution from each 
acrylamide was unknown.  
An HPLC study was carried out to determine the intrinsic reactivity of the PEG-linked acrylamide fragments in 
comparison to positive control 67, using glutathione as the model thiol. As shown in Figure 100, PEG-linked 
acrylamides 164 and 159 both demonstrated a slower intrinsic reactivity than positive control 67, with ca. 70-78 % 
remaining electrophile 180 min after glutathione treatment for 67 and 84-96/90-95 % remaining electrophile for 164 
and 159 respectively.*  
 
Figure 100 Rate of reaction of acrylamides 164 (blue traces, diamonds), 159 (black traces, squares), 67 (orange traces, circles) with 
reduced glutathione in ammonium bicarbonate (100 mM) pH 8 (measured as three separate reactions). Acrylamides at 1 mM and 
glutathione at 5 mM. Reactions monitored by HPLC in the presence of 4-aminobenzamide (0.5 mM) as an internal standard. All reactions 
were run in duplicate, with both traces indicated on the chart. Data is relative to internal standard and normalised to intensity at t = 0 min. 
Data for acrylamide 67 has been fit with a linear trendline whereas the data for acrylamides 159 and 164 are represented as straight 
marked scatter plots.  
                                                        
*Remaining electrophile at 180 min calculated by fitting a linear trendline to each set of data, and calculating the Y values at X = 180 min.  
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The data for both PEG-linked acrylamides 164 and 159 was significantly more unreliable than that for positive control 
acrylamide 67, Figure 100. Linear trendlines fitted to the data for PEG-acrylamides 159 and 164 gave R2 values of 
0.50, 0.84 and 0.65, 0.42 respectively, whereas the the R2 values for the data for acrylamide 67 were 0.99 and 1.0.* It 
may be that the PEG-linked acrylamides form micelle or other type aggregates in solution, which firstly obscure the 
acrylamide from the solution, resulting in very slow reaction with thiols, and secondly interfere with the UV absortion 
intensity leading to unreliable HPLC data. 
4.7. A new strategy for linker design 
To rapidly ascertain a more effective linker structure and length, a new strategy was adopted involving the synthesis 
of acrylamide-linker-fragments modified with only the negative and positive control fragments. A successful linker 
should allow the selection of only the positive control from a mixture of both fragments, a strategy that overcomes the 
necessity for the highly time consuming synthesis of a larger set of acrylamide-linker-fragments at the initial test 
stage. This strategy required access to gram quantites of both the positive and negative control amine fragments. This 
was possible for amine 72 using the previously developed route (Chapter 3, p55, Scheme 5). However, the route 
previously used to synthesise amine 122a (Chapter 3, p79, Scheme 19) was not suitable for the synthesis of significant 
quantites of material. This route involved three synthetic steps, commencing with an aziridination of allyl benzene, 
subsequent aziridine ring-opening and a final hydrogenation. Problems encountered during this synthesis included the 
aziridination step, which resulted in the isolation of aziridine 120 as an inseparable mixture with an unidentified 
impurity, and the aziridine ring-opening, which yielded a mixture of inseparable regioisomers 121a and 121b. During 
this previous work, the regioisomeric mixture was taken through the rest of the synthetic route as the mixture and 
separated after the final step. To access gram quantites of the pure negative control amine fragment 122a, an 
optimisation of this route was required.   
 
During optimisation of the first step, a set of recrystallisation trials and column chromatography conditions were 
investigated. Under optimised solvent conditions, an Rf  separation of 0.08 was achieved by TLC between the aziridine 
120 and the unwanted impurity. The impurity was therefore removed using a very wide silica packed column, to yield 
the desired pure aziridine 120 in yields of between 39-43 %. It was also found that recrystallisation from ether 
furnished the desired aziridine 120, although the yield was lower at 27 %.  
 
In the prior synthesis, ring-opening of the aziridine with TMSN3 generated a regioisomeric mixture of azides 121a and 
121b (8:1 selectivity in favour of the desired isomer 121a with ring-opening at the less hindered position), in a poor 
32 % overall yield, Table 17 (entry 1). Ring-opening of aziridine 120 with sodium azide in an acetonitrile:water 
mixture was reported with to proceed with complete regioselectivity in 98 % yield by Bisai et al. in 2003.[194] 
However, adopting a procedure similar to that reported led to the isolation of a 1:5 mixture of regiosomers, with 
selectivity for the desired isomer 121a (entry 2). Perhaps the lower regioselectivity was a feature of the reduced steric 
bulk of the nucleophile compared to TMSN3. Many aziridine ring-opening reactions with trimethylsilyl-nucleophiles 
are catalysed by Lewis acids, which activate the aziridine towards nucleophilic attack, Figure 101. These reactions 
                                                        
*As only a small percentage of the electrophile reacts during HPLC analysis, the data is linear as it represents the initial reaction rate.   
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often result in mixtures of regioisomers, depending on the aziridine substitution. Hou et al. developed an aziridine 
ring-opening based on activation of the nucleophile rather than the aziridine. Treatment of TMSCN with TBAF 
generated the activated ammonium cyanide nucleophile in situ, Figure 101.[195] Inspired by this work, Minakata et al. 
developed a highly regioselective aziridine ring-opening by activating TMS-nucleophiles with a Lewis base.[196] The 
authors proposed that the Lewis base TMEDA coordinates to the silicon atom to generate either 5- or 6-coordinate 
silicon (depending on solvent coordination), which increases the nucleophilicity of the Si-nucleophile bond. 
Regioselectivity is presumably increased by the steric bulk of the nucleophile, promoting attack at the less hindererd 
site.  
 
Figure 101 Catalysed TMS-nucleophile aziridine ring-opening reactions. LHS Lewis acid promoted ring-opening. Middle work by Hou 
et al. to activate the nucleophile. RHS Lewis base promoted ring-opening.  
Treatment of the aziridine 120 with TMSN3 in the presence of catalytic TMEDA gave a significantly higher 
regioselectivity of 121a/121b, 21:1 (entry 3). Unfortunately, upon scaling this reaction up from 0.3 to 13 mmol, none 
of the desired product could be isolated. The highly Lewis basic tris(2,4,6-trimethoxyphenyl)phosphine (TTMPP) was 
reported to catalyse the ring-opening of aziridines by trimethylsilyl-nucleophiles in a highly regioselective manner in 
2009 by Matsukawa et al.[197] The use of catalytic TTMPP rather than TMEDA for ring-opening of aziridine 120 
resulted in complete regioselectivity for the desired isomer on a small scale, although the reaction did not proceed 
satisfactorily within the 1 hour reported in the literature (entry 4). Increasing the reaction time to 5 h gave an 88 % 
conversion to product (entry 5), which increased to 100 % after 7.5 h (entry 6). This reaction was amenable to scale 
up from 0.5 to 2.5 mmol, although the isolated yield was slightly diminished to 55 % (entry 7).  
 
Table 17 Optimisation of the azido aziridine ring-opening. Conversions determined by 1H NMR. 
Treatment of the pure azide 121a with Pd/C (cat.) under an atmosphere of H2 (g) effected the desired hydrogenation to 
amine 122a in quantitative yield, Scheme 27. In the previous synthetic route, treatment of the mixture 
of amine regioisomers with acryloyl chloride at rt led to the desired acrylamide 119 in a poor 26 % 
yield, in addition to an unexpected and subsequently problematic side-product 123 in a 19 % yield, 
Figure 102. Addition of acryloyl chloride to pure amine 122a at 0 °C, rather than rt, furnished the 
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desired negative control 119 in a 56 % isolated yield, with no formation of the undesired reactive Michael acceptor 
123. The optimised route to the desired negative control acrylamide 119 is shown in Scheme 27.  
 
Scheme 27 Optimised synthesis of negative control amine 119.  
It was desirable for a number of linker lengths to be investigated, varying in length and flexibility. Natural units such 
as glycine, β-alanine and γ-aminobutyric acid conveniently provide an amine for generation of the acrylamide and a 
carboxylic acid as a handle with which to couple amine fragments, with both functionalities separated by varying 
carbon spacers. Additionally, a number of di-amines with short carbon spacers are commercially available and were 
considered as more flexible linkers suitable for coupling to a carboxylic acid fragment. Such a linker would be 
suitable for coupling to the original carboxylic acid N-tosyl D-proline 64 fragment reported by Erlanson et al.[51] rather 
than the positive control amine 67, and would therefore provide an interesting comparison between linker types. Some 
attempts were made to investigate glycine, β-alanine, and 1,3-diaminopropane as linkers for use in KTGT as 
discussed in the following section.  
4.7.1. Glycine 
Glycine was investigated as a linker during the early stages of the KTGT project with cdc25A as the target protein. A 
series of small heterocyclic fragments tethered to the active site cysteine via a glycine spacer were predicted to bind 
favourably in the small active site binding pocket, as determined by manual docking using an available crystal 
structure, Figure 103. Synthesis of acrylamide 165 was facile using Schotten-Baumann type conditions, but problems 
were encountered taking carboxylic acid 165 on to further reaction with amines, Scheme 28. The problems 
encountered during the synthesis were likely to be due to polymerisation with the acrylamide, as previously discussed 
for other synthetic routes. This suggested that for the synthesis of acrylamide-linker-fragments, the acrylamide should 
remain protected until the final step.   
 
Figure 103 Structure 167 manually tethered from tyr386 using the cdc25A crystal structure (PDB code 1C25) and WebLabViewer 
software. The glycine linker makes an interaction with a bound water molecule and the isoxazole fragment makes a number of 
interactions within the active site pocket.  
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Scheme 28  Attempted synthesis of glycine linked acrylamide-fragments.  
4.7.2. β-Alanine 
The first linker length to be thoroughly investigated for KTGT was β-alanine, which provides a two-carbon spacer 
between the acrylamide and the fragment, Figure 104. As this is a significantly shorter length than that employed in 
the previous PEG-linker it was hoped that effective molarity would be retained, whilst still providing some flexibility.     
 
Figure 104 β-alanine linker.  
Synthesis of β-alanine modified acrylamide-fragments 
As outlined retrosynthetically in Scheme 29, the acrylamide was taken through the synthesis protected as an α-
phenylselenide in a manner analogous to the PEG-linker synthesis. Deprotection in the final step by oxidation of the 
selenium and in situ elimination generates the desired acrylamide. The amine fragment is coupled to the linker in the 
penultimate step in order to diverge the synthesis at the latest possible point. The precursor for this coupling reaction, 
carboxylic acid 168, is synthesised from commercially available β-alanine and the previously synthesised carboxylic 
acid 145.  
 
Scheme 29 Retrosynthesis for acrylamide-fragments with β-alanine spacer.  
The synthetic route commenced with commercially available β-alanine methyl ester 169, with the ester protecting 
group to prevent reaction of the alanine carboxylic acid during the first step. Treatment of α-selenide carboxylic acid 
145 with oxalyl chloride and catalytic DMF in THF, with subsequent addition of β-alanine methyl ester and 
triethylamine led to generation of the desired amide 170 in isolated yields of between 61-65 %, Scheme 30. 
Hydrolysis of the ester furnished the desired carboxylic acid 168 in excellent isolated yields of between 94-100 %. 
Before coupling of carboxylic acid 168 with either the positive or negative control amines, a test reaction was carried 
out using N-phenylpiperazine 171. Treatment of carboxylic acid 168 with amine 171 and zirconocene dichloride in 
toluene led to a moderate isolated yield of 65 % for the desired amide 172. Oxidation of the selenium and in situ 
elimination led to the final acrylamide-fragment 173 in 48 % yield. Treatment of intermediate acid 168 with positive 
control amine 67 using the same zirconocene dichloride reflux conditions generated the desired amide 174 in 44 % 
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yield, with subsequent deprotection furnishing the desired compound 175 for screening in an excellent 94 % yield. 
Coupling of intermediate acid 168 with negative control amine 119 yielded the desired acrylamide 177 upon oxidation 
and elimination, although in only 18 % over the two steps.  
 
 
Scheme 30 Synthesis of a set of acrylamide-fragments with a β-alanine linker.  
An HPLC study was carried out to ascertain the intrinsic reactivity of the positive and negative β-alanine modified 
acrylamides, using reduced glutathione as the model thiol. As shown in Figure 105, both ligands reacted at a very 
similar rate (red and black traces for positive 175 and negative 177 ligands respectively) with both reactions slightly 
faster than that of the positive control 67 (blue trace). The percentage of electrophile which reacted per minute was 
calculated as 0.16 ± 0.2 and 0.19 ± 0.2 for the positive and negative control ligands 175 and 177 respectively, whereas 
that for positive control 67 was 0.14 ± 0.3.* As only a small percentage of the acrylamide reacts during this 
experiment, the data sets can be fitted with linear trendlines, which represent initial reaction rates.  
 
Figure 105 Rate of reaction of acrylamides 67 (blue trace, squares), 175 (red trace, diamonds), 177 (black trace, circles) with glutathione 
in ammonium bicarbonate (100 mM) pH 8 (measured as three separate reactions). Acrylamides at 1 mM and glutathione at 5 mM. 
Reactions monitored by HPLC in the presence of 4-aminobenzamide (0.5 mM) as an internal standard. All reactions were run in 
duplicate, with both traces indicated on the chart. Data is relative to internal standard and normalised to intensity at t = 0 min.  
Incubation of TS with a mixture of both positive and negative β-alanine-linked acrylamides 175 and 177, with each 
acrylamide at 100 µM, led to modification of the protein with both ligands over time, Figure 106. Reducing the 
                                                        
* Calculated from the average gradient of linear trendlines fit to two data sets. Error represents the standard deviation.  
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concentration of both acrylamides to 10 µM (stoichiometric with the protein), in an attempt to reduce the background 
reaction, led to no modification of the protein with either acrylamide, even after a 900 min incubation period. 
Increasing the concentration of each acrylamide to 200 µM led to generation of adducts with both ligands, although at 
a faster rate. As indicated in Figure 107, the rate of modification of TS with positive control 175 was faster than with 
negative control 177, at both 100 and 200 µM ligand concentrations. As positive control acrylamide 175 was found to 
have a slightly lower intrinsic reactivity than negative control acrylamide 177, this suggests that a kinetic template-
guided tethering effect accounts for the faster modification of protein thiol with positive control 175, whereas adduct 
formation between TS and negative control 177 is likely to represent the non-templated background reaction rate.  
 
 
Figure 106 TS (10 µM) in ammonium bicarbonate (10 mM) and DTT (1 mM) pH 8, with acylamides 175 and 177 each at a final 
concentration of 100 µM. Aliquots from the main reaction taken for ESI MS analysis at 10, 60 300 and 1020 min. 
 
Figure 107 Analysis of data from Figure 106 in addition to data generated with acrylamides at 200 µM. Chart shows formation of 
protein-acrylamide adducts over time normalised to total protein. Black traces (squares) represent positive control 175, red traces 
(diamonds) represent negative control 177, with full lines indicating acrylamides at 200 µM final concentration and dotted lines indicating 
acrylamides at 100 µM final concentration. Integrals for peaks were obtained after deconvolution of raw data using MaxEnt software. 
Integrals were normalised to the sum of the total protein.  
It was also considered that a favourable interaction between the linker and the protein surface might itself template the 
reaction, leading to a higher rate of background reaction for both fragments. The β-alanine linker was considered to 
potentially interact with the protein surface either through the direct formation of intermolecular H-bonds or by the 
formation of an intramolecular H-bond, generating a 6-membered ring fragment binder, Equation 8. To rule out the 
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formation of such favorable interactions, an acrylamide connected to the β-alanine linker, but without the fragment 
was desired. A propyl unit was considered to provide a good substitution for the N-tosyl D-proline fragment, Figure 
108.  
 
Equation 8 An intramolecular H-bond within the β-alanine linker generates a 6 m ring, which was considered a potential TS binder.  
 
Figure 108 Compound 178 was desired as a control for the β-alanine linker.  
Initial protection of β-alanine with a Z-group to generate Z-protected alanine 179 was carried out to protect the amine 
during amide synthesis. However, reaction of alanine 179 with N-propylamine under a range of conditions failed to 
generate the desired amide, Scheme 31. It was considered that the primary amide would also be suitable as the control 
compound for this experiment, and generation of this using ethyl chloroformate, with an aqueous ammonia quench 
furnished the desired product 180. Removal of the Z-group was facile to give amine 181, but reaction of this with 
acryloyl chloride under the conditions used to synthesise acrylamide 165 did not yield the desired acrylamide 182.  
 
Scheme 31 Attempted synthesis of a screening control for the β-alanine linker.  
However, reaction of acrylamide 183* with ethyl chloroformate, and a subsequent ammonia quench led to the desired 
amide 182, albeit in a poor 6 % yield, Equation 9. Screening of acrylamide 182 against TS to control for the effect of 
the linker should form part of the future work for this project.  
                                                        
* Synthesised by Masters student Madeline Ross.  
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Equation 9 
4.7.3. 1,3-Diaminopropane 
Alkyl diamine spacers were considered as potentially suitable for use in KTGT to link the acrylamide and the 
fragment. In comparison to the β-alanine linker, a 1,3-diaminopropane linker has a greater flexibility due to the 
replacement of the sp2 centre with an sp3 centre. A diamine linker would be suitable for coupling to fragments with a  
carboxylic acid handle, rather than the amines that were required for coupling to the β-alanine, Figure 109.  
 
Figure 109 Comparison between the β-alanine (green) and the 1,3-diamine linker (blue).   
Some initial work towards the synthesis of acrylamide-fragments with a 1,3-diamine linker was carried out. Initial 
attempts to sythesise the desired acrylamides modified with this linker and the positive and negative fragments began 
with attempts to mono-protect the diamine. Monoprotection with either a Boc or a Cbz protecting group was 
unsuccessful, with mono-Cbz protection leading to isolation of only the di-protected amine 184, Scheme 32. It has 
been proposed that the reaction between acid chlorides and alkyl diamines is so rapid that upon addition of one drop 
of the reagent to the diamine, the reaction is complete at the point of contact.[198] Therefore, before mixing has 
occurred, complete formation of the di-acylated product has taken place. Christensen et al. proposed 
benzylphenylcarbonate 185 as a less reactive acylating agent suitable for the monoprotection of polyamines.[199] 
Synthesis of carbonate 185 was completed using the reported literature procedure, but its use in the mono-protection 
of 1,3-diaminopropane to amine 186 was unsuccessful.  
 
Scheme 32 Unsuccessful attempts to mono-acylate 1,3-diaminopropane.  
O
HO N
H
O
H2N NH
Ethyl chloroformate, THF, 
Et3N, 0 °C, 30 min then aq. NH3
6 %
O O
182183
O
N
H
N
H
N
SO
O
N
H
N
H
N
SO
O
O
O
O
H2N NH2
Boc2O (0.3 eq.), CH2Cl2, rt, 12 h
O
OCl
O
OO67 %
Benzyl alcohol, pyridine, CH2Cl2
O
N
H
N
H
O
OO
Benzylchloroformate (1 eq.), Et3N 
(1.5 eq.), CH2Cl2, rt, 3 h
60 %
H2N NH2 H2N NH
O
O
O
N
H
O NH2
1,3-diaminopropane (1 eq.), EtOH
184
185 186
Kinetic Template-Guided Tethering of Fragments                                                                                        Chapter Four 
  109 
Applying a different strategy, ten equivalents of the diamine were refluxed in the presence of N-tosyl phenylalanine 
187 and zirconocene dichloride, Scheme 33. Assuming that reaction with one amine does not affect the reactivity of 
the second amine, the major product from this reaction should have been the mono-amide 188. However, this was 
actually only isolated in a 24 % yield, with the di-amide 189 isolated in a 52 % yield. Reaction of the mono-amide 
188 with acryloyl chloride was unsuccessful.  
 
 
Scheme 33 Attempts to synthesise a 1,3-diamino-acrylamide linker modified with the negative control ligand.  
4.8. Conclusions and further work 
It was desirable to incorporate a linker into KTGT in order to normalise acrylamide reactivity across the library, and 
to allow fragments the flexibility to bind across a range of protein systems. The incorporation of linkers that are 
longer than the exact distance between the binding points of two multivalent ligands has been deemed a justifiable 
strategy by Whitesides et al. due to the slow loss of effective molarity with length.[184] Work by Blaustein et al. also 
suggested this as an effective strategy, with longer linkers thought to have a greater number of binding conformations 
that shorter ones, which must adopt more improbable, fully extended conformations.[188]  
In this work, the use of a linker composed of 2.5 PEG units led to a very slow modification of the protein, with loss of 
the templated reaction for the positive control. The linker may have been too long and flexible, such that upon binding 
of the positive control ligand, no increase in effective molarity of the acrylamide at the cysteine thiol occurred. As the 
cysteine resides so close to the pocket in this system, the long linker may have resulted in placement of the acrylamide 
too far from the reactive thiol. Alternatively, the overall slow rate of reaction of these PEG-linked acrylamides with 
the small molecule thiol glutathione may suggest some sequestration of the acrylamide by the water soluble PEG-
linker in aqueous solvents. 
O
OH
NHS
O
O
O
OH
NH2
O
N
HNHS
O
O
NH2
.HCl
1,3-diaminopropane (10 eq.), 
ZrCp2Cl2 (cat.), toluene
DL-phenylalanine
TsCl, Na2CO3 (aq.), 6 d
14 %
O
N
H
H
NS
O
O
N
H
O H
N S
O
O
O
N
HNHS
O
O
N
H
O
Acryloyl chloride, Et3N, 
CH2Cl2, rt, 12 h
187
188 - 24 %
189 - 52 %
Kinetic Template-Guided Tethering of Fragments                                                                                        Chapter Four 
  110 
Changing the linker to a β-alanine unit led to the observation of a KTGT effect, with formation of an adduct to TS 
with the less intrinsically reactive positive control proceeding at a faster rate than with the negative control. Attempts 
to synthesise positive and negative acrylamides incorporating the slightly more flexible 1,3-diamine linker were made 
but not completed. It was unknown whether the more flexible linker would confer an advantage by allowing the 
reaction to take place with reduced strain, or whether the additional loss of entropy upon reaction would make this 
linker less favorable.  
Future work for this project should include cloning and expression of a TS mutant with the cysteine moved to a 
location outside the pocket. Incubation of this mutant with a library of acrylamides modified with the 2.5 PEG unit 
linker might lead to some interesting results. Further work should be carried out with this TS mutant to see how linker 
length and rigidity affect reaction rate. It would be interesting to compare the acrylamide and vinyl sulfonamide 
functional groups with respect to the linker chemistry.   
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5. Conclusions and future work for kinetic template-guided tethering 
The aim of this project was the development of a novel methodology for the site-directed discovery of protein-binding 
fragments. Early work included the investigation of acrylamide and vinyl sulfonamide functionalities as potential 
capture groups for use in this method. The reaction of each capture group with small molecule thiols was monitored in 
a series of HPLC experiments and shown to be irreversible. A protocol was developed for the analysis of protein-
ligand adducts using MALDI mass spectrometry and a quadruple mutant of cdc25A with one surface exposed 
cysteine. The results obtained from this work were difficult to interpret, and it was concluded that a model system was 
required for proof-of-concept studies.  
Thmidylate synthase was adopted as the model system, with a number of compounds available for use as controls 
from earlier work published by Erlanson et al.[51] The synthesis of positive controls and higher affinity positive 
controls with acrylamide and vinyl sulfonamide appendages was successfully completed. The synthesis of a negative 
control with an acrylamide appendage was successful. TS was cloned, expressed and purified, and a protocol was 
developed to observe protein and protein-adducts using ESI mass spectrometry. Both vinyl sulfonamide and 
acrylamide capture groups were demonstrated to select only the positive control ligand from certain mixtures during 
screening against TS. The design of library members was shown to need special consideration, and basic amines are 
probably best avoided. It was considered that the basic amine in the acrylamide-modified negative control led to its 
selection by TS by an intramolecular base catalysis. A second negative control ligand with an acrylamide appendage 
was synthesised, and shown not to be selected by TS. A further compound 54 with a basic amine was found to be 
selected by TS. Of the ligands used in this study, N-benzyl piperidine 54 was found to be the best inhibitor of TS, 
although with a very weak Ki of greater than 3 mM. It might be that this compound is also selected by TS by a base-
promoted intramolecular rate acceleration. This compound was not selected by TS when modified with a vinyl 
sulfonamide. Control proteins papain, p97 and cdc25 were shown to have a reactive cysteine thiol by modification 
with iodoacetamide, but did not select the positive control acrylamide. The described methodology rapidly identified 
binding ligands via the formation of an adduct, which was stable to proteolytic digestion. This allowed identification 
of the position of modification by MALDI analysis of the resulting peptides. Further work should include an 
investigation of the vinyl sulfonamide group for use in KTGT.  
In the final chapter, an attempt was made to develop a linker unit to insulate the acrylamide from the fragment, and 
therefore normalise reactivity to conjugate addition across the library. It was also hoped that the linker would allow 
the acrylamide greater flexibility to react with the nucleophilic thiol upon fragment binding. The synthesis of a library 
of compounds containing an acrylamide and a fragment connected by 2.5 PEG units was successful using a 
phenylseleno protecting group. However, this connecting structural element was found to be unsuitable for KTGT, 
with no rate acceleration observed for reaction with the acrylamide-positive control. A β-alanine linker was shown to 
be more appropriate with a small rate acceleration observed for adduct formation to the positive control over the 
negative control. As future work for this part of the project, it would be interesting to investigate a shorter linker such 
as glycine, in addition to to probing the effect of moving the reactive cysteine further from the binding site. 
Furthermore, it would be useful to probe the effect of the linker length on vinyl sulfonamide-based KTGT.  
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Future work for this project should include the synthesis of a larger library of suitable fragments and application of 
KTGT to a therapeutically useful target.  
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6. Design and synthesis of a chemical probe to dissect the cellular signalling cascade leading to 
cyclin D1 degradation after DNA damage 
6.1. Introduction 
6.1.1. The Eukaryotic cell cycle  
The mammalian cell cycle is composed of four main phases; gap 1 (G1), synthesis (S), G2 and mitosis (M), which 
result in the exact duplication of genetic material and cell division (cytokinesis).[200] The cell cycle is tightly regulated 
by a complex network of proteins in which the serine/threonine cyclin-dependent kinases (cdks) play a fundamental 
role, Figure 110.[201] Monomeric cdks have only negligible activity as kinases and require binding of a cyclin subunit 
as an initial activation step.[202] Activated heterodimeric cdk-cyclin units act to phosphorylate substrate proteins, which 
then drive the cell cycle through the key transition points. With the exception of the D-type cyclins, the expression of 
cyclins is oscillatory throughout the cell cycle, providing a means to regulate cdk activity in a phase-specific manner. 
D-type cyclins (D1, D2 and D3) are expressed in response to growth factors, and in combination with their cdk 
binding partners, cdk 4 and 6, are critical for the entry of cells into the cell cycle and for G1-S phase progression.[203, 
204] Cdk4/6-cyclin D complexes phosphorylate the retinoblastoma (rb) family of proteins which then release E2F 
transcription factors that activate many genes required for cell cycle progression, including cyclins A and E.[205-209] 
Cdk2-cyclin E complexes further phosphorylate rb proteins in mid-late G1, causing complete disruption of their 
interaction with E2Fs.[210, 211] Cdk2-cyclin E complexes in late G1 and cdk2-cyclin A complexes in S-phase activate 
DNA synthesis,[212-214] whilst cdk1-cyclin A and cdk1-cyclin B complexes activate and drive the cell through 
mitosis.[215-217] Cyclin degradation occurs in a ubiquitin-dependent manner throughout the cell cycle once each 
particular cyclin has played its required role.[218]   
 
Figure 110 The role played by the cdk-cyclin complexes in the cell cycle. The phases of the cell cycle G0, G1, S, G2 and M refer to 
quiescence, gap1, DNA synthesis, gap2 and mitosis respectively. Phosphorylation of the retinoblastoma protein (Rb) by  the cdk-cyclin 
complexes  leads to release of E2F transcription factors and subsequent DNA synthesis of target genes, including cyclins A and E.  
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6.1.2. Cyclin D1 and the DNA damage response 
The integrity of the genome is constantly challenged by agents such as ultraviolet (UV) light, reactive oxygen species 
(ROS) and ionising radiation (IR). DNA lesions must be rapidly detected by the cell and a response quickly mounted 
to either stall cell cycle progression to enable DNA repair or to coordinate cell death.[219] The cell has three regulatory 
pathways, G1/S, intra-S and G2/M, termed DNA damage checkpoints, which control cell cycle progression after DNA 
damage in order to preserve genomic integrity.[220] Rapid cell cycle arrest at G1, initiated by ubiquitin-mediated 
degradation of cyclin D1, is an important part of the DNA damage response, as activation of the G1/S checkpoint 
prevents the replication of damaged DNA in S phase.[221-223] Cyclin D1 is often found to be overexpressed in human 
cancers and can have a highly detrimental impact if not correctly regulated following the DNA damage response.[224] 
Understanding the function and regulation of cyclin D1 on a molecular level is therefore of fundamental importance.   
Phosphorylation of cyclin D1 on Thr286, which marks the protein for ubiquitination and proteolytic degradation 
under both normal cell conditions and under genotoxic stress, can be carried out by a number of kinases. Glycogen 
synthase kinase (GSK) 3β has been shown to implement this phosphorylation of cyclin D1 under conditions of 
mitogen deprivation[221] and in response to genotoxic stress.[222] IKKα, which along with IKKβ and IKKγ subunits 
constitutes the IKK complex, has also been shown to destabilise cyclin D1 through phosphorylation of Thr286.[225] 
The IKK complex also plays a central role in the regulation of NF-kB transcription factors, which activate a number 
of genes including cyclin D1.[226] NF-kB transcription factors are held inactive in the cytoplasm by IkB proteins. 
Phosphorylation of IkBα protein on serine residues 32 and 36 by IKK marks it for ubiquitin-mediated proteasomal 
degradation and releases NF-kB which translocates from the cytoplasm to the nucleus to implement gene 
activation.[227] DNA damage can initiate the degradation of IkBα protein by the IKK complex, releasing NF-kB and 
initiating NF-kB signalling cascades.[228, 229] The reported downregulation of cyclin D1 following DNA damage and 
the effect on this by IKK is yet to be fully understood.  
 
Figure 111 The role played by NF-kB, IkBα, and the IKK complex in the regulation of cyclic D1 in the cell.  
6.1.3. Previous work  
Two novel inhibitors 190 and 191, Figure 112, were reported by Pierce et al. to irreversibly inhibit TNFα induced 
phosphorylation of IkBα, leading to decreased NF-kB released from the cytoplasm into the nucleus.[230] This led to an 
observed anti-inflammatory effect in vivo due to the decreased transcription of NF-kB target genes, including those of 
adhesion molecules such as E-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. The 
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Mann group was interested in elucidating the effect of NF-kB signalling on the regulation of cyclin D1 levels 
following DNA damage and the reported inhibition of IkBα phosphorylation and therefore of NF-kB transcription 
factors by vinyl sulfone 190 suggested this compound as a potentially useful tool to probe this. It was found that 
treatment of U2OS cells with genotoxic agents (UV, IR, 4-nitroquinoline 1-oxide (4NQO) and H2O2) led to a 
reduction in cyclin D1 levels as expected.[231] Interestingly, pre-treatment of cells with vinyl sulfones 190 or 191 
attenuated this reduction, Figure 113. Cells treated with vinyl sulfone 190 in the absence of DNA damaging agents 
exhibited a reduction in cyclin D1 relative to control cells, potentially due a reduction in transcription of cyclin D1 by 
NF-kB. Sulfone 190 was found not to be a general inhibitor of proteolysis.    
 
Figure 112 
The role of the IKK complex in the response of cells to inhibitor 190 after DNA damage was also investigated.[231] 
IKKα kinase has been suggested to phosphorylate cyclin D1 at Thr286, leading to cyclin D1 ubiquitination and 
degradation by the proteasome. However, cells lacking IKKα, IKKβ or both exhibited a cyclin D1 response similar to 
wild-type cells. Inhibitor 190 was able to attenuate the degradation of cyclin D1 induced by 4NQO exposure in wild-
type, IKKα null, IKKβ null and double knock out 3T3 cells, indicating that the attenuation of cyclin D1 after DNA 
damage is, at least in part, independent of the IKK pathway. 
 
Figure 113 U2OS cells were exposed to DNA damaging agents to analyse of the effect of inhibitor 190 on cyclin D1 expression. Cells 
were treated with different doses of ultraviolet C radiation (UVC, A), ionizing radiation (IR, B), 4NQO (C) and H2O2 (D) in the absence 
or presence of 5mM inhibitor 190. Cells were lysed 3h post-exposure and whole cell lysates were resolved by SDS-PAGE and analysed 
by immunoblotting against cyclin D1, phospho-histone H2A variant (ser139) (γH2AX) (marker to assess the degree of the DNA damage 
response mounted by the cell) and α-tubulin (loading control). Results are representative of two independent experiments. MW as per 
Protein Molecular Weight Marker. Work carried out and figure generated by Alexandra Duarte, PhD Thesis 2012.[231]  
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6.1.4. The chemical proteomics approach to compound-based target elucidation 
To identify the molecular target(s) of inhibitors 190 and 191 and therefore potentially elucidate the mechanism 
responsible for the attenuation in cyclin D1 reduction after DNA damage, a chemical proteomic strategy was 
considered.[232, 233] The field of proteomics aims to identify the structure, function, expression, localisation, regulation 
and interaction partners of every single protein produced by the genome.[234] Within the field of proteomics, chemical 
proteomics employs the use of a carefully designed chemical probe to achieve some of these goals.[235] Chemical 
probes are designed to bind specifically and covalently to a protein (or protein class) to facilitate its identification 
from complex cellular extracts. Probes that target catalytic nucleophilic residues in enzyme active site pockets are 
termed activity-based probes (ABPs) to reflect the necessity for the enzyme to be active in order to be captured. 
Probes which target non-catalytic residues are termed affinity-based probes (AFBP). Chemical probes are usually 
composed of an analytical tag (often a fluorophore, radiolabel or biotin group) connected to the reactive inhibitor by a 
linker. The biotin or fluorescent group conjugated to the mechanism-based inhibitor often confers poor 
pharmacokinetic properties to the probe, in addition to potentially affecting the binding affinity of the inhibitor.[236] 
Such bulky probes are often added to cell lysates, as they are unable in most cases to permeate cell membranes, and 
the analytical tag is used to isolate or identify bound proteins by either in-gel fluorescence, streptavidin-biotin pull 
down, or mass spectrometry-based techniques.  
The development of two-step labelling strategies independently by the Cravatt and Overkleeft groups in 2003 
provided a means to overcome the limitation of cell permeability.[237, 238] Two-step labelling strategies involve the 
addition of a mechanism-based enzyme inhibitor, conjugated to a small latent bioorthogonal handle, to live cells 
where the inhibitor binds to target biomolecule(s). A bioorthogonal ligation reaction is then used to attach an 
analytical tag to the inhibitor after the cell has been lysed. Bioorthogonal reactions must fulfil two stringent 
requirements; they must proceed rapidly under physiological conditions and be inert to the myriad of other 
functionality present in the cell.  
The Staudinger ligation, a modification of the classic Staudinger reduction, was employed by the Overkleeft group 
who used an azide-modified vinyl sulfone to target proteasomes within the cell, with subsequent capture by a 
biotinylated trialkylphosphine probe.[238] The trialkylphosphine used in this reaction is a slight modification of 
triphenylphosphine with one of the phenyl groups containing a stratgically placed ortho methylester. After formation 
of the aza-ylide, key intramolecular amide formation with displacement of methanol occurs, preventing hydrolysis of 
the ylide to the amine and phosphine oxide. Subsequent hydrolysis generates the stable ligation product, Figure 114.  
An alternate use for the azide in bioorthogonal ligation chemistry is the Cu(I)-catalysed azide-alkyne 1,3-dipolar 
cycloaddition (CuAAC). This reaction is a variant of the initial Huisgen triazole synthesis which is typically quite a 
slow reaction.[102] Sharpless[239] and Meldal[240] reported the addition of a Cu(I) catalyst to significantly increase the 
reaction rate, and the bioothogonality of this reaction was demonstrated by Finn et al. in 2003.[241] CuAAC was first 
utilised in a two-step labelling  procedure by the Cravatt group who used an azide-conjugated phenylsulfonate ester to 
modify several enzymes in live cells.[237] An alkyne-modified rhodamine fluorophore was added to cell lysates to 
conjugate the fluorophore to the enzymes, which were subsequently separated using gel electrophoresis and visualised 
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using fluorescence scanning. The Cravatt group has since used this procedure to profile human breast cancer cells[242] 
and the P450 cytochrome enzyme family in vivo.[243] The CuAAC mediated two step labelling procedure is reported to 
be more efficient with the azide conjugated to the analytical tag and the alkyne to the electrophilic inhibitor, due to 
nonspecific modification of proteins with the alkyne-rhodamine tag, but not the azide-rhodamine tag in the presence 
of Cu(I). [242]  
 
Figure 114 Illustration of the 2-step labelling strategy and bioorthogonal ligation reactions.  
6.1.5. Design of the chemical probe 
A two-step chemical ligation strategy was thought to be particularly suitable for this project. Introduction of a small 
latent ligation site minimises disruption to the size and shape of the original inhibitor and furthermore, should not 
significantly alter the cell permeability. The CuAAC reaction was hypothesised to be more suitable than the 
Staudinger chemistry due to the small size of the alkyne in comparison to the trialkylphosphine. Both compound 190 
and related inhibitor 191 were postulated to exert their irreversible mechanism of action through the formation of an 
irreversible covalent bond to their target biomolecules via the unsual 3-sulfonylacrylonitrile electrophile. It was 
therefore critical to leave this functionality intact in the chemical probe. As both methyl and tertbutyl groups are 
tolerated on the phenyl ring at the para position, this was thought to be the position with greatest degree of flexibility 
and therefore suitability for installation of the alkyne, Figure 115. With the alkyne combined with the electrophilic 
inhibitor, the analytical tag requires an azide modification. This avoids addition of an alkyne-modified analytical tag 
to cellular extracts, which as previously discussed, leads to nonspecific protein modification and increased 
background reaction. The overall aim of this section of work was to develop a synthetic route to chemical probe 192 
and to synthesise enough material to use in chemical proteomic experiments.   
 
Figure 115 Design of the chemical probe 192 from literature inhibitors 190 and 191. 
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6.2. Synthesis of the alkyne-tagged chemical Probe 
6.2.1. Synthetic route one 
A retrosynthetic analysis to reach novel compound 192 was designed as shown in Scheme 34. The acrylonitrile 
functional group was expected to be an exceptionally good Michael acceptor and the synthetic route was therefore 
designed to install it in the final step using oxidation of α-selenide 193 and subsequent in situ 2,3-syn elimination of 
phenylselenenic acid. The route included a key ‘selenosulfonation’ of acrylonitrile to install the α-selenide 193 from 
selenosulfone 194. Aromatic sulfonation of phenylacetylene was expected to yield a mixture of ortho/para substituted 
products.   
 
Scheme 34 Initial retrosynthetic analysis to reach desired chemical probe 192.  
The aromatic sulfonation of phenylacetylene was an unprecedented transformation. Chlorosulfonic acid was chosen as 
the sulfonylating agent with which to attempt this reaction due to the range of successful examples in the literature.[244] 
Additionally, as chlorosulfonic acid is a more powerful sulfonylating agent than sulfuric acid, mild conditions can 
often be used to effect the desired reaction.[244] Upon addition of chlorosulfonic acid to phenylacetylene in chloroform 
at 0 °C a thick, black slurry was instantaneously generated with a number of products visible by TLC. Attempts to 
isolate the products using column chromatography led to degradation. Addition of the chlorosulfonic acid at -78 °C 
did not improve the reaction, and the alkyne was considered likely to be the source of the problem, perhaps leading to 
polymerisation side reactions. The sulfonation of bromobenzene using the same reagent was therefore attempted as 
this reaction is known with chlorobenzene,[244] and the bromine provides a handle for installation of the alkyne later in 
the synthesis. However, treatment of bromobenzene with chlorosulfonic acid resulted in the isolation of only diaryl 
sulfone 195 from the reaction mixture, Equation 10. Diaryl sulfones are known side-products of this reaction, and are 
thought to arise by reaction of the desired arylsulfonic acid with the starting aromatic.[244]  
 
Equation 10 
As 4-bromobenzenesulfonyl chloride 196 was commercially available, it was purchased as the starting point for the 
synthetic route. Reaction of this sulfonyl chloride with hydrazine hydrate furnished the intermediate sulfonyl 
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hydrazide 197 in 91 % yield. The sulfonylhydrazide was subsequently oxidized with benzene seleninic acid to 
generate selenosulfonate 198 in a moderate 74 % yield, Scheme 35. The reaction mechanism for this transformation, 
proposed by Back et al.[245] involves initial attack from the terminal sulfonylhydrazine N onto selenium with 
displacement of water, Scheme 36. Elimination of selenenic acid generates the sulfonyldiazene, which then reacts 
with the selenenic acid at the terminal N. Entropically favorable extrusion of N2 generates the desired selenosulfonate.  
 
Scheme 35 
 
Scheme 36 Mechanism proposed by Back et al. for formation of sulfur-selenide intermediate.[245] 
With the selenosulfonate intermediate 198 in hand, the key step for this reaction sequence was attempted. A reaction 
mechanism, proposed by Back and Collins, for the selenosulfonation reaction is shown in Scheme 37.[246] Initial 
homolysis of the Se-S bond generates two radical species, the sulfonyl radical, which is subsequently trapped by 
attack at the β-position of acrylonitrile, and the phenyl selenyl radical. The resulting alkyl radical attacks the selenium 
atom of a second molecule of starting selenosulfonate to generate the desired product and a sulfonyl radical to 
propagate the chain. The literature conditions for this reaction require refluxing of the two reaction components in 
chloroform, with the radical reaction initiated by heat.[246] The only example in the literature of the selenosulfonation 
of acrylonitrile employs R = p-tolyl,[246] and examples for the selenosulfonation of other olefins with aryl R groups 
include only R = phenyl, p-tolyl.[247-250] It was therefore unknown whether the aryl-bromide substituent would be 
tolerated.  
 
Scheme 37 Mechanism proposed by Back for the selenosulfonation of acrylonitrile. 
Following the literature conditions, the starting selenosulfonate 198 was refluxed in chloroform with one equivalent of 
acrylonitrile, but this led to an almost quantitative yield of diphenyl diselenide. This presumably results from the 
dimerisation of the initially generated phenylselenyl radical. The reaction was repeated in anhydrous, degassed 
chloroform with two equivalents of acrylonitrile to trap the sulfonyl radical more effectively and with gradual heating 
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over a longer period of time to more slowly initiate the radical reaction, but only starting material 198 and diphenyl 
diselenide were identified in the reaction mixture. Changing the solvent from chloroform to toluene with reflux at  
higher temperature gave no improvement in this reaction. It was noted that the starting material was unstable over the 
course of a few days in solvent at rt in the presence of light, with decomposition to diphenyl diselenide by TLC, 
indicating that this S-Se bond is susceptible to photolysis. Photolysis has been reported as an alternative method to 
intiate selenosulfonation reactions.[249]  
The use of DABCO to catalyse similar selenosulfonation reactions has been reported in the literature with α,β-
unsaturated ketones rather than acrylonitriles.[251] Presumably the mechanism for this reaction involves 1,4-conjugate 
addition of the tertiary amine catalyst onto the unsaturated ketone, followed by attack of the enolate through the 
carbon onto the selenium with loss of the sulfonate anion. E1CB elimination of the amine catalyst then regenerates the 
electrophilic α,β-unsaturated bond, which is subsequently attacked by the sulfonate anion to generate the desired 
selenosulfonation product. This reaction was attempted with acrylonitrile and selenosulfonate 198, but none of the 
desired product 199 and a 75 % yield of diphenyldiselenide was isolated from the reaction mixture, Equation 11.  
 
Equation 11 
During their efforts to develop desulfitative Heck reactions between readily available sulfonyl chlorides and olefins, 
the Vogel group reported that the corresponding vinyl sulfones were accessed at lower reaction temperatures.[252] 
Reaction between 4-chlorophenylsulfonyl chloride and styrene gave an impressive 60 % yield of the corresponding 
vinyl sulfone, demonstrating excellent selectivity over the aryl chloride bond, which agrees with the reported greater 
reactivity of sulfonyl chlorides towards oxidative addition compared with the analogous bromides and chlorides.[253, 
254] This indicated that there was reasonable precedent for the analogous Heck reaction between 4-
bromophenylsulfonyl chloride 196 and acrylonitrile, but the desired product 200 was only isolated in only 5 % yield 
along with the sulfonic acid 201 in 3 % yield, Equation 12.  
 
Equation 12 
The desired 3-sulfonylacrylonitrile 200 was obtained in an improved yield via generation of the sodium sulfinate salt 
202 from 4-bromosulfonyl chloride 196 and subsequent reaction with 2,3-dibromopropionitrile, Scheme 38.[255]  
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The authors suggest the mechanism for this reaction involves initial dehydrobromination mediated by a sulfinate 
anion, conjugate addition of a second sulfinate anion, SN2 displacement of the second bromide and a final elimination 
of sulfinic acid to generate the desired vinyl sulfone, Figure 116, mechanism 1. However, as they report scope for the 
reaction including R1 = alkyl and phenyl, the second step of this mechanism seems unlikely. Although the polar 
aprotic DMF solvent favours the SN2 reaction, this is still moderately unfavorable at the secondary carbon. The 
reaction may be more likely to proceed via an initial SN2 displacement of the primary halogen, followed by an E1CB 
elimination of the second bromide, mechanism 2.  
 
Figure 116 Possible mechanisms for the addition of aryl sodium sulfinate to 2,3-dibromo substrates.  
An 80 % isolated yield was quoted by the authors for the addition of sodium phenylsulfinate to 2,3-
dibromopropionitrile.[255] The use of these conditions with the sodium 4-bromophenylsulfinate substrate, with 1.5 eq. 
of the sulfinate and a 10 h reaction time, gave only a 37 % isolated yield of the desired vinyl sulfone 200, although 
pleasingly with complete selectivity for the trans isomer, Table 18 (entry 1). Using 1.5 equivalents and a 3 h reaction 
time, a slightly reduced yield of 25 % (1H NMR yield) was obtained (entry 2). Decreasing the number of equivalents 
of sulfinate to 1.1 decreased the yield to 25 % after 10 h (entry 3), whilst increasing the equivalents to 3.0 led to 
consumption of starting material by TLC after only 1 h, although this gave an isolated yield of only 44 % (entry 4). 
With 1.7 equivalents, the starting material was consumed after 1.5 h, although this only gave a 16 % isolated yield 
(entry 5). As 3 equivalents of sulfinate and a 1 h reaction time gave the highest isolated yield, the reaction was 
repeated with 3 equivalents and left for 3 hours. However, 1H NMR analysis identified that no product remained in the 
crude reaction mixture after this time (entry 6). On attempting to increase the reaction scale to 8mmol, only a 3 % 
yield of the product was isolated (entry 7) indicating that perhaps the reaction is not particularly amenable to scale up.  
 
Entry No. Eq. 202 time (h) Yield 200 (%) 
1 1.5 10 37 
2 1.5 3 25* 
3 1.1 10 25 
4 3.0 1.0 44 
5 1.7 1.5 16 
6 3.0 3 0* 
7 1.6 8 3** 
 
Table 18 Conditions to synthesise 3-sulfonylacrylonitrile 200. *Yield estimated by 1H NMR yield with 1,3,5-trimethoxybenzene internal 
standard. ** 8 mmol scale. Highest yielding reaction conditions highlighted in bold (entry 4). 
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Despite the low yields for generation of acrylonitrile 200, enough material was obtained to test the subsequent 
Sonogashira step. Although rate determining oxidative insertion of Pd(0) into iodoarene C-I bonds is faster than for 
the corresponding bromides, the starting bromoarene 200 was anticipated to be activated to oxidative addition of 
Pd(0) by the electron withdrawing sulfone. Conditions which have been reported previously for the Sonogashira 
coupling of electron deficient 4-bromobenzonitrile with TMS-acetylene were initially employed to convert 
bromoarene 200 to the TMS-protected acetylene 203, Table 19 (entry 1).[256] Two equivalents of TMS-acetylene were 
used in this procedure, presumably due to the expected copper mediated Glaser-Hay homodimerisation side reaction, 
which usually occurs upon incomplete exclusion of oxygen.[257] However, despite only obtaining 17 % isolated yield 
of the TMS-acetylene homodimer, none of the desired product was obtained. The use of Et3N base as the solvent for 
the reaction with gentle heating at 50 °C (entry 2) resulted in precipitation of a thick black solid, potentially 
containing the catalytically inactive palladium black, and resulting in a poor mass recovery. A procedure reported by 
Krause for the Sonogashira reaction of a range of activated bromoarenes was next applied to this transformation (entry 
3).[258] In this procedure, triphenylphosphine is added to stabilize the palladium catalyst and the copper (I) iodide is 
added 20 minutes after the other reagents. However, this actually resulted in an increase in the isolated yield of the 
TMS homodimer to 34 % whilst some starting material but none of the desired acetylene product was isolated. Using 
conditions reported for the successful Sonogashira reaction between 4-bromophenyl(methyl)sulfone and TMS-
acetylene, arylbromide 200 was treated with Et3N/CH2Cl2 (1:1), 5 mol % of CuI and of Pd(PPh3)2Cl2 and 2 
equivalents of TMS-acetylene (entry 4).[259] However, after 14 h at rt no conversion to product was indicated by 1H 
NMR of the crude reaction mixture and the starting material was re-isolated in an 82 % yield. For these reactions, no 
formal degassing of solvents was carried out, although the reaction was always purged thoroughly with argon by 
subjecting the flask to multiple vacuum-argon cycles.  
 
Entry Pd(PPh3)2Cl2 mol% CuI mol % Solvent  Base (eq.) TMS-acetylene eq.  Time (h) Temp (°C) Ligand 
1 10 10 THF/Et3N (4:1) n/a 2.0 16 rt No 
2 5 5 Et3N n/a 1.2 7 50 No 
3 5 1.2* THF Et3N (1.5) 1.5 22 rt PPh3  
4 5 5 CH2CH2/Et3N (1:1) n/a 2.0 14 rt No 
 
Table 19 Attempted Sonogashira to generate TMS-acetylene 203 from bromoarene 200. *The CuI was added to the reaction mixture 20 
minutes after the other reagents.   
A new set of Sonogashira conditions were adopted with the solvents sparged with argon for 10 min before use in the 
reaction. The reaction was initially tested on known substrate 4-cyano-3-fluorobromobenzene 204, which gave the 
desired TMS-acetylene 205 in a pleasing 72 % isolated yield, Scheme 39. Upon addition of Et3N to the reaction 
mixture, a very distinct colour change, as reported, from bright yellow to black was observed to indicate the necessary 
reduction of Pd(II) to Pd(0).[260] Application of the same conditions to aryl bromide 200 gave no distinct colour 
change. Analysis of the crude reaction mixture by 1H NMR indictated the TMS-acetylene dimer, but no starting 
material and no product with olefinic protons. It was considered that perhaps in this reaction, the palladium 
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coordinates across the unusual 3-sulfonylacrylonitrile system, leading to the stabilisation of Pd(II), consistent with the 
lack of colour change, and no generation of the desired Sonogashira product.  
 
Scheme 39 
An ‘aromatic Finklestein’ reaction, reported by Buchwald in 2002, was adopted in an attempt to synthesise the 
iodoarene from the bromoarene, on the basis that the Sonogashira reaction may prove more successful with the more 
reactive C-I bond.[261] Unfortunately, the excellent yields reported by Buchwald for this transformation could not be 
repeated using either using either catalytic trans-racemic-diamine 207 or N,N'-dimethylethylenediamine ligand with 
either aryl bromide 200 or known substrate 5-bromoindole, Scheme 40. 
 
Scheme 40 
It was decided that a new route to the desired chemical probe was required to avoid intermediate 200, which was not 
amenable to Pd or Cu catalysed reactions. It was thought that conjugate addition of phenylthiolate or benzeneselenide 
to sulfonyl acrylonitrile 200 might protect the olefin during the Sonogashira couping whilst also providing a handle 
for removal by oxidation and elimination. However, selectivity issues beween conjugate addition of the thiol/selenide 
to the olefin and aromatic substitution were anticipated, along with potential interference between sulfide/selenide and 
metal catalyst and so this reaction pathway was not pursued.  
Returning to a retrosynthesis similar to that outlined in Scheme 34, an attempt was made to generate 4-TMS-
acetylenebenzenesulfonyl chloride 208, on the basis that this would provide the necessary functionality to generate the 
sulfonate salt 209, and a subsequent addition to 2,3-dibromopropanenitrile and TMS-deprotection would yield the 
desired chemical probe 192. Selective coupling of the Ar-I bond of 4-iodobromobenzene 210 with TMS-aceylene 
generated bromoarene 211 in an excellent 96 % yield, Scheme 41. Halogen-lithium exchange using nBuLi and quench 
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with sulfonylchloride was hoped to yield arylsulfonyl chloride 208. However, this generated multiple products which 
were too difficult to separate using column chromatography, due to their high solubility in n-hexane. Changing the 
quench from sulfonyl chloride to sulfur dioxide gas pleasingly led directly to the lithium sulfinate salt 212. Although 
reaction of sulfinate 212 with 2,3-dibromopropionitrile did not generate any of the desired acrylonitrile 203, conjugate 
addition of sulfinate 212 to 2-chloroacrylonitrile and in situ elimination of HCl under the reaction conditions led 
directly to the desired acrylonitrile 203, a reaction that is unreported in the literature. A yield of only 16 % was 
achieved for this reaction but no further optimisation was carried out due to the concurrent success of a second 
synthetic route.   
 
Scheme 41 Synthesis of TMS-protected chemical probe 203 from 4-iodobromobenzene 210.  
6.2.2. Synthetic route two 
It was hypothesised that the 3-sulfonylacrylonitrile moiety within intermediate 200 rendered this compound unsuitable 
as a substrate for metal-catalysed reactions. It was predicted that the saturated 3-sulfonylpropionitrile analogue would 
not be susceptible to the same problems and could be desaturated using a number of methods later in the synthetic 
route.  
Synthesis of starting bromoarene 213 for the Sonogasira reaction was facile using a conjugate addition of sulfinate salt 
202 to acrylonitrile.[262] Application of the Sonogashira conditions used to generate aryl-TMS-alkynes 205 or 211 led 
to a poor 15 % yield of desired TMS-acetylene 214, with 67 % recovery of starting material, Table 20 (entry 1). 
However, upon gentle heating with an increased reaction time, a significant improvement to yield 66-68 % of the 
desired aryl-TMS-acetylene 214 was achieved (entry 2). In order to generate the 3-sulfonylacrylonitrile from the 
saturated 3-sulfonylpropionitrile system, two strategies were considered; α-selenation, oxidation and in situ 
elimination and dehydrogenation.  
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Entry Time (h) Temp (°C) Yield 214 (%) 
1 18 20 15 
2 24 40 66-68 
 
Table 20 Conditions for the Sonogashira reaction of arylbromide 213 to generate TMS-acetylene 214.  
Whilst there are currently no methods available to dehydrogenate alkyl sulfones or alkyl nitriles to vinyl sulfones or 
acrylonitriles respectively in one step, a number of one step dehydrogenations have been reported to take carbonyl 
groups to the the corresponding α,β-unsaturated compounds. These include the use of 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ),[263, 264] Chloranil[265] and o-iodobenzoic acid (IBX).[266, 267] IBX was reported as a highly efficient 
reagent to effect the dehydrogenation of ketones by K.C. Nicolaou in 2002.[266] It was suggested that this reaction 
proceeded via  a single electron transfer (SET) mechanism and it was considered that cyano-sulfone 214 may be more 
susceptible to such oxidation given the high degree of conjugation and therefore thermodynamic stability this 
desaturation would confer. The IBX reagent 215 was synthesised from 2-iodobenzoic acid and oxone in water using a 
procedure reported by Santagostino, Scheme 42.[268] IBX made by this method is proposed to pose much less of an 
explosion risk compared with that synthesised using potassium bromate.[266, 269] Using the Santagostino method, pure 
IBX was isolated as a precipitate from the reaction in a moderate 76 % yield. A second crystalline solid was observed 
to form within the filtrate over a 24 h period, which upon isolation was identified as pure iodosobenzoic acid (IBA) 
216, previously unreported as a side product in this reaction. Heating cyano-sulfone 214 with IBX in DMSO at 85 °C 
for 30 min led to complete recovery of starting material, whilst heating for longer periods led to slow degradation and 
formation of a complex mixture.  
 
Scheme 42 Synthesis of IBX 215 and attempted oxidation of cyano-sulfone 214.  
Development of α-selenation conditions 
The α-selenation of saturated sulfones or nitriles and subsequent oxidation and elimination has been previously 
reported as a strategy to generate vinyl sulfones[270-273] and acrylonitriles[274, 275] respectively. However, there is no 
reported example of the α-selenation of the 1,3-sulfonylnitrile system required here. As an initial test reaction to 
accomplish the desired α-selenation, 1,3-sulfonylnitrile 214 was added to LDA (generated in situ from iPr2NH and 
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nBuLi) to effect the deprotonation and PhSeCl was added to quench the anion in a 
subsequent step, Table 21 (entry 1). It was expected that a mixture of selenides would result 
from this reaction with possible deprotonation α to either the nitrile or the sulfone. 
Although exact pKa values for the relevant protons in 1,3-sulfonylnitrile 214  are unknown, 
examination of other substrates indicates that they are probably fairly similar, Figure 
117.[276] However, the reaction led only to the recovery of starting material (63 %), diphenyl 
diselenide and diaryl selenide 217 (17 %). Diaryl selenide 217 presumably results from the 
fast elimination of SO2 from the α-nitrile anion, resulting in the aryl lithium which is then quenched upon addition of 
the selenide electrophile. 1,3-Sulfonylnitrile 214 was treated with LiHMDS in the presence of PhSeCl in an attempt to 
quench the anion before decomposition (entry 2). Pleasingly, this led to the formation of a small quantity of an α-
selenation product 218 (8 %), along with the recovery of significant starting material 214 (59 %). Diphenyl diselenide 
and diaryselenide 217, were identified as components of the reaction mixture by TLC.  
There were a number of problems associated with this reaction. Firstly, a side reaction between PhSeCl and LiHMDS 
occurs, leading to the generation of the poorly electrophilic diphenyl diselenide, and using up the base within the 
reaction mixture. Degradation to the aryl lithium occurs if the reaction is carried out in the absence of the electrophilic 
selenium source, and to some extent even in the presence of the selenium source leading to the observed degradation 
product 217. To test the stability of sulfone 214 to basic conditions it was stirred with NaH in THF for 15 min, after 
which time there was no remaining starting material, and none of the degradation products could be identified by 1H 
NMR. Repeating this in the presence of N-(phenylseleno)phthalimide (NPSP) led to the generation of diphenyl 
diselenide and the recovery of starting material (entry 3). Treatment of a mixture of diphenyl diselenide and sulfone 
214 with LiHMDS gave no reaction at all, rather than either the degradation product 217 or the desired α-selenide 
(entry 5). Treatment of 1,3-sulfonylnitrile 214 with LiHMDS followed by PhSeCl led to the complete formation of 
degradation product 217 with no starting material remaining by TLC (entry 4). It was considered that perhaps a weak 
base could be used to carry out this reaction, but addition of Et3N to a solution of PhSeCl and 1,3-sulfonylnitrile 214 
led to only the formation of diphenyl diselenide and the recovery of starting material (entry 6).  
Interestingly, addition of LiHMDS to NPSP in CH2Cl2 followed by addition of sulfone 214 led to the generation of 22 
% of the desired product 218 with 51 % recovered starting material (entry 7). The addition of LiHMDS to a mixture 
of NPSP and 214 led to generation of only diphenyl diselenide and starting material (entries 8 and 9). The conditions 
for both these reactions involved addition of reagents at -78 °C with at least 30 min stirring at this temperature and 
subsequent warming to rt before addition of an aqueous quench. In an attempt to understand this reaction, 1,3-
sulfonylnitrile 214, as a solution in CH2Cl2, was treated with LiHMDS at -78 °C and quenched with D2O at either -78 
°C or 5 min after warming to rt. Unfortunately, these experiments were inconclusive with no deuterium incorporation 
observed by 1H NMR for either quench temperature. This may be due to an effect similar to that reported previously 
by Seebach, where incomplete deuterium incorporation was observed upon quenching lithium enolates generated by 
strong secondary amine bases.[277] Despite the anomalies observed with this reaction, enough material was brought 
through to test the remaining steps in the synthetic sequence.  
Figure 117 pKa values for  
protons α to sulfone or 
nitrile, indicated by asterix.  
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Entry No. 214 addn order Base Se Source Solvent 214 217 218 DPDS 
1 2 LDA (1) PhSeCl (3) THF 63 17 0 Y 
2 1 LiHMDS (3) PhSeCl (2) THF 59 Y 8 Y 
3 2 NaH (1) NPSP (2) THF Y N N Y 
4 1 LiHMDS (2) PhSeCl (3) THF N Y N Y 
5 1 LiHMDS (2) DPDS (1) THF Y N N Y 
6 1 Et3N (2) PhSeCl (1) CH2Cl2 Y N N Y 
7 3 LiHMDS (2) NPSP (1) CH2Cl2 51 N 22 Y 
8 1 LiHMDS (2) NPSP (1) CH2Cl2 Y N N Y 
9 2 LiHMDS (3) NPSP (1) CH2Cl2 Y N N Y 
 
Table 21 Reaction conditions tested to effect the α-selenation of 1,3-sulfonylnitrile 214. Numbers in brackets indicate the order of 
addition to the reaction mixture. Diphenyl diselenide (DPDS) observed by TLC.  
A decision was made to remove the TMS-protecting group from α-selenide 218 before revealing the acrylonitrile, to 
prevent Michael addition under the aqueous basic TMS-deprotection reaction conditions. However, treatment with 
potassium carbonate in MeOH to effect the TMS-deprotection led to the decomposition of α-selenide 218 to the cis 
and trans alkenes 219 and 220, Equation 13. These results confirmed that the selenide was α to the sulfone as opposed 
to the cyano group and suggested that in the previous α-selenation reaction, generation of the α-cyano anion led to 
rapid degradation to form selenide 217 unlike the α-sulfone anion, which was stable enough to react with the selenium 
electrophile.  
 
Equation 13 
The more readily accessible sulfone 214 was used to optimise the deprotection conditions, in anticipation that 1,3-
sulfonylnitrile 214 and α-selenide 218 would demonstrate similar base sensitivity. Treatment of 1,3-sulfonylnitrile 
214 with 1.0 M TBAF in THF at 0 °C led to rapid degradation, Table 22 (entry 1). However, significant improvement 
was observed using only one equivalent of TBAF in a THF solution, giving a 55 % isolated yield of the terminal 
alkyne 221 (entry 2).  
 
 
 
Table 22 Optimisation of TMS deprotection using test substrate 1,3-sulfonylnitrile 214.  
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Entry [TBAF] (M) Yield 214 (%) 
1 1.0 0 
2 0.07 (1 eq.) 55 
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Despite the assumption that 1,3-sulfonylnitrile 214 and α-selenide 218 would be similarly sensitive to base, 
application of the successful deprotection conditions to α-selenide 218 led to rapid degradation, Equation 14.  
 
Equation 14 Attempted deprotection of α-selenide 218. 
To avoid elimination across the 3-seleno-3-sulfonylpropane nitrile system or degradation during the TMS-
deprotection, the acrylonitrile was generated in the step prior to TMS-removal. Treatment of α-selenide 218 with 
sodium (meta)periodate in EtOH led to only a 25 % 1H NMR conversion of the selenide to the desired acrylonitrile 
203 after 16 h at rt, although no other side products were generated. Alternatively, oxidation of α-selenide 218 with 
mCPBA gave a slightly improved 36 % isolated yield of the desired sulfonylacrylonitrile 203 after 4 h, with recovery 
of 33 % starting material. Addition of 1 equivalent of TBAF to a solution of sulfonylacrylonitrile 203 in THF led to 
very rapid decomposition, again presumably due to the basic conditions generated by TBAF, Table 23 (entry 1). 
Deprotection of sulfonylacrylonitrile 203 was successfully carried out by buffering the solution with AcOH (0.35 M), 
yielding the desired chemical probe 192 in a moderate 48 % yield (entry 2).  
 
Entry [TBAF] (M) [AcOH] (M) Temp (°C) time (min) Yield 192 (%) 
1 0.04 (1 eq.) 0 0 5 0 
2 0.02 (1 eq.) 0.35 0 to rt 95 48 
 
Table 23 Optimisation of TMS deprotection of substrate 203. *Conversion by 1H NMR.   
6.3. Summary  
A small molecule with interesting cellular activity has been adapted as a chemical probe in order to identify its 
cellular target(s). Two concise synthetic routes to the target compound have been developed, Scheme 43, and enough 
material has been produced to carry out the desired biochemical screening. The first synthetic route, which reaches the 
desired synthetic target in only 4 steps, commenced with a C-I bond selective Sonogashira reaction, using 
commercially available 4-bromo-iodobenzene to install the TMS-acetylene in an excellent 96 % yield. Lithium-
halogen exchange and sulfur dioxide quench generated lithium sulfinate salt 212. A conjugate addition to 2-
chloroacrylonitrile and in situ elimination generated the desired acrylonitrile 203 before TMS deprotection to yield the 
final chemical probe. The second route reaches the desired synthetic target in 6 steps starting from the commercially 
available 4-bromosulfonyl chloride 196. Reduction to sodium sulfinate salt 202 using sodium sulfinate and sodium 
bicarbonate, and subsequent Michael addition of the sulfinate onto acrylonitrile through the S atom, generated 
bromoarene 213 as a precursor for the Sonogashira reaction. The Sonogashira coupling reaction was optimised from 
15 to 66-68 %, and although the subsequent α-selenation reaction proved problematic, the desired α-selenide 218 was 
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Design and synthesis of a chemical tag                                                                                                            Chapter Six 
  129 
successfully generated in a 22 % yield. Oxidation of the selenide and concomitant syn elimination generated the 
desired sulfonylacrylonitrile 203, which was deprotected with a solution of TBAF buffered with AcOH to yield the 
desired alkyne chemical probe 192 in a moderate 48 % yield.  
 
Scheme 43 Summary of the two synthetic routes developed to reach chemical probe 192.  
Future work 
Future work should include chemical proteomics experiments to investigate the cellular targets of inhibitors 190 and 
191 using chemical probe 192. Initial experiments conducted with inhibitors 190 or 191 should be repeated with 
compound 192 to check that the chemical probe has the same effect on cyclin D1 after DNA damage. If this is the 
case, after addition of probe 192 to cells, and generation of the cell lysate, a fluorophore attached to an azide and a 
source of Cu(I) should  be added to initiate the Cu-catalysed Huisgen cycloaddition. Subjection of the cell lysate to 
SDS PAGE and subsequent analysis by in-gel fluorescence allows identification of proteins modified with probe 192. 
If the fluorophore is conjugated to biotin, the tagged proteins can be enriched by streptavidin-biotin purification 
before analysis by in-gel fluorescence. Mass spectrometry techniques such as liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) can be used to identify labelled proteins.  
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7. Biochemistry materials and methods 
Materials  
Tetrahydrofolate, dUMP, Sypro Orange and Bradford reagent were purchased from Sigma-Aldrich. Sypro Orange 
was purchased as a 5000 x solution in DMSO. All reagents were used as commercially supplied. p97 was kindly 
supplied by Prof. Paul Freemont. Papain and carbonic anhydrase were purchased as lyophilised powders from Sigma-
Aldrich and were stored at -20 °C.  
 
Buffer constitutions 
Buffer A   25 mM TRIS-HCl pH 7.5, 2 mM DTT, 1 mM EDTA 
Cdc25 assay buffer  100 mM TRIS-HCl pH 8, 150 mM NaCl, 1 mM EDTA, 0.1 % βME, 400 µM 
OMFP 
Coomassie destain solution 10 % (v/v) AcOH, 10% (v/v) MeOH 
Coomassie stain solution 0.4 % (w/v) Coomassie brilliant blue dye R-250, 10 % (v/v) AcOH, 10% (v/v)  
MeOH 
GeneClean wash solution 50 mM NaCl, 10 mM TRIS-HCl pH 7.5, 2.5 mM EDTA, 50 % (v/v)   EtOH 
KOD Buffer 1 1.2 M TRIS-HCl, 100 mM KCl, 60 mM (NH4)2SO4, 1% (v/v) Triton X-100, 
0.01% (w/v) BSA, pH 8.0 
KOD DNA polymerase 2.5 U µL-1 KOD, 50 mM TRIS-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 
50% (v/v) glycerol, 0.1% (v/v) NP40, 0.1% (v/v) Tween, pH 8.0 
LB 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) bactoyeast extract, pH 7.0 
5 x SDS Loading buffer 160 mM TRIS-HCl, 24% (v/v) glycerol, 5% (w/v) SDS, 12.5% (v/v) βME, 0.1% 
(w/v) bromophenol blue, pH 6.8 
SDS PAGE stacking gel  0.1% (v/v) SDS, 5% (v/v) acrylamide, 0.1 M TRIS-HCl, pH 6.8 
SDS PAGE resolving gel  0.2% (v/v) SDS, 10% (v/v) acrylamide, 0.4 M TRIS-HCl, pH 8.8 
SDS running buffer 7.8 mM TRIS-HCl, 80 mM glycine, 10% (v/v) MeOH, 10% (w/v) SDS 
Solution II   0.2 M NaOH, 1% SDS   
Solution III   3 M KOAc, 5 M glacial acetic acid 
TAE    40 mM TRIS-acetate, 1 mM EDTA, pH 8.0 
5 x TAE loading buffer  TAE + 0.04% (w/v) bromophenol blue, 2.5% (w/v) ficoll 
Taq PCR buffer  100 mM TRIS-HCl, 500 mM KCl, 0.8% (v/v) NP40, pH 8.8 
Trypsin reconstitution buffer  50 mM acetic acid 
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Recombinant DNA techniques 
Transformation of bacterial cells via electroporation 
Competent E. coli DH5α or BL21 (DE3) cells were taken from -80 °C storage and thawed on ice before addition of 
plasmid DNA (1 µL). The cells were transferred to a chilled 2 mm gap cuvette (Geneflow) and subjected to 
electroporation at a capacitance of 25200 mFD and 22,000-23,000 Volts using a BioRad Gene Pulser. LB culture 
medium (1 mL) was added to the electroporated cells and 900 µL of the LB removed after centrifugation (13000 rpm, 
1 s). The cells were resuspended in the remaining LB medium, spread onto LB agar medium supplemented with 
ampicilin and incubated at 37 °C for 15-20 h to select transformants.     
Agarose gel electrophoresis 
 1 % agarose gels were made up with 1 x TAE buffer containing ethidium bromide (1 µL/mL). Electrophoresis of 
samples was carried out by applying 80 mA of constant current through the gel (45-60 min). DNA was visualised 
using UV-A (non-preparative samples) or UV-C (preparative samples) and for preparative samples the required DNA 
bands excised and extracted using GeneClean or Jetsorb (<500 bases) DNA purification procedures.  
GeneClean DNA purification 
Sodium iodide (500 mL, 6M) was added to the excised agarose gel band containing DNA and the mixture heated at 65 
°C for 5 min. A suspension of silica (5 µL) was added and the mixture kept on ice for 5 min, before brief 
centrifugation (13000 rpm). The supernatant was removed and the pellet washed three times with ice cold Gene clean 
wash solution before resuspension in milli Q. The resulting suspension was incubated at 65 °C for 5 min, centrifuged 
(13000 rpm) and the supernatant retained.  
Genomed Jetsorb Purification 
Buffer A1 (300 μL) and Jetsorb bead suspension (10 μL) were added to the excised agarose gel band containing DNA 
and the mixture incubated at 65 °C for 15 min, with mixing every 3 min. The resulting sample was centrifuged (13000 
rpm, 30 s), the supernatant removed and the pellet washed with buffer A1 (300 μL) and buffer A2 (300 μL). The dry 
pellet was then resuspended in sterile Milli Q water (20 μL), incubated at 65 °C for 5 min and centrifuged to give the 
desired solution of DNA. 
DNA ligation 
Ligations were carried out in a 20 µL volume in 0.5M TRIS-HCl pH 7.6, 10 mM MgCl2, 10 mM DTT and 50 µg/ml 
BSA with 10 ng digested vector, 500 ng digested insert and T4 DNA ligase. Samples were left at room temperature 
for at least 1 h.  
Enzymatic digestion of DNA 
DNA digests were carried out in a total volume of 20 µL with 8-10 µg DNA (inserts) or 0.5 µg DNA (plasmids), 2 µL 
enzyme and 2 µL of appropriate 10 x buffer. Samples were incubated for 1 h at 37 °C. 4 µL 5 x TAE loading buffer 
was added and samples run on a 1 % (w/v) agarose gel.  
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Two step PCR reaction 
A mixture of the DNA template (1 µL), the 5’-primer (1 ug) and the 3’-primer (1 µg), the oligonucleotides containing 
the mutation (each 1 µg), Thermococcus  kodakaraensis (KOD1) DNA polymerase (2.5 µL), 2 mM dNTPs (2.5 µL), 
25 mM MgCl2 (2 µL) and KOD Buffer 1 (2.5 µL) as commercially supplied (Novagen) was made up to 50 µL with 
sterile water and subjected to PCR conditions dictated by the properties of the oligonucleotides used (containing 
denaturation, annealing and ligation steps with 25-50 cycles). The resulting mixtures were separated by agarose gel 
electrophoresis. 
T-tailing 
Gene-cleaned or Jetsorb-cleaned PCR DNA fragments (6 µL) were subjected to heating at 72 °C for 20 min in the 
presence of Taq DNA polymerase (1 µL), 1 mM dATP, 2.5 mM MgCl2 and 10 x PCR buffer in a total volume of 20 
µL. The product was purified by the GeneClean or Jetsorb procedures and ligated into pGEM-T (Promega).  
DNA Sequencing 
Plasmids were sequenced commercially by COGENICS.  
Preparation of plasmid DNA  
Small scale (mini-prep)  
Single colonies were picked and shaken in LB medium supplemented with ampicilin (2 mL) at 37 °C for a minimum 
of 8 h. 1.5 mL of each culture was centrifuged (13000 rpm) and the supernatant removed. Each pellet was re-
suspended in milli Q water (100 µL) by vortexing. The cells were lysed by addition of Solution II (200 µL) and then 
immediately neutralised by addition of Solution III  (150 µL). After centrifugation (3 min, 13000 rpm) the 
supernatants were retained and nucleic acid precipitated by addition of EtOH (1 mL). The mixtures were centrifuged 
(3 min, 13000 rpm) and the supernatant removed. Milli Q water (50 µL) was added, with care taken not to over-vortex 
the pellet and the solutions centrifuged (1 min, 13000 rpm) before analytical enzymatic digestion.  
Large scale (maxi-prep) 
The remaining culture (ca. 0.5 mL) from Mini-Prep containing the required plasmid was transferred to ampicillin-
supplemented LB (200 mL) and shaken at 37 °C for 16 h. After centrifugation (5000 rpm, 4 °C, 5 min) the 
supernatant was removed and the pellet re-suspended in milli Q water (10 mL) by vortexing. The cells were lysed by 
addition of Solution II (20 mL) and the mixture neutralised by addition of Solution III (15 mL). The lysate was 
centrifuged (9000 rpm, 4 °C, 5 min) to remove contaminants and the filtered supernatant retained. Isopropanol (45 
mL) was added to precipitate nucleic acid and the pellet obtained by centrifugation (9000 rpm, 4 °C, 5 min). The dry 
pellet was re-suspended in milli Q water (3 mL) and ice-cold LiCl (4 mL) and kept on ice for 5 min to precipitate high 
molecular weight RNA. The mixtures were centrifuged (13000 rpm, 5 min) and EtOH (14 mL) added to the 
supernatant to precipitate nucleic acid. The mixtures were left on ice for 5 min and centrifuged (5000 rpm, 4 °C, 5 
min) and the supernatant discarded. The dry pellet was re-suspended in milli Q water (500 µL) and small molecular 
weight RNA digested with RNase A (10 µL) for 15 min at 37 °C. DNA was precipitated by addition of 2.5 M NaCl, 
20 % PEG-4000 solution (600  µL) and the mixture kept on ice for 5 min, centrifuged (13000 rpm, 5 min) and the 
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supernatant removed. The pellet was re-suspended in milli Q water (500 µL) by vortexing, and the contaminating 
protein denatured with 1:1 (v/v) phenol/chloroform and the aqueous layer separated by centrifugation (13000, 5 min) 
and subsequently extracted with chloroform to remove traces of phenol. 3M NaOAc, pH 5.2 (50 µL) and EtOH (1 
mL) were added to precipitate the DNA plasmid. The suspension was centrifuged (13000 rpm, 5 min), the supernatant 
removed and the pellet dissolved in milli Q water to give a concentration of 1 µg/µL, as determined by UV (260 nm, 
Pharmacia LKB UltroSpec III). A 10 µL aliquot from all Maxi preps was sent was for sequencing.   
Measure of DNA concentration 
DNA obtained from Maxi-Prep (5 µL) was added to a quartz cuvette containing milli Q (1 mL), and the absorbance at 
260 nm measured relative to milli Q water using a Pharmacia LKB UltroSpec III. The DNA concentration (µg/µL) 
was calculated as absorbance x 5.  
General protein Analysis 
Determination of concentration by Bradford assay 
Various dilutions of the protein stock solution (5 µL) were mixed with 250 µL Bradford reagent/H2O, 1:4 (v/v)  in a 
clear 96-well plate (TC Microwell 96F, Nunc). The optical density (OD) was measured at 595 nm (Spectramax 340 
PC, Molecular Devices) and the protein concentration determined from a standard curve generated using solutions of 
known concentrations of BSA. All samples were run in triplicate.  
SDS polyacrylamide gel electrophoresis 
Samples were mixed with an equal volume of 2 x SDS loading buffer and  subjected to electrophoresis at 200 V for 
ca. 1 h with SDS running buffer. Gels comprised a 4 % stacking gel and a 10 % resolving gel and were polymerised 
using 50 µL ammonium persulfate as a radical initiator and 50 µL tetramethylethylenediamine as a radical catalyst 
and allowed to set for at least 30 minutes at rt before use.  
InstantBlue™ staining  
SDS-PAGE gels were stained with InstantBlue™ (Expedeon) with gentle rocking for 20 minutes to visualise protein. 
Coomassie staining  
SDS PAGE gels were incubated at rt for 1 h with gentle rocking in Coomassie Blue staining solution  preheated to 60 
°C. Stained gels were washed once with water followed by incubation with de-stain solution at rt for ca. 12 h with 
gentle rocking.    
Reconstitution of trypsin for protein digestion 
Lyophilised sequencing grade modified Trypsin was purchased from Promega in 20 µg aliquots. Aliquots were 
resuspended in the supplied Trypsin reconstitution buffer to 0.5 µg/µL and the reconstituted enzyme stored at -70 °C. 
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Cdc25A Y386C C441S C430S C476S (cdc25A’)  
Cloning 
 The catalytic domain (residues 335-538) was constructed using the two step PCR amplification procedure, using the 
standard PCR components. The primers 5’ GAATTCAGAGCTTCTTCAGACGACTGTACATCTCC 3’ and 5’ 
GTTATCATCGACTGTCGATGTCCATATGAATACGAG 3’ were used to construct the 3’ end, and the primers 5’ 
GGATCCCTTATAGGAGACTTCTCCAAGGGTTATC 3’ and 5’ CTCGTATTCATATGGACATCGACAGTCGA- 
TGATAAC 3’ were used to construct the 5’ end and plasmid cdc25A C441S C430S C476S (triple mutant) was used 
as the template. Both PCR amplification steps used 25 cycles with denaturation at 98°C for 15 s, annealing at 79 °C 
for 1 min and ligation at 72 °C for 50 s. An adenosine base was added to the 3’ ends of the final PCR product using 
the standard t-tailing conditions. The construct was ligated into the pGEM-T vector, and the resulting plasmid 
transformed into E. coli DH5α (genotype F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–) cells. 12 single colonies were selected and grown overnight at 37°C in 
LB supplemented with ampicillin (2 mL). A Mini-Prep was carried out to extract the DNA from the cells, and these 
were digested with BamHI and EcoRI to identify cells transformed with the correct plasmid. Cells correctly 
transformed were grown overnight at 37°C in LB supplemented with ampicillin (200 mL), and a Maxi-Prep carried 
out to isolate the plasmid (0.25 µg/µL). Following digestion with BamHI and EcoRI the construct was subcloned into 
the BamHI and EcoRI sites of the pET21a vector and the plasmid isolated by Maxi-Prep.   
Expression 
 pET21a containing the catalytic domain of cdc25A’ was transformed into E. coli BL21 (DE3) (genotype F– ompT gal 
dcm lon hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5])) cells, and a single colony grown overnight at 
37°C in LB supplemented with ampicillin (2 mL). This was scaled up to 200 mL of media and incubated at 37°C for 
12 hours, and finally to 2000 mL and incubated for a further 1 hour. Protein expression was then induced by the 
addition of IPTG to a final concentration of 1 µM. The cells were shaken overnight at 18°C, and harvested by 
centrifugation at 5000 rpm for 5 min at 4°C.  
Purification by ion exchange chromatography and gel filtration 
The cells overexpressing cdc25A’ were resuspended in Buffer A, and lysed by sonication (2 x 18W, 30 s). Following 
centrifugation (9000 rpm, 4°C, 20 min) the cleared lysate was bound to 8 mL of SP-Sepharose beads equilibrated in 
Buffer A. Cdc25A’ was eluted with a NaCl gradient (0.05-0.50 M) in Buffer A at 4°C using a thin glass walled 
column with a frit. The collected fractions were run by SDS PAGE and those with a band at the correct molecular 
weight identified. Fractions were cleared of precipitate by centrifugation and the cleared solution concentrated and 
purified further by gel filtration using a GE Pharmacia AKTA purifier with a Sephadex-300 column. The precipitate 
collected from the fractions was redissolved in TRIS-HCl (25 mM), EDTA (1 mM), urea (6 M) and dialysed over 48 
h at 4 °C into TRIS-HCl (25 mM), EDTA (1 mM) with no urea via TRIS-HCl (25 mM), EDTA (1 mM) with 3 M and 
1 M urea respectively.  
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Cdc25  fluorescence based activity assay 
Cdc25A assay buffer (190 µL), was added to the appropriate wells of a 96-well microfluor black plate (Fischer 
Scientific). 10 µL from each fraction collected from an ion exchange chromatography column purification was added 
to each well and the fluorescence measured (Cary Eclipse software) using Ex/Em, 471/530 nm.   
Thymidylate Synthase  
Cloning 
The primers 5’ CATATGAAACAGTATTTAGAACTGATGC 3’ and 5’ GAATTCAGATAGCCACCGGCGCTTTA-
ATGCC 3’ were used in PCR amplification with E. coli (BL21-DE3) cells for 25 cycles with denaturation at 98 °C, 
annealing at 55 °C and ligation at 72 °C. An adenosine base was added to the 3’ ends of the final PCR product using 
the standard t-tailing conditions. The construct was ligated into the pGEM-T vector, and the resulting plasmid 
transformed into E. coli DH5α cells. 12 single colonies were selected and grown overnight at 37°C in LB 
supplemented with ampicillin (2 mL). A Mini-Prep was carried out to extract the DNA from the cells, and these were 
digested with PvuI to identify cells transformed with the correct plasmid. Cells correctly transformed were grown 
overnight at 37°C in LB supplemented with ampicillin (200 mL), and a Maxi-Prep carried out to isolate the plasmid 
(0.62 µg/µL), pGEM-TS. Following digestion with NdeI, the construct was cloned into the NdeI site of the pET21a 
vector, and the resulting plasmid transformed into E. coli DH5α cells. 12 single colonies were selected and grown 
overnight at 37°C in LB supplemented with ampicillin (2 mL). A Mini-Prep was carried out to extract the DNA from 
the cells, and these were digested with PstI to identify cells transformed with the correct plasmid. Cells correctly 
transformed were grown overnight at 37°C in LB supplemented with ampicillin (200 mL), and a Maxi-Prep carried 
out to isolate the plasmid (0.06 µg/mL), pET21a-TSNdeI. The plasmid pGEM-TS was then digested with AscI and 
EcoRI and the insert cloned into pET21a-TSNdeI pre-digested with AscI and EcoRI. The resulting plasmid was 
transformed into E. coli DH5α cells. 12 single colonies were selected and grown overnight at 37°C in LB 
supplemented with ampicillin (2 mL). A Mini-Prep was carried out to extract the DNA from the cells, correct 
transformants grown overnight in LB supplemented with ampicillin (200 mL) and a Maxi-Prep carried out to isolate 
the final plasmid, pET21a-TS.      
Expression 
 pET21a containing the catalytic domain of TS was transformed into E. coli BL21 (DE3) cells, and a single colony 
grown overnight at 37°C in LB supplemented with ampicillin (2 mL). This was scaled up to 200 mL and incubated at 
37°C for 12 hours, and finally to 1000 mL and incubated for a further 1 hour at 37°C. Protein expression was then 
induced by the addition of IPTG to a final concentration of 1 µM. The cells were shaken overnight at 37 °C, and 
harvested by centrifugation (5000 rpm, 20 min, 4°C). The pellet was washed twice with 10 mM TRIS-HCl (pH 7.5), 
10 mM MgCl2, and the cells stored at -80 °C until required.   
Purification 
The pellet was resuspended in 20 mM TRIS-HCl (pH 7.5), 10 mM MgCl2, 5 mM DTT (100 mL) and sonicated twice 
for 30 s at 18 W, with cooling on ice. The solution was centrifuged (9000 rpm, 20 min, 4 °C) and the supernatant 
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collected. 5 % streptomycin sulfate (15 mL/100 mL of the supernatant fraction) (v/v) was added and stirred for 10 min 
at 4 °C. The resulting nucleic acid precipitate was removed by centrifugation (9000 rpm, 30 min, 4 °C). Solid 
ammonium sulfate was added to the resulting supernatant fraction to 50 % saturation and the solution stirred at 4 °C 
for 10 min. The resulting precipitate was collected by centrifugation (9000 rpm, 20 min, 4 °C) and discarded and solid 
ammonium sulfate added to the supernatant fraction to increase saturation to 80 %. After stirring at 4 °C for 10 min the 
resulting precipitate was collected by centrifugation (9000 rpm, 4 °C, 20 min) and stored at -80 °C prior to further 
purification. The ammonium sulfate pellet was thawed, dissolved in 20 mM TRIS-HCl pH 7.5, 1 mM DTT (40 mL) 
and loaded onto DE-52 beads pre-equilibrated with 20 mM TRIS-HCl pH 7.5, 1 mM DTT. The protein was spun with 
the beads at 4 °C for at least 1 h. The beads were loaded into a thin glass column equipped with a frit and a tap. 20 mM 
TRIS-HCl pH 7.5, 1 mM DTT (20 mL) was passed through the beads, followed by 20 mL portions of the same buffer 
containing an increasing concentration of NaCl from 0.13 to 0.25 M, whilst fractions of 2-3 mL were collected. 
Fractions containing TS were combined and ammonium sulfate added to 80 % saturation with stirring for 10 min at 4 
°C to precipitate the protein. The protein was collected by centrifugation (5000 rpm, 4°C, 60 min) and stored at -80 °C 
until required.    
Spectrophotometric assay  
The purified TS pellet was thawed, dissolved in 25 mM potassium phosphate, pH 7.5 or 10 mM ammonium 
bicarbonate, 1 mM DTT and dialysed for 48 h against 4 x 2 L changes of the same buffer respectively. The protein 
concentration was measured using a Bradford assay. The appropriate amount of protein was then added to mixture I 
(40 mM TRIS-HCl (pH 7.6), 100 mM βME, 1 mM EDTA, 25 mM MgCl2, 15 mM formaldehyde) to make the final 
protein concentration 0.2 mg/mL. 10 mL of 16 mM tetrahydrofolate in mixture I and 10 µL of 4.6 mM dUMP in 
mixture I were added to the solution to give a final volume of 1 mL. A second sample with no dUMP was also 
prepared as a reference. Absorbance was then measured at 340 nm over a 20 minute period using a Cary 
spectrophotometer for both samples and the absorbancy difference plotted as a function of time.    
Spectrophotometric assay to determine IC50 values 
Initial reaction rates were measured spectrophotometrically at 25 °C by the increase in absorbance at 340 nm due to 
the enzymatic generation of dihydrofolate from methylene tetrahydrofolate. Reaction mixtures contained 40 mM 
TRIS-HCl (pH 7.5), 20 mM MgCl2, 100 mM βME, 12 mM formaldehyde, 750 μM EDTA, 20 μM dUMP, 150 μM 
tetrahydrofolate, 100 nM thymidylate synthase, 0.1 % Tween-20 and 4 % DMSO. Enzymatic reaction was initiated 
by the addition of a methylene tetrahydrofolate and dUMP mixture. Final reaction volumes were 1 mL and 3 x 250 
μL added to multiwell plate to run samples in triplicate. A sample containing no dUMP was used as a reference for 
all runs. Reactions were monitored over a five minute period with readings every 11 seconds. Initial reaction rate was 
calculated as the gradient of the initial linear portion. Buffers and dUMP/methylene tetrahydrofolate stock solutions 
were made up freshly on the day of use and kept on ice. Data was collected in a 96-well transparent Sterilin plate 
using a SpectraMax 340PC Absorbance Microplate Reader. Data was fitted to a non-linear sigmoidal curve with 
iterations until convergence using OriginPro 8.5. IC50 values were obtained from dose-response curves using average 
velocites of three separate runs with IC50 errors determined from the standard error of the three separate IC50 values. 
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Errors on dose-response curves were standard errors calculated from the velocities of the three separate runs at each 
point.  
Hydrolytic stability of acrylamides in the presence of papain 
Mini tests for TLC analysis 
To 10 µM papain in ammonium bicarbonate (10 mM), DTT (1 mM) was added one acrylamide (49, 55 and 67) from a 
60 mM stock solution in MeOH to give a final acrylamide concentration of 2.5 µM. Identical samples with the papain 
omitted were used as controls. Samples were analysed by TLC initially and after 7 h (1:1 EtOAc/n-hex). After 7 hours 
incubation, the original acrylamides were still present as the main organic component by TLC for both + papain and - 
papain samples. There was also a small spot on the baseline of the plate for all + papain samples but not for - papain 
samples which may correspond to hydrolysed acrylamide.  
Preparative test 
To 10 µM papain in ammonium bicarbonate (10 mM), DTT (1 mM) was added acrylamide 67 to a final concentration 
of 2.5 mM and a total sample volume of 4.5 mL. After incubation at rt for 16 h the solvent was removed from the 
sample under a high vacuum and the resulting residue analysed by TLC and NMR, to indicate the acrylamide present 
with only a trace of the hydrolysis products.  
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8. HPLC, Mass spectrometry and Thermofluor methods 
HPLC Experiments 
Irreversibility tests for addition of thiol to vinyl sulfonamide and acrylamide 
A spherisorb 5µ C18 316 x 4 mm column was used with either an Agilent HPLC machine equipped with single 
UV/vis detection at 254 nm or a JASCO HPLC machine with a UV-2077 plus 4-l intelligent UV/Vis detector. The 
mobile phases were HPLC grade water (0.1 % TFA) and acetonitrile, degassed using either a Hewlett Packard 1100 
Series G1322A degasser or a JASCO DG-2080-53 3 line degasser. Solvents were passed through the HPLC at a rate 
of between 0.5-0.7 mL/min. Injections were 2 μL. An example method to monitor the conjugate addition of thiol to 
vinyl sulfonamide is as follows. Samples were run in 100 mM ammonium bicarbonate at pH 7.95 with 10 % total 
DMSO and acrylamides/vinyl sulfonamides generally present at 1 mM. Stock solutions of thiols in H2O were always 
prepared on the day of use and kept at 4 °C.  
An example HPLC method is as follows: 
 
Comparision of reaction rate for conjugate addition of thiol to acrylamide-fragments 
A Phenomenex Luna 5µ C18 250 x 4.60 mm column was used with a LaserChrom HPLC machine equipped with 
single UV/vis detection at 240 nm. The mobile phases were HPLC grade water (0.1 % TFA) and acetonitrile (0.1 % 
TFA) or methanol (0.1 % TFA), degassed using a LaserChrom CSI6150 vacuum degasser. Injections were 2 μL. 
Recipe to make up samples: 980 μL ammonium bicarbonate (100 mM) at pH 7.95, 2 μL acrylamide 1 at 0.5 M in 
DMSO, 2 μL acrylamide 2 at 0.5 M in DMSO, 6 µL DMSO, 10 μL freshly prepared reduced glutathione at 0.5 M in 
H2O.  
An example HPLC method is as follows: 
 
Comparison of reaction rate for conjugate addition of thiol to vinyl sulfonamide and acrylamide  
A Phenomenex Luna 5µ C18 250 x 4.60 mm column was used with a LaserChrom HPLC machine equipped with 
single UV/vis detection at 254 or 225 nm. The mobile phases were HPLC grade water (0.1 % formic acid) and 
methanol, degassed using a LaserChrom CSI6150 vacuum degasser. Injections were 2 μL. Recipe to make up 
samples: 980 μL ammonium bicarbonate (100 mM) at pH 7.95, 10 μL acrylamide or vinyl sulfonamide at 0.5 M in 
DMSO, 10 μL glutathione at 0.5 M in H2O. Acrylamides monitored at λ = 254 nm, vinyl sulfonamides at λ = 225 nm. 
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Vinyl sulfonamides do not absorb at 254 nm when at a concentration of 5 mM. Acrylamides absorb too strongly at 
225 nm at 5 mM, such that they reach the limit of the detector.  
HPLC method: 
 
Reaction of acrylamides with reduced glutathione in the presence of an internal standard 
A Phenomenex Luna 5µ C18 250 x 4.60 mm column was used with a LaserChrom HPLC machine equipped with 
single UV/vis detection at 254 nm. The mobile phases were HPLC grade water (0.1 % formic acid) and methanol (0.1 
% formic acid), degassed using a LaserChrom CSI6150 vacuum degasser. Injections were 2 μL. Recipe to make up 
samples: 979 μL ammonium bicarbonate (100 mM) pH 7.95, 1 μL 4-amino benzylamide (0.5 M in DMSO), 10 μL 
ligand (0.1 M in DMSO), 10 μL freshly prepared reduced glutathione (0.5 M in H2O).  
HPLC method:  
 
Thermal shift experiments 
Thermal denaturations were carried out in sealed, fast optical MicroAmp 96-well plates (Applied Biosystems) using 
an Applied Biosystems StepOne Plus Real-Time PCR System. The system contains a Peltier-based thermal cycling 
system for rapid heating/cooling and monitors fluorescence using an LED-based optical system. The 96-well plates 
were heated from 25-65 °C at a ramp of 0.5 °C per minute. Fluorescence was monitored at the emission wavelength of 
FAM dye (Ex/Em: 495/520 nm) or SYBR green dye (Ex/Em: 497/520 nm), which overlaps with the emission from 
Sypro Orange (Ex/Em: 470/569 nm). Samples were composed of 100 µM protein (15 µL), Sypro Orange (2000 x 
dilution of commerical stock with sterilised Milli Q water) (5 µL) or protein (14 µL), Sypro Orange (2000 x dilution 
of commerical stock with sterilised Milli Q water) (5 µL) and organic ligand (1 µL) at various concentrations from 
DMSO stock solution.  
Analysis of protein by Electrospray or MALDI MS 
Preparation of TS for ESI or MALDI MS 
The ammonium sulfate TS pellet was allowed to thaw on ice before addition of 10 mM ammonium bicarbonate, 1 
mM DTT, pH 8. The protein was then dialysed for 48 h against 4 x 2 L changes of the same buffer. The dialysate was 
centrifuged to remove any insoluble impurities and the concentration adjusted to 10 µM using a Bradford assay. The 
protein solution was then stored at 4 °C ready for use.   
time 
(mins)
0
5
35
40
%
MeOH (0.1 % formic acid)
5
5
95
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%
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5
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Analysis of TS samples by MALDI MS 
10 μM TS (in ammonium bicarbonate (10 mM), DTT (1 mM)) (192 µL) was added to organic compound 54, 67 or 68 
(from stock solution at 10 mM in MeOH) (8 µL) and the solutions allowed to react at rt for 2 h. The resulting 
solutions were washed through a spin filter to remove any unreacted organic compound and concentrated to 25 µL 
total sample volume. Reconstituted trypsin (2 µL) was added to the sample before incubation at 37 °C for 4 h. To 
prepare the trypsinised solution for MALDI analysis, 0.5 % formic acid and MeCN were added to the sample to give 
1:1 aqueous/organic and an overall 2.4 x dilution. The sample was then mixed thoroughly with a matrix, α-cyano 4-
hydroxy cinnamic acid (v/v, 1:1), and 1 µL of this solution added to the target plate and allowed to dry. MALDI 
spectrometry was carried out using a Micromass MALDI micro MX which has a laser desorption ion source coupled 
to a time-of-flight analyser. Pulsed laser energy was fired at the target in the UV range (337 nm) and either fired 
randomly, or focused on the centre of the target. The method used detected positive ions in the 1000-4000 Da range.  
Analysis of cdc25A’ samples by MALDI 
Cdc25A’ was dialysed from storage buffer (TRIS-HCl (25 mM), EDTA (1mM) with 50 % glycerol) into ammonium 
bicarbonate (50 mM, pH 8) or TRIS-HCl (50 mM, pH 8) buffers prior to experiment.  Acrylamides or sulfonamides 
were added to protein samples from stock solutions in acetonitrile or methanol to give 4 % overall organic solvent.  
βME was added to protein samples from freshly prepared stock solutions in ammonium bicarbonate or TRIS-HCl 
buffer. For digestion, reconstituted trypsin (2 µL) was added to protein samples (usually 25 µL) and samples 
incubated overnight at 37 °C. The aqueous buffer from samples was removed in vacuo and the sample diluted to 
approximately 0.1 mg/mL with acetonitrile/water (0.1 % TFA), 1:1. The sample was then mixed with a matrix, α-
cyano 4-hydroxy cinnamic acid (v/v, 1:1), and 1 µL of this solution added to the target plate and allowed to dry. 
MALDI spectrometry was carried out using a Micromass MALDI micro MX which has a laser desorption ion source 
coupled to a time-of-flight analyser. Pulsed laser energy was fired at the target in the UV range (337 nm) and either 
fired randomly, or focused on the centre of the target. The method used detected positive ions in the 300-5000 Da 
range.   
General procedure for protein analysis by electrospray MS 
Protein at a concentration of 10 μM in ammonium bicarbonate (10 mM), DTT (1 mM) and acrylamide from stock 
solution in MeOH (to give maximum 4 % MeOH) were incubated at rt. To a 25 μL aliquot of the reaction, 0.5 % 
formic acid (50 μL) and MeOH (50 μL) were added and the mixture loaded into a syringe (Hamilton microsyringe). A 
syringe driver was used to inject the sample onto the mass spectrometer at 30 μL/min and data collected in the m/z 
range 900-3000. Spectra were deconvoluted with Maximum Entropy software from Waters. A Micromass LCT 
Premier was used to obtain all ESI mass spectrometry data. This instrument has an electrospray ionisation source 
coupled to a time-of-flight analyser, and was operated in W reflectron mode. A Waters 1525µ LC pump was used to 
deliver the mobile phase to the source.     
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9. Organic chemistry experimental 
General Procedures 
NMR Spectroscopy 
1H NMR spectra were recorded on a Bruker AV400 spectrometer operating at 400 MHz in deuterated solvents as 
indicated. All spectra were referenced to solvent as indicated and peaks labelled as s (singlet), d (doublet), t (triplet), q 
(quartet), multiplet (m), b (broad). All chemical shifts (δ) are quoted in parts per million (ppm). Coupling constants 
(J) for 1H NMR spectroscopy are given in Hz. 13C NMR spectra were recorded on a Bruker AV400 spectrometer 
operating at 101 MHz in deuterated solvents as indicated. All spectra were referenced to solvent as indicated.  
Infrared spectroscopy 
IR spectra were recorded as thin films or compressed solids on a Perkin Elmer Spectrum 100 FT-IR spectrometer with 
Universal ATR Sampling Accessory.  
Mass spectrometry  
Low resolution mass spectra (m/z) were recorded on either VG 707E, VG Autospec Q, VG platform or VG Prospec 
spectrometers. Only molecular ions (M+) and major fragmentation peaks are reported. High resolution mass spectra 
were recorded on a VG prospec spectrometer.  
Melting Points 
Melting points were determined on a Reichert microscope melting point apparatus.  
Silica Chromatography 
Analytical thin layer chromatography (TLC) was performed on glass backed plates pre-coated with silica (0.2 mm, 60 
F524). Compounds were visualised by UV at 254 nm, potassium permanganate stain (potassium permanganate (3 g), 
potassium carbonate (20 g), 5 % aqueous sodium hydroxide solution (5 mL) and water (300 mL)) or ninhydrin stain. 
Retention factor (Rf) values are quoted with respected to the solvent system used to develop the plate. Flash column 
chromatography was performed on silica gel (Merck Kieselgel 60 F254 230-400 mesh) eluting with solvents as 
described.  
Solvents and reagents 
Anhydrous Toluene, THF, CH2Cl2 and MeOH were obtained from a PureSoIvTM solvent purification system 
(Innovative Technologies Inc.). Commercial anhydrous grade DMF, DMSO and MeCN were used without further 
purification. Where specified, solvents were degassed by sparging with argon for 30 min. All other reagents were used 
as commercially supplied and handled in accordance with COSHH regulations. Petroleum ether refers to the fraction 
which boils between 40-60 °C.  
General 
All reactions were carried out in either oven-dried or flame-dried glassware under an argon atmosphere with magnetic 
stirring. Room temperature is taken to be 20 °C. Compound names were generated using CS ChemDraw Ultra 6.0.  
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9.1. Vinyl sulfonamide/acrylamide library and derivatives 
Ethenesulfonic acid 4-[1,2,3]thiadiazol-4-yl-benzylamide 39   
 
2-Chloroethanesulfonyl chloride (23 µL, 0.22 mmol, 1 eq.) was added to a stirred solution of 4-(1,2,3-thiadiazole-4-
yl)benzylamine HCl salt (50 mg, 0.22 mmol, 1 eq.) and Et3N (107 µL, 0.77 mmol, 3.5 eq.) in CH2Cl2 (1 mL) at 0 °C. 
Stirring was continued at 0 °C for 1.5 h and at rt for 0.5 h, before dilution with CH2Cl2 (10 mL). The diluted reaction 
mixture was washed with brine (2 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude mixture 
was purified by flash chromatography on silica (EtOAc/n-hexane, 2:1) to isolate the desired vinyl sulfonamide 39 (10 
mg, 16 %) as a white powder, mp = 117-120 °C; Rf = 0.3 (EtOAc/n-hexane, 2:1); νmax /cm-1  3270, 3066, 1147, 1424, 
1319, 1224, 1138, 1073, 1068, 968, 938, 813; δH (400 MHz, CDCl3) 8.67 (1H, s, thiadiazole-H), 8.02 (2H, d, J 7.0, 
ArH), 7.47 (2H, d, J 7.0, ArH), 6.52 (1H, dd, J 10.4, J 17.4, NHSO2CHCH2), 6.28 (1H, d, J 17.4, NHSO2CHCH2 cis 
to SO2), 5.95 (1H, d, J 10.4, NHSO2CHCH2 trans to SO2), 4.90 (1H, bt, J 6.0, NH), 4.28 (2H, d, J 6.0, NHCH2); δC 
(101 MHz, CDCl3) 162.4, 138.0, 136.1, 130.7, 130.5, 128.8, 127.9, 127.2, 46.9; m/z (CI) 282 [MH]+, 299 [MNH4]+; 
found: [MNH4]+, 299.0640 C11H15N4O2S2 requires 299.0636 Δ 1.2 ppm.      
Ethenesulfonic acid benzylamide 40  
 
To a solution of benzylamine (0.22 mL, 2.0 mmol, 1 eq.) and chloroethanesulfonyl chloride (0.21 mL, 2.0 mmol, 1 
eq.) in anhydrous CH2Cl2 (30 mL) at 0 °C was added Et3N (0.60 mL, 4.2 mmol, 2.1 eq.) dropwise. The reaction 
mixture was warmed to rt and stirred for 3 h, the solvent evaporated in vacuo to 15 mL and the white precipitate 
Et3NHCl salt removed by filtration. The filtrate was purified on silica (EtOAc/n-hexane, 1:1) and (EtOAc/n-hexane, 
3:7) to yield the desired vinyl sulfonamide 40 (156.3 mg, 40 %) as a colourless oil; Rf = 0.22 (EtOAc/n-hexane, 3:7); 
νmax /cm-1 3291, 1497, 1456, 1425, 1386, 1322, 1142, 1084, 1060, 1028, 971, 841, 734, 698, 657; δH (400 MHz, 
CDCl3) 7.35-7.26 (5H, m, Ph), 6.44 (1H, dd, J 16.5, J 9.9, SO2CHCH2), 6.17 (1H, d, J 16.5, SO2CHCH2 cis to SO2), 
5.85 (1H, d, J 9.9, SO2CHCH2 trans to SO2), 5.30 (1H, bt, J 6.3, NH), 4.15 (2H, d, J 6.3, PhCH2); δC (101 MHz, 
CDCl3) 136.7, 135.8, 128.6, 127.9, 127.8, 126.6, 46.8; m/z (CI) 215 [MNH4]+; found [MNH4]+ 215.0859 C9H15N2O2S 
requires 215.0854, Δ 2.2 ppm. Data in agreement with literature values.[278] 
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Ethenesulfonic acid 4-methoxy-benzylamide 41 
 
2-Chloroethanesulfonyl chloride (0.21 mL, 2.1 mmol, 1.0 eq.) was added dropwise to a stirred solution of 4-methoxy-
benzylamine (0.27 mL, 2.1 mmol, 1.0 eq.) and Et3N (1.00 mL, 7.3 mmol, 3.5 eq.) in CH2Cl2 (10 mL) at 0 °C. After 
addition, stirring was continued at 0 °C for 2 h. The mixture was diluted with CH2Cl2 (10 mL), washed with brine (2 x 
5 mL), dried over MgSO4 and the solvent removed in vacuo to yield a yellow oil which was purified on silica 
(EtOAc/n-hexane, 3:7) to yield the desired vinyl sulfonamide 41 (230.3 mg, 48 %) as a white solid, mp = 71-73 °C; Rf 
= 0.22 (EtOAc/n-hexane, 3:7); νmax /cm-1  3287, 1514, 1316, 1247, 1175, 1138, 1030, 979, 960, 868, 816, 753, 661; δH 
(400 MHz, CDCl3) 7.22 (2H, d, J 9.0, ArH2’), 6.84 (2H, d, J 9.0, ArH3’), 6.43 (1H, dd, J 16.0, J 9.0, SO2CHCH2), 
6.17 (1H, d, J 16.0, SO2CHCH2 cis to SO2), 5.87 (1H, d, J 9.0, SO2CHCH2 trans to SO2), 5.17 (1H, bt, J 6.0, NH), 
4.09 (2H, d, J 6.0, ArCH2NH), 3.77 (3H, s, ArCH3); δC (101 MHz, CDCl3) 159.2, 135.9, 129.3, 128.7, 126.6, 114.0, 
55.3, 46.4; m/z (CI)  245 [MNH4]+; found [MNH4]+, 245.0960 C10H17N2O3S requires 245.0960, Δ 0 ppm.   
1-Ethenesulfonyl-4-phenyl-piperazine 42 
 
2-Chloroethanesulfonyl chloride (0.31 mL, 3.0 mmol, 1 eq.) was added dropwise to a stirred solution of 1-
phenylpiperazine (0.46 mL, 3.0 mmol, 1 eq.) and Et3N (1.46 mL, 0.5 mmol, 3.5 eq.) in CH2Cl2 (10 mL) at 0 °C under 
argon. The solution was stirred at 0 °C for 1 h and at rt overnight. The reaction mixture was diluted with CH2Cl2 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude yellow solid was purified by 
flash column chromatography on silica (EtOAc/n-hex, 2:3) to yield the desired vinyl sulfonamide 42 (241.3 mg, 32 
%) as a white powder, mp = 125-127 °C; Rf = 0.31 (EtOAc/n-hex, 2:3); νmax /cm-11597, 1495, 1448, 1381, 1336, 1325, 
1269, 1232, 1150, 1117, 972, 759; δH (400 MHz, CDCl3) 7.34-7.30 (2H, m, ArH), 6.98-6.94 (3H, m, ArH), 6.50 (1H, 
dd, J 16.8, J 10.5, NHSO2CHCH2), 6.32 (1H, d, J 16.8, NHSO2CHCH2 cis to SO2), 6.12 (1H, d, J 10.5, 
NHSO2CHCH2 trans to SO2), 3.37-3.29 (8H, m, piperazine-H); δC (101 MHz, CDCl3) 150.7, 132.3, 129.4, 129.4, 
121.1, 117.1, 49.5, 45.7; m/z (ESI) 253 [MH]+; found: [MH]+, 253.1023 C12H17N2O2S requires 253.1011, Δ 4.7 ppm. 
4-(Ethenesulfonylamino-methyl)-benzoic acid methyl ester 43  
 
To a solution of methyl 4-(aminomethyl)benzoate HCl salt (200 mg, 1 mmol, 1 eq.) in CH2Cl2 (4 mL) at rt was added 
pyridine (0.12 mL, 1.5 mmol, 1.5 eq.), DMAP (12.2 mg, 0.1 mmol, 0.1 eq.), triethylamine (0.15 mL, 1.1 mmol, 1.1 
eq.) and 2-chloroethanesulfonyl chloride (0.1 mL, 1 mmol, 1 eq.) to give a bright yellow solution which quickly 
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turned pink. The resulting mixture was stirred at rt for 5 min before dilution with EtOAc (20 mL). The organic phase 
was washed with 2N HCl (2 x 20 mL), dried (MgSO4) and concentrated in vacuo. The residue was dissolved in 
CH2Cl2 (4 mL) and triethylamine (0.4 mL, excess) and the resulting bright yellow solution stirred at rt for 16 h. The 
reaction was diluted with EtOAc and the organic phase washed with aq. HCl (2N), brine, dried (MgSO4) and 
concentrated in vacuo. The crude mixture was purified by flash chromatography on silica (EtOAc/n-hexane, 1:1) to 
give the desired sulfonamide 43 (43.6 mg, 17 %) as a white solid, mp = 66-68 °C; Rf = 0.29 (EtOAc/n-hexane, 1:1); 
νmax /cm-1  3284, 1718, 1435, 1328, 1283, 1148, 1111; δH (400 MHz, CDCl3) 8.01 (2H, d, J 8.3, ArH), 7.40 (2H, d, J 
8.3, ArH), 6.49 (1H, dd, J 9.6, J 16.0, NHSO2CHCH2), 6.26 (1H, d, J 16.0, NHSO2CHCH2 cis to SO2), 5.94 (1H, d, J 
9.6, NHSO2CHCH2 trans to SO2), 4.82 (1H, bs, NH), 4.27 (2H, d, J 6.4, NHCH2Ar), 3.91 (3H, s, OCH3); δC (101 
MHz, CDCl3) 166.8, 141.8, 136.1, 130.2, 130.0, 127.9, 127.3, 52.4, 46.8; m/z (CI) 273 [MNH4]+; found: [MNH4]+, 
273.0911 C11H17N2O4S requires 273.0909. Δ 0.7 ppm. Data in agreement with literature values.[279] 
Ethenesulfonic acid (1-benzyl-piperidin-4-yl)-amide 44 
 
2-Chloroethanesulfonyl chloride (0.21 mL, 2 mmol, 1 eq.) was added dropwise to a stirred solution of 4-
aminobenzylpiperidine (0.41 mL, 2 mmol, 1 eq.) and triethylamine (0.97 mL, 7.0 mmol, 3.5 eq.) in CH2Cl2 (10 mL) at 
0 °C under argon. After addition, stirring was continued at 0 °C for 1 h and at rt overnight. The reaction mixture was 
diluted with CH2Cl2, poured into aq. NH4Cl (2 M), the layers separated and the organic layer dried over MgSO4, 
filtered and the solvent removed in vacuo. The resulting crude oil was triturated in ether to remove insoluble 
impurities to yield the desired vinyl sulfonamide 44 (125 mg, 22 %) as a clear oil. νmax /cm-1 3276, 2802, 2761, 1328, 
1153, 1073, 970, 907, 735; δH (400 MHz, CDCl3) 7.35-7.25 (5H, m, ArH), 6.57 (1H, dd, J 15.7, J 10.0, 
NHSO2CHCH2), 6.26 (1H, d, J 15.7, NHSO2CHCH2 cis to SO2), 5.91 (1H, d, J 10.0, NHSO2CHCH2 trans to SO2), 
3.51 (2H, s, ArCH2), 3.22 (1H, m, SO2NHCH), 2.81 (2H, bd, J 12.0, piperidine-H), 2.11 (2H, bt, J 11.0, piperidine-
H), 1.95 (2H, dd, J 12.0, J 4.0, piperidine-H), 1.61 (2H, qd, J 12.0, J 4.0, piperidine-H); δC (101 MHz, CDCl3) 138.2, 
137.2, 129.1, 128.3, 127.1, 125.8, 62.9, 51.9, 50.9, 33.3; m/z (ESI) 281 [MH]+; found: [MH]+, 281.1324 C14H21N2O2S 
requires 281.1324, Δ 0 ppm.       
Ethenesulfonic acid 4-fluoro-benzylamide 45 
 
2-Chloroethanesulfonyl chloride (0.21 mL, 2.1 mmol, 1 eq.) was added dropwise to a solution of 4-fluorobenzylamine 
(262.8 mg, 2.1 mmol, 1 eq.) and triethylamine (1 mL, 7.35 mmol, 3.5 eq.) in CH2Cl2 (10 mL) at 0 °C. After addition, 
stirring was continued at 0 °C for 1 h and at rt overnight. The mixture was diluted with CH2Cl2 (10 mL), washed with 
brine (2 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude yellow oil was purified using 
flash chromatography on silica (gradient elution EtOAc/n-hexane, 3:7 to EtOAc/n-hexane, 1:1) to give the desired 
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vinyl sulfonamide 45 (205.6 mg, 45 %) as a white solid, mp = 52-55 °C; νmax /cm-1  3291 (b), 1606, 1510, 1428, 1387, 
1325, 1222, 1146, 1061, 972, 833; δH (400 MHz, CDCl3) 7.29-7.27 (2H, m, ArH), 7.06-7.01 (2H, m, ArH), 6.47 (1H, 
dd, J 17.5,  J 10.0, SO2CHCH2), 6.25 (1H, d, J 17.5, SO2CHCH2 cis to SO2), 5.94 (1H, d, J 10.0, SO2CHCH2 trans to 
SO2), 4.67 (1H, bs, NH), 4.18 (2H, d, J 6.0, ArNHCH2); δC (101 MHz, CDCl3) 162.6 (d, J 243, ArC4’), 136.0, 132.3, 
129.7 (d, J 9, ArC2’), 127.0, 115.7 (d, J 18, ArC3’), 46.5; m/z (CI) 233 [MNH4]+; found: [MNH4]+, 233.0763 
C9H14N2O2SF requires 233.0760, Δ 1.3 ppm.              
N-(4-[1,2,3]Thiadiazol-4-yl-phenyl)-acrylamide 46 
 
To a solution of 4-(1,2,3-thiadiazol-4-yl)benzylamine HCl salt (100.0 mg, 0.44 mmol, 1.0 eq.) in CH2Cl2 (1 mL) at 0 
°C was added Et3N (0.13 mL, 0.92 mmol, 2.1 eq.) and acryloyl chloride (0.04 mL, 0.48 mmol, 1.1 eq.) and the 
mixture stirred at rt for 4 h. The reaction was quenched with sat. NaHCO3, extracted with CH2Cl2 (x 3), dried over 
MgSO4 and the solvent removed in vacuo. The crude residue was purified on silica (EtOAc/n-hexane, 3:2) to yield the 
desired acrylamide 46 (37.8 mg, 35 %) as a white solid, mp = 190-193 °C; Rf = 0.27 (EtOAc/n-hexane, 3:2); νmax /cm-
1 2926, 2855, 2397, 1652, 1616, 1461, 1454, 1224, 800; δH (400 MHz, MeOD) 9.24 (1H, s, thiadiazole-H), 8.08 (2H, 
d, J 8.9, ArH3’), 7.47 (2H, d, J 8.9, ArH2’), 6.36-6.25 (2H, m, NHCOCHCH2), 5.71 (1H, dd, J 8.8, J 3.1, 
NHCOCHCH2), 4.55 (2H, s, CH2); δC (101 MHz, MeOD) 166.7, 162.4, 139.9, 131.3, 130.5, 129.9, 128.0, 127.1, 
125.7, 42.4; m/z (CI) 246 [MH]+, 263 [MNH4]+; found [MH]+ 246.0705 C12H12N3OS requires 246.0701, Δ 1.6 ppm.  
N-Benzyl-acrylamide 47 
 
To a solution of benzylamine (0.22 mL, 2.0 mmol, 1.0 eq.) in CH2Cl2 (5 mL) at 0 °C was added Et3N (0.31 mL, 2.2 
mmol, 1.1 eq.) and acryloyl chloride (0.18 mL, 2.2 mmol, 1.1 eq.) and the mixture stirred at rt for 1 h. The reaction 
was quenched with sat. NaHCO3 and extracted with CH2Cl2 (3 x 20 mL). The organics were combined and dried 
(MgSO4) and the solvent removed in vacuo. The crude mixture was purified on silica (gradient elution, 
EtOAc/petroleum ether 40-60, 3:7 to 100 % EtOAc) to yield the desired acrylamide (316.6 mg, 98 %) as a white 
solid, mp = 68-70 °C; Rf = 0.18 (EtOAc/petroleum ether 40-60, 3:7); νmax /cm-1 3284, 1651, 1623, 1610, 1557, 1533, 
1495, 1455, 1407, 1238, 1075, 1027, 996, 956, 743, 692; δH (400 MHz,CDCl3) 7.38-7.29 (5H, m, Ph), 6.35 (1H, dd, J 
17.0, J 1.3, NHCOCHCH2 cis to C=O), 6.15 (1H, dd, J 10.3, J 17.0, NHCOCHCH2), 6.02 (1H, bs, NH), 5.69 (1H, dd, 
J 1.3, J 10.3, NHCOCHCH2 trans to C=O), 4.54 (2H, d, J 5.8, ArCH2NH); δC (101 MHz, CDCl3) 165.4, 138.0, 130.6, 
128.8, 128.0, 127.7, 126.9, 43.7; m/z (CI)  162 [MH]+; found [MH]+ 162.0910 C10H12NO requires 162.0919, Δ 5.6 
ppm. Data in agreement with literature values.[280] 
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N-(4-Methoxy-benzyl)-acrylamide 48 
 
To a solution of p-methoxybenzylamine (0.26 mL, 2.0 mmol, 1.0 eq.) in CH2Cl2 (5 mL) at 0 °C was added Et3N (0.31 
mL, 2.2 mmol, 1.1 eq.) and acryloyl chloride (0.18 mL, 2.2 mmol, 1.1 eq.) and the mixture stirred at rt for 1 h. The 
reaction was quenched with sat. NaHCO3, extracted with CH2Cl2 (20 mL x 3), the combined organic extracts dried 
(MgSO4) and the solvent removed in vacuo. The crude product was purified on silica (EtOAc/petroleum ether 40-60, 
2:3) to give the desired amide (213.8 mg, 56 %) as a white powder, mp = 100-103 °C; Rf = 0.23 (EtOAc/petroleum 
ether 40-60, 2:3); νmax /cm-1 3244, 1665, 1650, 1611, 1549, 1511, 1464, 1456, 1444, 1409, 1301, 1244, 1221, 1176, 
1111, 1029, 983, 968, 831, 817, 755, 569; δH (400 MHz, CDCl3) 7.23 (2H, d, J 9.0, ArH), 6.87 (2H, d, J 9.0, ArH), 
6.32 (1H, dd, J 1.3, J 17.1, NHCOCHCH2 cis to C=O), 6.09 (1H, dd, J 10.3, J 17.1, NHCOCHCH2), 5.80 (1H, bs, 
NH), 5.66 (1H, dd, J 1.3, J 10.3, NHCOCHCH2 trans to C=O), 4.46 (2H, d, J 6.0, ArCH2NH), 3.80 (3H, s, OCH3); δC 
(101 MHz, CDCl3) 165.6, 159.0, 130.9, 130.3, 129.2, 126.5, 114.0, 55.3, 43.1; m/z (CI) 192 [MH]+, 209 [MNH4]+; 
found [MH]+ 192.1025 C11H14NO2 requires 192.1025, Δ 0 ppm. Data in agreement with literature values.[281] 
1-(4-Phenyl-piperazin-1-yl)-propenone 49 
 
To a solution of 1-phenyl piperazine (0.61 mL, 4.0 mmol, 1 eq.) in CH2Cl2 (10 mL) at 0 °C under argon was added 
triethylamine (0.83 mL, 6.0 mmol, 1.5 eq.) and acryloyl chloride (0.36 mL, 4.4 mmol, 1.1 eq.) and the reaction 
mixture stirred at rt for 2 h. The reaction mixture was poured into aq. NH4Cl (2M) (20 mL), extracted with CH2Cl2 (x 
3), the combined organics dried over MgSO4, filtered and the solvent removed in vacuo. The crude orange oil was 
purified by flash column chromatography on silica (EtOAc/n-hexane, 85:15) to give the desired acrylamide (465.4 
mg, 54 %) as a white powder, mp = 73-74 °C; Rf = 0.45 (EtOAc/n-hex, 19:1); νmax /cm-1 1638, 1604, 1497, 1456, 
1439, 1385, 1329, 1312, 1226, 1204, 1154, 1036, 1029, 968, 945, 901, 789, 771, 697; δH (400 MHz, CDCl3) 7.31 (2H, 
t, J 8.0, Ph), 6.97-6.92 (3H, m, Ph), 6.64 (1H, dd, J 10.8, J 16.7, NHCOCHCH2), 6.36 (1H, dd, J 16.7, J 1.7, 
NHCOCHCH2 cis to C=O), 5.76 (1H, dd, J 10.8, J 1.7, NHCOCHCH2 trans to C=O), 3.88-3.74 (4H, m, piperazine-
H), 3.23-3.20 (4H, m, piperazine-H); δC (101 MHz, CDCl3) 165.4, 150.9, 129.3, 128.2, 127.3, 120.7, 116.7, 49.9, 
49.4, 45.7, 41.9; m/z (CI) 217 [MH]+; found: [MH]+, 217.1350 C13H17N2O requires 217.1341, Δ 4.2 ppm.   
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4-(Acryloylamino-methyl)-benzoic acid methyl ester 50 
 
To a solution of methyl 4-(aminomethyl)-benzoate HCl salt (322.0 mg, 1.6 mmol, 1.0 eq.) in CH2Cl2 (2 mL) at 0 °C 
was added Et3N (0.47 mL, 3.36 mmol, 2.1 eq.) and acryloyl chloride (0.14 mL, 1.8 mmol, 1.1 eq.) and the mixture 
stirred at rt for 4 h. The reaction was quenched with sat. NaHCO3, extracted with CH2Cl2 (x 3), dried over MgSO4 and 
the solvent removed in vacuo. The crude yellow oil was purified on silica (EtOAc/n-pentane, 2:3) to give the desired 
product (150.5 mg, 43 %) as a white solid, mp = 114-116 °C; Rf = 0.20 (EtOAc/n-pentane, 2:3); νmax /cm-1 3273, 1718, 
1652, 1621, 1555, 1437, 1412, 1278, 1246, 1107, 965, 754, 708; δH (400 MHz, CDCl3) 7.86 (2H, d, J 7.0, ArH2’), 
7.34 (1H, bt, NH), 7.23 (2H, d, J 7.0, ArH3’), 6.25-6.15 (2H, m, NHCOCHCH2), 5.58 (1H, dd, J 8.3, J 3.5, 
NHCOCHCH2), 4.42 (2H, d, J 6.7, CH2), 3.84 (3H, s, CH3); δC (101 MHz, CDCl3) 166.9, 166.0, 143.6, 130.6, 129.8, 
129.0, 127.3, 126.7, 52.1, 43.0; m/z (CI) 220 [MH]+, 237 [MNH4]+; found [MH]+ 220.0970 C12H14NO3 requires 
220.0974, Δ 1.8 ppm.     
N-(5-Ethyl-[1,3,4]thiadiazol-2-yl)-acrylamide 51 
 
To a solution of 5-ethyl-[1,3,4]thiadiazol-2-ylamine (206.5 mg, 1.60 mmol, 1.0 eq.) in CH2Cl2 (2 mL) was added Et3N 
(0.24 mL, 1.76 mmol, 1.1 eq.), the solution cooled to 0 °C and acryloyl chloride (0.14 mL, 1.76, 1.1 eq.) added 
dropwise. The mixture was stirred at rt overnight, and subsequently quenched with NaHCO3, extracted with CH2Cl2 (x 
3), dried over MgSO4 and the solvent removed in vacuo. The crude residue was purified on silica (EtOAc/n-hexane, 
3:2) to give the desired acrylamide 51 (72.1 mg, 25 %) as a white solid, mp = 194-198 °C; Rf = 0.20 (CH2Cl2/MeOH, 
97:3); νmax /cm-1 1683, 1559, 1401, 1323, 1289, 1198, 982, 968, 936, 836, 794, 710, 682; δH (400 MHz, CDCl3) 6.91 
(1H, dd, J 17.2, J 10.0, NHCOCHCH2), 6.68 (1H, dd, J 1.4, J 17.2, NHCOCHCH2 cis to C=O), 6.01 (1H, dd, J 10.0, J 
1.4, NHCOCHCH2 trans to C=O), 3.10 (2H, q, J 7.7, CH2), 1.44 (3H, t, J 7.7, CH3); δC (101 MHz, CDCl3) 167.0, 
163.7, 160.8, 131.3, 129.3, 23.7, 14.2; m/z (ESI) 184 [MH]+; found [MH]+ 184.0552 C7H10N3OS requires 184.0545, Δ 
3.8 ppm.          
N-(3-Trifluoromethyl-phenyl)-acrylamide 52 
 
To a solution of 3-(trifluoromethyl)-aniline (0.5 mL, 4.0 mmol, 1 eq.) in CH2Cl2 (10 mL) at 0 °C under argon was 
added triethylamine (0.83 mL, 6.0 mmol, 1.5 eq.) and acryloyl chloride (0.36 mL, 4.4 mmol, 1.1 eq.) and the reaction 
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mixture stirred at 0 °C for 15 min and then at rt for 1 h. The reaction mixture was poured into aq. NH4Cl (2M) (20 
mL), extracted with CH2Cl2 (x 3) and the combined organics dried over MgSO4, filtered and concentrated in vacuo. 
The crude yellow oil was purified by flash column chromatography on silica (EtOAc/n-hexane, 35:65) to yield the 
desired acrylamide 52 (617.3 mg, 72 %) as a white solid, mp = 82-83 °C. Rf = 0.61 (EtOAc/n-hexane, 1:1); νmax /cm-1 
1668, 1626, 1557, 1494, 1408, 1334, 1177, 1161, 1111, 1098, 1070, 963, 880, 794, 721, 695; δH (400 MHz, CDCl3) 
8.02 (1H, bs, NH), 7.91 (1H, s, ArH2’), 7.81 (1H, d, J 8.0, ArH6’), 7.45 (1H, t, J 8.0, ArH5’), 7.39 (1H, d, J 8.0, 
ArH4’), 6.48 (1H, dd, J 16.0, J 1.0, NHCOCHCH2 cis to C=O), 6.32 (1H, dd, J 16.0, J 10.0, NHCOCHCH2), 5.82 
(1H, dd, J 10.0, J 1.0, NHCOCHCH2 trans to C=O); δC (101 MHz, CDCl3) 164.0, 138.3, 131.9, 131.6, 131.2, 130.9, 
130.7, 129.6, 128.7, 125.2, 122.5, 121.2, 116.9; m/z (CI) 216 [MH]+ 233 [MNH4]+; found: [MH]+, 216.0645 
C10H9NOF3 requires 216.0636, Δ 4.1 ppm. 
N-(2-Morpholin-4-yl-ethyl)-acrylamide 53 
 
To a solution of 4-(2-aminoethyl)morpholine (0.66 mL, 5.0 mmol, 1.0 eq.) in anhydrous CH2Cl2 (25 mL) at 0 °C 
under argon was added Et3N (1.04 mL, 7.5 mmol, 1.5 eq.) and acryloyl chloride (0.45 mL, 5.5 mmol, 1.1 eq.) and the 
resulting bright yellow solution warmed to rt and stirred for 1 h. The reaction mixture was poured in H2O and 
extracted with CH2Cl2 (x 3). The aqueous layer was basified with 20 % saturated NaOH to pH 12 and further 
extracted with CH2Cl2. Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. The 
crude yellow solid was purified on silica (EtOAc/MeOH, 4:1) to yield the desired acrylamide (651.8 mg, 71 %) as a 
white solid, mp = 96-97 °C; Rf = 0.32 (EtOAc/MeOH, 4:1); νmax /cm-1 3283, 3097, 2973, 2958, 2941, 2917, 2892, 
2858, 2813, 2790, 2777, 2769, 1655, 1627, 1565, 1450, 1413, 1303, 1282, 1263, 1244, 1169, 1149, 1134, 1115, 1092, 
1013, 1002, 977, 914, 867, 734; δH (400 MHz, CDCl3) 6.25 (1H, dd, J 1.5, J 17.0, CH2CHCONH cis to C=O), 6.14 
(1H, bs, NH), 6.10 (1H, dd, J 10.2, J 17.0, CH2CHCONH), 5.61 (1H, dd, J 1.5, J 10.2, CH2CHCONH trans to C=O), 
3.68 (4H, t, J 4.6, morpholine-H2’), 3.41 (2H, q, J 5.7, NHCH2), 2.49 (2H, t, J 6.0, NHCH2CH2), 2.43 (4H, m, 
morpholine-H3’); δC (101 MHz, CDCl3) 165.6, 131.0, 126.5, 67.1, 57.1, 53.5, 35.8; m/z (ESI) 185 [MH]+; found 
[MH]+ 185.1285 C9H17N2O2 requires 185.1290, Δ 2.7 ppm.  
N-(1-Benzyl-piperidin-4-yl)-acrylamide 54 
 
To a solution of 4-amino-N-benzyl piperidine (0.40 mL, 1.98 mmol, 1.0 eq.) in CH2Cl2 (10 mL) at 0 °C under argon 
was added Et3N (0.41 mL, 2.98 mmol, 1.5 eq.) and acryloyl chloride (0.18 mL, 2.18 mmol, 1.1 eq.). The reaction 
mixture was stirred for 1 h, poured into aq. NH4Cl (20 mL) and extracted with CH2Cl2 (x 1) and the organic layer 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude yellow oil was triturated in ether to yield the 
desired acrylamide 54 (148.9 mg, 31 %) as a white solid, mp = 115-116 °C; νmax /cm-1 3299, 1656, 1626, 1539, 1233, 
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981, 943, 731, 695; δH (400 MHz, CDCl3) 7.36-7.25 (5H, m, Ph), 6.30 (1H, dd, J 17.0, J 1.4, NHCOCHCH2 cis to 
C=O), 6.10 (1H, dd, J 17.0, J 10.2, NHCOCHCH2), 5.65 (1H, dd, J 10.2, J 1.4, NHCOCHCH2 trans to C=O), 3.96-
3.86 (1H, m, NHCH), 3.53 (2H, s, PhCH2), 2.87-2.84 (2H, m, piperidine-H), 2.16 (2H, td, J 12.0, J 1.5, piperidine-H), 
1.98-1.94 (2H, m, piperidine-H), 1.52 (2H, qd, J 12.0, J 4.0, piperidine-H); δC (101 MHz, CDCl3) 164.9, 138.4, 131.2, 
129.2, 128.4, 127.2, 126.5, 63.2, 52.4, 46.7, 32.3; m/z (ESI) 245 [MH]+; found: [MH]+, 245.1654 C15H21N2O requires 
245.1654, Δ 0 ppm.            
N-(4-Fluoro-benzyl)-acrylamide 55 
 
To a solution of 4-fluorobenzylamine (200.0 mg, 1.60 mmol, 1.0 eq.) in CH2Cl2 (5 mL) at 0 °C was added Et3N (0.24 
mL, 1.76 mmol, 1.1 eq.) and acryloyl chloride (0.14 mL, 1.76 mmol, 1.1 eq.) and the mixture stirred at rt for 1 h. The 
reaction was quenched with sat. NaHCO3 and extracted with CH2Cl2 (3 x 20 mL). The organics were combined and 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude mixture was purified on silica (gradient 
elution, EtOAc/n-pentane, 2:3 to 100 % EtOAc) to yield the desired acrylamide 55 (210.9 mg, 74 %) as a white 
powder, mp = 119-121 °C; Rf  = 0.19 (EtOAc/n-hexane, 2:3); νmax /cm-1 3270, 1654, 1621, 1545, 1509, 1214, 1159, 
981, 951, 850, 826, 804, 698; δH (400 MHz, CDCl3) 7.24-7.20 (2H, m, ArH2’), 7.00-6.95 (2H, m, ArH3’), 6.41 (1H, 
bs, NH), 6.27 (1H, dd, J 17.1, J 1.7, NHCOCHCH2 cis to C=O), 6.12 (1H, dd, J 10.3, J 17.1, NHCOCHCH2), 5.63 
(1H, dd, J 10.3, J 1.7, NHCOCHCH2 trans to C=O), 4.42 (2H, d, J 5.8, ArCH2NH); δC (101 MHz, CDCl3) 165.6, 
162.3 (d, J 246), 134.0 (d, J 2), 130.6, 129.7 (d, J 8), 127.2, 115.7 (d, J 22), 43.1; m/z (CI) 180 [MH]+, 197 [MNH4]+; 
found [MH]+ 180.0820 C10H11NOF requires 180.0825, Δ 2.8 ppm.   
2-Benzylsulfanyl-ethanesulfonic acid benzylamide 56 
 
To a solution of vinyl sulfonamide 40 (60 mg, 0.30 mmol, 1 eq.) in MeCN (6 mL) and water (1 mL), benzylthiol (45 
mg, 0.37 mmol, 1.2 eq.) and Et3N (36.9 mg, 0.37 mmol, 1.2 eq.) were added, and the mixture stirred at rt for 1 h. The 
acetonitrile was removed in vacuo, water (10 mL) added to the resultant slurry, and this extracted with CH2Cl2 (2 x 10 
mL). Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo to yield the desired 
sulfonamide 56 (83.9 mg, 87 %) as a white solid, mp = 96-99 °C; Rf = 0.53 (EtOAc/n-hexane, 1:1); νmax /cm-1  3294, 
1455, 1429, 1324, 1304, 1145, 1134, 1065, 855, 698; δH (400 MHz, CDCl3) 7.41-7.28 (10H, m, ArH), 5.00 (1H, t, J 
6.0, NH), 4.22 (2H, d, J 6.0, NHCH2), 3.68 (2H, s, SCH2Ph), 3.06 (2H, t, J 8.0, SO2CH2), 2.76 (2H, t, J 8.0, 
SO2CH2CH2); δC (101 MHz, CDCl3) 137.5, 136.8, 128.9, 128.9, 128.8, 128.2, 128.0, 127.5, 52.8, 47.1, 36.5, 24.8;  
m/z (CI) 339 [MNH4]+, 322 [MH]+; found: [MH]+, 322.0921 C16H20NO2S2 requires 322.0935, Δ 4.3 ppm.     
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2-Benzylsulfanyl-ethanesulfonic acid 4-methoxy-benzylamide 57  
 
To a stirred solution of vinyl sulfonamide 41 (50 mg, 0.22 mmol, 1 eq.) in MeCN (6 mL) and water (1 mL), 
benzylthiol (32.8 mg, 0.26 mmol, 1.2 eq.) and Et3N (26.7 mg, 0.26 mmol, 1.2 eq.) were added, and the mixture stirred 
at rt for 1 h. The MeCN was removed in vacuo, and the resultant slurry diluted with additional water (5 mL) and 
extracted with diethylether (2 x 10 mL). The combined organics were dried (MgSO4) and concentrated in vacuo to 
give the desired sulfonamide 57 (65.4 mg, 85 %) as a white solid, mp = 91-95 °C; Rf  = 0.47 (EtOAc/n-hexane, 1:1); 
νmax /cm-1  3296, 1614, 1515, 1454, 1321, 1300, 1257, 1145, 1133, 1120, 1043, 1029, 845, 816, 698; δH (400 MHz, 
CDCl3) 7.35-7.23 (7H, m, ArH), 6.90 (2H, d, J 7.3, ArH) 4.87 (1H, t, J 5.5, NH), 4.15 (2H, d, J 5.5, NHCH2), 3.81 
(3H, s, OCH3), 3.68 (2H, s, SCH2Ph), 3.05 (2H, t, J 7.3, SO2CH2), 2.75 (2H, t, J 7.3, SO2CH2CH2); δC (101 MHz, 
CDCl3) 159.5, 137.5, 129.4, 128.9, 128.8, 128.8, 127.5, 114.3, 55.4, 52.8, 46.7, 36.6, 24.9; m/z (CI) 369 [MNH4]+, 352 
[MH]+; found: [MH]+, 352.1038 C17H22NO3S2 requires 352.1041, Δ 0.9 ppm.   
(R)-3-(2-Benzylsulfamoyl-ethylsulfanyl)-2-carboxyamino-propionic acid 58 
 
Method 1: To a stirred solution of vinyl sulfonamide 40 (50 mg, 0.25 mmol, 1 eq.) in acetonitrile (6 mL) and water (6 
mL), N-acetyl L-cysteine (49.7 mg, 0.30 mmol, 1.2 eq.) and triethylamine (61.6 mg, 0.60 mmol, 2.4 eq.) were added, 
the mixture stirred at rt for 1 h, and the acetonitrile removed in vacuo. The resultant slurry was acidified to pH 3 with 
aq. HCl (2N), extracted with EtOAc (3 x 10 mL), and the combined organics dried (MgSO4). The solvent was 
removed in vacuo and the crude product purified by flash chromatography on silica (gradient elution, 100 % CH2Cl2 
to 100 % MeOH) to give the desired sulfonamide 58 (83 mg, 92 %) as a white powder.  
Method 2: To a stirred solution of vinyl sulfonamide 40 (26.8 mg, 0.136 mmol, 1 eq.) at rt in acetonitrile (1 mL) was 
added N-acetyl L-cysteine (22.2 mg, 0.136 mmol, 1 eq.) in acetonitrile: water 1:1, and triethylamine (33.0 mg, 0.326 
mmol, 2.4 eq.) in acetonitrile (2 mL). Stirring was continued at rt for 9 hours before the acetonitrile was removed in 
vacuo, and the resulting slurry acidified to pH 3 with aq. HCl (2N). The resulting white precipitate was filtered under 
reduced pressure and subsequently washed with aq. HCl (2N) and ether to yield the desired sulfonamide 58 (49 mg, 
100 %) as a white powder.  
Mp = 115-120 °C; Rf = 0 (EtOAc/n-hexane, 3:2); νmax /cm-1  3298 (b), 1603, 1419, 1325, 1146; δH (400 MHz, DMSO-
d6) 12.87 (1H, bs, COOH), 8.27 (1H, d, J 8.6, NHAc), 7.76 (1H, t, J 6.4, NHSO2), 7.37-7.25 (5H, m, ArH), 4.40-4.35 
(1H, m, AcNHCH), 4.16 (2H, d, J 6.4, ArCH2NHSO2), 3.20-3.15 (2H, m, SO2CH2), 2.89 (1H, dd, J 14.0, J 4.0, 
SO2CH2CH2SCH2), 2.78-2.69 (3H, m, SO2CH2CH2 (1H) and SO2CH2CH2SCH2 (2H)), 1.86 (3H, s, NHCOOCH3); δC 
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(101 MHz, DMSO-d6) 173.2, 168.7, 138.5, 128.4, 127.6, 127.2, 53.9, 52.1, 45.9, 34.7, 25.1, 22.9; m/z (ESI) 383 
[MNa]+, 361 [MH]+; found [MH]+ 361.0877 C14H21N2O5S2 requires 361.0892, Δ 4.2 ppm.  
(R)-2-Carboxyamino-3-[2-(4-methoxy-benzylsulfamoyl)-ethylsulfanyl]-propionic acid 59 
 
To a stirred solution of vinyl sulfonamide 41 (50.0 mg, 0.22 mmol, 1.0 eq.) in MeCN (6 mL) and water (1 mL), N-
acetyl L-cysteine (43.1 mg, 0.26 mmol, 1.2 eq.) and Et3N (55.7 mg, 0.55 mmol, 2.5 eq.) were added and the mixture 
stirred at rt for 1 h. The MeCN was removed in vacuo, water (10 mL) added to the resultant slurry, the aqueous 
solution acidified to pH 2 with aq. HCl (2N) and extracted with EtOAc (3 x 10 mL). The combined organics were 
dried over MgSO4, filtered and the solvent removed in vacuo to yield the desired sulfonamide 59 (75.2 mg, 87 %) as a 
white solid, mp = 100-105 °C; Rf = 0 (EtOAc/n-hexane, 3:2); νmax /cm-1  3299 (b), 1702, 1611, 1541, 1515, 1428, 
1331, 1322, 1304, 1246, 1146, 1026, 818; δH (400 MHz, DMSO-d6) 8.26 (1H, d, J 8.6, AcNHCH), 7.65 (1H, t, J 5.7, 
SO2NH), 7.25 (2H, d, J 8.6, ArH2’), 6.90 (2H, d, J 8.6, ArH3’), 4.38-4.34 (1H, m, AcNHCH), 4.08 (2H, d, J 5.7, 
SO2NHCH2), 3.73 (3H, s, OCH3), 3.16-3.12 (2H, m, SO2CH2), 2.89 (1H, dd, J 13.0, J 5.0, SO2CH2CH2SCH2), 2.77-
2.69 (3H, m, SO2CH2CH2 (2H) and SO2CH2CH2SCH2 (1H)), 1.86 (3H, s, NHCOCH3); δC (101 MHz, DMSO-d6) 
172.3, 169.7, 158.8, 130.4, 129.3, 113.9, 55.3, 52.2, 52.1, 45.7, 33.3, 25.3, 22.6; m/z (ESI) 413 [MNa]+, 391 [MH]+; 
found [MH]+ 391.0979 C15H23N2O6S2 requires 391.0998, Δ 4.9 ppm.    
(R)-2-Acetylamino-3-(2-benzylcarbamoyl-ethylsulfanyl)-propionic acid 60 
 
To a solution of acrylamide 47 (25 mg, 0.16 mmol, 1.0 eq.) in acetonitrile (1 mL) under argon was added N-acetyl L-
cysteine (25.3, 0.16 mmol, 1.0 eq.) in H2O (1 mL) and triethylamine (0.11 mL, 0.78 mmol, 5 eq.) and the mixture 
stirred at rt for 72 h. The reaction mixture was washed with EtOAc and the solvent removed from the aqueous layer to 
yield the desired thioether 60 (41.2, 62 %) as a clear oil; Rf = 0 (100 % EtOAc); νmax /cm-1 3280, 1646, 1606, 1556, 
1455, 1379; δH (400 MHz, MeOD) 7.34-7.21 (5H, m, ArH), 4.44 (1H, dd, J 7.1, J 4.7, HOOCCH), 4.38 (2H, s, 
PhCH2NH), 3.11 (1H, dd, J 13.3, J 4.7, HOOCCH(NHCOCH3)CH2), 2.88-2.83 (3H, m, SCH2CH2CONH and 
HOOCCH(NHCOCH3)CH2), 2.54 (2H, td, J 6.6, J 1.6, SCH2CH2CONH), 1.98 (3H, s, NHCOCH3); δC (101 MHz, 
MeOD) 176.6, 174.0, 172.8, 139.9, 129.5, 128.6, 128.2, 55.4, 48.8, 37.3, 35.5, 29.1, 22.7; m/z (ESI) 325 [MH]+; 
found: [MH]+, 325.1222. C15H21N2O4S requires 325.1222, Δ 0 ppm.               
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(R)-2-Acetylamino-3-[2-(4-methoxy-benzylcarbamoyl)-ethylsulfanyl]-propionic acid 61 
 
To a solution of acrylamide 48 (25 mg, 0.131 mmol, 1.0 eq.) in MeCN (1 mL) under argon was added N-acetyl L-
cysteine (21.3 mg, 0.131 mmol, 1.0 eq.) in H2O (1 mL) and Et3N (0.18 mL, 1.31 mmol, 10 eq.) and the mixture stirred 
at rt for 16 h. The MeCN was removed in vacuo and the aqueous layer was acidified to pH 1 with aq. HCl (2N) and 
extracted with EtOAc (x 3), chloroform (x 3) and chloroform/EtOH, 2:1 (x 1). The organics were combined, dried 
over MgSO4, filtered and the solvent removed in vacuo to yield the desired thioether 61 (27.7 mg, 60 %) as a clear oil; 
Rf = 0 (100 % EtOAc); νmax /cm-1 3276, 2827, 1648, 1548, 1514, 1421, 1375, 1301, 1249, 1179, 1032; δH (400 MHz, 
MeOD); 7.24 (2H, d, J 8.6, ArH2’), 6.89 (2H, d, J 8.6, ArH3’), 4.62 (1H, dd, J 8.0, J 4.7, HOOCCH), 4.33 (2H, s, 
ArCH2), 3.79 (3H, s, ArOCH3), 3.07 (1H, dd, J 13.9, J 4.7, HOOCCH(NHCOCH3)CH2), 2.91-2.85 (3H, m, 
SCH2CH2CONH and HOOCCH(NHCOCH3)CH2), 2.53 (2H, t, J 7.2, SCH2CH2CONH), 2.01 (3H, s, NHCOCH3); δC 
(101 MHz, MeOD) 172.4, 172.3, 172.0, 159.0, 130.4, 128.6, 113.5, 54.3, 52.4, 42.3, 35.8, 33.2, 27.9, 21.0; m/z (ESI) 
355 [MH]+, 377 [MNa]+; found: [MH]+, 355.1322 C16H23N2O5S requires 355.1328, Δ 1.7 ppm.  
(R)-4-([3-(2-Acetylamino-2-carboxy-ethylsulfanyl)-propionylamino]-methyl)-benzoic acid methyl ester 62 
 
To a solution of acrylamide 50 (25 mg, 0.114 mmol, 1.0 eq.) in acetonitrile (1 mL) was added N-acetyl L-cysteine 
(18.6 mg, 0.114 mmol, 1.0 eq.) in H2O (1 mL) and triethylamine (0.16 mL, 1.14 mmol, 10 eq.) and the mixture stirred 
at rt for 16 h. The acetonitrile was removed in vacuo, the aqueous layer was acidifed to pH 1 with aq. HCl (2N) and 
extracted with EtOAc (x 6). The combined organics were dried (MgSO4) and the solvent removed in vacuo to yield 
the desired thioether 62 (44 mg, 100 %) as a clear oil; Rf = 0 (100 % EtOAc); νmax /cm-1 3305, 1720, 1650, 1616, 1548, 
1434, 1417, 1377, 1285, 1114; δH (400 MHz, MeOD); 7.98 (2H, d, J 8.2, ArH3’), 7.43 (2H, d, J 8.2, ArH2’), 4.64 
(1H, m, HOOCCH), 4.47 (2H, s, ArCH2NHCO), 3.90 (3H, s, COOCH3), 3.08 (1H, dd, J 4.9, J 14.2, 
HOOCCH(NHCOCH3)CH2), 2.93-2.87 (3H, m, SCH2CH2CONH and HOOCCH(NHCOCH3)CH2), 2.58 (2H, t, J 7.1, 
SCH2CH2CONH), 2.02 (3H, s, NHCOCH3); δC (101 MHz, MeOD) 174.1, 173.4, 168.4, 145.6, 131.0, 130.7, 130.1, 
128.5, 53.7, 52.6, 43.8, 37.1, 34.6, 29.2, 22.4; m/z (ESI) 383 [MH]+, 405 [MNa]+; found [MH]+ 383.1275 
C17H23N2O6S requires 383.1277, Δ 0.5 ppm.             
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9.2. Pyrrolidine analogues 
1-(Toluene-4-sulfonyl)-(R)-pyrrolidine-2-carboxylic acid 64 
 
D-proline (300 mg, 2.61 mmol, 1.0 eq.) was dissolved in aqueous 2 M NaOH (2.6 mL, 5.21 mmol, 2.0 eq.) at 0 °C. A 
solution of TsCl (497.6 mg, 2.61 mmol, 1.0 eq.) in Et2O (3 mL) was added dropwise with stirring over 10 min. The 
solution was stirred at rt overnight. The ethereal solution was separated and the aqueous solution acidified to pH 2 
with aqueous 1 M HCl. The aqueous layer was extracted with EtOAc (x 3) and combined EtOAc extracts dried over 
MgSO4, filtered and concentrated in vacuo. The crude clear oil was washed with CHCl3 (x 5) to remove traces of 
EtOAc to yield the desired N-tosyl D-proline 64 (597.3 mg, 85 %) as a clear oil which solidified at -20 °C to a white 
solid, mp = 46-48 °C; Rf = 0 (100 % EtOAc); [α]24D = + 77.0 (c = 1.27, CHCl3); νmax /cm-1 1722, 1337, 1197, 1154, 
1092, 1010, 911, 815, 729, 661, 589; δH (400 MHz, CDCl3) 7.77 (2H, d, J 8.0, ArH), 7.35 (2H, d, J 8.0, ArH), 4.26 
(1H, dd, J 3.6, J 8.2, HOOCCH), 3.55-3.50 (1H, m, pyrrolidine-H5’), 3.28-3.22 (1H, m, pyrrolidine-H5’), 2.45 (3H, s, 
ArCH3), 2.19-2.14 (1H, m, pyrrolidine-H3’), 2.00-1.87 (2H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 1.79-1.70 (1H, 
m, pyrrolidine-H4’); δC (101 MHz, CDCl3) 177.4, 144.1, 134.5, 130.0, 127.6, 60.5, 48.8, 30.9, 24.7, 21.6; m/z (ESI) 
270 [MH]+; found [MH]+ 270.0796 C12H16NO4S requires 270.0800, Δ 1.5 ppm.   
N-[1-(Toluene-4-sulfonyl)-(R)-pyrrolidin-2-ylmethyl]-acrylamide 67 
Method one Staudinger reduction 
 
Triphenylphosphine (187.3 mg, 0.714 mmol, 2 eq.) was added to a solution of azide 76 (100 mg, 0.357 mmol, 1 eq.) 
in THF/H2O (2.5 mL/0.25 mL). The mixture was stirred at rt for 2.5 h. 1M HCl (1 mL) was added and the aqueous 
layer washed with Et2O (x 3). The aqueous layer was basified with 2N NaOH to pH 12-14 and extracted with EtOAc 
(x 5). The combined EtOAc layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. To 
a solution of the crude amine 72 (80 mg, 0.315 mmol, 1 eq.) in CH2Cl2 (2 mL) at 0 °C under argon was added 
triethylamine, (0.07 mL, 0.519 mmol, 1.5 eq.) and acryloyl chloride (0.03 mL, 0.346 mmol, 1.1 eq.) and the reaction 
stirred at 0 °C (15 min) and then at rt overnight. The reaction mixture was poured into aqueous 2M NH4Cl and 
extracted with CH2Cl2, dried over MgSO4, filtered and concentrated in vacuo. The crude yellow oil was purified by 
flash column chromatography on silica (EtOAc/n-hex, 4:1) to give the desired acrylamide 67 (14.2 mg, 13 %) as a 
clear oil.  
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Method 2 Hydrogenation 
 
To a solution of azide 76 (700 mg, 2.50 mmol, 1.0 equiv.) in EtOAc (23 mL) under argon was added Pd/C (121 mg, 
cat.) and the mixture stirred at rt under a H2 atmosphere for 24 h. The reaction mixture was filtered over celite, washed 
through with EtOAc and MeOH and the solvent removed under reduced pressure. The crude residue was purified on 
silica (10 % MeOH/CH2Cl2 to 100 % MeOH) to yield the desired amine 72 (532.9 mg, 84 %) as a clear oil.  
 
To a solution of amine 72 (242.0 mg, 0.95 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (7 mL) at 0 °C under argon was 
added Et3N (0.20 mL, 1.43 mmol, 1.5 equiv.) and acryloyl chloride (0.12 mL, 1.43 mmol, 1.5 equiv.) and the resulting 
solution stirred at 0 °C for 15 min and at rt overnight. The reaction mixture was poured into 2M aqueous NH4Cl and 
extracted with CH2Cl2 (x 3), dried over Na2SO4, filtered and the solvent removed in vacuo. The crude residue was 
purified on silica (4:1, EtOAc/n-hex) to yield the desired acrylamide 67 (216.3 mg, 74 %) as a clear oil.  
Rf  = 0.4 (n-Hex/EtOAc, 4:1); [α]18D = + 67.7 (c = 0.41, CHCl3); νmax /cm-1 1662, 1627, 1599, 1540, 1342, 1158, 1093, 
989, 817, 666; δH (400 MHz, CDCl3) 7.73 (2H, d, J 8.1, ArH), 7.36 (2H, d, J 8.1, ArH), 6.33 (1H, dd, J 17.3, J 1.6, 
NHCOCHCH2 cis to C=O), 6.21 (1H, dd, J 17.3, J 9.7, NHCOCHCH2), 5.69 (1H, dd, J 9.7, J 1.6, NHCOCHCH2 
trans to C=O), 3.78-3.72 (1H, m, pyrrolidine-H2’), 3.64-3.58 (1H, m, pyrrolidine-CH2), 3.50-3.45 (1H, m, 
pyrrolidine-CH2), 3.39-3.33 (1H, m, pyrrolidine-H5’), 3.30-3.23 (1H, m, pyrrolidine-H5’), 2.46 (3H, s, ArCH3), 1.88-
1.47 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’); δC (101 MHz, CDCl3) 166.1, 144.0, 133.8, 131.1, 129.9, 127.6, 
126.2, 59.6, 49.7, 44.0, 29.9, 24.2, 21.6; m/z (CI) 309 [MH]+, 326 [MNH4]+; HRMS (ESI) found: [MH]+, 309.1266 
C15H21N2O3S requires 309.1273, Δ 2.3 ppm. 
(R)-N-(1-Methyl-pyrrolidin-2-ylmethyl)-acrylamide 68 
 
To amine 112 (37.3 mg, 0.12 mmol, 1.0 eq.) and paraformaldehyde (13.0 mg, 0.43 mmol, 3.5 eq.) was added MeOH 
(4 mL) and the suspension heated at reflux for 20 min. The resulting cloudy white suspension was cooled to 0 °C and 
NaCNBH3 (77.9 mg, 1.24 mmol, 10 eq.) added. The reaction was warmed to rt and stirred overnight. To the colourless 
solution was added 10 % NaHCO3 (1 mL) to quench the reaction. The resulting mixture was washed with CHCl3 (x 1) 
and the organic layer dried over Na2SO4, filtered and the solvent removed in vacuo. The crude residue was washed 
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with 1:1 THF/MeOH (2 x 25 mL) and dried under high vacuum to yield the desired N-methyl pyrrolidine 113 (33.6 
mg, 97 %) which was taken straight onto the next step. δH (400 MHz, CDCl3) 7.39-7.36 (2H, m, ArH), 7.33-7.29 (2H, 
m, ArH), 7.24-7.19 (1H, m, ArH), 6.19 (1H, bs, NH), 3.61 (1H, ddd, J 13.7, J 7.7, J 2.8, NHCH2), 3.24 (2H, t, J 7.2, 
SCH2), 3.14-3.04 (2H, m, NHCH2 and pyrrolidine-H2’), 2.52 (2H, t, J 7.2, SCH2CH2), 2.45-2.39 (1H, m, pyrrolidine-
H5’), 2.33 (3H, s, NCH3), 2.28-2.22 (1H, m, pyrrolidine-H5’), 1.94-1.84 (1H, m, pyrolidine-H3’), 1.75-1.55 (3H, m, 
pyrrolidine-H3’ and pyrrolidine-H4’).   
To the N-methyl pyrrolidine thioether 113 (33.6 mg, 0.12 mmol, 1.0 equiv.) was added KOtBu as a 1.0 M solution in 
THF (Sigma-Alrich, SureSeal) (1.0 mL, 1.0 mmol, 9.4 eq.) at rt under argon. After 3 h the reaction mixture was 
loaded onto a silica column (3:7, MeOH/CH2Cl2) to yield the desired N-methyl pyrrolidine acrylamide 68 (10.5 mg, 
52 %) as a clear oil. Rf = 0.17 (3:7, MeOH/CH2Cl2); [α]24D = + 72.0 (c = 0.67, MeOH); νmax /cm-1; 1662, 1627, 1606, 
1554, 1457, 1410, 1245, 985, 957; δH (400 MHz, MeOD) 6.30-6.19 (2H, m, CH2CHCONH cis to C=O and 
CH2CHCONH), 5.67 (1H, dd, J 8.8, J 3.6, CH2CHCONH trans to C=O), 3.56 (1H, dd, J 13.0, J 4.3, NHCH2), 3.18 
(1H, dd, J 13.0, J 7.3, NHCH2), 3.08 (1H, quintet, J 4.8, pyrrolidine-H2’), 2.49-2.44 (1H, m, pyrrolidine-H5’), 2.42 
(3H, s, NCH3), 2.31 (1H, dd, q, J 9.0, pyrrolidine-H5’), 2.04-1.95 (1H, m, pyrrolidine-H4’), 1.80-1.73 (2H, m, 
pyrrolidine-H4’ and -H3’), 1.65-1.56 (1H, m, pyrrolidine-H3’); δC (101 MHz, CDCl3) 168.5, 132.1, 127.0, 66.7, 58.3, 
42.8, 41.2, 30.1, 23.1; m/z (ESI) 169 [MH]+; found [MH]+ 169.1335  C9H17N2O requires 169.1341, Δ 3.5 ppm.     
(R)-N-(1-Methyl-pyrrolidin-2-ylmethyl)-acrylamide 68 
 
 
 
To acrylamide 114 (107.7 mg, 0.29 mmol, 1.0 eq.) was added KOtBu as 1.0 M solution in THF (Sigma-Aldrich, 
SureSeal, 2.90 mL, 2.90 mmol, 10 eq.) at rt under an atmosphere of argon. The reaction mixture was stirred at rt for 1 
h before addition of sat. aq. NaHCO3 and the layers separated. The aqueous layer was further washed with ether (x 1) 
and combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue was 
purified on silica (CH2Cl2/MeOH, 7:3) to yield the desired acrylamide 68 (56.6 mg, 58 %) as a clear oil. Data in 
agreement with above.  
2-(S)-[4-[2-(R)-(Acryloylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoylamino]-pentanedioic acid 69 
 
A solution of acrylamide 91 (58.2 mg, 0.10 mmol, 1 eq.) in CHCl3 (3.75 mL) at 0 °C was treated with trifluoroacetic 
acid (3 mL). The reaction mixture was allowed to warm to rt and stirred for 72 h. The solvent was removed in vacuo 
and the resulting brown residue triturated with ether. The tan coloured precipitate was filtered, washed on the filter 
paper with cold ether and dried under high vacuum to yield the desired acrylamide 69 (24.7 mg, 53 %) as a tan 
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coloured powder. Rf = 0 (100 % EtOAc); νmax /cm-11717, 1649, 1625, 1601, 1540, 1448, 1437, 1411, 1399, 1336, 
1291, 1247, 1199, 1152, 1092, 1046, 1013, 986, 932, 857, 804, 762, 734, 697; δH (400 MHz, MeOD) 8.08 (2H, d, J 
7.6, ArH), 8.01 (2H, d, J 7.6, ArH), 6.34-6.23 (2H, m, CH2CHCONH cis to C=O and CH2CHCONH), 5.71 (1H, dd, J 
9.5, J 3.8, CH2CHCONH trans to C=O), 4.69 (1H, bs, ArCONHCH), 3.87-3.81 (1H, m, pyrrolidine-H2’), 3.62-3.57 
(1H, m, CH2CHCONHCH2), 3.53-3.47 (1H, m, CH2CHCONHCH2), 3.44-3.38 (1H, m, pyrrolidine-H5’), 3.30-3.23 
(1H, m, pyrrolidine-H5’), 2.52 (2H, t, J 6.1, HOOCCH2), 2.39-2.33 (1H, m, HOOCCH2CH2), 2.18-2.09 (1H, m, 
HOOCCH2CH2), 1.91-1.82 (1H, m, pyrrolidine-H3’), 1.75-1.70 (1H, m, pyrrolidine-H3’), 1.60-1.50 (2H, m, 
pyrrolidine-H4’); m/z (ESI) 468 [MH]+; found: [MH]+, 468.1444 C20H26N3O8S requires 468.1441, Δ 0.6 ppm.   
(R)-Ethenesulfonic acid [1-(toluene-4-sulfonyl)-pyrrolidin-2-ylmethyl]-amide 70 
 
2-Chloroethanesulfonyl chloride (0.08 mL, 0.75 mmol, 1.0 eq.) was added dropwise to a stirred solution of amine 72 
(190 mg, 0.75 mmol, 1.0 eq.) and triethylamine (0.36 mL, 2.61 mmol, 3.5 eq.) in dry CH2Cl2 (4 mL) at 0 °C under 
argon. After addition, stirring was continued at 0 °C for 1 h and at rt overnight. The mixture was diluted with CH2Cl2, 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude brown amorphous solid was 
purified by flash column chromatography on silica (EtOAc/n-hex, 1:1) to yield the desired vinyl sulfonamide 70 
(108.5 mg, 42 %) as a clear oil. Rf = 0.34 (EtOAc/n-hex, 1:1); [α]20D =  +109.1 (c = 0.37, CHCl3); νmax /cm-1 1598, 
1495, 1451, 1428, 1384, 1328, 1255, 1200, 1149, 1091, 1040, 972, 915, 867, 817, 729, 663; δH (400 MHz, CDCl3) 
7.71 (2H, d, J 8.3, ArH), 7.34 (2H, d, J 8.3, ArH), 6.60 (1H, dd, J 9.7, J 16.6, NHSO2CHCH2), 6.26 (1H, d, J 16.6, 
NHSO2CHCH2 cis to C=O), 5.98 (1H, d, J 9.7, NHSO2CHCH2 trans to C=O), 5.36 (1H, t, J 5.5, NH), 3.70-3.64 (1H, 
m, pyrrolidine-H2’), 3.47-3.41 (1H, m, pyrrolidine-H5’), 3.26-3.13 (3H, m, pyrrolidine-H5’ and pyrrolidine-CH2), 
2.43 (3H, s, ArCH3), 1.84-1.76 (2H, m, pyrrolidine-H3’), 1.72-1.61 (1H, m, pyrrolidine-H4’), 1.50-1.41 (1H, m, 
pyrrolidine-H4’); δC (101 MHz, CDCl3) 144.2, 135.9, 133.5, 130.0, 127.7, 126.8, 59.4, 50.0, 47.4, 29.6, 24.1, 21.7; 
m/z (CI) 345 [MH]+, 362 [MNH4]+; found: [MH]+, 345.0943 C14H21N2O4S2 requires 345.0943, Δ 0 ppm.  
2-(S)-(4-[2-(R)-(Ethenesulfonylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoylamino)-pentanedioic acid 71 
 
To a solution of sulfonamide 95 (651.6 mg, 1.06 mmol, 1 equiv.) in anhydrous CH2Cl2 (20 mL) was added TFA (15 
mL) and Et3SiH (0.84 mL, 5.28 mmol, 5 equiv.) at 0 °C under argon. The reaction was allowed to warm to rt and 
stirred for 4 days. The solvent was removed in vacuo and ether added to the brown residue. The resulting tan coloured 
precipitate was filtered under reduced pressure and washed thoroughly on the filter paper with ether to give the 
desired vinyl sulfonamide 71 (500.0 mg, 94 %) as a tan coloured powder, mp = 135-140 °C; Rf = 0 (100 % EtOAc); 
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νmax /cm-1 1707, 1642, 1603, 1544, 1420, 1324, 1200, 1143, 1090, 855, 799, 733, 616; δH (400 MHz, DMSO-d6) 12.50 
(2H, bs, COOH), 8.86 (1H, bs, ArCHNH), 8.10 (2H, d, J 7.3, ArH), 7.91 (2H, d, J 7.3, ArH), 7.52 (1H, t, J 5.5, 
SO2NH), 6.74 (1H, dd, J 9.0, J 18.2, NHSO2CHCH2), 6.07 (1H, d, J 18.2, NHSO2CHCH2 cis to sulfonamide), 6.02 
(1H, d, J 9.0, NHSO2CHCH2 trans to sulfonamide), 4.41 (1H, bs, ArCONHCH), 3.60-3.56 (1H, m, pyrrolidine-H2’), 
3.38-3.33 (1H, m, pyrrolidine-H5’), 3.13-3.15 (1H, m, pyrrolidine-H5’), 3.04-3.10 (1H, m, SO2NHCH2), 2.89-2.82 
(1H, m, SO2NHCH2), 2.38 (2H, bs, CH2COOH), 2.12 (1H, bs, CH2CH2COOH), 1.97 (1H, bs, CH2CH2COOH), 1.78-
1.71 (2H, m, pyrrolidine-H4’), 1.49-1.39 (2H, m, pyrrolidine-H3’); m/z (ESI) 504 [MH]+, 526 [MNa]+; found: [MH]+, 
504.1117 C19H26N3O9S2 requires 504.1110, Δ 1.4 ppm.       
(R)-[1-(Toluene-4-sulfonyl)-pyrrolidin-2-yl]-methylamine 72 
 
Triphenylphosphine (748.6 mg, 2.85 mmol, 2 eq.) was added to a solution of azide 76 (400 mg, 1.43 mmol, 1 eq.) in 
THF/H2O (10/1 mL) and the mixture stirred for 3 h at rt under argon. 1 M HCl (4 mL) was added to the reaction and 
the aqueous layer washed with Et2O (x 3). The aqueous layer was basified with 2N NaOH to pH 12-14 and extracted 
with EtOAc (x 5). The combined EtOAc layers were dried over MgSO4, filtered and concentrated in vacuo. The crude 
yellow oil was purified by flash column chromatography on silica (gradient elution CH2Cl2/MeOH, 9:1 to 100 % 
MeOH) to yield the desired amine 72 (190 mg, 52 %) as a light yellow oil. Rf = 0 (EtOAc/n-hex, 1:1); [α]21D = +147.4 
(c = 0.38, CHCl3); νmax /cm-1 2953, 2869, 1335, 1154, 1090, 816, 662; δH (400 MHz, CDCl3) 7.64 (2H, d, J 8.0, ArH), 
7.24 (2H, d, J 8.0, ArH), 3.55-3.50 (1H, m, pyrrolidine-H2’), 3.34-3.28 (1H, m, pyrrolidine-H5’), 3.16-3.10 (1H, m, 
pyrrolidine-H5’), 2.75 (2H, d, J 5.5, pyrrolidine-CH2), 2.34 (3H, s, ArCH3), 1.72-1.33 (4H, m, pyrrolidine-H3’ and 
pyrrolidine-H4’); δC (101 MHz, CDCl3) 143.4, 134.2, 129.6, 127.4, 62.4, 49.3, 46.4, 28.9, 24.0, 21.4; m/z (CI) 255 
[MH]+; found: [MH]+, 255.1170 C12H19N2O2S requires 255.1167, Δ 1.2 ppm.      
(R)-Toluene-4-sulfonic acid 1-(toluene-4-sulfonyl)-pyrrolidin-2-ylmethyl ester 73 
Method one: from D-proline 
 
LiAlH4 (516 mg, 12.88 mmol, 1.5 eq.) was cooled to 0 °C under argon before addition of anhydrous THF (16 mL) and 
D-proline (1.00 g, 8.69 mmol, 1.0 eq.) portionwise as a solid. The resultant mixture was stirred at 0 °C for 1 h and at rt 
for 1 h. 20 % aqueous NaOH (2 mL) was added dropwise with vigorous evolution of H2 (g). The resultant white 
precipitate was filtered through celite under reduced pressure and the filtrate dried over Na2SO4, filtered and the 
solvent removed in vacuo. To the resultant yellow oil at 0 °C under argon was added a solution of TsCl (4.97 g, 26.07 
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mmol, 3.0 eq.) in pyridine (8 mL) dropwise. The resulting black solution was warmed to rt and stirred overnight. The 
reaction mixture was poured into H2O and extracted with CH2Cl2 (x 3). Combined organics were washed with 1M 
HCl (x 3), dried over MgSO4, filtered and the solvent removed in vacuo. The crude black residue was purified on 
silica (EtOAc/n-hex, 1:3) to yield the desired bis tosylate 73 (1.76 g, 49 %) as a white solid.   
Method 2: from D-prolinol 
 
To a solution of p-toluenesulfonyl chloride (2.90 g, 15.2 mmol, 3.0 eq.) in dry pyridine (5.2 mL) at 0 °C under argon 
was added D-prolinol (0.50 mL, 5.1 mmol, 1.0 eq.) dropwise and the mixture allowed to warm to rt and stirred for 12 
h. The solution was poured into ice-water and extracted with CH2Cl2 (x 4). The combined organics were dried over 
MgSO4, filtered and the solvent removed in vacuo. The crude red oil was purified by flash column chromatography on 
silica (EtOAc/n-hexane, 2:3) to give the bis-tosylated D-prolinol 73 (1.93 g, 100 %) as a white solid, mp = 94-96 °C; 
Rf = 0.28 (EtOAc/n-pentane, 1:3); [α]22D = + 108.1 (c = 1.17, CHCl3); νmax /cm-1 1599, 1454, 1345, 1189, 1175, 1158, 
1094, 1044, 967, 908, 730; δH (400 MHz, CDCl3) 7.78 (2H, d, J 8.5, ArH), 7.62 (2H, d, J 8.5, ArH), 7.35 (2H, d, J 
8.5, ArH), 7.28 (2H, d, J 8.5, ArH), 4.24 (1H, dd, J 3.2, J 10.5, TsOCH2), 3.95 (1H, dd, J 6.3, J 10.5, TsOCH2), 3.73-
3.67 (1H, m, pyrrolidine-H2’), 3.37-3.32 (1H, m, pyrrolidine-H5’), 3.04-2.98 (1H, m, pyrrolidine-H5’), 2.42 (3H, s, 
ArCH3), 2.38 (3H, s, ArCH3), 1.82-1.69 (2H, m, pyrrolidine-H4’), 1.62-1.46 (2H, m, pyrrolidine-H3’); δC (101 MHz, 
CDCl3) 145.1, 143.9, 133.4, 130.0, 129.8, 129.8, 127.9, 127.5, 71.5, 57.6, 49.3, 28.5, 23.7, 21.6, 21.5; m/z (CI) 410 
[MH]+, 427 [MNH4]+; found: [MH]+, 410.1087 C19H24NO5S2 requires 410.1096, Δ 2.2 ppm. 
(R)-[1-(Toluene-4-sulfonyl)-pyrrolidin-2-yl]-methanol 74 
 
To D-proline (200 mg, 1.74 mmol, 1.0 eq.) in anhydrous THF (1 mL) at 0 °C under argon was added LiAlH4 as a 1.0 
M solution in THF (Sigma-Aldrich, SureSeal) (2.6 mL, 2.61 mmol, 1.5 eq.) The reaction mixture was stirred at 0 °C 
for one hour and at rt for one hour. 20 % aqueous NaOH (0.40 mL) was added dropwise to give vigorous evolution of 
hydrogen gas and a thick white precipitate. The mixture was filtered through celite, dried over Na2SO4 and 
concentrated to approximately 20 mL. TsCl (332 mg, 1.74 mmol, 1.0 eq.) in anhydrous THF (3 mL) was added 
dropwise and the resulting brown solution stirred at rt for 7 h. The reaction was quenched with brine and extracted 
with Et2O (x 1).The organic layer was dried over Na2SO4, filtered and the solvent removed in vacuo. The resulting 
crude brown residue was purified on silica (1:1, n-hexane/EtOAc) to yield the desired N-tosylate D-prolinol 74 (256 
mg, 58 %) as a white solid, mp = 89-91 °C; Rf  = 0.19 (1:1, EtOAc/n-hexane); [α]20D = + 58.1 (c = 0.87, CHCl3); νmax 
/cm-1 3464 (b), 2956, 2874, 1339, 1157, 1092, 1044, 817, 665, 588; δH (400 MHz, CDCl3) 7.71 (2H, d, J 8.2, ArH), 
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7.31 (2H, d, J 8.2, ArH), 3.70-3.57 (3H, m, HOCH2 and pyrrolidine-H2’), 3.46-3.40 (1H, m, pyrrolidine-H5’), 3.27-
3.20 (1H, m, pyrrolidine-H5’), 2.41 (s, 3H, ArCH3), 1.82-1.72 (1H, m, pyrrolidine-H4’), 1.68-1.63 (2H, m, 
pyrrolidine-H4’ and -H3’), 1.46-1.37 (1H, m, pyrrolidine-H3’); δC (101 MHz, CDCl3) 144.0, 134.1, 130.0, 127.8, 
66.1, 62.1, 50.3, 29.1, 24.5, 21.7; m/z (ESI) 256 [MH]+; found [MH]+ 256.0998 C12H18NO3S requires 256.1007, Δ 3.5 
ppm. 
(R)-1-(Toluene-4-sulfonyl)-pyrrolidine-2-carbaldehyde 75 
 
To D-prolinol 74 (125.8 mg, 0.49 mmol, 1.0 eq.) and Dess-Martin periodinane (523.3 mg, 1.23 mmol, 2.5 eq.) at 0 °C 
was added anhydrous CH2Cl2 (3.0 mL) and the mixture stirred at rt for 1.5 h. The mixture was diluted with CH2Cl2 
and washed with saturated aq. NaHCO3 (x 2) and saturated aq. Na2S2O3 and the aqueous layer extracted with CH2Cl2 
(x 1). The organic layer was washed with saturated Na2S2O3, dried over anhydrous Na2SO4, filtered and the solvent 
removed in vacuo. The crude product was purified on silica (1:1, EtOAc/n-hex) to yield the desired aldehyde 75 (44.3 
mg, 36 %) as a white solid, mp = 135-137 °C; [α]28D = + 206.2 (c = 2.90, CHCl3); νmax /cm-1 1732, 1338, 1158, 1093, 
906, 727, 663, 588; δH (400 MHz, CDCl3) 9.70 (1H, d, J 2.0, aldehyde-H), 7.74 (2H, d, J 8.2, ArH), 7.37 (2H, d, J 8.2, 
ArH), 3.86-3.83 (1H, m, pyrrolidine-H2’), 3.59-3.55 (1H, m, pyrrolidine-H5’), 3.24-3.18 (1H, m, pyrrolidine-H5’), 
2.46 (3H, s, ArCH3), 2.11-2.04 (1H, m, pyrrolidine-H4’), 1.89-1.79 (2H, m, pyrrolidine-H4’ and pyrrolidine-H3’), 
1.71-1.62 (1H, pyrrolidine-H3’). δC (101 MHz, CDCl3) 200.4, 144.4, 133.6, 130.1, 127.9, 66.7, 49.3, 27.7, 24.8, 21.7; 
m/z (ESI) 254 [MH]+; found [MH]+ 254.0843 C12H16NO3S requires 254.0851, Δ 3.1 ppm. 
(R)-2-Azidomethyl-1-(toluene-4-sulfonyl)-pyrrolidine 76 
 
A mixture of bis-tosylate 73 (1.085 g, 2.65 mmol, 1 eq.) and sodium azide (397.6 mg, 6.12 mmol, 2.15 eq.) in 
diethylene glycol (4.2 mL) was stirred and heated at 100 °C for 1h. The solution was cooled to 60 °C and diluted 
slowly with iced water (5.2 mL). The resulting white precipitate was filtered and washed thoroughly with cold water. 
The crude white solid was recrystallised from ethanol/water to give the desired azide 76 (556.5 mg, 76 %) as long 
white needles, mp = 82-84 °C; Rf = 0.64 (EtOAc/n-hex, 1:1); [α]26D = + 89.7 (c = 1.36, CHCl3); νmax /cm-1 2102, 2078, 
1342, 1330, 1311, 1292, 1204, 1158, 1094, 1052, 1028, 975, 826, 722; δH (400 MHz, CDCl3) 7.75 (2H, d, J 7.9, ArH), 
7.36 (2H, d, J 7.9, ArH), 3.72-3.69 (1H, m, pyrrolidine-H2’), 3.60-3.45 (3H, m, CH2N3 and pyrrolidine-H5’), 3.20-
3.14 (1H, m, pyrrolidine-H5’), 2.46 (3H, s, ArCH3), 1.94-1.52 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’); δC (101 
MHz, CDCl3) 144.0, 134.2, 130.0, 127.8, 59.1, 55.4, 49.7, 29.5, 24.2, 21.7; m/z (CI) 281 [MH]+, 298 [MNH4]+; found: 
[MH]+, 281.1072 C12H17N4O2S requires 281.1072, Δ 0 ppm. 
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4-Chlorosulfonyl-benzoic acid methyl ester 77  
 
A procedure reported by Winans et al. was used.[282] 4-Chlorosulfonyl benzoic acid (5.0 g, 23 mmol, 1 eq.) was 
suspended in thionyl chloride (20 mL) and dichloroethane (10 mL) and the mixture heated to reflux for 1 h. The 
reaction mixture was concentrated in vacuo to a light brown solid which was chilled on ice before addition of ice cold 
methanol (40 mL). The resulting mixture was stirred at 0 °C for 5 min and at rt for 10 min before addition of ice cold 
H2O (40 mL). The resulting white precipitate was filtered under reduced pressure, washed with ice cold H2O and dried 
under vacuum to yield the desired methyl ester 77 (5.0 g, 93 %) as a white solid, mp = 64-66 °C; Rf = 0.69 (EtOAc/n-
hex, 1:1); δH (400 MHz, CDCl3) 8.30 (2H, d, J 8.5, ArH), 8.14 (2H, d, J 8.5, ArH), 4.01 (3H, s, OCH3); δC (101 MHz, 
CDCl3) 165.1, 147.6, 136.2, 131.1, 127.3, 53.2. Data in agreement with literature values.[282]  
4-methyl ester benzenesulfonic acid 1-(R)-(4-methyl ester-benzenesulfonyl)-pyrrolidin-2-ylmethyl ester 78 
 
To a solution of 4-chlorosulfonyl-benzoic acid methyl ester 77 (713.4 mg, 3.04 mmol, 3 eq.) in anhydrous CH2Cl2 (5 
mL) was added triethylamine (0.42 mL, 3.04 mmol, 3 eq.) and D-prolinol (0.1 mL, 1.013 mmol, 1 eq.) at 0 °C under 
argon, and the mixture stirred at rt overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (x 2), 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude white solid was purified by flash column 
chromatography on silica (EtOAc/n-hex, 1:1) to yield the desired bis-sulfonylated pyrrolidine 78 (152.8 mg, 30 %) as 
a white solid, mp = 184-185 °C; Rf  = 0.33 (EtOAc/n-hex, 1:1); [α]20D = + 96.8 (c = 3.1, CHCl3); νmax /cm-1 1718, 
1435, 1401, 1367, 1348, 1275, 1183, 1163, 1109, 1091, 1014, 986, 966, 907, 859, 791, 765, 733, 694; δH (400 MHz, 
CDCl3) 8.20 (2H, d, J 8.5, ArH), 8.13 (2H, d, J 8.5, ArH), 7.97 (2H, d, J 8.5, ArH), 7.79 (2H, d, J 8.5, ArH), 4.26 (1H, 
dd, J 10.0, J 7.0, ArSO3CH2), 4.03 (1H, dd, J 10.0, J 7.0, ArSO3CH2), 3.94 (1H, s, OCH3), 3.92 (1H, s, OCH3), 3.73-
3.69 (1H, m, pyrrolidine-H), 3.40-3.34 (1H, m, pyrrolidine-H), 3.05-2.98 (1H, m, pyrrolidine-H), 1.87-1.74 (2H, m, 
pyrrolidine-H), 1.65-1.48 (2H, m, pyrrolidine-H); δC (101 MHz, CDCl3) 165.5, 165.3, 140.3, 139.4, 135.1, 134.2, 
130.6, 130.4, 128.1, 127.5, 71.9, 57.8, 52.8, 52.7, 49.4, 28.6, 23.8; m/z (ESI) 498 [MH]+; found: [MH]+, 498.0874 
C21H24NO9S2 requires 498.0893, Δ 3.8 ppm. 
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4-(2-(R)-Hydroxymethyl-pyrrolidine-1-sulfonyl)-benzoic acid methyl ester 79 
 
To a solution of sulfonyl chloride 77 (1.90 g, 8.12 mmol, 1.0 eq.) in anhydrous CH2Cl2 (15.8 mL) was added D-
prolinol (0.80 mL, 8.12 mmol, 1.0 eq.) and triethylamine (1.35 mL, 9.74 mmol, 1.2 eq.) at 0 °C under argon and the 
mixture stirred at rt for 1 h. The reaction was quenched with H2O and extracted with CH2Cl2 (x 2). The combined 
organics were washed with 2N HCl, dried over MgSO4, filtered and the solvent removed in vacuo to give the desired 
pyrrolidine 79 (2.28 g, 94 %) as a white solid, mp = 86-88 °C; Rf = 0.19 (EtOAc/n-hex, 1:1); [α]20D = + 53.0 (c = 1.43, 
CHCl3); νmax /cm-1 3468, 1725, 1445, 1437, 1399, 1337, 1284, 1197, 1156, 1108, 1091, 1038, 1012, 987, 857, 808, 
761, 734, 693; δH (400 MHz, CDCl3) 8.18 (2H, d, J 8.3, ArH), 7.90 (2H, d, J 8.3, ArH), 3.94 (3H, s, OCH3), 3.71-3.59 
(3H, m, pyrrolidine-CH2OH and pyrrolidine-H), 3.50-3.44 (1H, m, pyrrolidine-H), 3.26-3.20 (1H, m, pyrrolidine-H), 
2.39 (1H, bs, OH), 1.85-1.59 (3H, m, pyrrolidine-H), 1.48-1.38 (1H, m, pyrrolidine-H); δC (101 MHz, CDCl3) 165.8, 
141.0, 134.3, 130.6, 127.8, 65.9, 62.2, 52.9, 50.2, 29.0, 24.4; m/z (ESI) 300 [MH]+; found: [MH]+, 300.0902 
C13H18NO5S requires 300.0906, Δ 1.3 ppm. 
4-(2-(R)-Formyl-pyrrolidine-1-sulfonyl)-benzoic acid methyl ester 80 
 
To a solution of alcohol 79 (50 mg, 0.17 mmol, 1 eq.) in CH2Cl2 (1.5 mL) was added Dess-Martin periodinane (85 
mg, 0.20 mmol, 1.2 eq.) at 0 °C and the mixture stirred at rt for 1.5 h. To the mixture was added sat. NaHCO3 aq. and 
the aqueous layer extracted with CH2Cl2 (x 2). The combined organics were washed with brine (x 1) and dried over 
MgSO4, filtered and the solvent removed in vacuo. The crude clear oil was purified by flash column chromatography 
on silica (EtOAc/n-hex, 2:3) to yield the desired aldehyde 80 (34 mg, 69 %) as a white solid, mp = 107-109 °C; Rf = 
0.8 (100 % EtOAc); [α]26D = + 157.6 (c = 1.57, CHCl3); νmax /cm-1 1726, 1437, 1400, 1349, 1977, 1160, 1110, 1091, 
766, 733, 695; δH (400 MHz, CDCl3) 9.64 (1H, d, J 2.2, aldehyde-H), 8.18 (2H, d, J 8.9, ArH), 7.88 (2H, d, J 8.9, 
ArH), 3.93 (3H, s, OCH3), 3.88-3.84 (1H, m, pyrrolidine-H), 3.58-3.53 (1H, m, pyrrolidine-H), 3.21-3.15 (1H, m, 
pyrrolidine-H), 2.08-2.00 (1H, m, pyrrolidine-H), 1.86-1.76 (2H, m, pyrrolidine-H), 1.68-1.60 (1H, m, pyrrolidine-H);  
δC (101 MHz, CDCl3) 199.5, 165.5, 140.5, 134.4, 130.5, 127.6, 66.6, 52.8, 49.2, 27.6, 24.7; m/z (CI) 298 [MH]+, 315 
[MNH4]+; HRMS (ESI) found: [MH]+, 298.0751 C13H16NO5S requires 298.0749, Δ 0.7 ppm. 
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4-[2-(R)-(Toluene-4-sulfonyloxymethyl)-pyrrolidine-1-sulfonyl]-benzoic acid methyl ester 81 
 
To a solution of alcohol 79 (1.74 g, 5.8 mmol, 1.0 eq.) and p-toluene sulfonyl chloride (3.32 g, 17.4 mmol, 3.0 eq.) in 
anhydrous CH2Cl2 (10 mL) at 0 °C under argon was added triethylamine (2.42 mL, 17.4 mmol, 3.0 eq.) and the 
mixture stirred at rt for 6 h. The reaction mixture was poured into aqueous 2N HCl and extracted with CH2Cl2 (x 1). 
The organic layer was dried over MgSO4, filtered and the solvent removed in vacuo. The crude solid was purified by 
flash column chromatography on silica (7:3, n-hex/EtOAc) to yield the desired bis-sulfone 81 (2.35 mg, 89 %) as a 
white solid, mp = 124-125 °C; [α]20D = + 97.1 (c = 1.4, CHCl3); Rf  = 0.31 (EtOAc/n-hex, 3:7); νmax /cm-1 1720, 1598, 
1435, 1403, 1360, 1345, 1279, 1189, 1160, 1112, 1092, 1052, 1016, 1003, 994, 963, 907, 845, 814, 783, 765, 734, 
696, 666; δH (400 MHz, CDCl3) 8.15 (2H, d, J 8.1, ArH), 7.82 (2H, d, J 8.1, ArH), 7.79 (2H, d, J 8.1, ArH), 7.36 (2H, 
d, J 8.1, ArH), 4.22 (1H, dd, J 10.5, J 3.4, pyrrolidine-CH2), 3.97-3.93 (1H, m, pyrrolidine-CH2), 3.94 (3H, s, 
ArCO2CH3), 3.77-3.72 (1H, m, pyrrolidine-H), 3.42-3.38 (1H, m, pyrrolidine-H), 3.07-3.01 (1H, m, pyrrolidine-H), 
2.45 (3H, s, ArCH3), 1.91-1.76 (2H, m, pyrrolidine-H), 1.66-1.51 (2H, m, pyrrolidine-H); δC (101 MHz, CDCl3) 
165.8, 145.4, 140.7, 134.4, 132.7, 130.6, 130.2, 128.2, 127.7, 71.4, 58.1, 52.9, 49.6, 28.8, 24.0, 21.9; m/z (ESI) 454 
[MH]+, 476 [MNa]+; found: [MH]+, 454.1006 C20H24NO7S2 requires 454.0994, Δ 2.6 ppm. 
4-(2-(R)-Azidomethyl-pyrrolidine-1-sulfonyl)-benzoic acid methyl ester 82 
 
A solution of pyrrolidine 81 (200 mg, 0.44 mmol, 1 eq.) and NaN3 (61.6 mg, 0.95 mmol, 2.15 eq.) in DMF (5 mL) 
was heated with stirring to 50 °C for 1.5 h and to 90 °C for 3h. The reaction mixture was diluted with 2M aq. NH4Cl 
and extracted with EtOAc (x 3). The combined organics were dried over MgSO4, filtered and the solvent removed in 
vacuo to yield the desired azide 82 (133.7 mg, 94 %) as a white powder, mp = 61-62 °C; [α]23D = + 101.3 (c = 1.0, 
CHCl3); Rf = 0.56 (EtOAc/n-hex, 1:1); νmax /cm-1 2101, 1727, 1437, 1400, 1350, 1278, 1199, 1161, 1109, 1090, 1044, 
1016, 990, 766, 742, 734, 695, 620, 580; δH (400 MHz, CDCl3) 8.18 (2H, d, J 8.3, ArH), 7.90 (2H, d, J 8.3, ArH), 
3.94 (3H, s, OCH3), 3.73-3.68 (1H, m, pyrrolidine-H), 3.56-3.44 (3H, m, pyrrolidine-H and pyrrolidine-CH2), 3.18-
3.12 (1H, m, pyrrolidine-H), 1.92-1.77 (2H, m, pyrrolidine-H), 1.70-1.49 (2H, m, pyrrolidine-H); δC (101 MHz, 
CDCl3) 165.8, 141.1, 134.3, 130.6, 127.7, 59.3, 55.3, 52.9, 49.7, 29.5, 24.3; m/z (ESI) 325 [MH]; found: [MH]+, 
325.0956 C13H17N4O4S requires 325.0971, Δ 4.6 ppm.      
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4-(2-(R)-Aminomethyl-pyrrolidine-1-sulfonyl)-benzoic acid methyl ester 83 
 
Method One: Staudinger Reduction  
Triphenylphosphine (161.7 mg, 0.62 mmol, 2 eq.) was added to a solution of azide 82 (100 mg, 0.31 mmol, 1 eq.) in 
THF/H2O (2.5/0.25 mL). The mixture was stirred at rt for 3h before removal of the solvent in vacuo. The crude 
mixture was purified by flash column chromatography on silica (CH2Cl2/MeOH, 9:1) to yield the desired amine 83 
(44.8 mg, 48 %) as a clear oil. The intermediate iminophosphorane 84 was also isolated (40.7 mg, 24 %) as a clear oil.  
Method Two: Hydrogenation  
To a solution of azide 82 (109 mg, 0.34 mmol, 1 eq.) in EtOAc (3 mL) was added Pd/C (15 mg, cat.). The mixture 
was stirred at rt under a H2 balloon for 24 h, then filtered through celite and the filter cake washed with EtOAc and 
MeOH. Removal of the solvent under reduced pressure yielded the desired amine 83 (102.5 mg, quant.) as a clear oil.  
[α]23D = + 59.3 (c = 1.1, CHCl3); Rf  = 0 (EtOAc/n-hex, 1:1); νmax /cm-1 1728, 1437, 1400, 1344, 1282, 1197, 1162, 
1111, 1090, 1015, 990, 767, 733, 696, 623, 581; δH (400 MHz, CDCl3) 8.12 (2H, d, J 8.5, ArH), 7.85 (2H, d, J 8.5, 
ArH) 3.89 (3H, s, OCH3), 3.60-3.54 (1H, m, pyrrolidine-H), 3.40-3.35 (1H, m, pyrrolidine-H), 3.18-3.12 (1H, m, 
pyrrolidine-H), 2.83-2.75 (2H, m, H2NCH2), (2H, bs, NH2), 1.79-1.70 (1H, m, pyrrolidine-H), 1.68-1.60 (1H, m, 
pyrrolidine-H), 1.54-1.47 (1H, m, pyrrolidine-H), 1.45-1.36 (1H, m, pyrrolidine-H); δC (101 MHz, CDCl3) 165.7, 
141.4, 134.0, 130.4, 127.6, 62.6, 52.8, 49.5, 46.4, 29.1, 24.2; m/z (ESI) 299 [MH]+; found: [MH]+, 299.1059 
C13H19N2O4S requires 299.1066, Δ 2.3 ppm.      
4-(2-(R)-(triphenylphosphineimine)methyl-pyrrolidine-1-sulfonyl)-benzoic acid methyl ester 84 
 
Rf = 0 (EtOAc/n-hex, 1:1); δH (400 MHz, CDCl3) 8.12 (2H, d, J 8.5, ArH), 7.94-7.88 (6H, m, ArH), 7.83-7.79 (3H, m, 
ArH), 7.72-7.68 (6H, m, ArH), 7.62 (2H, d, J 8.5, ArH), 3.97 (3H, s, CH3), 3.50-3.30 (3H, m), 2.95 (1H, td, J 9.5, J 
6.6), 2.59-2.53 (1H, m), 1.97-1.89 (2H, m), 1.57-1.47 (2H, m); m/z (ESI) 559 [MH]+; found: [MH]+, 559.1810 
C31H32N2O4SP requires 559.1820, Δ 1.8 ppm.      
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4-[2-(R)-(Acryloylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoic acid methyl ester 85 
 
To a solution of amine 83 (615.8 mg, 2.06 mmol, 1.0 eq.) in anhydrous CH2Cl2 (12 mL) at 0 °C under argon was 
added Et3N (0.43 mL, 3.09 mmol, 1.5 eq.) and acryloyl chloride (0.18 mL, 2.27 mmol, 1.1 eq.) and the resulting 
yellow solution stirred at 0 °C for 15 min and at rt for 22 h. The reaction mixture was poured into aqueous NH4Cl (2 
M), extracted with CH2Cl2 (x 3), dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified on silica (EtOAc/n-hex, 4:1) to yield the desired acrylamide 85 (524.1 mg, 72 %) as a clear oil. [α]26D = 
+105.4 (c = 1.1, CHCl3); Rf  = 0.34 (EtOAc/n-hex, 4:1); νmax /cm-1 1729, 1661, 1627, 1604, 1540, 1437, 1401, 1349, 
1281, 1162, 1110, 1091, 1045, 1016, 989, 963, 766, 734, 696, 622, 609, 580, 573; δH (400 MHz, CDCl3) 8.16 (2H, d, 
J 8.5, ArH), 7.87 (2H, d, J 8.5, ArH), 6.71 (1H, bt, J 4.0, NH), 6.27 (1H, dd, J 1.7, J 16.7, COCHCH2 cis to C=O), 
6.15 (1H, dd, J 16.7, J 10.0, COCHCH2), 5.63 (1H, dd, J 10.0, J 1.7, COCHCH2 trans to C=O), 3.93 (3H, s, OCH3), 
3.75-3.69 (1H, m, pyrrolidine-H2’), 3.59-3.53 (1H, m, NHCH2), 3.48-3.42 (1H, m, NHCH2), 3.38-3.31 (1H, m, 
pyrrolidine-H5’), 3.23-3.16 (1H, m, pyrrolidine-H5’), 1.84-1.41 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’); δC 
(101 MHz, CDCl3) 166.1, 165.5, 140.6, 134.3, 131.1, 130.5, 127.6, 126.4, 59.9, 52.7, 49.7, 43.8, 29.8, 24.1; m/z (ESI) 
353 [MH]+, 375 [MNa]+; found: [MH]+, 353.1168 C16H21N2O5S requires 353.1171, Δ 0.8 ppm.      
4-[2-(R)-(Acryloylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoic acid 86 
 
To a solution of ester 85 (500 mg, 1.42 mmol, 1 eq.) in MeOH (10 mL) was added aqueous 2M LiOH (10 mL). The 
reaction mixture was stirred at rt for 10 minutes and the MeOH removed in vacuo. The aqueous solution was acidified 
to pH 2 with HCl (2N) and extracted with EtOAc (x 3). The combined organics were dried over MgSO4, filtered and 
the solvent removed in vacuo. The crude compound was purified on silica (CH2Cl2, 20 % MeOH) and subsequently 
triturated in n-hexane/EtOAc/MeOH, 1:1:1 to yield the desired carboxylic acid 86 (447.4 mg, 93 %) as a white solid, 
mp > 230 °C; [α]21D = + 90.0 (c = 0.27, CH3CH2OH); Rf = 0 (100 % EtOAc); νmax /cm-1 1657, 1596, 1551, 1460, 1404, 
1334, 1300, 1255, 1201, 1161, 1139, 1090, 1046, 1013, 984, 869, 856, 803, 782, 730, 699, 617, 578; δH (400 MHz, 
DMSO-d6) 8.38 (1H, bt, NH), 8.12 (2H, d, J 7.5, ArH), 7.78 (2H, d, J 7.5, ArH), 6.27 (1H, dd, J 10.0, J 17.5, 
NHCOCHCH2), 6.09 (1H, d, J 17.5, NHCOCHCH2 cis to C=O), 5.59 (1H, d, J 10.0, NHCOCHCH2 trans to C=O), 
3.68-3.62 (1H, m, pyrrolidine-H), 3.53-3.32 (2H, m, NHCH2), 3.21-3.15 (1H, m, pyrrolidine-H), 3.11-3.05 (1H, m, 
pyrrolidine-H), 1.75-1.69 (1H, m, pyrrolidine-H), 1.62-1.59 (1H, m, pyrrolidine-H), 1.39-1.27 (2H, m, pyrrolidine-H); 
δC (101 MHz, DMSO-d6) 169.1, 164.9, 142.6, 137.2, 131.7, 129.8, 126.7, 125.2, 59.1, 49.1, 42.9, 28.3, 23.2; m/z (ESI) 
339 [MH]+; found: [MH]+, 339.1023 C15H19N2O5S requires 339.1015, Δ 2.4 ppm.        
N
H2N
SO
O
COOMe
83
N
N
H
SO
O
COOMe
85
O
N
N
H
SO
O
COOMe
85
O
N
N
H
SO
O
COOH
86
O
 Chapter Nine Organic chemistry experimental 
  165 
N-benzyloxycarbonyl-(L)-glutamic acid 89 
 
To a solution of NaHCO3 (5.0 g, 59.6 mmol, 4.4 eq.) in H2O (150 mL) was added L-glutamic acid (2.0 g, 13.6 mmol, 1 
eq.) and benzyl chloroformate (3.70 g, 21.6 mmol, 1.6 eq.) at 0 °C and the mixture stirred at rt for 24 h. Ether (150 
mL) was added to the reaction mixture and the layers separated. The aqueous layer was acidified to pH 1 with 2N HCl 
and extracted with EtOAc (x 3), and the combined EtOAc organics dried over MgSO4, filtered and concentrated in 
vacuo to yield the desired Cbz-protected L-glutamic acid 89 (3.73 g, 98 %) as a white solid, mp = 114-116 °C; [a]22D = 
- 13.3 (c = 0.75, CH3CH2OH); νmax /cm-1 3297, 1699, 1685, 1547, 1526, 1419, 1298, 1255, 1229, 1214, 1181, 1168, 
1051, 1015, 952, 945, 910, 903, 868, 786, 779, 753, 734, 721, 694; δH (400 MHz, DMSO-d6) 12.40 (2H, bs, COOH), 
7.59 (1H, d, J 8.0, NH), 7.39-7.21 (5H, m, ArH), 5.03 (2H, s, ArCH2), 4.04-3.97 (1H, m, ZNHCH), 2.37-2.23 (2H, m, 
CH2COOH), 2.01-1.91 (1H, m, CH2CH2COOH), 1.80-1.71 (1H, m, CH2CH2COOH); δC (101 MHz, DMSO-d6) 173.7, 
173.6, 156.2, 137.0, 128.4, 127.8, 127.7, 65.4, 53.0, 30.1, 26.1; m/z (ESI) 282 [MH]+, 304 [MNa]+; found: [MH]+, 
282.0982 C13H16NO6 requires 282.0978, Δ 1.4 ppm.      
2-(S)-[4-[2-(R)-(Acryloylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoylamino]-pentanedioic acid ditertbutyl ester 91 
 
Di-tertbutyl L-glutamate HCl salt was dissolved in EtOAc and washed with saturated NaHCO3 (x 1). The organic 
layer was dried over MgSO4, filtered and the solvent removed in vacuo to yield the desired amine as the free base, as a 
clear oil. 
To a solution of carboxylic acid 86 (544.2 mg, 1.61 mmol, 1.2 eq.) in CH2Cl2 (6 mL) was added H2O (13.5 mL), di-
tert butyl L-glutamate (348.2 mg, 1.34 mmol, 1.0 eq.) in CH2Cl2 (7.5 mL) and HOBt (217.5 mg, 1.61 mmol, 1.2 eq.). 
The reaction was cooled to 0 °C and 1,3-dimethylaminopropyl-3-ethylcarbodiimide HCl (308.6 mg, 1.61 mmol, 1.2 
eq.) was added. The reaction was allowed to warm to 14 °C over 5 h, then stirred at rt for 60 h, diluted with H2O and 
extracted with CH2Cl2. Combined organics were dried over MgSO4 and the solvent removed in vacuo. The crude 
product was purified by flash column chromatography on silica (1:1, EtOAc/n-hex) to yield the desired acrylamide 91 
(572.3 mg, 74 %) as a clear oil, Rf = 0.48 (7:3, EtOAc/n-hex); [α]20D = +88.8 (c = 0.65, CHCl3); νmax /cm-1 1731, 1661, 
1628, 1602, 1540, 1485, 1452, 1394, 1368, 1346, 1290, 1248, 1201, 1151, 1103, 754; δH (400 MHz, CDCl3) 7.96 (2H, 
d, J 8.6, ArH), 7.83 (2H, d, J 8.6, ArH), 7.44 (1H, d, J 7.5, ArCONH), 6.78 (1H, t, J 4.8, NHCH2), 6.26 (1H, dd, J 
17.1, J 1.9, CH2CHCONH cis to C=O), 6.15 (1H, dd, J 17.1, J 9.5, CH2CHCONH), 5.62 (1H, dd, J 9.5, J 1.9, 
CH2CHCONH trans to C=O), 4.59 (1H, ddd, J 7.8, J 7.5, J 4.7, ArCONHCH), 3.72-3.66 (1H, m, pyrrolidine-H2’), 
3.56-3.50 (1H, m, CH2CHCONHCH2), 3.45-3.40 (1H, m, CH2CHCONHCH2), 3.37-3.30 (1H, m, pyrrolidine-H5’), 
3.18-3.12 (1H, m, pyrrolidine-H5’), 2.45-2.28 (2H, m, tBuOOCCH2), 2.22-2.14 (1H, m, tBuOOCCH2CH2), 2.08-1.99 
(1H, m, tBuOOCCH2CH2), 1.82-1.48 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 1.45 (9H, s, tBu), 1.38 (9H, s, 
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tBu); δC (101 MHz, CDCl3) 173.1, 171.1, 166.3, 165.6, 139.5, 138.3, 131.1, 128.3, 127.8, 126.6, 82.8, 81.4, 60.0, 
53.5, 49.8, 44.0, 31.8, 29.9, 28.2, 28.2, 27.0, 24.2; m/z (ESI) 580 [MH]+, 602 [MNa]+; found: [MH]+, 580.2687 
C28H42N3O8S requires 580.2693, Δ 1.0 ppm.   
2-(S)-(4-Nitro-benzoylamino)-pentanedioic acid di-tert-butyl ester 92 
 
To a solution of 4-nitrobenzoic acid (24.7 mg, 0.148 mmol, 1.0 eq.) in CH2Cl2 (1.5 mL) was added H2O (1.5 mL), di-
tertbutyl L-glutamate hydrochloride salt (43.8 mg, 0.148 mmol, 1.0 eq.), Et3N (62 μL, 0.444 mmol, 3.0 eq.) and 1-
hydroxybenzotriazole (20.0 mg, 0.148 mmol, 1.0 eq.). The reaction mixture was cooled to 0 °C and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (31.2 mg, 0.163 mmol, 1.1 eq.) was added. The reaction was 
allowed to warm to rt and stirred for 24 h before dilution with H2O and extraction with CH2Cl2. The combined 
organics were dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was purified on silica 
(EtOAc/n-hex, 1:1) to yield the desired nitrobenzene 92 (27.0 mg, 45 %) as a clear oil. Rf = 0.8 (EtOAc/n-hex, 1:1); 
[α]21D = +1.66 (c = 1.21, CHCl3); νmax /cm-1 1730, 1672, 1652, 1603, 1527, 1488, 1455, 1393, 1368, 1346, 1300, 1256, 
1150, 1110, 870, 845, 720; δH (400 MHz, CDCl3) 8.28-8.25 (2H, m, ArH3’), 8.00-7.97 (2H, m, ArH2’), 7.42 (1H, d, J 
6.7, NH), 4.63-4.58 (1H, m, NHCH), 2.48-2.03 (4H, m, CH2CH2), 1.47 (9H, s, tBu), 1.40 (9H, s, tBu); δC (101 MHz, 
CDCl3) 173.3, 171.0, 165.2, 149.9, 139.7, 128.6, 124.0, 82.9, 81.5, 53.6, 31.9, 28.3, 28.2, 27.0; m/z (ESI) 409 [MH]+; 
found: [MH]+, 409.1976 C20H29N2O7 requires 409.1975, Δ 0.2 ppm.   
4-[2-(R)-(Ethenesulfonylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoic acid methyl ester 93 
 
2-Chloroethanesulfonyl chloride (0.47 mL, 4.45 mmol, 1 eq.) was added dropwise to a stirred solution of amine 83 
(1.328 g, 4.45 mmol, 1 eq.) and Et3N (1.86 mL, 13.35 mmol, 3.5 eq.) in anhydrous CH2Cl2 (10 mL) at 0 °C under 
argon. After addition, stirring was continued at 0 °C for 1 h and at rt overnight. The mixture was diluted with CH2Cl2, 
washed with brine, dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was purified on 
silica (EtOAc/n-hex, 1:1) to yield the desired vinyl sulfonamide 93 (1.01 g, 58 %) as a white solid, mp = 111-113 °C; 
Rf = 0.21 (EtOAc/n-hex, 1:1); [α]22D = +95.5 (c = 6.20, CHCl3); νmax /cm-1 1726, 1436, 1400, 1332, 1280, 1200, 1152, 
1110, 1090, 1016, 971, 766, 734, 696, 621, 581, 555; δH (400 MHz, CDCl3) 8.15 (2H, d, J 8.0, ArH), 7.86 (2H, d, J 
8.0, ArH), 6.54 (1H, dd, J 10.0, J 16.0, CH2CHSO2NH), 6.21 (1H, d, J 16.0, CH2CHSO2NH cis to SO2), 5.94 (1H, d, J 
10.0, CH2CHSO2NH trans to SO2), 5.29 (1H, t, J 6.4, NH), 3.91 (3H, s, OCH3), 3.66-3.61 (1H, m, pyrrolidine-H2’), 
3.44-3.40 (1H, m, SO2NHCH2), 3.21-3.10 (3H, m, SO2NHCH2 and pyrrolidine-H5’), 1.84-1.73 (2H, m, pyrrolidine-
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H4’), 1.66-1.55 (1H, m, pyrrolidine-H3’), 1.46-1.37 (1H, m, pyrrolidine-H3’); δC (101 MHz, CDCl3); 165.6, 140.3, 
135.7, 134.3, 130.5, 127.6, 126.9, 59.6, 52.8, 49.9, 47.2, 29.4, 24.0; m/z (ESI) 389 [MH]+ 411 [MNa]+; found: [MH]+, 
389.0836 C15H21N2O6S2 requires 389.0841, Δ 1.3 ppm.   
4-[2-(R)-(Ethenesulfonylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoic acid 94 
    
To a solution of vinyl sulfonamide 93 (1.0 g, 2.6 mmol, 1 eq.) in THF (10 mL) was added 2M LiOH (10 mL) at 0 °C. 
The reaction mixture was allowed to warm to rt and stirred for a further 10 min. The THF was removed in vacuo and 
the basic aqueous solution acidified to pH 2 with 2N HCl. The resulting thick white precipitate was filtered under 
gravity and washed thoroughly with cold ether to yield the desired carboxylic acid 94 (975.0 mg, 100 %) as a white 
solid, mp = 164-167 °C ; Rf = 0 (100 % EtOAc); [α]23D = + 98.0 (c = 1.00, MeOH); νmax /cm-1 1691, 1602, 1573, 1425, 
1402, 1385, 1345, 1314, 1285, 1140, 1159, 1149, 1126, 1113, 1086, 1038, 1015, 995, 979, 966, 932, 862, 771, 716, 
690, 659, 618, 575; δH (400 MHz, MeOD) 8.26 (2H, d, J 8.4, ArH), 8.00 (2H, d, J 8.4, ArH), 6.70 (1H, dd, J 15.7, J 
9.8, SO2CHCH2), 6.22 (1H, d, J 15.7, SO2CHCH2 cis to SO2), 6.04 (1H, d, J 9.8, SO2CHCH2 trans to SO2), 3.75-3.69 
(1H, m, pyrrolidine-H2’), 3.52-3.46 (1H, m, NHCH2), 3.32-3.28 (1H, dd, J 13.5, J 3.9, pyrrolidine-H5’), 3.30 (1H, m, 
NHCH2), 3.05 (1H, dd, J 13.5, J 8.4, pyrrolidine-H5’), 1.94-1.82 (2H, m, pyrrolidine-H4’), 1.66-1.50 (2H, m, 
pyrrolidine-H3’); δC (101 MHz, MeOD) 166.7, 140.4, 136.1, 134.8, 130.2, 127.5, 125.4, 59.7, 49.5, 46.6, 28.4, 23.2; 
m/z (ESI) 375 [MH]+; found: [MH]+, 375.0687 C14H19N2O6S2 requires 375.0685, Δ 0.5 ppm.   
2-(S)-(4-[2-(R)-(Ethenesulfonylamino-methyl)-pyrrolidine-1-sulfonyl]-benzoylamino)-pentanedioic acid di-tert-butyl 
ester 95 
 
Di-tertbutyl L-glutamate.HCl was dissolved in EtOAc and washed with saturated NaHCO3 (x 1). The organic layer 
was dried over MgSO4 and the solvent removed in vacuo to give the desired amine.  
To a solution of carboxylic acid 94 (603.1 mg, 1.61 mmol, 1.2 equiv.) in CH2Cl2 (6 mL) was added H2O (13.5 mL), 
ditertbutyl L-glutamate (348.2 mg, 1.34 mmol, 1.0 equiv.) in CH2Cl2 (7.5 mL) and HOBt (217.5 mg, 1.61 mmol, 1.2 
equiv.). The reaction was cooled to 0 °C and EDC.HCl (308.6 mg, 1.61 mmol, 1.2 equiv.) was added. The reaction 
was allowed to warm to rt and stirred for 70 h, diluted with brine and extracted with CH2Cl2 (x 3). Combined organics 
were dried over MgSO4, filtered and the solvent removed in vacuo. The crude was purified on silica (100 % EtOAc) to 
yield the desired vinyl sulfonamide 95 (698.4 mg, 85 %) as an oily white solid, mp = 57-59 °C; [α]25D = +49.7 (c = 
1.05, CHCl3); Rf = 0.71 (EtOAc/n-hex, 4:1); νmax /cm-1 1728, 1658, 1535, 1368, 1334, 1254, 1150, 1096, 846, 733, 
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622; δH (400 MHz, CDCl3) 7.99 (2H, d, J 7.7, ArH), 7.87 (2H, d, J 7.7, ArH), 7.37 (1H, d, J 6.2, CONH), 6.56 (1H, 
dd, J 9.2, J 15.4, SO2CHCH2), 6.24 (1H, d, J 15.4, SO2CHCH2 cis to SO2), 5.97 (1H, d, J 9.2, SO2CHCH2 trans to 
SO2), 5.10 (1H, t, J 6.7, SO2NH), 4.63-4.58 (1H, m, ArCONHCH), 3.64-3.59 (1H, m, pyrrolidine-H2’), 3.47-3.43 
(1H, m, SO2NHCH2), 3.25-3.22 (1H, m, SO2NHCH2), 3.19-3.11 (2H, m, pyrrolidine-H5’), 2.48-2.30 (2H, m, 
tBuOOCCH2CH2), 2.25-2.16 (1H, m, tBuOOCCH2CH2), 2.11-2.04 (1H, m, tBuOOCCH2CH2), 1.87-1.76 (2H, m, 
pyrrolidine-H4’), 1.71-1.62 (2H, m, pyrrolidine-H3’); δC (101 MHz, MeOD) 173.3, 171.1, 165.6, 139.1, 138.5, 135.9, 
128.4, 128.0, 127.2, 82.9, 81.5, 77.4, 59.8, 50.2, 47.4, 31.9, 29.8, 28.3, 28.2, 27.1, 24.2; m/z (ESI) 616 [MH]+, 638 
[MNa]+; found: [MH]+, 616.2353 C27H42N3O9S2 requires 616.2362, Δ 1.5 ppm.      
(R)-(1-Methylpyrrolidin-2-yl)-methanol 97 
 
A procedure reported by Zhu et al. was used with some modifications.[283] D-prolinol (0.50 mL, 5.12 mmol, 1.0 equiv.) 
was added to formic acid (1 mL) at 0 °C followed by 37 % aqueous formaldehyde (0.75 mL). The reaction mixture 
was warmed to reflux whereby a vigorous evolution of carbon dioxide was observed. The mixture was stirred at reflux 
for 20 h before acidification with 5N HCl (1.25 mL) and evaporation in vacuo to afford a yellow gum. The residue 
was dissolved in a minimum quantity of saturated NaOH and extracted with chloroform (x 6). The combined organic 
extracts were dried over MgSO4, filtered and the solvent removed in vacuo to leave the desired methylated prolinol 97 
(389.5 mg, 66 %) as a clear oil. δH (400 MHz, CDCl3) 4.21 (1H, bs, OH), 3.41 (1H, dd, J 3.6, J 10.9, pyrrolidine-
CH2), 3.29 (1H, dd, J 3.6, J 10.9, pyrrolidine-CH2), 2.90-2.86 (1H, m, pyrrolidine-H2’), 2.18 (3H, s, NCH3), 2.17-2.13 
(1H, m, pyrrolidine-H5’), 2.10-1.99 (1H, m, pyrrolidine-H5’), 1.76-1.49 (4H, m, pyrrolidine-H4’ and pyrrolidine-
H3’); δC (101 MHz, CDCl3) 66.6, 62.3, 57.5, 41.0, 27.4, 22.9. m/z (CI) 116 [MH]+; found [MH]+ 116.1068 C6H14NO 
requires 116.1075, Δ 6.0 ppm.  
2-(R)-Hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 99 
Method one  from D-proline 
 
The method of Pericàs et al.[284] was used with some small modifications. To D-proline (1.00 g, 8.69 mmol, 1.0 eq.) in 
anhydrous THF (3 mL) at 0 °C under argon was added LiAlH4 as a 1.0 M solution in THF (Sigma-Aldrich, SureSeal) 
(13.0 mL, 13.0 mmol, 1.5 eq.) with vigorous effervescence. The reaction mixture was stirred for one hour at 0 °C and 
for one hour at rt to give a cloudy grey solution. 20 % aqueous NaOH (2 mL) was added with vigorous effervescence 
to give a thick white precipitate. The mixture was filtered through celite, dried over Na2SO4 and concentrated to 
approximately 30 mL before addition of Boc2O (2.85 g, 13.0 mmol, 1.5 eq.) in anhydrous THF (6 mL) dropwise. The 
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resulting bright orange solution was stirred at rt overnight. NaHCO3 was added and the reaction mixture extracted 
with Et2O (x 3). Combined organics were dried over Na2SO4, filtered and the solvent removed in vacuo. The crude 
orange oil was purified on silica (1:1, n-hexane/EtOAc) and dried under high vacuum to yield the desired N-Boc D-
prolinol 99 (1.19 g, 68 %) as a white powder.     
Method two  from D-prolinol 
 
To a solution of D-prolinol (0.40 mL, 4.10 mmol, 1.0 equiv.) and triethylamine (0.64 mL, 4.61 mmol, 1.1 equiv.) in 
anhydrous CH2Cl2 (5 mL) under argon at 0 °C was added di-tertbutyl dicarbonate (1.06 g, 4.61 mmol, 1.1 equiv.) in 
CH2Cl2 (3.5 mL) and the mixture warmed to rt and stirred for 16 h. The reaction mixture was quenched with NaHCO3 
and the organic layer washed with brine (x 1) and dried over MgSO4. The solvent was removed in vacuo to yield the 
desired N-Boc D-Prolinol 99 (603.0 mg, 73 %) as a clear oil which solidified under vacuum to a white solid.  
Rf = 0.38 (2:1, EtOAc/n-nex); [α]20D = + 42.4 (c = 0.61, CHCl3); νmax /cm-1 3400 (b), 2974, 2876, 1692, 1669, 1395, 
1367, 1166, 1125, 1107, 1052; δH (400 MHz, CDCl3) 3.95-3.89 (1H, m, pyrrolidine-H2’), 3.62-3.53 (2H, m, 
pyrrolidine-H5’), 3.46-3.40 (1H, m, pyrrolidine-CH2), 3.31-3.52 (1H, m, pyrrolidine-CH2), 2.02-1.94 (1H, m, 
pyrrolidine-H), 1.86-1.70 (2H, m, pyrrolidine-H), 1.60-1.54 (1H, bm, pyrrolidine-H), 1.44 (9H, s, tBu); δC (101 MHz, 
CDCl3) 157.5, 80.4, 67.9, 60.4, 47.7, 28.9, 28.7, 24.2. Data in agreement with literature values.[285]  
(R)-2-(Toluene-4-sulfonyloxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 100 
 
To a solution of N-Boc D-prolinol 99 (552.3 mg, 2.74 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (5 mL) was added tosyl 
chloride (1.57 g, 8.23 mmol, 3.0 equiv.) and triethylamine (1.14 mL, 8.23 mmol, 3.0 equiv.) and the reaction stirred 
under argon at rt for 16 h. The reaction mixture was poured into brine and extracted with CH2Cl2 (x 3). Combined 
organics were dried over MgSO4, filtered and the solvent removed in vacuo. The crude oil was purified on silica (4:1, 
n-hex/EtOAc) to yield the desired tosylated pyrrolidine 100 (996 mg, 100 %) as a colourless oil. Rf = 0.29 (3:1, n-
hex/EtOAc); [α]20D = + 44.0 (c = 1.41, CHCl3); νmax /cm-1 2974, 1691, 1392, 1363, 1174, 1097, 968, 815, 666; δH (400 
MHz, CDCl3) 7.75 (2H, d, J 8.2, ArH), 7.38-7.35 (2H, bm, ArH), 4.12-3.89 (3H, m, TsOCH2 and pyrrolidine-H2’), 
3.37-3.30 (2H, m, pyrrolidine-H5’), 2.47 (3H, s, ArCH3), 1.98-1.72 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 
1.37 (3H, s, tBu), 1.33 (6H, s, tBu); δC (101 MHz, CDCl3, isomers) 154.5, 145.1, 133.1, 130.1, 128.1, 80.1, 79.8, 70.1, 
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55.7, 47.1, 46.7, 28.5, 27.8, 24.0, 23.0, 21.8; m/z (ESI) 378 [MNa]+; found [MNa]+ 378.1345 C17H25NO5SNa requires: 
378.1351, Δ 1.6 ppm. Data in agreement with literature values.[286] 
(R)-2-Azidomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 101 
 
Tosylate 100 (375 mg, 1.06 mmol, 1.0 equiv.) was dissolved in anhydrous DMSO (12 mL) and NaN3 (411 mg, 6.33 
mmol, 6.0 equiv.) was added. The reaction was heated to 65 °C and stirred for 19 h under an atmosphere of argon. 
The reaction was diluted with Et2O (20 mL) and washed with H2O (16 mL x 3) and brine (1 x 8 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo to yield the desired azide 101 (187.6 mg, 78 %) as a clear oil. Rf = 
0.75 (100 % EtOAc); [α]19D = + 47.9 (c = 2.38, CHCl3); νmax /cm-1 2974, 2881, 2100, 1693, 1392, 1366, 1165, 1106; 
δH (400 MHz, CDCl3) 3.90 (1H, bm, pyrrolidine-H2’), 3.55-3.34 (4H, bm, pyrrolidine-H5’ and N3CH2), 2.03-1.73 
(4H, bm, pyrrolidine-H3’ and pyrrolidine-H4’), 1.44 (9H, s, C(CH3)3); δC (101 MHz, CDCl3, isomers) 154.7, 79.9, 
56.7, 54.0, 52.9, 47.2, 46.9, 29.6, 28.7, 24.0, 23.2. Data in agreement with literature values.[287]  
 (R)-2-Aminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 102 
 
To Boc-azidomethylpyrrolidine 101 (188 mg, 0.83 mmol, 1.0 equiv.) dissolved in MeOH (5 mL) was added 10 % 
Pd/C (16 mg, cat.) and the reaction mixture stirred for 24 h under an atmosphere of H2 (g). The reaction mixture was 
filtered through celite, washed through with MeOH and the solvent evaporated from the filtrate in vacuo to yield the 
desired amine 102 (157.9 mg, 95 %) as a clear oil. Rf = 0 (100 % EtOAc); [α]23D = + 54.0 (c = 0.93, MeOH); νmax /cm-
1 2975, 1692, 1397, 1366, 1171, 1112;  δH (400 MHz, MeOD) 3.89-3.76 (1H, bm, pyrrolidine-H2’), 3.42-3.34 (2H, 
bm, pyrrolidine-H5’), 2.91-2.87 (1H, bm, H2NCH2), 2.78-2.65 (1H, bm, H2NCH2), 2.06-1.81 (4H, bm, pyrrolidine-
H3’, pyrrolidine-H4’), 1.47 (9H, s, OC(CH3)3); δC (101 MHz, MeOD, isomers) 156.9, 156.6, 81.1, 80.8, 60.7, 60.6, 
48.2, 47.8, 45.5, 29.8, 29.5, 29.0, 24.7, 24.0; m/z (ESI) 201 [MH]+; found [MH]+ 201.1602 C10H21N2O2 requires 
201.1603, Δ 0.5 ppm. Data in agreement with literature values.[287]  
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(R)-2-(Acryloylamino-methyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 103 
 
To a solution of amine 102 (138.8 mg, 0.69 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (4 mL) at 0 °C under argon was 
added Et3N (0.14 mL, 1.035 mmol, 1.5 equiv.) and acryloyl chloride (0.10 mL, 1.23 mmol, 1.8 equiv.) and the 
resulting light yellow solution stirred at 0 °C for 15 min and at rt for 20 h. The resulting bright yellow solution was 
poured into aqueous NH4Cl (2M) and extracted with CH2Cl2 (x 2). Combined organics were dried over MgSO4, 
filtered and the solvent removed in vacuo. The crude yellow residue was purified on silica (gradient EtOAc/n-hex, 1:1 
to EtOAc/n-hex, 1:0) to yield the desired acrylamide 103 (127.2 mg, 72 %) as a yellow oil. Rf = 0.41 (100 % EtOAc); 
[α]20D = + 68.4 (c = 1.17, CHCl3); νmax /cm-1 3293 (b), 2972, 1693, 1662, 1627, 1548, 1395, 1366, 1246, 1169, 1111;  
δH (400 MHz, CDCl3) 7.65 (1H, bs, NH), 6.10-5.95 (2H, m, CH2CHCON cis to C=O and CH2CHCONH), 5.45 (1H, d, 
J 8.9, CH2CHCONH trans to C=O), 3.96-3.74 (1H, bm, pyrrolidine-H2’), 3.35-3.05 (4H, bm NHCH2 and pyrrolidine-
H5’), 1.91-1.62 (4H, bm, pyrrolidine-H3’ and pyrrolidine-H4’), 1.33 (9H, s, OC(CH3)3); δC (101 MHz, CDCl3) 166.0, 
156.7, 131.5, 125.2, 80.0, 56.2, 47.0, 45.8, 29.3, 28.4, 23.8; m/z (ESI) 277 [MNa]+; found [MNa]+ 277.1521 
C13H22N2O3Na requires 277.1528, Δ 2.5 ppm.  
(R)-Octahydro-pyrrolo[1,2-a][1,4]diazepin-3-one 104 
 
 
 
N-Boc pyrrolidine 103 (120 mg, 0.48 mmol, 1 eq.) was dissolved in a 1:1 mixture of TFA and CH2Cl2 (3 mL) and the 
solution stirred at room temperature for 30 min. The solvent was removed in vacuo, the pH adjusted to pH 8 with sat. 
aq. NaHCO3 and the aqueous phase extracted with CH2Cl2 (x 3). Combined organics were dried over Na2SO4, filtered 
and the solvent removed in vacuo. The crude mixture was passed through a column of silica with MeOH to isolate 
bicyclic structure 104 (7.9 mg, 11%) as a white solid. νmax /cm-1 1645, 1540, 730; δH (400 MHz, CDCl3) 8.70 (1H, br 
m, NH), 3.74-3.68 (1H, m), 3.31 (1H, bt, J 8.0), 3.23-3.12 (2H, m), 2.69-2.59 (2H, m), 2.40 (1H, dt, J 17.2 J 3.1), 2.30 
(1H, dt, J 12.2 J 3.6), 2.22-2.16 (1H, m), 1.98-1.83 (2H, m), 1.74-1.61 (2H, m); δC (101 MHz, CDCl3) 173.1, 63.1, 
53.0, 49.9, 38.4, 33.8, 27.3, 22.7; m/z (ESI) 155 [M+H], 309 [2M+H]+; found [2M+H]+ 309.2273 C16H29N4O2 requires 
309.2291, Δ 5.8 ppm. m/z (EI) 308 [2M]+; found [2M]+ 308.2207 C16H28N4O2 requires 308.2212, Δ 1.6 ppm.   
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N-Benzyl-3-phenylsulfanyl-propionamide 109 
 
To a solution of benzylamine (0.44 mL, 4.0 mmol, 1.0 eq.) in anhydrous CH2Cl2 (10 mL) at 0 °C was added Et3N 
(0.62 mL, 4.4 mmol, 1.1 eq.) and acryloyl chloride (0.36 mL, 4.4 mmol, 1.1 eq.) and the cloudy white mixture stirred 
at rt for 1 h. The reaction was quenched with aqueous NH4Cl (2 M), acidified to pH 2 with 2N HCl and extracted with 
CH2Cl2 (x 3). The combined organics were dried over MgSO4, filtered and the solvent removed in vacuo to yield the 
desired acrylamide 47 (691 mg, > 95 % pure), which was taken straight on to the next step.  
To a solution of the benzyl acrylamide 47 (640 mg, 3.97 mmol, 1.0 equiv) in anhydrous CH2Cl2 (1 mL) at 0 °C was 
added Et3N (0.55 mL, 3.97 mmol, 1.0 equiv.) and thiophenol (0.51 mL, 4.96 mmol, 1.25 equiv.) and the bright yellow 
solution warmed to rt resulting in the production of a thick precipitate. Stirring was continued for a further 5 min 
before addition of further anhydrous CH2Cl2 (5 mL). Stirring was continued at rt for another 10 min before the 
reaction mixture was diluted with CH2Cl2 and washed with 5 % NaOH (x 3), 1 N HCl (x 1), sat. NaHCO3 (x 1) and 
brine (x 2). The organic layer was dried over MgSO4, filtered and the solvent removed in vacuo to yield a crude white 
solid. This was recrystallised from CH2Cl2 and the filtrate subjected to a second recrystallisation from CH2Cl2 to yield 
the desired thioether 109 (446mg, 41 %) as a grey crystalline solid, mp = 115-122 °C; Rf = 0.31 (EtOAc/n-hex, 1:1); 
νmax /cm-1 3273, 1639, 1553, 1479, 1452, 1437, 1428, 1373, 1354, 1278, 1235, 1183, 1092, 1070, 1023, 733, 687; δH 
(400 MHz, CDCl3) 7.34-7.24 (9H, m, ArH), 7.18 (1H, tt, J 1.0, J 7.3, ArH),  5.75 (1H, bs, NH), 4.42 (2H, d, J 6.2, 
NHCH2), 3.24 (2H, t, J 7.7, NHCOCH2CH2S), 2.49 (2H, t, J 7.7, NHCOCH2CH2S); δC (101 MHz, DMSO-d6) 170.1, 
139.4, 136.0, 129.1, 128.3, 128.1, 127.2, 126.8, 125.7, 42.1, 34.9, 28.2; m/z (ESI) 294 [MNa]+, 272 [MH]+; found 
[MH]+ 272.1105 C16H18NOS requires 272.1109, Δ 1.5 ppm.        
(±)-3-Benzenesulfinyl-N-benzyl-propionamide 110 
 
To thioether 109 (200 mg, 0.74 mmol, 1.0 eq.) and sodium metaperiodate (252 mg, 1.18 mmol, 1.6 eq.) was added 
MeOH (4 mL) at 0 °C and the suspension stirred rapidly at rt for 24 h. H2O was added to the reaction mixture and the 
aqueous layer extracted with CHCl3 (x 3). Combined organics were dried over Na2SO4, filtered and the solvent 
removed in vacuo. The crude product was purified on silica (100 % EtOAc) to yield the desired sulfoxide 110 (180 
mg, 85 %) as a white solid, mp = 93-96 °C; Rf = 0.29 (100 % EtOAc); νmax /cm-1 3283, 3064, 2921, 1651, 1548, 1444, 
1250, 1085, 1034, 998, 747, 693; δH (400 MHz, CDCl3)  7.62 (1H, bt, J 5.8, NH), 7.52-7.46 (5H, m, ArH), 7.29-7.18 
(5H, m, ArH), 4.39 (1H, dd, J 5.8, J 15.6, ArCH2), 4.33 (1H, dd, J 5.8, J 15.6, ArCH2), 3.27-3.19 (1H, m, SOCH2), 
2.93-2.86 (1H, m, SOCH2), 2.82-2.75 (1H, m, SOCH2CH2), 2.56-2.49 (1H, m, SOCH2CH2); δC (101 MHz, CDCl3) 
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170.0, 142.8, 138.3, 131.1, 129.3, 128.6, 127.8, 127.3, 123.9, 52.1, 43.6, 28.3; m/z (ESI) 310 [MNa]+, 288 [MH]+; 
found [MH]+ 288.1045 C16H18NO2S requires 288.1058, Δ 4.5 ppm.   
2-(R)-[(3-Phenylsulfanyl-propionylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 111 
 
To acrylamide 103 (293.0 mg, 1.15 mmol, 1.0 eq.) in THF (10 mL) was added thiophenol (0.38 mL, 3.69 mmol, 3.2 
eq.) and triethylamine (0.72 mL, 5.18 mmol, 4.5 eq.) and the reaction stirred at rt for 20 h. The solvent was removed 
in vacuo and the crude yellow oil purified on silica (EtOAc/n-hex, 1:1) to yield the desired thioether 111 (272.2 mg, 
65 %) as a clear oil. Rf  = 0.70 (100 % EtOAc); [α]22D = + 20.1 (c = 14.2, CHCl3); νmax /cm-1 3309, 2972, 1689, 1650, 
1480, 1392, 1365, 1344, 1254, 1165, 1133, 1108, 737, 691; δH (400 MHz, CDCl3) 7.47 (1H, bs, NH), 7.30 (2H, d, J 
7.2, ArH2’), 7.21 (2H, t, J 7.2, ArH3’), 7.12 (1H, t, J 7.2, ArH4’), 3.97-3.93 (1H, m, pyrrolidine-H2’), 3.42-3.23 (3H, 
m, NHCH2 and pyrrolidine-H5’), 3.20-3.08 (3H, m, pyrrolidine-H5’ and ArSCH2), 2.48-2.36 (2H, m, ArSCH2CH2), 
1.98-1.74 (3H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 1.64-1.55 (1H, m, pyrrolidine-H3’), 1.39 (9H, s, tBu); δC 
(101 MHz, CDCl3) 171.1, 156.8, 135.8, 129.6, 129.0, 126.3, 80.1, 56.3, 47.2, 46.1, 36.4, 29.5, 29.5, 28.5, 24.0; m/z 
(ESI) 387 [MNa]+; found [MH]+ 365.1894  C19H29N2O3S requires 365.1899, Δ 1.4 ppm.       
(R)-3-Phenylsulfanyl-N-pyrrolidin-2-ylmethyl-propionamide 112 
 
Thioether 111 (213.4 mg, 0.59 mmol, 1.0 eq.) was dissolved in 4M HCl in dioxane (2.0 mL) and the reaction stirred at 
rt for 50 min until complete by TLC. The solvent was removed under reduced pressure and the residue washed 
thoroughly with CHCl3 to yield the desired amine 112 (172.9 mg, 97 %) as a clear oil. Rf  = 0 (100 % EtOAc); [α]22D = 
+ 52.0 (c = 3.0, CHCl3); νmax /cm-1 3321 (b), 2931, 2756, 1651, 1549, 1481, 1439, 1368, 1261, 741, 692; δH (400 MHz, 
CDCl3) 9.78 (1H, bs, NH), 9.08 (1H, bs, NH), 8.15 (1H, bs, NH), 7.30 (2H, d, J 7.5, ArH2’), 7.23 (2H, t, J 7.5, 
ArH3’), 7.13 (1H, t, J 7.5, ArH4’), 3.79 (1H, bs, pyrrolidine-H2’), 3.57 (2H, bs, NHCH2), 3.24 (2H, bs, ArSCH2), 
3.18 (2H, bs, pyrrolidine-H5’), 2.58 (2H, bs, ArSCH2CH2), 2.03-1.93 (3H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 
1.76 (1H, bs, pyrrolidine-H3’); δC (101 MHz, CDCl3) 173.1, 135.6, 129.3, 129.1, 126.3, 60.8, 45.3, 40.1, 35.9, 29.4, 
27.4, 24.1; m/z (ESI) 265 [MH]+; found [MH]+ 265.1376 C14H21N2OS requires 265.1375, Δ 0.4 ppm.       
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(R,R)-N-(1-Methyl-1-(2-[(1-methyl-pyrrolidin-2-ylmethyl)-carbamoyl]-ethyl)-pyrrolidin-2-ylmethyl)-acrylamide 114 
 
 
 
N-boc pyrrolidine 103 (356.9 mg, 1.40 mmol, 1.0 eq.) was stirred in HCl (2.0 M in ether, Sigma-Aldrich, SureSeal) 
(20 mL) for 3 h. The solvent was removed in vacuo and the product dried under high vacuum. To the resulting residue 
was added paraformaldehyde (147.1 mg, 4.9 mmol, 3.5 eq.) and MeOH (20 mL) and the mixture heated to reflux for 
20 min. The solution was cooled to 0 °C and NaBH3CN (879.8 mg, 14.0 mmol, 10 eq.) was added all at once. The 
reaction mixture was warmed to rt and stirred overnight. 10% aqueous NaHCO3 (11 mL) was added to quench the 
reaction and the mixture washed with CHCl3 (x 3). Combined organics were dried over MgSO4, filtered and the 
solvent removed in vacuo. The residue was washed with THF/MeOH, 1:1 (2 x 10 mL) to remove any traces of the 
borate esters. The crude yellow oil was purified on silica (CH2Cl2/MeOH, 7:3) to yield the acrylamide 114 (134.6 mg, 
52 %) as a clear oil. [α]22D = + 84.5 (c = 0.95, MeOH); Rf  = 0.18 (CH2Cl2/MeOH, 7:3); νmax /cm-1 1654, 1623, 1555, 
1456, 1121, 979; δH (500 MHz, MeOD, HSQC, NOESY) 6.28 (1H, dd, J 13.7, J 7.4, CH2CHCONH), 6.22 (1H, dd, J 
13.7, J 2.1, CH2CHCONH cis to C=O), 5.66 (1H, dd, J 7.4, J 2.1, CH2CHCONH trans to C=O), 3.80 (2H, t, J 4.9, 
NCH2CH2CONH), 3.56 (1H, dd, J 10.8, J 3.2, NHCH2), 3.51 (1H, dd, J 10.8, J 3.2, NHCH2), 3.18 (1H, dd, J 10.8, J 
5.8, NHCH2), 3.12 (1H, dd, J 10.8, J 5.8, NHCH2), 3.09-3.06 (2H, m, pyrrolidine-H2’), 2.67 (2H, t, J 4.9, 
NCH2CH2CONH), 2.48-2.42 (2H, m, pyrrolidine-H5’), 2.42 (3H, s, NCH3), 2.41 (3H, s, NCH3), 2.33-2.28 (2H, m, 
pyrrolidine-H5’), 2.02-1.95 (2H, m, pyrrolidine-H3’), 1.79-1.73 (4H, m, pyrrolidine-H3’ and pyrrolidine-H4’), 1.64-
1.57 (2H, m, pyrrolidine-H4’); δC (500 MHz, MeOD) 172.5, 168.2, 132.0, 126.7, 66.5, 66.5, 58.2, 58.1, 48.8, 48.7, 
42.6, 41.2, 41.1, 41.1, 39.9, 29.9, 29.8, 22.9; m/z (ESI) 373 [MH]+, 337 [M-Cl]+; found [M-Cl]+ 337.2593 C18H33N4O2 
requires 337.2604, Δ 3.3 ppm.              
9.3. Negative control two 
Synthesis as a mixture of regioisomers 
(±)-2-Benzyl-1-(toluene-4-sulfonyl)-aziridine 120 
 
A procedure reported by Sharpless et al. was used with some modifications.[177] To a solution of allyl benzene (4.0 
mL, 30 mmol, 1.0 eq.) and chloramine-T trihydrate (9.30 g, 33 mmol, 1.1 eq.) in MeCN (150 mL) was added 
trimethylphenylammonium tribromide (1.11 g, 3.0 mmol, 0.1 eq.) and the yellow reaction mixture stirred vigorously 
at rt under argon for 43 h. The solvent was removed from the reaction in vacuo and the crude residue partitioned 
between EtOAc and brine. The layers were separated and the aq. layer washed with EtOAc (x 1). Combined organics 
were dried over MgSO4, filtered and the solvent removed in vacuo. The crude orange oil (10.2 g) was purified on 
silica (EtOAc/n-hex, 1:4) to yield the desired aziridine 120 (3.74 g, 43 %) as a white solid, mp = 64-66 °C; δH (400 
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MHz, CDCl3) 7.69 (2H, d, J 8.2, tol-H3’), 7.20 (2H, d, J 8.2, tol-H2’), 7.17-7.14 (3H, m, Ph), 7.05-7.03 (2H, m, Ph), 
2.96-2.92 (1H, m, PhCH2CH), 2.81 (1H, dd, J 5.2, J 14.5, PhCH2), 2.71 (1H, d, J 7.1, PhCH2CH(NTs)CH2), 2.67 (1H, 
dd, J 7.2, J 14.5, PhCH2), 2.41 (3H, s, ArCH3), 2.16 (1H, d, J 4.5, PhCH2CH(NTs)CH2); δC (101 MHz, CDCl3) 144.3, 
137.0, 134.8, 129.6, 128.7, 128.5, 127.9, 126.5, 41.2, 37.5, 32.8, 21.6; m/z (ESI) 288 [MH]+; found [MH]+ 288.1047 
C16H18NO2S requires 288.1058, Δ 3.8 ppm. Data in agreement with literature values.[288]      
(±)-N-(1-Azidomethyl-2-phenyl-ethyl)-4-methyl-benzenesulfonamide 121a and (±)-N-(2-Azido-3-phenyl-propyl)-4-
methyl-benzenesulfonamide 121b 
 
Trimethylsilyl azide (0.21 mL, 1.60 mmol, 1.0 eq.) was added to N-tosyl aziridine 120 (459.2 mg, 1.60 mmol, 1.0 eq.) 
in DMF (13 mL) under an atmosphere of argon and the colourless solution stirred at 40 °C for 16 h. The reaction 
mixture was then allowed to cool to rt, diluted with EtOAc and washed with H2O (x 6). The organic layer was dried 
over MgSO4, filtered and the solvent removed in vacuo. The crude clear oil was purified on silica (n-hex/EtOAc, 4:1) 
and the resulting mixture repurified on silica (n-hex/Et2O, 1:1) to give azides 121a and 121b (170.0 mg, 32%) as a 
colourless oil as an inseparable mixture of regioisomers (8:1). δH (400 MHz, CDCl3) 7.73 (2Hb, d, J 8.2, tol-H2’), 7.63 
(2Ha, d, J 8.3, tol-H2’), 7.32-7.27 (5Hb, m, Ph), 7.23-7.19 (5Ha, m, Ph), 7.14-7.12 (2Hb, m, tol-H3’), 7.01-6.98 (2Ha, 
m, tol-H3’), 5.27 (1Hb, t, J 6.4, TsNH), 5.13 (1Ha, d, J 7.7, TsNH), 4.19-4.12 (1Hb, m, N3CH), 3.57-3.49 (1Ha, m, 
TsNHCH), 3.38-3.28 (2Ha, m, N3CH2), 3.26-3.17 (2Hb, m, TsNHCH2), 3.07 (1Hb, dd, J 7.8, J 14.2, PhCH2), 2.81-2.67 
(2Ha, m, PhCH2), 2.44 (3Hb, s, ArCH3), 2.41 (3Ha, s, ArCH3).  
(±)-N-[3-Phenyl-2-(toluene-4-sulfonylamino)-propyl]-acrylamide 119 
 
To a solution of azides 121a and 121b (165.3 mg, 0.50 mmol, 1.0 eq.) in EtOAc (5 mL) under an argon atmosphere 
was added palladium on carbon (30 mg, cat.) and the mixture stirred under a H2 atmosphere for 18 h at rt. The 
reaction mixture was filtered through celite and the solvent removed from the filtrate in vacuo to yield an inseparable 
mixture of amines 122a and 122b. To the crude mixture of amines (109.4 mg, 0.36 mmol, 1.0 eq.) in anhydrous 
CH2Cl2 (1.8 mL) under argon at rt was added Et3N (0.08 mL, 0.50 mmol, 1.5 eq.) and acryloyl chloride (0.03 mL, 0.4 
mmol, 1.1 eq.). The resulting pale yellow solution was stirred at rt for 4 h before dilution with CH2Cl2 and addition of 
H2O. The layers were separated and the aqueous layer further washed with CH2Cl2 (x 1). Combined organics were 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude mixture was purified on silica (1:1, EtOAc/ 
n-hex) to yield the desired acrylamide 119 (41.9 mg, 26 %) as a white powder and the bis-Michael acceptor 123 (28.2 
mg, 19 %) as a clear oil. A small portion of the desired acrylamide was repurified using a prep LC-MS (1:1 
MeOH/H2O  to 100 % MeOH) to give the desired acrylamide 119 as a white solid in high purity for screening.  
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(±)-N-[3-Phenyl-2-(toluene-4-sulfonylamino)-propyl]-acrylamide 119 
 
Mp 119-120 °C; Rf = 0.11 (1:1 EtOAc/n-hexane); νmax /cm-1 2925, 1662, 1626, 1601, 1543, 1496, 1455, 1430, 1408, 
1324, 1306, 1290, 1245, 1158, 1091, 978; δH (400 MHz, CDCl3) 7.56 (2H, d, J 8.2, tol-H2’), 7.20-7.17 (5H, m, Ph), 
6.98-6.96 (2H, m, tol-H3’), 6.26 (1H, dd, J 17.0, J 1.2, CH2CHCONH cis to C=O), 6.22 (1H, bt, acrylamide-NH), 
6.03 (1H, dd, J 17.0, J 10.3, CH2CHCONH), 5.65 (1H, dd, J 1.2, J 10.3, CH2CHCONH trans to C=O), 5.26 (1H, d, J 
6.5, sulfonamide-NH), 3.51-3.31 (3H, m, NHCH2CH), 2.73 (2H, d, J 6.8, PhCH2), 2.40 (3H, s, ArCH3); δC (101 MHz, 
CDCl3) 166.6, 143.4, 136.7, 136.3, 130.6, 129.8, 129.2, 128.8, 127.0, 126.9, 126.9, 55.7, 43.2, 39.7, 21.5; m/z (ESI) 
359 [MH]+; found [MH]+ 359.1427 C19H23N2O3S requires 359.1429, Δ 0.6 ppm.  
(±)-N-[2-(acryloyl(toluene-4-sulfonyl)amino)-3-phenylpropyl]acrylamide 123 
 
Rf = 0.19 (1:1 EtOAc/n-hexane); δH (400 MHz, CDCl3) 7.39 (2H, d, J 8.3, tol-H3’), 7.22-7.20 (3H, m, Ph), 7.16 (2H, 
d, J 8.3, tol-H2’), 7.09-7.06 (2H, m, Ph), 6.67 (1H, dd, J 16.6, J 10.4, NC(O)CHCH2), 6.32 (1H, dd, J 16.6, J 1.2, 
NC(O)CHCH2 cis to C=O), 6.22 (1H, dd, J 17.0, J 1.2, NC(O)CHCH2 cis to C=O), 6.13 (1H, bt, J 5.5, NH), 6.02 (1H, 
dd, J 17.0, J 10.4, NC(O)CHCH2), 5.70 (1H, dd, J 10.4, J 1.2, NC(O)CHCH2 trans to C=O), 5.61 (1H, dd, J 10.4, J 
1.2, NC(O)CHCH2 trans to C=O), 4.70-4.63 (1H, m, PhCH2CH), 4.03 (1H, ddd, J 14.3, J 8.4, J 6.5, 
PhCH2CHCH2NH), 3.71 (1H, dt, J 14.3, J 5.0, PhCH2CHCH2NH), 3.28 (1H, dd, J 13.8, J 8.5, PhCH2), 3.13 (1H, dd, 
J 13.8, J 6.8, PhCH2), 2.39 (3H, s, ArCH3); δC (101 MHz, CDCl3) 167.2, 165.9, 144.9, 137.9, 136.4, 130.9, 130.7, 
130.1, 130.0, 129.4, 128.9, 127.6, 126.9, 126.5, 62.4, 42.1, 37.0, 21.7; m/z (ESI) 413 [MH]+, 435 [MNa]+; found 
[MH]+ 413.1518 C22H25N2O4S requires 413.1535, Δ 4.1 ppm. 
Regioselective synthesis 
(±)-N-(1-Azidomethyl-2-phenyl-ethyl)-4-methyl-benzenesulfonamide 121a 
 
A procedure reported by Maksukawa et al. was used with some modifications.[197] To a solution of tris(2,4,6-
trimethoxyphenyl)phosphine (26.6 mg, 0.05 mmol, 0.1 eq.) and aziridine 120 (143.7 mg, 0.50 mmol, 1.0 eq.) in 
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anhydrous DMF (1 mL) was added trimethylsilyl azide (0.1 mL, 0.75 mmol, 1.5 eq.) at rt and the reaction stirred for 
7.5 h before addition of H2O (2 mL). The resulting mixture was extracted with EtOAc (x 1) and the organic layer 
washed with H2O (x 5) to remove the remaining DMF. The crude residue was purified on silica (EtOAc/n-hexane, 
1:4) to yield the desired azide 121a (114.8 mg, 70 %) as a clear oil, as a single regioisomer. Rf  = 0.34 (EtOAc/n-
hexane, 1:4); νmax /cm-1 2101 (N3), 1664, 1604, 1578, 1447, 1330, 1293, 1252, 1227, 1157, 1126, 1089, 965, 816, 729, 
697; δH (400 MHz, CDCl3) 7.63 (2H, d, J 8.3, tol-H3’), 7.23-7.18 (5H, m, ArH), 7.02-6.98 (2H, m, ArH), 5.09 (1H, d, 
J 7.8, NH), 3.57-3.49 (1H, m, CHNHSO2tol), 3.36 (1H, dd, J 12.3, J 4.9, N3CH2), 3.30 (1H, dd, J 12.3, J 4.2, N3CH2), 
2.77 (1H, dd, J 13.8, J 7.4, PhCH2), 2.69 (1H, dd, J 13.8, J 6.9, PhCH2), 2.41 (3H, s, PhCH3); δC (101 MHz, CDCl3) 
143.5, 137.1, 136.3, 129.8, 129.2, 128.8, 127.0, 126.9, 54.5, 53.8, 38.6, 21.6; m/z (ESI) 331 [MH]+; found [MH]+ 
331.1230 C16H19N4O2S requires 331.1229, Δ 0.3 ppm. Data in agreement with literature values.[196]  
(±)-N-(1-aminomethyl-2-phenyl-ethyl)-4-methyl-benzenesulfonamide 122a 
 
To a solution of azide 121a (456.5 mg, 1.38 mmol, 1.0 eq.) in EtOAc (13 mL) under argon was added Pd/C (80 mg, 
cat.) and the mixture stirred under an H2 atmosphere for 24 h. The reaction mixture was filtered through celite and the 
solvent removed in vacuo to yield the desired amine 122a (419.3 mg, 100 %) as a clear oil. Rf = 0 (4:1, n-hex/EtOAc); 
νmax /cm-1 3060, 3029, 2924, 2866, 1599, 1496, 1455, 1320, 1304, 1289, 1151, 1091, 952, 813, 733, 699; δH (400 
MHz, CDCl3) 7.65 (2H, d, J 8.0, tol-H2’), 7.12 (2H, d, J 8.0, tol-H3’), 7.06-7.05 (3H, m, Ph), 6.94-6.92 (2H, m, Ph), 
5.39 (3H, bs, NH), 3.59-3.53 (1H, bm, TsHNCH), 2.99-2.87 (2H, m, NH2CH2), 2.68 (2H, d, J 6.4, PhCH2), 2.34 (3H, 
s, ArCH3); δC (101 MHz, CDCl3) 143.0, 137.5, 137.0, 129.6, 129.2, 128.4, 127.0, 126.4, 55.7, 43.9, 38.7, 21.5; m/z 
(ESI) 305 [MH]+; found [MH]+ 305.1315 C16H21N2O2S requires 305.1324, Δ 2.9 ppm.  
(±)-N-[3-Phenyl-2-(toluene-4-sulfonylamino)-propyl]-acrylamide 119  
 
To a rapidly stirred solution of amine 122a (80 mg, 0.26 mmol, 1.0 eq.) and Et3N (54.2 µL, 0.39 mmol, 1.5 eq.) in 
anhydrous CH2Cl2 (3.5 mL) at 0 °C was added acryloyl chloride (21.4 µL, 0.26 mmol, 1.0 eq.) and the reaction 
mixture stirred at 0 °C for 1 h before warming to rt and stirring for a further 13 h. The solvent was removed from the 
reaction mixture in vacuo and the clear oil purified on silica (1:1, EtOAc/n-hex) to yield the desired acrylamide 119 
(52.6 mg, 56 %) as a clear oil. Data in agreement with above.  
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9.4. Non-tethering control ligands 
N-(4-Fluoro-benzyl)-acetamide 124 
 
To a solution of p-fluorobenzylamine (0.50 mL, 4.37 mmol, 1.0 equiv.) in Et2O (13 mL) was added Et3N (1.22 mL, 
8.75 mmol, 2.0 equiv.) and the solution cooled to 0 °C. Acetyl chloride (0.62 mL, 8.75 mmol, 2.0 equiv.) was added 
dropwise and the resulting thick white precipitate stirred at 0 °C for 5 min and at rt for 10 min. The mixture was 
filtered under reduced pressure and the filter cake washed with Et2O. The crude solid was purified on silica (100 % 
EtOAc) to yield the desired acetamide 124 (501.6 mg, 69 %) as a white powder, mp = 98-99 °C. Rf = 0.33 (100 % 
EtOAc); νmax /cm-1 3286, 1637, 1552, 1509, 1465, 1432, 1419, 1374, 1355, 1304, 1281, 1214, 1160, 1092, 1018, 852, 
835, 827, 762, 726, 707, 600; δH (400 MHz, CDCl3) 7.23-7.18 (2H, m, ArH2’), 7.00-6.94 (2H, m, ArH3’), 5.99 (1H, 
bs, NH), 4.35 (2H, d, J 5.6, CH2Ar), 1.98 (3H, s, CH3); δC (101 MHz, CDCl3) 170.2, 162.4 (d, J 245, ArC4’), 134.3, 
129.7 (d, J 9, ArC2’), 115.7 (d, J 22, ArC3’), 43.2, 23.4; m/z (ESI) 168 [MH]+; found [MH]+ 168.0824 C9H11NOF 
requires 168.0825, Δ 0.6 ppm. Data in agreement with literature values.[289]  
N-(4-Methoxy-benzyl)-acetamide 125 
 
To a solution of p-methoxybenzylamine (0.50 mL, 3.83 mmol, 1.0 eq.) in Et2O (11.5 mL) was added Et3N (1.06 mL, 
7.65 mmol, 2.0 eq.) and the mixture cooled to 0 °C. Acetyl chloride (0.54 mL, 7.65 mmol, 2.0 eq.) was added 
dropwise to give immediate precipitation of a white solid. The reaction mixture was warmed to rt and stirred for a 
further 5 min. The reaction mixture was filtered under reduced pressure and the filter cake washed with Et2O. The 
crude light tan solid was purified on silica (gradient elution 1:1 to 1:0 EtOAc/n-hexane) to yield the desired amide 125 
(402.2 mg, 59 %) as a white solid, mp = 97-99 °C. Rf  = 0.25 (100 % EtOAc); νmax /cm-1 3281, 1628, 1611, 1552, 
1500, 1465, 1368, 1289, 1250, 1229, 1173, 1110, 1094, 1014, 807, 755, 746, 624, 603; δH (400 MHz, MeOD) 7.21-
7.18 (2H, m, ArH2’), 6.88-6.85 (2H, m, ArH3’), 4.27 (2H, s, NHCH2), 3.76 (3H, s, ArOCH3), 1.96 (3H, s, 
NHCOCH3); δC (101 MHz, MeOD) 173.1, 160.6, 132.1, 130.1, 115.1, 55.8, 43.9, 22.7; m/z (ESI) 180 [MH]+; found 
[MH]+ 180.1028 C10H14NO2 requires 180.1025, Δ 1.7 ppm. Data in agreement with literature values.[290]    
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1-(4-Phenyl-piperazin-1-yl)-ethanone 126 
 
To a solution of N-phenyl piperazine (0.50 mL, 3.27 mmol, 1.0 eq.) in Et2O (10 mL) was added Et3N (0.91 mL, 6.55 
mmol, 2.0 eq.) and the mixture cooled to 0 °C. Acetyl chloride (0.47 mL, 6.55 mmol, 2.0 eq.) was added dropwise to 
give immediate precipitation of a white solid. The mixture was warmed to rt and stirred for a further 5 min, filtered 
under reduced pressure and the filter cake washed with Et2O and dried under high vacuum. The crude yellow solid 
was purified on silica (100 % EtOAc) to yield the desired amide 126 (384.9 mg, 58 %) as a crystalline white solid, mp 
= 89-91 °C. Rf = 0.31 (100 % EtOAc); νmax /cm-1 2819, 1624, 1598, 1496, 1443, 1428, 1387, 1343, 1279, 1227, 1158, 
1001, 976, 908, 769, 699, 588; δH (400 MHz, MeOD) 7.27-7.22 (2H, m, ArH3’), 7.00-6.97 (2H, m, ArH2’), 6.89-6.84 
(1H, m, ArH4’), 3.73 (2H, t, J 5.0, piperazine-H3’), 3.68 (2H, t, J 5.0, piperazine-H3’), 3.18 (2H, t, J 5.0, piperazine-
H2’), 3.13 (2H, t, J 5.0, piperazine-H2’), 2.14 (3H, s, CH3); δC (101 MHz, MeOD) 171.8, 152.7, 130.3, 121.8, 118.1, 
51.2, 50.8, 47.6, 42.9, 21.3; m/z (ESI) 205 [MH]+; found [MH]+ 205.1341 C12H17N2O requires 205.1341, Δ 0 ppm. 
Data in agreement with literature values.[291]   
(±)-N-(1-Benzyl-piperidin-4-yl)-acetamide 127 
 
To 4-amino-N-benzyl piperadine (0.50 mL, 2.45 mmol, 1.00 eq.) in anhydrous CH2Cl2 (1.5 mL) at rt, under argon, 
was added acetic anhydride (0.24 mL, 2.57 mmol, 1.05 eq.) dropwise to bring to solution to reflux. The reaction was 
then refluxed for 1 h before cooling on ice and addition of 20 % aqueous NaOH. The layers were separated and the 
organic layer dried over MgSO4, filtered and the solvent removed in vacuo. The crude white solid was purified on 
silica (gradient elution, 2 % MeOH to 20 % MeOH in CH2Cl2) to yield the desired amide 127 (514.6 mg, 90 %) as a 
white solid, mp = 144-145 °C. Rf = 0.29 (CH2Cl2/MeOH, 24:1); νmax /cm-1 3263, 3082, 2940, 2806, 2762, 1633, 1557, 
1494, 1453, 1445, 1431, 1364, 1324, 1307, 1293, 1265, 1244, 1142, 1125, 1110, 1101, 1074, 1028, 1013, 982, 971, 
793, 738, 699, 613, 592; δH (400 MHz, CDCl3) 7.35-7.24 (5H, m, ArH), 5.66 (1H, bd, J 7.4, NH), 3.85-3.75 (1H, m, 
HNCH), 3.50 (2H, s, ArCH2), 2.85-2.82 (2H, m, piperidine-H2’), 2.15-2.09 (2H, m, piperidine-H2’), 1.97 (3H, s, 
NHCOCH3), 1.92-1.89 (2H, m, piperadine-H3’), 1.52-1.42 (2H, m, piperadine-H3’); δC (101 MHz, CDCl3) 100.5, 
92.6, 90.3, 90.1, 89.8, 73.7, 80.0, 69.6, 65.9, 63.8; m/z (ESI) 233 [MH]+; found [MH]+ 233.1652 C14H21N2O requires 
233.1654, Δ 0.9 ppm. Data in agreement with literature values.[292]    
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N-[1-(Toluene-4-sulfonyl)-(R)-pyrrolidin-2-ylmethyl]-acetamide 128  
 
To a solution of amine 72 (187.7 mg, 0.74 mmol, 1.0 eq.) and Et3N (0.12 mL, 0.89 mmol, 1.2 eq.) in anhydrous 
CH2Cl2 (5 mL) at 0 °C was added acetyl chloride (0.06 mL, 0.89 mmol, 1.2 eq.) dropwise and the reaction stirred at 0 
°C for 1 h. The reaction mixture was poured into brine and extracted with CH2Cl2 (x 2), dried over Na2SO4, filtered 
and the solvent removed in vacuo. The crude product was purified on silica (100 % EtOAc) to give the desired 
acetamide 128 (148.0 mg, 68 %) as a white powder, mp = 171-174 °C; [α]24D = + 90.0 (c = 0.67, CHCl3); Rf  = 0.29 
(100 % EtOAc); νmax /cm-1 3298, 1658, 1637, 1570, 1339, 1308, 1290, 1253, 1198, 1156, 1106, 1040, 977, 818, 727, 
709, 662, 602, 584; δH (400 MHz, CDCl3) 7.68 (2H, d, J 8.9, ArH3’), 7.31 (2H, d, J 8.9, ArH2’), 6.57 (1H, bs, NH), 
3.70-3.64 (1H, m, pyrrolidine-H2’), 3.50-3.39 (2H, m, NHCH2), 3.23-3.16 (2H, m, pyrrolidine-H5’), 2.42 (3H, s, 
ArCH3), 2.02 (3H, s, CH3CONH), 1.79-1.72 (1H, m, pyrrolidine-H4’), 1.61-1.41 (3H, m, pyrrolidine-H3’ and 
pyrrolidine-H4’); δC (101 MHz, CDCl3) 171.0, 144.2, 133.9, 130.1, 127.8, 59.7, 49.9, 44.2, 30.0, 24.3, 23.5, 21.8; m/z 
(ESI) 297 [MH]+, 319 [MNa]+; found [MH]+ 297.1263 C14H21N2O3S requires 297.1273, Δ 3.4 ppm. 
N-Benzyl-acetamide 129 
 
To benzylamine (0.50 mL, 4.58 mmol, 1.00 eq.) in anhydrous CH2Cl2 (3 mL) at rt under argon was added acetic 
anhydride (0.45 mL, 4.81 mmol, 1.05 eq.) dropwise bringing the reaction mixture to reflux. The colourless solution 
was further refluxed for 3 h before cooling on ice and addition of 20 % NaOH (aq.) dropwise. The aqueous and 
organic layers were separated and the aqueous layer extracted with CH2Cl2 (x 1). Combined organics were dried over 
MgSO4, filtered and the solvent removed in vacuo. The crude white solid was purified on silica (100 % EtOAc) to 
yield the desired acetamide 129 (512.6 mg, 71 %) as a white solid, mp = 64-65 °C; Rf = 0.38 (100 % EtOAc); νmax 
/cm-1 3294, 1640, 1632, 1543, 1498, 1452, 1375, 1353, 1280, 748, 716, 692; δH (400 MHz, CDCl3) 7.35-7.26 (5H, m, 
ArH), 6.43 (1H, bs, NH), 4.39 (2H, d, J 5.6, CH2), 1.98 (3H, s, CH3); δC (101 MHz, CDCl3) 170.2, 138.4, 128.7, 
127.8, 127.4, 43.6, 23.1; m/z (ESI) 150 [MH]+; found [MH]+ 150.0916 C9H12NO requires 150.0919, Δ 2.0 ppm. Data 
in agreement with literature values.[293]   
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4-(Acetylamino-methyl)-benzoic acid methyl ester 130 
 
To a solution of methyl 4-(aminomethyl) benzoate hydrochloride (1.00 g, 4.96 mmol, 1.0 eq.) in anhydrous THF (20 
mL) under argon was added Et3N (2.4 mL, 17.36 mmol, 3.5 eq.) and the mixture cooled to 0 °C before addition of 
acetyl chloride (0.35 mL, 4.96 mmol, 1.0 eq.) dropwise. The thick white precipitate was stirred for 24 h at rt before 
addition of 1 M HCl (aq.) and the mixture extracted with EtOAc (x 2). Combined organics were dried over MgSO4, 
filtered and the solvent removed in vacuo. The crude white solid was purified on silica (EtOAc/n-hexane, 4:1) to yield 
the desired acetamide 130 (666.7 mg, 65%) as a white powder. A small portion was recrystallised from EtOAc/n-
hexane to yield the desired acetamide 130 as colourless crystals, mp = 112-115 °C; Rf = 0.26 (EtOAc/n-hexane, 4:1); 
νmax /cm-1 3271 (NH), 1721 (ester C=O), 1643, 1632, 1612, 1555, 1435, 1416, 1378, 1274, 1236, 1194, 1181, 1171, 
1112, 1106, 1019, 752, 697; δH (400 MHz, CDCl3) 7.95 (2H, d, J 8.2, ArH2’), 7.29 (2H, d, J 8.2, ArH3’), 4.44 (2H, d, 
J 5.9, ArCH2), 3.87 (3H, s, COOCH3), 2.01 (3H, s, NHCOCH3); δC (101 MHz, CDCl3) 170.2, 166.9, 143.7, 130.1, 
129.4, 127.6, 52.2, 43.4, 23.3; m/z (ESI) 208 [MH]+; found [MH]+ 208.0963 C11H14NO3 requires 208.0974, Δ 5.3 
ppm.    
9.5. Oligo(ethyleneglycol) linker 
N-[2-(2-Hydroxy-ethoxy)-ethyl]-acrylamide 132 
 
To 2-(2-aminoethoxy)ethanol 133 (0.50 mL, 4.98 mmol, 1.0 eq.) in anhydrous CH2Cl2 (5 mL) at 0 °C was added 
acryloyl chloride (0.40 mL, 4.98 mmol, 1.0 eq.) and triethylamine (0.69 mL, 4.98 mmol, 1.0 equiv.) and the reaction 
mixture stirred at 0 °C for 15 min and at rt overnight. The solvent was removed from the reaction mixture and the 
crude residue purified on silica (100 % EtOAc) to yield the desired acrylamide 132 (527.2 mg, 67 %) as a clear oil. Rf  
= 0.13 (100 % EtOAc); νmax /cm-1 3282 (b), 2928, 2874, 1656, 1642, 1547, 1456, 1410, 1351, 1317, 1247, 1121, 1062, 
985, 961, 886, 805; δH (400 MHz, CDCl3) 7.41 (1H, bt, J 4.9, NH), 6.16 (1H, dd, J 17.1, J 2.4, CH2CHONH cis to 
C=O), 6.07 (1H, dd, J 17.1, J 10.0, CH2CHONH), 5.49 (1H, dd, J 10.0, J 2.4, CH2CHONH trans to C=O), 4.26 (1H, 
bs, OH), 3.61-3.59 (2H, m, OCH2CH2OH), 3.48-3.44 (4H, m, OCH2CH2NH and OCH2CH2OH), 3.42-3.38 (2H, m, 
OCH2CH2NH); δC (101 MHz, CDCl3) 166.2, 130.7, 126.3, 72.2, 69.5, 61.3, 39.3; m/z (ESI) 182 [MNa]+; found 
[MNa]+ 182.0790  C7H13NO3Na requires 182.0793, Δ 1.6 ppm.       
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[2-(2-Acryloylamino-ethoxy)-ethoxy]-acetic acid tert-butyl ester 134  
 
To amine 135 (100 mg, 0.46 mmol, 1.0 eq.) in anhydrous CH2Cl2 (5 mL) at 0 °C was added acryloyl chloride (0.06 
mL, 0.69 mmol, 1.5 eq.) and triethylamine (0.10 mL, 0.69 mmol, 1.5 eq.) and the bright yellow reaction mixture 
stirred under argon at 0 °C for 15 min and at rt overnight. H2O was added to the reaction mixture and the layers 
separated. The organic layer was dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue was 
purified on silica (100 % EtOAc) to give the desired acrylamide 134 (27.2 mg, 22 %) as a clear oil. Rf = 0.37 (100 % 
EtOAc); νmax /cm-1 1745, 1661, 1628, 1540, 1369, 1230, 1145, 1120; δH (400 MHz, CDCl3) 6.54 (1H, bs, NH), 6.26 
(1H, dd, J 17.3, J 1.8, CH2CHCONH cis to C=O), 6.15 (1H, dd, J 17.3, J 10.0, CH2CHCONH), 5.57 (1H, dd, J 10.0, J 
1.8, CH2CHCONH trans to C=O), 3.98 (2H, s, OCH2COOtBu), 3.67-3.62 (4H, m, CH2), 3.61-3.58 (2H, m, CH2), 
3.54-3.49 (2H, m, CH2), 1.45 (9H, s, tBu); δC (101 MHz, CDCl3) 169.7, 165.7, 131.1, 126.1, 81.9, 70.8, 70.0, 69.8, 
68.9, 39.2, 28.1; m/z (ESI) 296 [MNa]+; found [MNa]+ 296.1469 C13H23NO5Na requires 296.1474, Δ 1.7 ppm.   
[2-(2-Amino-ethoxy)-ethoxy]-acetic acid tert-butyl ester 135 
Method One: from monobenzylated amine 140 
 
To monobenzylamine 140 (1.38 g, 4.5 mmol, 1.0 eq.) in MeOH (25 mL) under argon was added Pd(OH)2/C (313 mg, 
cat.) all at once, and the mixture stirred at rt under a H2 (g) atmosphere for 3 days. The reaction mixture was filtered 
through celite and the solvent removed in vacuo to yield the desired amine 135 (1.0 g, 100 %) as a yellow oil.  
Method Two: from dibenzylated amine 139 
 
A mixture of dibenzylamine 139 (100 mg, 0.25 mmol, 1.0 eq.), Pd(OH)2/C (25 mg, cat.) and NH4.HCO2 (71.3 mg, 
1.13 mmol, 4.5 eq.) in MeOH (5 mL) was heated to 75 °C for 24 h. The reaction mixture was allowed to cool to rt, 
filtered through celite and the solvent removed in vacuo to yield the desired amine 135 (55.0 mg, 100 %) as a clear 
oil. Rf = 0 (100 % EtOAc); νmax /cm-1 3399 (NH), 2513, 1735, 1457, 1370, 1240, 1141, 1112; δH (400 MHz, MeOD) 
4.08 (2H, s, NH2), 3.78-3.72 (8H, m, 3 x CH2 and OCH2COOtBu), 3.18-3.15 (2H, m, CH2), 1.52 (9H, s, tBu); δC (101 
MHz, MeOD) 170.3, 81.6, 70.4, 69.8, 69.0, 68.3, 39.9, 27.0; m/z (ESI) 220 [MH]+; found [MH]+ 220.1548 C10H22NO4 
requires 220.1549, Δ 0.5 ppm.      
O ON
H
O
O
OO OH2N
O
O
135 134
N
H
O O
O
O
140
H2N
O O
O
O
135
N
O O
O
O
139
H2N
O O
O
O
135
 Chapter Nine Organic chemistry experimental 
  183 
2-(2-Dibenzylamino-ethoxy)-ethanol 136 
 
A procedure reported by Visintin et al. was used with some modifications.[190] A mixture of 2-(2-aminoethoxy)ethanol 
(5.00 mL, 49.8 mmol, 1.0 eq.), potassium carbonate (17.21 g, 124.5 mmol, 2.5 eq.) and benzyl bromide (11.83 mL, 
99.6 mmol, 2.0 eq.) in MeCN (250 mL) was stirred at 50 °C for 20 h. The solid was filtered under reduced pressure 
and the solvent removed from the filtrate. The residue was dissolved in HCl (0.1 M) and washed with EtOAc (2 x 25 
mL). The aqueous layer was basified with NaOH and extracted with CH2Cl2 (4 x 25 mL). The combined CH2Cl2 
layers were washed with H2O (x 1), added to the EtOAc layers, and combined organics dried over MgSO4, filtered 
and the solvent removed in vacuo to yield the desired dibenzylamino alcohol 136 (10.10 g, 71 %) as a clear oil. Rf  = 
0.64 (100 % EtOAc); νmax /cm-1 1495, 1453, 1367, 1244, 1119, 1049, 1027, 744, 732, 696; δH (400 MHz, CDCl3) 7.50 
(4H, d, J 7.6, ArH2’), 7.43 (4H, t, J 7.6, ArH3’), 7.34 (2H, t, J 7.6, ArH4’), 3.76-3.74 (6H, m, ArCH2N and 
OCH2CH2OH), 3.67 (2H, t, J 6.2, NCH2CH2O), 3.55 (2H, t, J 4.9, HOCH2CH2O), 3.35 (1H, bs, OH) 2.80 (2H, t, J 
6.2, NCH2CH2O); δC (101 MHz, CDCl3) 139.2, 128.8, 128.2, 126.9, 72.1, 69.4, 61.6, 58.8, 52.8; m/z (ESI) 286 [MH]+; 
found [MH]+ 286.1805 C18H24NO2 requires 286.1807, Δ 0.7 ppm.      
[2-(2-Dibenzylamino-ethoxy)-ethoxy]-acetic acid 137  
 
A procedure reported by Visintin et al. was used with some modifications.[190] 2-[(Dibenzylamino)ethoxy]ethanol 136 
(2.00 g, 7.0 mmol, 1.0 eq.) was dissolved in anhydrous THF (15 mL) before cooling to 0 °C and addition of NaH 
(1.12 g, 28.0 mmol, 4.0 eq.) portionwise followed by α-bromoacetic acid (1.46 g, 10.5 mmol, 1.5 eq.) and the 
suspension refluxed under argon overnight. Water (0.5 mL) was added dropwise and the reaction stirred for a further 
5 min before addition of further water (15 mL) and extraction with Et2O:n-hexane (1:1) (16 mL x 2). The aqueous 
layer was acidified to pH 2-3 with 1M HCl and extracted with Et2O (7 mL x 3). The aqueous layer was then basified 
to pH 6-7 with saturated NaOH and then saturated with NaCl before extraction with CH2Cl2 (4 x 20 mL) and CHCl3 
(4 x 20 mL). Chlorinated organics were combined and the solvent removed in vacuo to give the desired carboxylic 
acid 137 (1.53 g, 63 %) as an oily white solid. Rf  = 0 (100 % EtOAc); νmax /cm-1 3400 (b), 1601, 1495, 1454, 1427, 
1324, 1250, 1108, 1028, 751, 736, 700; δH (400 MHz, MeOD) 7.49-7.47 (4H, m, ArH2’), 7.41-7.33 (6H, m, ArH3’ 
and ArH4’), 4.07 (4H, s, ArCH2N), 3.93 (2H, s, OCH2COOH), 3.67 (2H, t, J 5.7, NCH2CH2O), 3.63-3.56 (4H, m, 
OCH2CH2O), 2.99 (2H, t, J 5.7, NCH2CH2O); δC (101 MHz, MeOD) 177.3, 135.6, 131.6, 130.0, 129.8, 79.6, 71.3, 
71.2, 68.1, 59.6, 53.1; m/z (ESI) 344 [MH]+; found [MH]+ 344.1848  C20H26NO4 requires 344.1862, Δ 4.1 ppm.      
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[2-(2-Amino-ethoxy)-ethoxy]-acetic acid 138 
 
A procedure reported by Visintin et al. was used with some modifications.[190] Dibenzyl amine 137 (1.42 g, 4.12 
mmol, 1.0 eq.) was dissolved in MeOH (17 mL), palladium on carbon (10 %) (710 mg, cat.) was added and the 
mixture stirred under a H2 atmosphere for 20 h at 45 °C. The reaction mixture was filtered through celite and the 
solvent removed in vacuo. The crude residue was dried under high vacuum to yield the desired amine 138 (657 mg, 
98 %) as a white residue. Rf  = 0 (100 % EtOAc); νmax /cm-1 3370 (b), 2918, 1586, 1411, 1323, 1094, 1026, 704; δH 
(400 MHz, MeOD) 3.90 (2H, s, OCH2COOH), 3.71-3.65 (6H, m, OCH2CH2OCH2CH2NH2), 3.07 (2H, t, J 5.0, 
H2NCH2); δC (101 MHz, MeOD) 178.0, 71.6, 71.0, 71.0, 69.3, 40.7; m/z (ESI) 164 [MH]+; found [MH]+ 164.0916  
C6H14NO4 requires 164.0923, Δ 4.3 ppm.   
(2-(2-[Benzyl-(2-methylene-pent-3-enyl)-amino]-ethoxy)-ethoxy)-acetic acid tert-butyl ester 139 
 
To a solution of alcohol 136 (2.10 mL, 8.18 mmol, 1.0 eq.) in anhydrous THF (12 mL) at 0 °C was added KOtBu (1.0 
M solution in THF, Sigma-Aldrich SureSeal, 12.26 mL, 12.26 mmol, 1.5 eq.) and bromo-acetic acid tert-butyl ester 
(1.81 mL, 12.26 mmol, 1.5 eq.) and the thick yellow suspension stirred at 0 °C for 3 h. H2O (5 mL) was added to 
quench the reaction before addition of further H2O and CH2Cl2. The layers were separated and the aqueous layer 
washed with further CH2Cl2. Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. 
Purification of the crude product on silica (n-hex/EtOAc, 3:1), combination of appropriate fractions, and repurification 
of the partially pure product on silica (n-hex/EtOAc, 5:1) yielded the desired tertbutyl ester 139 (2.44 g, 75 %) as a 
clear oil. Rf = 0.41 (n-hex/EtOAc, 3:1); νmax /cm-1 1747, 1495, 1454, 1367, 1301, 1249, 1226, 1141, 1116, 1028, 844, 
744, 733, 698; δH (400 MHz, CDCl3) 7.40 (4H, d, J 7.3, ArH2’), 7.33 (4H, t, J 7.3, ArH3’), 7.25 (2H, t, J 7.3, ArH4’), 
4.04 (2H, s, OCH2COOtBu), 3.71-3.69 (2H, m, CH2), 3.68 (4H, s, ArCH2N), 3.63-3.59 (4H, m, CH2), 2.73 (2H, t, J 
6.3, NCH2CH2O), 1.50 (9H, s, tBu); δC (101 MHz, CDCl3) 176.6, 146.7, 135.6, 135.1, 133.7, 88.4, 84.3, 83.9, 83.6, 
75.9, 65.8, 59.6, 35.0; m/z (ESI) 400 [MH]+, 422 [MNa]+; found [MH]+ 400.2481 C24H34NO4 requires 400.2488, Δ 1.7 
ppm.   
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[2-(2-Benzylamino-ethoxy)-ethoxy]-acetic acid tert-butyl ester 140 
 
To dibenzylamine 139 (2.44 g, 6.1 mmol, 1.0 eq.) in MeOH (25 mL) under argon was added Pd/C (740 mg, cat.) and 
the mixture stirred for 20 h at 45 °C under an atmosphere of H2 (g). The reaction mixture was filtered through celite 
and the solvent removed in vacuo to yield the monobenzylated amine 140 (1.9 g, 100 %) as a white wax. Rf = 0.81 
(CH2Cl2/MeOH, 2:1); δH (400 MHz, MeOD) 7.53-7.45 (5H, m, ArH), 4.27 (2H, s, NHCH2Ph), 4.04 (2H, s, 
OCH2COOtBu), 3.81-3.79 (2H, m, CH2), 3.72-3.70 (4H, m, 2 x CH2), 3.27-3.25 (2H, m, CH2), 1.47 (9H, s, tBu); δC 
(101 MHz, MeOD) 170.3, 131.1, 129.7, 129.3, 128.9, 81.8, 70.4, 69.7, 68.1, 65.2, 50.7, 46.6, 26.9.   
(±)-2-Phenylselanyl-propionic acid ethyl ester 142 
 
Using an adaption of a literature method,[294] NaBH4 (454 mg, 12 mmol, 3.00 equiv.) was added portionwise to a 
solution of diphenyldiselenide (1.25 g, 4.0 mmol, 1.00 eq.) in EtOH (30 mL) at 0 °C  to give vigorous evolution of H2 
(g). The resulting bright yellow precipitate was stirred at 0 °C under argon to give a cloudy grey suspension. Ethyl 2-
(bromo)propionate 141 (1.30 mL, 10.0 mmol, 1.25 eq.) was added dropwise and the mixture stirred at 0 °C for 1 h and 
allowed to warm to rt. The reaction was quenched by dropwise addition of water and extracted with ether. The ether 
layer was washed with water, brine, dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue 
was purified on silica (n-hex/EtOAc, 4:1) to yield the desired ester 142 (1.78 g, 87 %) as a clear oil. Rf = 0.47 
(EtOAc/n-hex, 1:5); νmax /cm-1 1725, 1477, 1439, 1369, 1325, 1254, 1207, 1145, 1066, 1057, 1021, 740, 692; δH (400 
MHz, CDCl3) 7.59-7.57 (2H, m, ArH), 7.34-7.24 (3H, m, ArH), 4.07 (2H, q, J 7.3, COOCH2CH3), 3.75 (1H, q, J 7.0, 
EtOCOCH), 1.52 (3H, d, J 7.0, EtOCOCH(SePh)CH3), 1.15 (3H, t, J 7.3, COOCH2CH3); δC (101 MHz, CDCl3) 
173.7, 136.0, 129.2, 128.7, 128.1, 61.2, 37.6, 17.8, 14.2; m/z (CI) 276 [MNH4]+. Data in agreement with literature 
values.[294]  
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(±)-N-[2-(2-Hydroxy-ethoxy)-ethyl]-2-phenylselanyl-propionamide 143 
Method One 
 
To a solution of carboxylic acid 145 (103.9 mg, 0.45 mmol, 1.00 eq.) in anhydrous THF (1 mL) was added oxalyl 
chloride (0.04 mL, 0.48 mmol, 1.05 eq.) and a drop of DMF (cat.) and the reaction stirred at room temperature under 
argon for 10 minutes, at which point all effervescence ceased. The resultant mixture was added dropwise to a stirred 
solution of 2-(2-aminoethoxy)ethanol (0.07 mL, 0.68 mmol, 1.5 eq.) and Et3N (0.16 mL, 1.13 mmol, 2.5 eq.) in THF 
(1 mL) to give vigorous evolution of gas. The resulting thick white precipitate was stirred under argon at rt for 3 h 
before loading directly onto a silica column (100 % EtOAc) to give the desired amide 143 (88.2 mg, 63 %) as a clear 
oil and bis-acetylated 146 (15.9 mg, 14 %) as a yellow oil.  
(±)-N-[2-(2-Hydroxy-ethoxy)-ethyl]-2-phenylselanyl-propionamide 143 
 
Rf = 0.19 (100 % EtOAc); νmax /cm-1 3291 (b), 1643, 1546, 1477, 1438, 1371, 1351, 1245, 1122, 1064, 1022, 886, 739, 
691; δH (400 MHz, CDCl3) 7.56-7.55 (2H, m, ArH), 7.33-7.26 (3H, m, ArH), 6.63 (1H, bt, NH), 3.77 (1H, q, J 7.2, 
NHCOCH), 3.69 (2H, t, J 4.4, CH2), 3.51-3.49 (2H, m, CH2), 3.46-3.45 (2H, m, CH2), 3.41-3.38 (2H, m, CH2), 2.74 
(1H, bs, OH), 1.58 (3H, d, J 7.2, CH3); δC (101 MHz, MeOD) 172.8, 134.9, 129.3, 128.5, 128.4, 72.3, 69.8, 61.8, 40.8, 
39.7, 18.4; m/z (ESI) 318 [MH]+, 340 [MNH4]+; found [MH]+ 318.0616 C13H20NO380Se requires 318.0608, Δ 2.5 ppm.   
(±)-2-Phenylselanyl-propionic acid 2-[2-(2-phenylselanyl-propionylamino)-ethoxy]-ethyl ester 146 
 
Rf = 0.19 (100 % EtOAc); δH (400 MHz, CDCl3) 7.64-7.55 (4H, m, ArH), 7.38-7.27 (6H, m, ArH), 6.40 (1H, s, NH), 
4.20 (2H, m, CH2), 3.38-3.74 (2H, m, CH3CH(SePh)CONH and CH3CH(SePh)COO), 3.56-3.52 (2H m, CH2), 3.45-
3.35 (4H, m, CH2), 1.61-1.54 (6H, m, 2 x CH3).  
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Method Two 
 
To a solution of carboxylic acid 145 (11.26 g, 49.1 mmol, 1.0 eq.) in anhydrous THF (75 mL) under argon at 0 °C was 
added oxalyl chloride (4.2 mL, 49.1 mmol, 1.0 eq.) dropwise and a few drops of DMF (cat.) and the reaction allowed 
to warm to rt and stirred for 2 h.  
To a stirred solution of  2-(2-aminoethoxy)ethanol (9.9 mL, 98.3 mmol, 2.0 eq.) in THF (75 mL) at 0 °C under argon 
was added Et3N (10.2 mL, 73.7, 1.5 eq.) and the acid chloride solution dropwise. The thick white precipitate was 
stirred overnight before quenching by dropwise addition of H2O. The layers were separated and the aqueous further 
washed with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. 
The resulting yellow oil was dissolved in EtOH (100 mL) before addition of 30 % aqueous KOH (100 mL) dropwise 
and stirring at rt for 15 min. The EtOH was removed in vacuo and the aqueous layer washed with CH2Cl2 (x 2). 
Combined organics were washed with 5 % aq. KOH, dried over MgSO4, filtered and the solvent removed in vacuo to 
give the desired amide 143 (12.19 g, 79 %) as a clear oil. Data in agreement with above.  
 (±)-(2-[2-(2-Phenylselanyl-propionylamino)-ethoxy]-ethoxy)-acetic acid 144 
 
To a solution of alcohol 143 (798.8 mg, 2.53 mmol, 1.1 eq.) and freshly recrystallised iodoacetic acid (427.0 mg, 2.30 
mmol, 1.0 eq.) in anhydrous THF (20 mL) was added 60% NaH in mineral oil (368.0 mg, 9.20 mmol, 4.0 eq.) 
portionwise and the reaction stirred at rt for 16 h. The white suspension was quenched with H2O (8 mL) and extracted 
with Et2O (x 4) and CH2Cl2 (x 3). The aqueous layer was acidified to pH 1 with 1 M aqueous HCl and extracted with 
Et2O (x 6). Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue 
was dissolved in CH2Cl2, dried over MgSO4, filtered and the solvent removed in vacuo to yield the desired carboxylic 
acid 144 (537 mg, 63 %) as a yellow oil. Rf = 0 (100 % EtOAc); νmax /cm-1 1730, 1634, 1533, 1437, 1372, 1356, 1213, 
1147, 1107, 1022, 741, 692; δH (400 MHz, CDCl3) 10.11 (1H, bs, COOH), 7.58-7.55 (2H, m, ArH), 7.33-7.26 (3H, m, 
ArH), 6.71 (1H, bt, J 5.4, NH), 4.14 (2H, s, HOOCCH2), 3.84 (1H, q, J 7.4, CH3CH(SePh)CONH), 3.70-3.68 (2H, m, 
CH2), 3.60-3.59 (2H, m, CH2), 3.49-3.47 (2H, m, CH2), 3.41-3.39 (2H, m, CH2), 1.61-1.56 (3H, d, J 7.4  
CH3CH(SePh)CONH); δC (101 MHz, CDCl3) 173.2, 173.1, 134.9, 129.2, 128.3, 128.3, 71.0, 70.1, 69.7, 68.4, 40.5, 
39.6, 18.2; m/z (ESI) 376 [MH]+, 398 [MNa]+; found [MH]+ 376.0661 C15H22NO580Se requires 376.0663, Δ 0.5 ppm.   
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(±)-2-Phenylselanyl-propionic acid 145 
 
KOH (30 % aqueous, 40 mL) was added to a solution of ester 142 (1.77 g, 6.88 mmol, 1.0 eq.) in EtOH (40 mL) at rt. 
After 1 h, H2O and ether were added to the reaction mixture and the layers separated. The aqueous layer was acidified 
to pH 1 with conc. HCl and extracted with ether (x 2). Combined organics from both extractions were dried over 
MgSO4, filtered and the solvent removed in vacuo to yield the desired carboxylic acid 145 (1.28 g, 81 %) as a white 
crystalline solid, mp = 46-48 °C. Rf = 0 (100 % EtOAc); νmax /cm-1 1683, 1473, 1449, 1428, 1378, 1330, 1299, 1243, 
1078, 1062, 1019, 999, 948, 910, 861, 734, 686, 662, 576; δH (400 MHz, MeOD) 7.62-7.60 (2H, m, ArH), 7.36-7.28 
(3H, m, ArH), 3.77 (1H, q, J 7.1, HOOCH), 1.49 (3H, d, J 7.1, CH3); δC (101 MHz, MeOD) 177.3, 136.7, 130.2, 
129.6, 129.5, 38.7, 18.5; m/z (ESI) 157 [PhSe]-, 229 [M-H]-; found [M-H]- 228.9776 C9H9O2Se requires 228.9768, Δ 
3.5 ppm.   
Allyloxymethyl-benzene 149  
 
A procedure reported by Westwood et al. was used.[192] To a suspension of NaH (160 mg, 4.00 mmol, 1.1 eq.) in 
anhydrous THF (4 mL) was added benzyl alcohol (0.38 mL, 3.64 mmol, 1.0 eq.) and the reaction stirred at rt under 
argon for 2 h. Allyl bromide (0.35 mL, 4.00 mmol, 1.1 eq.) was then added dropwise and the suspension stirred 
overnight at rt. The reaction was quenched with H2O and extracted with Et2O (x 3). Combined organics were dried 
over MgSO4, filtered and the solvent removed in vacuo. Coversion to product was measured using the benzyl CH2 
peaks in the 1H NMR for starting material and product. Conversions of 60, 61 and 61 % were measured for the three 
sources of NaH tested with recovered masses of 475.3, 489.9 and 486.1 mg respectively. δH (400 MHz, CDCl3) 7.39-
7.28 (10 H, m, ArH (benzyl alcohol) and ArH (149)), 6.04-6.95 (1H, m, OCH2CH), 5.35 (1H, dq, J 17.4, J 1.7, 
OCH2CHCH2 cis to CH2O (149)), 5.25 (1H, dq, J 10.2, J 1.2, OCH2CHCH2 trans to CH2O (149)), 4.63 (2H, s, PhCH2 
(benzyl alcohol)), 4.55 (2H, s, PhCH2 (149)), 4.06 (2H, dt, J 5.6, J 1.3, OCH2CHCH2 (149)). Data in agreement with 
literature values.[295]    
(±)-N-(2-(2-[(1-Benzyl-piperidin-4-ylcarbamoyl)-methoxy]-ethoxy)-ethyl)-2-phenylselanyl-propionamide 150 
 
A solution of carboxylic acid 144 (415.0 mg, 1.11 mmol, 1.0 eq.), 4-aminobenzyl piperidine (0.23 mL, 1.11 mmol, 
1.0 eq.) and bis(cyclopentadienyl)zirconium(IV) dichloride (16.0 mg, 5 mol%) in anhydrous toluene (30 mL) was 
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heated at reflux under argon for 12 h. The reaction mixture was allowed to cool to rt and filtered. The solvent was 
removed from the filtrate to yield the desired amide 150 (567.7 mg, 94 %) as a yellow oil. Rf = 0.53 (CH2Cl2/MeOH, 
9:1); νmax /cm-1 3294 (NH), 2939, 2807, 2243, 1657, 1629, 1533, 1452, 1241, 1138, 1104, 985, 909, 726, 698; δH (400 
MHz, CDCl3, mixture of diastereomers) 7.55-7.53 (2H, m, ArH), 7.31-7.20 (6H, m, ArH), 6.66-6.64 (2H, m, ArH), 
3.94 (2H, s, OCH2CONH), 3.86-3.76 (1H, m, piperidine-H4’), 3.79 (1H, q, J 7.1, CH3CH(SePh)CONH), 3.62-3.59 
(2H, m, CH2), 3.55-3.52 (2H, m, CH2), 3.47 (2H, s, piperidine-NCH2Ar), 3.47-3.45 (2H, m, CH2), 3.42-3.38 (2H, m, 
CH2), 2.81-2.79 (2H, m, piperidine-H2’), 2.11-2.06 (2H, m, piperidine-H2’), 1.88-1.85 (2H, m, piperidine-H3’), 1.57 
(3H, d, J 7.1, CH3CH(SePh)CONH), 1.51-1.42 (2H, m, piperidine-H3’); δC (101 MHz, CDCl3) 172.5, 169.1, 138.3, 
134.6, 129.2, 129.0, 128.4, 128.2, 128.2, 127.0, 70.8, 70.5, 70.1, 69.8, 63.0, 52.2, 46.0, 40.5, 39.4, 32.2, 18.4; m/z 
(ESI) 548 [MH]+, 570 [MNa]+; found [MH]+ 548.2015 C27H38N3O480Se requires 548.2028, Δ 2.4 ppm. 
(±)-N-(2-(2-[2-Oxo-2-(4-phenyl-piperazin-1-yl)-ethoxy]-ethoxy)-ethyl)-2-phenylselanyl-propionamide 151 
 
A solution of carboxylic acid 144 (414.0 mg, 1.11 mmol, 1.0 eq.), bis(cyclopentadienyl)zirconium(IV) dichloride 
(16.2 mg, 5 mol%) and N-phenylpiperazine (0.17 mL, 1.11 mmol, 1.0 eq.) in anhydrous toluene (30 mL) was heated 
to reflux under argon for 24 h. The pink coloured solution was filtered under reduced pressure and the solvent 
removed from the filtrate in vacuo. The crude residue was purified on silica (CH2Cl2/MeOH, 19:1) to yield the desired 
amide 151 (429.8 mg, 75 %) as a yellow oil. Rf = 0.28 (CH2Cl2/MeOH, 19:1); νmax /cm-1 3298 (NH), 2917, 2865, 
2822, 1641 (C=O), 1598, 1541, 1496, 1476, 1437, 1229, 1149, 1117, 1097, 1023, 758, 742, 691; δH (400 MHz, 
CDCl3) 7.58-7.56 (2H, m, ArH), 7.32-7.25 (4H, m, ArH), 6.93-6.90 (4H, m, ArH), 4.24 (2H, s, OCH2CON), 3.85 (1H, 
q, J 7.2, CH3CH(SePh)CONH), 3.75-3.72 (2H, m, CH2), 3.69-3.66 (2H, m, CH2), 3.64-3.59 (4H, m, CH2), 3.52-3.45 
(2H, m, CH2), 3.43-3.39 (2H, m, CH2), 3.18-3.13 (4H, m, CH2), 1.59 (3H, d, J 7.2, CH3CH(SePh)CONH); δC (101 
MHz, CDCl3, dept90, dept135, hmqc) 172.5 (C), 167.6 (C), 150.7 (C), 134.7 (CH), 129.2 (CH), 129.0 (CH), 128.4 
(C), 128.0 (CH), 120.5 (CH), 116.5 (CH), 70.5 (CH2), 70.1 (CH2), 69.6 (CH2), 49.6 (CH2), 49.2 (CH2), 44.7 (CH2), 
41.6 (CH2), 40.4 (CH), 39.4 (CH2), 18.4 (CH3); m/z (ESI) 520 [MH]+, 542 [MNa]+; found [MH]+ 520.1691 
C25H34N3O480Se requires 520.1715, Δ 4.6 ppm. 
(±)-N-(2-(2-[(4-Methoxy-benzylcarbamoyl)-methoxy]-ethoxy)-ethyl)-2-phenylselanyl-propionamide 153 
 
To a solution of carboxylic acid 144 (362.6 mg, 0.97 mmol, 1.0 eq.), DCC (299.2 mg, 1.45 mmol, 1.5 eq.) and HOBt 
(261.8 mg, 1.94 mmol, 2 eq.) in anhydrous CH2Cl2 (10 mL) under argon was added p-methoxybenzyl amine (0.15 
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mL, 1.16 mmol, 1.2 eq.) and the reaction stirred at rt for 3 h. The reaction mixture was filtered and the solvent 
removed from the filtrate in vacuo. The crude residue was resuspended in acetonitrile and filtered. The solvent was 
removed from the filtrate and the residue dissolved in CH2Cl2 and washed with 1 M HCl (x 1), sat. aq. NaHCO3 (x 1), 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue was purified on silica 
(CH2Cl2/MeOH, 19:1) and the resulting product suspended in acetonitrile and filtered. The solvent was removed from 
the filtrate to yield the desired amide 153 (330.7 mg, 69 %) as a clear oil. Rf = 0.50 (CH2Cl2/MeOH, 9:1); νmax /cm-1 
3304 (NH), 2929, 2869, 1646 (C=O), 1612, 1532, 1512, 1476, 1456, 1437, 1244, 1176, 1109, 1031, 815, 740, 692; δH 
(400 MHz, CDCl3) 7.51-7.48 (2H, m, ArH), 7.29-7.15 (5H, m, ArH), 6.82-6.79 (2H, m, ArH), 6.47 (1H, bt, J 5.2, 
NH), 4.37-4.35 (2H, m, ArCH2), 3.97 (2H, s, OCH2CONH), 3.73 (3H, s, OCH3), 3.69 (1H, q, J 7.2, 
CH3CH(SePh)CONH), 3.59-3.57 (2H, m, CH2), 3.48-3.46 (2H, m, CH2), 3.34-3.31 (2H, m, CH2), 3.23 (2H, q, J 3.9, 
CH2), 1.51 (3H, d, J 7.2, CH3CH(SePh)CONH); δC (101 MHz, CDCl3, dept135, dept90) 171.9 (C), 169.1 (C), 158.2 
(C), 134.0 (CH), 131.4 (C), 129.1 (CH), 128.7 (CH), 128.7 (C), 127.7 (CH), 113.6 (CH), 70.2 (CH2), 70.0 (CH2), 69.4 
(CH2), 68.9 (CH2), 55.0 (CH3), 41.1 (CH2), 39.5 (CH), 38.7 (CH2), 18.8 (CH3); m/z (ESI) 495 [MH]+, 517 [MNa]+; 
found [MH]+ 495.1390 C23H31N2O5Se requires 495.1398, Δ 1.6 ppm.     
(±)-N-(2-[2-(Benzylcarbamoyl-methoxy)-ethoxy]-ethyl)-2-phenylselanyl-propionamide 154 
 
To carboxylic acid 144 (227.8 mg, 0.61 mmol, 1.0 eq.), DCC (188.4 mg, 0.91 mmol, 1.5 eq.) and HOBt (164.8 mg, 
1.22 mmol, 2.0 eq.) in anhydrous CH2Cl2 (20 mL) was added benzylamine (0.08 mL, 0.73 mmol, 1.2 eq.) and the 
mixture stirred at rt for 3 h. The reaction mixture was filtered under reduced pressure and the filtrate washed with 1M 
aqueous HCl, sat. NaHCO3, dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue was 
purified on silica (gradient elution, 100 % CH2Cl2 to 95:5 CH2Cl2/MeOH) and the resulting residue suspended in 
MeCN and filtered to remove the urea. The desired amide 154 (256.9 mg, 91 %) was isolated as a clear oil. Rf = 0.48 
(CH2Cl2/MeOH, 9:1); νmax /cm-1 1638, 1454, 1436, 1356, 1248, 1106, 1022, 1000, 739, 693; δH (400 MHz, CDCl3) 
7.53-7.50 (2H, m, ArH), 7.33-7.22 (8H, m, ArH), 4.45 (2H, s, OCH2CONH), 4.02 (2H, s, NHCH2Ph), 3.69 (1H, q, J 
7.2, CH3CH(SePh)CONH), 3.62-3.60 (2H, m, CH2), 3.51-3.49 (2H, m, CH2), 3.34 (2H, t, J 5.2, CH2), 3.24-3.21 (2H, 
m, CH2), 1.53 (3H, d, J 7.2, CH3CH(SePh)CONH); δC (101 MHz, MeOD) 172.3, 169.8, 138.0, 134.6, 129.2, 128.7, 
128.4, 128.2, 127.7, 127.5, 70.9, 70.5, 70.0, 69.7, 42.7, 40.4, 39.2, 18.3; m/z (ESI) 465 [MH]+; found [MH]+ 465.1288 
C22H29N2O4Se requires 465.1293, Δ 1.1 ppm.    
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(±)-N-(2-(2-[(4-Fluoro-benzylcarbamoyl)-methoxy]-ethoxy)-ethyl)-2-phenylselanyl-propionamide 155 
 
A solution of carboxylic acid 144 (434.4 mg, 1.16 mmol, 1.0 eq.), p-fluorobenzylamine (0.13 mL, 1.16 mmol, 1.0 eq.) 
and bis(cyclopentadienyl)zirconium(IV) dichloride (17 mg, 5 mol%) in anhydrous toluene (30 mL) was heated to 
reflux under argon for 4 h. The reaction mixture was allowed to cool to rt and filtered. The solvent was removed from 
the filtrate to yield the desired amide 155 (525.2 mg, 94 %) as a clear oil. Rf  = 0.14 (CH2Cl2/MeOH, 19:1); νmax /cm-1 
3304 (NH), 3068, 2925, 2866, 1646 (C=O), 1531 (NH), 1508 (NH), 1437, 1219, 1100 (C-F), 824, 740, 692; δH (400 
MHz, CDCl3) 7.56-7.52 (2H, m, ArH), 7.33-7.23 (5H, m, ArH), 7.18 (1H, bt, NH), 7.04-6.98 (2H, m, ArH), 6.40 (1H, 
bt, NH), 4.49-4.40 (2H, m, ArCH2), 4.05 (2H, s, NHCOCH2O), 3.74 (1H, q, J 7.1, CH3CH(SePh)CONH), 3.66-3.64 
(2H, m, CH2), 3.55-3.53 (2H, m, CH2), 3.40 (2H, t, J 5.0, CH2), 3.36-3.26 (2H, m, CH2), 1.57 (3H, d, J 7.1, 
CH3CH(SePh)CONH); δC (101 MHz, CDCl3) 172.4, 169.9, 163.3, 160.9, 134.5, 134.0, 129.5, 129.4, 129.2, 128.3, 
128.2, 115.6, 115.4, 70.9, 70.5, 70.0, 69.8, 42.0, 40.6, 39.4, 18.3; m/z (ESI) 483 [MH]+, 505 [MNa]+; found [MH]+ 
483.1221 C22H28N2O4FSe requires 483.1198, Δ 4.8 ppm.     
(±)-4-[(2-(2-[2-(2-Phenylselanyl-propionylamino)-ethoxy]-ethoxy)-acetylamino)-methyl]-benzoic acid methyl ester 
156 
 
A solution of carboxylic acid 144 (390.0 mg, 1.04 mmol, 1.0 eq.), methyl 4-(aminomethyl)benzoate hydrochloride 
(209.7 mg, 1.04 mmol, 1.0 eq.) and bis(cyclopentadienyl)zirconium(IV) dichloride (15.2 mg, 5 mol%) in anhydrous 
toluene (30 mL) was heated at reflux under argon for 12 h. The reaction mixture was allowed to cool to rt and filtered. 
The crude residue was purified on silica (CH2Cl2/MeOH, 19:1) and re-purified on silica (CH2Cl2/MeOH, 97:3) to 
yield the desired amide 156 (123.3 mg, 23 %) as a brown oil. Rf  = 0.22 (CH2Cl2/MeOH, 19:1); νmax /cm-1 3308 (b), 
2921, 1718, 1648, 1612, 1529, 1435, 1416, 1278, 1105; δH (400 MHz, CDCl3) 7.98 (2H, d, J 8.3, ArH), 7.52-7.50 
(2H, m, ArH), 7.36-7.23 (5H, m, ArH), 6.39 (1H, bt, J 5.8, NH), 4.57-4.47 (2H, m, CONHCH2Ar), 4.05 (2H, s, 
OCH2CONH), 3.90 (3H, s, ArCOOCH3), 3.71 (1H, q, J 7.1, PhSeCH), 3.66-3.64 (2H, m, CH2), 3.55-3.52 (2H, m, 
CH2), 3.38 (2H, t, J 5.4, CH2), 3.31-3.26 (2H, m, CH2), 1.54 (3H, d, J 7.1, CH3CH(SePh)CONH); δC (101 MHz, 
CDCl3) 172.4, 170.0, 166.8, 143.4, 134.6, 130.0, 129.3, 129.2, 128.3, 128.2, 127.5, 71.0, 70.6, 70.0, 69.8, 52.2, 42.4, 
40.6, 39.4, 18.3; m/z (ESI) 523 [MH]+, 545 [MNa]+; found [MH]+ 523.1356 C24H31N2O680Se requires 523.1347, Δ 1.7 
ppm.       
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(±)-N-(2-[2-(([1-(Toluene-4-sulfonyl)-pyrrolidin-2-(R)-ylmethyl]-carbamoyl)-methoxy)-ethoxy]-ethyl)-acrylamide 157 
 
A solution of carboxylic acid 144 (89.5 mg, 0.24 mmol, 1.0 eq.), amine 72 (60.8 mg, 0.24 mmol, 1.0 eq.) and 
bis(cyclopentadienyl)zirconium(IV) dichloride (3.5 mg, 5 mol%) in anhydrous toluene (25 mL) was refluxed for 18 h 
under argon. The mixture was allowed to cool and filtered under reduced pressure. The solvent was removed from the 
filtrate in vacuo to yield the desired amide 157 (159.6 mg, 100 %) as a clear oil. [α]21D = + 39.3 (c = 10.64, CHCl3); Rf 
= 0.65 (CH2Cl2/MeOH, 9:1); νmax /cm-1 3329 (NH), 2925, 2876, 1657 (C=O), 1535, 1341, 1158, 1108, 1093, 664; δH 
(400 MHz, CDCl3) 7.66 (2H, d, J 7.7, tol H3’), 7.57-7.53 (3H, m, SeArH), 7.30 (2H, d, J 7.7, tol H2’), 7.25-7.23 (2H, 
m, SeArH), 6.73-6.69 (1H, bm, NH), 4.00 (2H, s, OCH2CONH), 3.83-3.77 (1H, m, CH3CH(SePh)CONH), 3.76-3.70 
(1H, m, pyrrolidine-H2’), 3.68-3.63 (2H, m, OCH2CH2O), 3.61-3.58 (2H, m, OCH2CH2O), 3.54-3.46 (3H, m, 
NCH2CH2O), 3.44-3.27 (4H, m, NCH2CH2O and pyrrolidine-CH2NH and pyrrolidine-H5’), 3.19-3.12 (1H, m, 
pyrrolidine-H5’), 2.40 (3H, s, ArCH3), 1.80-1.70 (1H, m, pyrrolidine-H4’), 1.64-1.56 (2H, m, pyrrolidine-H4’ and 
pyrrolidine-H3’), 1.54 (3H, d, J 7.1, CH3CH(SePh)CONH), 1.47-1.38 (1H, m, pyrrolidine-H3’); δC (101 MHz, 
CDCl3) 172.6, 170.6, 143.9, 134.7, 133.7, 129.8, 129.0, 128.5, 128.0, 127.5, 71.1, 70.6, 70.0, 69.8, 59.5, 49.4, 43.2, 
40.4, 39.4, 29.5, 24.0, 21.5, 18.3; m/z (ESI) 612 [MH]+, 634 [MNa]+; found [MH]+ 612.1648 C27H38N3O6S80Se 
requires 612.1647, Δ 0.2 ppm. 
(±)-N-(2-(2-[(1-Benzyl-piperidin-4-ylcarbamoyl)-methoxy]-ethoxy)-ethyl)-acrylamide 158 
 
Selenide 150 (415.8 mg, 0.76 mmol, 1.0 eq.) and sodium (meta)periodate (260.3 mg, 1.22 mmol, 1.6 eq.) were stirred 
in MeOH (2 mL) at rt overnight. To the resulting off-white precipitate was added H2O (8 mL) and the reaction 
mixture extracted with CH2Cl2 (x 2). The combined CH2Cl2 layers were washed with 1 M HCl (aq.) and the aqueous 
layers combined and basified to pH 14 with sat. aq. NaOH. The basic aqueous layer was extracted with EtOAc (x 3) 
and combined organics dried over MgSO4, filtered and the solvent removed in vacuo. The crude clear oil was purified 
on basic alumina (CH2Cl2/MeOH, 49:1) to yield the desired acrylamide 158 (145.2 mg, 49 %) as a clear oil. Rf = 0.24 
(CH2Cl2/MeOH, 49:1); νmax /cm-1 3294, 2939, 1657, 1629, 1533, 1104, 909, 726, 698; δH (400 MHz, CDCl3) 7.31-7.20 
(5H, m, ArH), 6.72-6.67 (2H, bm, NH), 6.28 (1H, dd, J 1.8, J 16.8, CH2CHCONH cis to C=O), 6.15 (1H, dd, J 10.1, J 
16.8, CH2CHCONH), 5.59 (1H, dd, J 1.8, J 10.1, CH2CHCONH trans to C=O), 3.95 (2H, s, OCH2CONH), 3.87-3.77 
(1H, m, piperidine-H4’), 3.66-3.64 (2H, m, CH2), 3.61-3.57 (4H, m, 2 x CH2), 3.54-3.50 (2H, m, CH2), 3.47 (2H, s, 
piperidine-NCH2Ar), 2.84-2.79 (2H, m, piperidine-H2’), 2.11-2.05 (2H, m, piperidine-H2’), 1.90-1.84 (2H, m, 
piperidine-H3’), 1.48 (2H, qd, J 11.4, J 3.8, piperidine-H3’); δC (101 MHz, CDCl3) 169.2, 165.7, 138.2, 130.7, 129.0, 
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128.2, 127.0, 126.4, 70.9, 70.6, 70.2, 69.9, 63.0, 52.2, 45.9, 39.2, 32.2; m/z (ESI) 390 [MH]+, 412 [MNa]+; found 
[MH]+ 390.2389 C21H32N3O4 requires 390.2393, Δ 1.0 ppm. 
N-(2-(2-[2-Oxo-2-(4-phenyl-piperazin-1-yl)-ethoxy]-ethoxy)-ethyl)-acrylamide 159 
 
To selenide 151 (421.9 mg, 0.81 mmol, 1.0 eq.) and sodium (meta)periodate (278.5 mg, 1.30 mmol, 1.6 eq.) was 
added EtOH (3 mL) and the orange solution stirred for 18 h at rt. To the resulting thick off-white precipitate was 
added H2O and the mixture extracted with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the 
solvent removed in vacuo. The crude orange oil was purified on silica (EtOAc/MeOH, 19:1) and re-purified on silica 
(EtOAc/MeOH, 9:1) to yield the desired acrylamide 159 (62.3 mg, 21 %) as a yellow oil. Rf = 0.13 (EtOAc/MeOH, 
19:1); νmax /cm-1 3286, 2863, 1647, 1627, 1598, 1543, 1495, 1442, 1229, 1115, 1098, 1025, 991, 759, 693; δH (400 
MHz, CDCl3) 7.32-7.31 (2H, m, ArH), 6.96-6.91 (3H, m, ArH), 6.32 (1H, dd, J 17.1, J 2.3, CH2CHCONH cis to 
C=O), 6.24 (1H, dd, J 9.5, J 17.1, CH2CHCONH), 5.61 (1H, dd, J 9.5, J 2.3, CH2CHCONH trans to C=O), 4.29 (2H, 
s, OCH2CONH), 3.81-3.78 (2H, m, CH2), 3.74-3.71 (2H, m, CH2), 3.69-3.65 (4H, m, CH2), 3.63 (2H, t, J 4.8, CH2), 
3.57-3.53 (2H, m, CH2), 3.21-3.17 (4H, m, CH2); δC (101 MHz, CDCl3) 167.9, 165.8, 150.9, 131.1, 129.3, 126.1, 
120.8, 116.8, 70.7, 70.4, 70.2, 69.9, 49.9, 49.5, 44.9, 41.9, 39.4; m/z (ESI) 362 [MH]+, 382 [MNa]+; found [MH]+ 
362.2067 C19H28N3O4 requires 362.2080, Δ 3.6 ppm. 
N-(2-(2-[(4-Methoxy-benzylcarbamoyl)-methoxy]-ethoxy)-ethyl)-acrylamide 160 
 
A solution of selenide 153 (307.7 mg, 0.62 mmol, 1.0 eq.) and sodium (meta)periodate (213.4 mg, 1.0 mmol, 1.6 eq.) 
in EtOH (2 mL) was stirred vigorously overnight. To the resulting yellow precipitate was added H2O (8 mL) and the 
mixture extracted with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent removed in 
vacuo. The crude mixture was purified on silica (29:1, CH2Cl2:MeOH) to yield a mixture of the desired acrylamide 
160 with the starting material 153. To the mixture was added sodium meta periodate (213.4 mg, 1.0 mmol, 1.6 eq.) 
and EtOH (2 mL) and the mixture stirred vigorously overnight. To the resulting thick white precipitate was added 
H2O (8 mL) and the aqueous layer extracted with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered 
and the solvent removed in vacuo. The crude residue was purified on silica (29:1, CH2Cl2/MeOH) to yield the desired 
acrylamide 160 (157.5 mg, 76 %) as a clear oil which crystallised upon standing to yield a white waxy solid, mp = 70-
71 °C; Rf = 0.14 (CH2Cl2/MeOH, 29:1); νmax /cm-1 3294, 2929, 1655, 1627, 1611, 1535, 1512, 1244, 1109, 1031, 987, 
958, 808, 728; δH (400 MHz, CDCl3) 7.22 (2H, d, J 8.6, ArH), 7.08 (1H, bs, NH) 6.86 (2H, d, J 8.6 ArH), 6.26 (1H, 
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dd, J 1.6, J 17.0, CH2CHCONH cis to C=O), 6.05 (1H, dd, J 17.0, J 10.3, CH2CHCONH), 5.89 (1H, bs, NH), 5.62 
(1H, dd, J 10.3, J 1.6, CH2CHCONH trans to C=O), 4.42 (2H, d, J 5.8, ArCH2NHCO), 4.05 (2H, s, OCH2CONH), 
3.78 (3H, s, ArOCH3), 3.68-3.66 (2H, m, CH2), 3.58-3.56 (2H, m, CH2), 3.47 (2H, t, J 5.0, CH2), 3.41-3.38 (2H, m, 
CH2); δC (101 MHz, CDCl3) 170.0, 165.6, 159.2, 130.8, 130.2, 129.3, 126.7, 114.2, 71.1, 70.8, 70.3, 70.1, 55.4, 42.5, 
39.3; m/z (ESI) 337 [MH]+, 359 [MNa]+; found [MH]+ 337.1767 C17H25N2O5 requires 337.1763, Δ 1.2 ppm. 
N-(2-[2-(Benzylcarbamoyl-methoxy)-ethoxy]-ethyl)-acrylamide 161 
 
To selenide 154 (194.8 mg, 0.42 mmol, 1.0 eq.) and NaIO4 (143.9 mg, 0.67 mmol, 1.6 eq.) was added EtOH (1.5 mL) 
and the clear solution rapidly stirred for 24 h at rt. The resulting thick white precipitate was diluted with H2O and 
washed with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude yellow oil was purified on silica (100 % EtOAc) to yield the desired acrylamide 161 (115.8 mg, 90 %) as a 
clear oil. Rf = 0.18 (100 % EtOAc); νmax /cm-1 1655, 1627, 1536, 1245, 1107, 700; δH (400 MHz, CDCl3) 7.38-7.26 
(5H, m, ArH), 6.26 (1H, dd, J 16.5, J 1.1, H2CCHCONH cis to C=O), 6.21 (1H, bs, NH), 6.07 (1H, dd, J 9.9, J 16.5, 
H2CCHCONH), 5.50 (1H, dd, J 9.9, J 1.1, H2CCHCONH trans to C=O), 4.49 (2H, d, J 6.4, ArCH2NHCO), 4.07 (2H, 
s, OCH2CONH), 3.69-3.67 (2H, m, CH2), 3.59-3.57 (2H, m, CH2), 3.48 (2H, t, J 5.1, CH2), 3.41-3.37 (2H, m, CH2); 
δC (101 MHz, CDCl3) 170.2, 165.8, 138.1, 130.8, 128.9, 127.9, 127.7, 126.4, 71.1, 70.7, 70.3, 70.0, 43.0, 39.2; m/z 
(ESI) 307 [MH]+, 329 [MNa]+; found [MH]+ 307.1653 C16H23N2O4 requires 307.1658, Δ 1.6 ppm.    
N-(2-(2-[(4-Fluoro-benzylcarbamoyl)-methoxy]-ethoxy)-ethyl)-acrylamide 162 
 
A solution of selenide 155 (525.2 mg, 1.09 mmol, 1.0 eq.) and sodium (meta)periodate (373.4 mg, 1.75 mmol, 1.6 eq.) 
in EtOH (3 mL) was stirred vigorously overnight. To the resulting thick white precipitate was added H2O and the 
mixture extracted with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent removed in 
vacuo. The crude residue was purified on silica (EtOAc/MeOH, 9:1) to yield the desired acrylamide 162 (221.0 mg, 
63 %) as a clear oil. Rf = 0.41 (EtOAc/MeOH, 9:1); νmax /cm-1 3297 (NH), 3075, 2929, 2873, 1657 (C=O), 1628, 1606, 
1538, 1510, 1221, 1110; δH (400 MHz, CDCl3) 7.25 (1H, bs, NH), 7.22-7.18 (2H, m, ArH), 6.97-6.91 (2H, m, ArH), 
6.40 (1H, bs, NH), 6.19 (1H, dd, J 16.9, J 1.7, CH2CHCONH cis to C=O), 6.04 (1H, dd, J 10.3, J 16.9, 
CH2CHCONH), 5.54 (1H, dd, J 10.3, J 1.7, CH2CHCONH trans to C=O), 4.38 (2H, d, J 6.0, NHCH2Ar), 3.98 (2H, s, 
OCH2CONH), 3.62-3.59 (2H, m, CH2), 3.56-3.52 (2H, m, CH2), 3.45 (2H, t, J 5.2, CH2), 3.38-3.35 (2H, m, CH2); δC 
(101 MHz, CDCl3) 170.0, 165.7, 163.3, 160.9, 134.0, 134.0, 130.7, 129.4, 129.4, 126.4, 115.6, 115.4, 71.0, 70.6, 70.1, 
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69.8, 42.0, 39.1; m/z (ESI) 325 [MH]+, 347 [MNa]+; found [MH]+ 325.1567 C16H22N2O4F requires 325.1564, Δ 0.9 
ppm. 
4-((2-[2-(2-Acryloylamino-ethoxy)-ethoxy]-acetylamino)-methyl)-benzoic acid methyl ester 163 
 
To selenide 156 (123.3 mg, 0.22 mmol, 1.0 eq.) and sodium (meta)periodate (76.4 mg, 0.35 mmol, 1.6 eq.) was added 
EtOH (1 mL) and the orange solution stirred at rt for 36 h. To the resulting thick yellow precipitate was added H2O 
and the mixture extracted with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent 
removed in vacuo. The resulting residue was purified on silica (EtOAc/MeOH, 9:1) and subsequently re-purified on 
silica (EtOAc/MeOH, 4:1) to yield the desired acrylamide 163 (44.1 mg, 55 %) as a clear oil. Rf  = 0.32 
(EtOAc/MeOH, 9:1); νmax /cm-1 3298, 1718, 1656, 1532, 1278, 1107; δH (400 MHz, CDCl3) 7.98 (2H, d, J 8.0, ArH), 
7.34 (2H, d, J 8.0, ArH), 7.29 (1H, bs, NH), 6.23 (1H, dd, J 16.9, J 1.5, CH2CHCONH cis to C=O), 6.06 (1H, bs, 
NH), 6.03 (1H, dd, J 16.9, J 10.3, CH2CHCONH), 5.58 (1H, dd, J 10.3, J 1.5, CH2CHCONH trans to C=O), 4.53 
(2H, d, J 6.3, CONHCH2Ar), 4.06 (2H, s, OCH2CONH), 3.89 (3H, s, ArCOOCH3), 3.69-3.67 (2H, m, CH2), 3.60-3.58 
(2H, m, CH2), 3.49 (2H, t, J 5.2, CH2), 3.43-3.39 (2H, m, CH2); δC (101 MHz, CDCl3) 170.3, 166.8, 165.7, 143.4, 
130.7, 130.1, 129.5, 127.6, 126.7, 71.1, 70.7, 70.3, 70.0, 52.2, 42.5, 39.2; m/z (ESI) 365 [MH]+, 387 [MNa]+; found 
[MH]+ 365.1704 C18H25N2O6 requires 365.1713 Δ 2.5 ppm. 
(R)-N-(2-[2-(([1-(Toluene-4-sulfonyl)-pyrrolidin-2-ylmethyl]-carbamoyl}-methoxy)-ethoxy]-ethyl)-acrylamide 164 
 
 
Selenide 157 (159.6mg, 0.26 mmol, 1.0 eq.) and sodium (meta)periodate (89.5 mg, 0.42 mmol, 1.6 eq.) were stirred 
vigorously in EtOH (2 mL) for 16 h. To the resulting thick white precipitate was added H2O and the mixture extracted 
with CH2Cl2 (x 3). Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo. The crude 
residue was purified on silica (EtOAc/MeOH, 9:1) to yield the desired acrylamide 164 (57.2 mg, 49 %) as a clear oil. 
[α]22D = + 44.9 (c = 0.71, CHCl3); Rf = 0.29 (EtOAc/MeOH, 9:1); νmax /cm-1 3301 (NH), 2929, 2873, 1658, 1627, 
1532, 1340, 1243, 1156, 1106, 1092, 1040, 987, 817, 663; δH (400 MHz, CDCl3) 7.65 (2H, d, J 8.2, tol H3’), 7.59 
(1H, bt, J 4.8, NH), 7.29 (2H, d, J 8.2, tol H2’), 6.62 (1H, bs, NH), 6.24 (1H, dd, J 17.0, J 2.1, CH2CHCONH cis to 
C=O), 16.15 (1H, dd, J 17.0, J 9.8, CH2CHCONH), 5.54 (1H, dd, J 9.8, J 2.1, CH2CHCONH trans to C=O), 4.01 
(2H, s, OCH2CONH), 3.76-3.68 (3H, m), 3.66-3.44 (7H, m), 3.40-3.26 (2H, m), 3.19-3.13 (1H, m), 2.39 (3H, s, 
ArCH3), 1.79-1.69 (1H, m, pyrrolidine-H4’), 1.64-1.49 (2H, m, pyrrolidine-H4’ and pyrrolidine-H3’), 1.46-1.37 (1H, 
m, pyrrolidine-H3’); δC (101 MHz, CDCl3) 171.0, 165.9, 144.2, 133.8, 131.2, 130.1, 127.7, 126.3, 71.4, 70.8, 70.3, 
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70.2, 59.8, 49.6, 43.4, 39.4, 29.7, 24.3, 21.7; m/z (ESI) 454 [MH]+, 476 [MNa]+; found [MH]+ 454.1995 C21H32N3O6S 
requires 454.2012, Δ 3.7 ppm. 
9.6. Glycine, β-alanine and 1,3-diaminopropane linkers 
N-Acryloylglycine 165 
 
To a solution of glycine (2.00 g, 26.64 mmol, 1.0 eq.) in KOH (2M) (28.0 mL, 55.94 mmol, 2.1 eq.) at 0 °C was 
added acryloyl chloride (2.6 mL, 31.97 mmol, 1.2 eq.) dropwise, with vigorous stirring. The solution was stirred at rt 
for 45 min and subsequently washed with ether (20 mL x 2). The aqueous layer was then acidified to pH 3 by addition 
of aq. HCl (2N) and extracted with ethyl acetate (6 x 20 mL). The combined EtOAc extractions were dried over 
MgSO4, filtered and the solvent removed in vacuo to yield the desired acrylamide 165 (3.05 g, 89 %) as a white 
powder, mp = 119-121 °C; Rf = 0 (100 % EtOAc); νmax/cm-1 3321, 1720, 1649, 1611, 1549, 1226; δH (400 MHz, 
DMSO-d6) 12.61 (1H, bs, OH), 8.43 (1H, bt, J 5.5, NH), 6.29 (1H, dd, J 9.4, J 15.9, NHCOCHCH2), 6.10 (1H, dd, J 
2.4, J 15.9, NHCOCHCH2 cis to C=O), 5.62 (1H, dd, J 2.4, J 9.4, NHCOCHCH2 trans to C=O), 3.83 (2H, d, J 5.5, 
NHCH2); δC (101 MHz, DMSO-d6) 171.26, 164.92, 131.32, 125.73, 40.65; m/z (CI) 147 [MNH4]+, 130 [MH]+; found: 
[MNH4]+, 147.0772 C5H11N2O3 requires 147.0770, Δ 1.6 ppm. Data in agreement with literature values.[296]    
(±)-3-(2-Phenylselanyl-propionylamino)-propionic acid 168 
 
To a solution of methyl ester 170 (985.4 mg, 3.14 mmol, 1.0 eq.) in MeOH (7 mL) was added 1 M NaOH (7 mL) and 
the reaction stirred at rt overnight. The MeOH was removed in vacuo and the aqueous residue acidified with 1 M HCl 
and extracted with EtOAc. Combined organics were dried over MgSO4, filtered and the solvent removed in vacuo to 
yield the desired carboxylic acid 168 (947.3 mg, 100 %) as a yellow oil. Rf  = 0 (EtOAc/n-hexane, 1:1); νmax /cm-1 
1715 (C=O carboxylic acid), 1638 (amide), 1537, 1438, 1193; δH (400 MHz, CDCl3) 9.60 (1H, bs, OH), 7.56-7.54 
(2H, m, Ph), 7.35-7.27 (3H, m, Ph), 6.72 (1H, bt, J 6.0, NH), 3.79 (1H, q, J 7.1, CH3CH(SePh)), 3.47 (2H, q, J 6.0, 
NHCH2), 2.48 (2H, t, J 6.0, NHCH2CH2), 1.59 (3H, d, J 7.1, CH3CH(SePh)); δC (101 MHz, CDCl3) 176.7, 173.2, 
134.9, 129.4, 128.5, 128.1, 40.6, 35.1, 33.7, 18.2; m/z (ESI) 301 [MH]+; found [MH]+ 301.0219 C12H15O3NSe requires 
301.0212, Δ 0.4 ppm.    
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(±)-3-(2-Phenylselanyl-propionylamino)-propionic acid methyl ester 170 
 
To a solution of α-selenide 145 (250.0 mg, 1.09 mmol, 1.0 eq.) in anhydrous THF (3 mL) at 0 °C under argon was 
added oxalyl chloride (0.10 mL, 1.14 mmol, 1.05 eq.) and DMF (2 drops, cat.) and the light yellow solution stirred at 
rt for 110 min. To the reaction mixture was added β-alanine methyl ester hydrochloride (304.3 mg, 2.18 mmol, 2.0 
eq.) all at once, Et3N (0.53 mL, 3.82 mmol, 3.5 eq.) dropwise (care - vigorous evolution of HCl gas) and THF (5 mL) 
to aid stirring. The thick yellow precipitate was stirred for 24 h at rt before dilution with ether. The organic layer was 
washed with brine (x 1), dried over MgSO4 and the solvent removed in vacuo. The crude yellow oil (258.4 mg) was 
purified on silica (EtOAc/n-hexane, 1:1) to yield the desired ester 170 (210.1 mg, 61 %) as a clear oil. Rf  = 0.3 
(EtOAc/n-hexane, 1:1); νmax /cm-1 3297 (NH), 1736 (ester), 1646 (amide), 1544, 1438,1368, 1242, 1198, 1174, 742, 
692; δH (400 MHz, CDCl3) 7.52-7.50 (2H, m, Ph), 7.30-7.22 (3H, m, Ph), 6.62 (1H, bt, J 6.1, NH), 3.73 (1H, q, J 7.1, 
CH3CH(SePh)), 3.63 (3H, s, COOCH3), 3.42 (2H, q, J 6.1, NHCH2), 2.39 (2H, t, J 6.1, NHCH2CH2), 1.55 (3H, d, J 
7.1, CH3CH(SePh)); δC (101 MHz, CDCl3) 172.8, 172.3, 134.6, 129.2, 128.3, 128.2, 51.7, 40.6, 35.1, 33.6, 18.2; m/z 
(ESI) 315 [MH]+; found [MH]+ 315.0361C13H17O3NSe requires 315.0368, Δ 2.2 ppm.  
(±)-N-[3-Oxo-3-(4-phenyl-piperazin-1-yl)-propyl]-2-phenylselanyl-propionamide 172 
 
To a solution of carboxylic acid 168 (123.2 mg, 0.41 mmol, 1.0 eq.) and zirconocene dichloride (6.0 mg, 0.02 mmol, 
5 mol %) in anhydrous toluene (10 mL) was added N-phenyl piperazine (0.06 mL, 0.41 mmol, 1.0 eq.) and the 
mixture heated to reflux. After 24 h the resulting orange solution was cooled to rt and filtered, and the solvent 
removed from the filtrate in vacuo. The resulting crude orange oil was purified on silica (100 % EtOAc) to yield the 
desired amide 172 (118.1 mg, 65 %) as a clear oil. Rf = 0.44 (EtOAc/n-hexane, 1:1 on neutral alumina); νmax /cm-1 
3308 (NH), 1639 (amide), 1599, 1497, 1439,1230, 1024, 759, 742, 692; δH (400 MHz, CDCl3) 7.56-7.54 (2H, m, Ph), 
7.32-7.24 (5H, m, Ph), 6.95-6.88 (3H, m, Ph), 6.87 (1H, bt, J 5.8, NH), 3.78-3.73 (3H, m, CH3CH(SePh) and 2H 
piperazine), 3.56-3.45 (4H, m, NHCH2 and 2H piperazine), 3.17-3.13 (4H, m, 4H piperazine), 2.45-2.42 (2H, m, 
NHCH2CH2), 1.62-1.57 (3H, m, CH3CH(SePh)); δC (101 MHz, CDCl3) 172.4, 169.9, 150.7, 134.6, 129.3, 129.1, 
128.6, 128.1, 120.8, 116.7, 49.7, 49.4, 45.2, 41.4, 40.8, 35.3, 32.7, 18.3; m/z (ESI) 468 [MNa]+; found [MNa]+ 
468.1163 C22H27N3O2NaSe requires 468.1166, Δ 0.6 ppm.  
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N-[3-Oxo-3-(4-phenyl-piperazin-1-yl)-propyl]-acrylamide 173 
 
To α-selenide 172 (113.4 mg, 0.26 mmol, 1.0 eq.) and NaIO4 (186 mg, 0.41 mmol, 3.3 eq.) was added EtOH (1 mL) 
and the suspension rapidly stirred at rt for 10 h before dilution with CH2Cl2 and brine. The layers were separated and 
the aqueous layer washed with CH2Cl2 (x 2). Combined organics were dried over MgSO4, filtered and the solvent 
removed in vacuo. The crude oil (176.1 mg) was purified on silica (100 % EtOAc) and the resulting residue repurified 
on silica (EtOAc:MeOH, 19:1). The obtained residue was dissolved in CH2Cl2 and washed with 1 M HCl (x 3). 
Combined aqueous layers were basified with saturated NaOH (aq.) and extracted with CH2Cl2 (x 3) and EtOAc (x 1). 
Combined organics from the basic extraction were dried over MgSO4, filtered and the solvent removed in vacuo. The 
residue was purified on silica (gradient elution EtOAc to EtOAc/MeOH, 19:1) to yield the desired acrylamide 173 
(36.0 mg, 48 %) as a white powder, mp = 105-107 °C; Rf  = 0.27 (100 % EtOAc); νmax /cm-1 3297, 1621, 1598, 1496, 
1440, 1228, 1211, 1025, 991, 760, 694; δH (400 MHz, CD2Cl2) 7.29-7.24 (2H, m, Ph), 6.93-6.91 (2H, m, Ph), 6.90-
6.85 (1H, m, Ph), 6.66 (1H, bs, NH), 6.20 (1H, dd, J 17.0, J 2.1, CH2CHCONH cis to C=O), 6.11 (1H, dd, J 17.0, J 
9.8, CH2CHCONH), 5.58 (1H, dd, J 9.8, J 2.1, CH2CHCONH trans to C=O), 3.75 (2H, t, J 5.2, 2H piperazine), 3.62-
3.56 (4H, m, 4H piperazine), 3.16-3.12 (4H, m, 2H piperazine and NHCH2), 2.59 (2H, t, J 5.7, NHCH2CH2); δC (101 
MHz, CD2Cl2) 170.5, 165.6, 165.5, 151.7, 131.9, 131.9, 129.7, 126.0, 120.7, 117.0, 50.0, 49.8, 45.7, 41.9, 35.6, 35.4, 
33.3; m/z (ESI) 310 [MNa]+; found [MNa]+ 310.1528 C16H21N3O2Na requires 310.1531, Δ 1.0 ppm.   
(±)-2-Phenylselanyl-N-(2-(R)-([1-(toluene-4-sulfonyl)-pyrrolidin-2-ylmethyl]-carbamoyl)-ethyl)-propionamide 174 
 
A solution of amine 72 (563.9 mg, 1.89 mmol, 1.0 eq.), carboxylic acid 168 (567.3 mg, 1.89 mmol, 1.0 eq.) and 
zirconocene dichloride (28 mg, 5 mol %) was refluxed in toluene (60 mL) for 17 h. The reaction was allowed to cool 
to rt, the solvent removed in vacuo and the resultant brown oil purified on silica (100 % EtOAc) twice to give the 
desired amide 174 (443.4mg, 44 %) as a white foam as an inseparable mixture of diastereoisomers. Rf = 0.39 (100 % 
EtOAc); νmax /cm-1 3301 (NH), 1646 (amide), 1537, 1446, 1338, 1156, 1093, 747, 664; δH (400 MHz, CDCl3) 7.62 
(2H, d, J 8.1, tol H3’), 7.48 (2H, td, J 7.7, J 1.5, ArH), 7.25-7.15 (5H, m, ArH), 6.99-6.94 (1H, m, NH), 6.86-6.81 
(1H, m, NH), 3.74-3.67 (2H, m), 3.47-3.32 (4H, m), 3.20-3.08 (2H, m), 2.34 (3H, s, tol CH3), 2.34-2.28 (2H, m), 1.73-
1.64 (1H, m, pyrrolidine), 1.55-1.35 (3H, m, pyrrolidine), 1.48 (3H, d, J 7.0, CH3CH(SePh)); δC (101 MHz, CDCl3) 
172.4, 172.3, 171.9, 171.8, 143.8, 134.9, 134.8, 133.6, 129.8, 129.0, 128.3, 128.2, 128.0, 128.0, 127.4, 59.3, 59.3, 
49.3, 43.7, 43.6, 40.5, 40.5, 35.7, 35.3, 35.3, 29.2, 23.9, 21.4, 18.3, 18.2; m/z (EI) 537 [M]+, 382 [M-SO2tol]+, 224 [M- 
SO2tol-SePh]+, 155 [SO2tol]+; found [M]+ 537.1199 C24H31O4N3SSe requires 537.1195, Δ 0.8 ppm.   
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(R)-N-(2-([1-(Toluene-4-sulfonyl)-pyrrolidin-2-ylmethyl]-carbamoyl)-ethyl)-acrylamide 175 
 
To α-(phenyl)selenide 174 (413.2 mg, 0.77 mmol, 1.0 eq.) and NaIO4 (263.3 mg, 1.23 mmol, 1.6 eq.) was added 
EtOH (6 mL) and the suspension stirred rapidly at rt for 90 h. The thick yellow precipitate was diluted with CH2Cl2 
and washed with H2O. The aqueous layer was further washed with CH2Cl2 (x 1) and the organic layers combined, 
dried over MgSO4 and the solvent removed in vacuo. The crude residue was purified on silica (gradient elution, 
EtOAc to EtOAc/MeOH, 9:1) to yield the desired acrylamide 175 (276.5 mg, 94 %) as a clear oil. [α]27D = + 67.4 (c = 
8.37, CHCl3); Rf = 0.13 (100 % EtOAc); νmax /cm-1 3290 (NH), 1654, 1627, 1539, 1339, 1156, 1092, 752, 664; δH (400 
MHz, CDCl3) 7.59 (2H, d, J 8.1, tosyl ArH3’), 7.21 (2H, d, J 8.1, tosyl ArH2’), 7.16 (2H, bt, J 5.4, 2 x NH), 6.16-6.04 
(2H, m, CH2CHCONH cis to C=O and CH2CHCONH), 5.46 (1H, dd, J 2.6, J 9.1, CH2CHCONH trans to C=O), 3.71-
3.66 (1H, m), 3.59-3.46 (2H, m), 3.36-3.28 (2H, m), 3.21-3.15 (1H, m), 3.09-3.03 (1H, m), 2.43 (2H, t, J 6.1, 
CH2CONH), 2.31 (3H, s, tosyl CH3), 1.72-1.62 (1H, m), 1.53-1.45 (1H, m), 1.42-1.31 (2H, m); δC (101 MHz, CDCl3) 
172.1, 165.7, 143.8, 133.6, 131.0, 129.7, 127.3, 125.8, 59.2, 49.2, 43.6, 35.6, 35.5, 29.0, 23.8, 21.3; m/z (ESI) 402 
[MNa]+, 380 [MH]+; found [MNa]+ 402.1472 C18H25O4N3SNa requires 402.1463, Δ 2.2 ppm.   
(±)-N-(2-[3-phenyl-2-(toluene-4-sulfonylamino)propylcarbamoyl]-ethyl)-acrylamide 177 
 
To carboxylic acid 168 (334.0 mg, 1.11 mmol, 1.0 eq.) and zirconocene (16.2 mg, 5 mol%) was added amine 121a 
(339.0 mg, 1.11 mmol, 1 eq.) in anhydrous toluene (25 mL) and the mixture refluxed for 17 h. The reaction mixture 
was allowed to cool to rt, filtered to remove insoluble and the solvent removed in vacuo. The crude brown residue 
(501 mg) was purified on silica (gradient elution EtOAc/n-hex, 1:1 to EtOAc/MeOH, 9:1). Relevant fractions were 
combined and the solvent removed in vacuo to yield the desired amide 176 as a 1:1 mixture of diastereoisomers 
(151.1 mg) as a clear oil. To this was added NaIO4 (88 mg, 0.41 mmol, 1.6 eq.) and the mixture stirred vigourously in 
EtOH (3 mL) for 24 h. The reaction mixture was diluted with CH2CH2 (10 mL) and washed with H2O (10 mL). The 
aqueous layer was washed with CH2CH2 (10 mL) and the combined organics dried over MgSO4, filtered and the 
solvent removed in vacuo. The crude yellow oil (164.6 mg) was purified on silica (gradient elution EtOAc to 
EtOAc/MeOH, 9:1) to yield the desired acrylamide 177 (86.8 mg, 18 % over 2 steps) as a clear oil. Rf = 0.22 (100 % 
EtOAc); νmax /cm-1 3287, 1656, 1626, 1599, 1539, 1498, 1454, 1429, 1321, 1288, 1241, 1154, 1091, 982, 813, 732, 
701, 664; δH (400 MHz, CDCl3) 7.56 (2H, d, J 8.2, tolyl H3’), 7.16 (2H, d, J 8.2, tolyl H2’), 7.12-7.03 (5H, m, Ph), 
6.96-6.94 (2H, m, NH), 6.26-6.13 (3H, m, CH2CHCONH cis to C=O and CH2CHCONH and NH), 5.57 (1H, dd, J 9.1, 
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J 2.8, CH2CHCONH trans to C=O), 3.65 (3H, m), 3.30-3.21 (2H, m), 2.63 (2H, d, J 6.9, PhCH2), 2.42-2.40 (2H, m), 
2.37 (3H, s, ArCH3); δC (101 MHz, CDCl3) 173.0, 166.2, 143.3, 137.7, 136.9, 131.1, 129.7, 129.3, 128.6, 126.8, 
126.7, 126.5, 55.7, 43.2, 39.5, 35.9, 35.8, 21.6; m/z (ESI) 430 [MH]+, 452 [MNa]+; found [MNa]+ 452.1610 
C22H27O4N3SNa requires 452.1620, Δ 2.2 ppm.  
3-Benzyloxycarbonylaminopropionic acid 179 
 
Benzyl chloroformate (0.79 mL, 5.5 mmol, 1.1 eq.) was added dropwise to a solution of β-alanine (445 mg, 5 mmol, 1 
eq.) in 2M NaOH (5 mL) at 0 °C and the mixture allowed to warm to rt and stirred vigorously for 12 h. The reaction 
mixture was washed with ether (x 3), acidified to pH 5 with conc. aq. HCl and washed with EtOAc (x 1). The organic 
EtOAc layer was dried over MgSO4, filtered and the solvent removed in vacuo to yield the desired carbamate 179 
(729.6 mg, 65 %) as a white crystalline powder, mp = 98-101 °C; νmax /cm-1 3330, 1682, 1531, 1320, 1261, 1247, 
1216, 1027, 949, 728, 695; δH (400 MHz, MeOH) 7.39-7.26 (5H, m, Ph), 5.07 (2H, s, CH2Ph), 3.39-3.35 (2H, m, CH-
2NH), 2.50 (2H, t, J 6.8, CH2CH2NH); δC (101 MHz, MeOH) 175.5, 158.9, 138.5, 129.6, 129.1, 128.9, 67.6, 38.0, 
35.3; m/z (ESI) 222 [M-H]-; found [M-H]- 222.0763 C11H12NO4 requires 222.0766, Δ 1.4 ppm. Data in agreement 
with literature values.[297] 
 (2-Carbamoylethyl)carbamic acid benzyl ester 180 
 
To a solution of Cbz-protected β-alanine 179 (251.9 mg, 1.13 mmol, 1.0 eq.) in anhydrous THF (1.6 mL) at 0 °C 
under Ar was added anhydrous Et3N (0.16 mL, 1.13 mmol, 1.0 eq.) and ethyl chloroformate (0.11 mL, 1.13 mmol, 1 
eq.) and the thick white precipitate stirred at 0 °C for 30 min. Aqueous ammonia (28%, 0.29 mL) was added to the 
stirred reaction mixture and stirring continued for a further 30 min. The reaction mixture was diluted with EtOAc (20 
mL) washed with H2O (x 1) and concentrated in vacuo to ca. 10 mL. The thick white precipitate was filtered and dried 
under high vacuum to yield the desired primary amide 180 (115.9 mg, 46 %) as a white solid, mp 158-162 °C; δH (400 
MHz, DMSO-d6) 7.34 (6H, bs, Ph and NH), 7.22 (1H, bs, NH), 6.81 (1H, bs, NH), 5.00 (2H, s, CH2Ph), 3.20-3.15 
(2H, m, CH2NH), 2.23 (2H, bt, J 6.2, CH2CH2NH). Data in agreement with literature values.[298]  
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N-(2-carbamoylethyl)acrylamide 182 
 
To a stirred solution of β-alanine N-acrylamide 183 (250 mg, 1.75 mmol, 1.0 eq.) in dry THF (2.5 mL) at 0 °C under 
argon was added Et3N (0.24 mL, 1.75 mmol, 1.0 eq.) and ethyl chloroformate (0.17 mL, 1.75 mmol, 1.0 eq.) and the 
reaction mixture stirred at 0 °C for 30 min. To the resultant white precipitate was added 28 % aqueous NH3 (0.46 ml) 
and the mixture stirred for a further 30 min. The thick white precipitate was filtered and the solvent removed from the 
filtrate. The crude brown residue was purified on silica (MeOH/EtOAc, 1:4) to yield the desired amide 182 (13.8 mg, 
6 %) as a white solid, mp = 145-146 °C; Rf = 0.32 (EtOAc/MeOH, 4:1); νmax /cm-1 3353, 3323, 3256, 3179, 2407, 
1652, 1626, 1555, 1529, 1432, 1406, 1242, 944; δH (400 MHz, MeOD) 6.27-6.18 (2H, m, CH2CHCONH cis to C=O 
and CH2CHCONH ), 5.65 (1H, dd, J 7.8, J 4.1, CH2CHCONH trans to C=O), 3.51 (2H, t, J 6.9, CH2CHCONHCH2), 
2.46 (2H, t, J 6.9, NH2COCH2); δC (101 MHz, MeOD) 176.5, 168.4, 132.1, 126.9, 37.0, 36.1; m/z (CI) 143 [MH]+; 
found [MH]+ 143.0842 C6H11N2O2 requires 143.0821, Δ 14.7 ppm. 
(3-Benzyloxycarbonylamino-propyl)-carbamic acid benzyl ester 184 
 
To a solution of propane-1,3-diamine (0.84 mL, 10 mmol, 1.0 eq.) in CH2Cl2 (20 mL) was added triethylamine (2.2 
mL, 15 mmol, 1.5 eq.) and benzylchloroformate (1.4 mL, 10 mmol, 1.0 eq.) dropwise yielding immediate formation 
of a white precipitate and an exotherm, which brings the solution to reflux. The reaction mixture was stirred for 3 h, 
diluted with CH2Cl2 and extracted with 5 % aq. citric acid. The CH2Cl2  layer was then washed with 1M aq. HCl and 
the acidic layer back extracted with CH2Cl2. Combined CH2Cl2 layers were dried over MgSO4, filtered and the solvent 
removed in vacuo to yield di-carbamate 184 (1.03 g, 60 %) as a white solid. Rf = 0.68 (100 % EtOAc); δH (400 MHz, 
CDCl3) 7.43-7.32 (10H, m, ArH), 5.24 (2H, bs, NH), 5.12 (4H, OCH2Ph), 3.29-3.25 (4H, m, 2 x CH2), 1.70-1.63 (2H, 
m, CH2).    
Carbonic acid benzyl ester phenyl ester 185 
 
A procedure reported by Pittelkow et al. was used with some modifications.[199] To a solution of benzyl alcohol (3.1 
mL, 30 mmol, 1.0 eq.) and pyridine (2.9 mL, 36 mmol, 1.2 eq.) in anhydrous CH2Cl2 (30 mL) under argon was added 
phenyl chloroformate (3.76 mL, 30 mmol, 1.0 eq.) dropwise over ca. 5 min bringing the reaction mixture to reflux. A 
thick white precipitate was formed from the colourless solution after addition was complete, and the slurry stirred at rt 
for 4 h. The reaction mixture was diluted with CH2Cl2, washed with H2O (x 1) and 2M H2SO4 (x 2), dried over 
O
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MgSO4, filtered and the solvent removed in vacuo. The crude oil was purified by vacuum distillation (0.3 mmHg, 
170-175 °C) to yield the desired carbonate 185 (4.57 g, 67 %) as a clear oil. Rf = 0.61 (EtOAc/n-hexane, 1:5); νmax 
/cm-1 1759 (carbonate), 1231, 1206, 694, 687; δH (400 MHz, CDCl3) 7.50-7.39 (7H, m, ArH), 7.30-7.26 (1H, m, ArH), 
7.23-7.20 (2H, m, ArH), 5.31 (2H, s, CH2); δC (101 MHz, CDCl3) 153.8, 151.3, 134.9, 129.6, 128.9, 128.8, 128.7, 
126.2, 121.2, 70.5; m/z (CI) 246 [MNH4]+; found [MNH4]+ 246.1125 C14H16O3N requires 246.1130, Δ 2.0 ppm. Data 
in agreement with literature values.[199]  
N-tosyl-DL-phenylalanine 187 
 
A procedure reported by Hersh et al. was used with some modifications.[299] To a solution of DL-phenylalanine (8.33 
g, 50 mmol, 1.0 eq.) and sodium carbonate (12.83 g, 121 mmol, 2.4 eq.) in H2O (100 mL) was added tosyl chloride 
(11.54 g, 61 mmol, 1.2 eq.) in 3 portions (0 h, 18 h, 26 h) and the thick white precipitate stirred at rt for 6 days. The 
reaction mixture was washed with Et2O and the resulting aqueous layer acidified with conc. HCl and washed with 
EtOAc (x 2). The EtOAc layers were combined, dried over MgSO4 and the solvent removed in vacuo to yield the 
desired tosylate 187 (2.3 g, 14 %) as a white powder. A small portion (1.8 g) was recrystallised from toluene to yield 
the desired tosylate 187 (1.42 g) as a white powder, mp = 115-120 °C; Rf = 0.35 (100 % EtOAc); νmax /cm-1 1712, 
1695, 1342, 1329, 1169, 1156, 1089, 931, 817, 698, 686; δH (400 MHz, CDCl3) 7.59 (2H, d, J 8.3, tolyl H3’), 7.24-
7.20 (5H, m, ArH), 7.08-7.06 (2H, m, ArH), 5.07 (1H, d, J 8.7, NH), 4.23-4.18 (1H, m, CHCOOH), 3.10 (1H, dd, J 
13.9, J 5.4, PhCH2), 3.00 (1H, dd, J 13.9, J 6.4, PhCH2), 2.40 (3H, s, PhCH3); δC (101 MHz, DMSO-d6) 172.3, 142.3, 
138.2, 136.7, 129.3, 129.2, 128.2, 126.5, 126.3, 57.4, 37.8, 21.0; m/z (CI) 320 [MH]+; found [MH]+ 320.0951 
C16H18O4NS requires 320.0957, Δ 1.7 ppm. Data in agreement with literature values.[299] 
(±)-3-[3-Phenyl-2-(toluene-4-sulfonylamino)propionylamino]propylammonium HCl salt 188 
 
To N-tosyl phenylalanine 187 (319 mg, 1 mmol, 1 eq.) and zirconocene dichloride (15 mg, 5 mol %) was added 
anhydrous toluene (30 mL) and 1,3-diaminopropane (0.83 mL, 10 mmol, 10 eq.) and the thick precipitate heated to 
reflux. The resulting colourless solution was heated at reflux with stirring for 3 h, allowed to cool to rt and the toluene 
removed in vacuo. To the resulting residue was added HCl (1 M) (3 mL) and EtOAc (5 mL) and the resulting 
precipitate filtered to yield the desired amine 188 (97.2 mg, 24 %) as a white solid, mp = 174-180 °C (decomposition). 
The filtrate was washed with EtOAc to obtain diacylated diamine 189 (175.8 mg, 52 %) as a clear oil.  
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(±)-3-[3-Phenyl-2-(toluene-4-sulfonylamino)propionylamino]propylammonium HCl salt 188 
 
νmax /cm-1 1638, 1570, 1494, 1373, 1285, 1153, 1095, 972, 947, 901, 857, 806, 694; δH (400 MHz, DMSO-d6) 7.58 
(2H, d, J 8.1, tol-H3’), 7.31 (2H, d, J 8.1, tol-H2’), 7.20-7.13 (5H, m, Ph), 3.37 (1H, t, J 5.0, TsNHCH), 2.96 (1H, dd, 
J 13.4, J 4.7, TsNHCHCH2Ph), 2.88 (1H, dd, J 13.4, J 5.4, TsNHCHCH2Ph), 2.76 (4H, t, J 7.1, 
CONHCH2CH2CH2NH2), 2.35 (3H, s, ArCH3), 1.71 (2H, p, J 7.1, CONHCH2CH2CH2NH2); δC (101 MHz, DMSO-d6) 
171.7, 142.4, 138.4, 137.4, 129.9, 129.4, 127.6, 126.7, 125.7, 58.1, 38.3, 36.8, 27.4, 20.9; m/z (ESI) 376 [MH]+; found 
[MH]+ 376.1704 C19H26N3O3S requires 376.1695, Δ 2.4 ppm.    
 3-Phenyl-N-{3-[3-phenyl-2-(toluene-4-sulfonylamino)-propionylamino]-propyl}-2-(toluene-4-sulfonyla mino)-
propionamide 189 
 
δH (400 MHz, CDCl3) 7.96 (1H, bs, NH), 7.48 (2H, d, J 8.1, tosyl-H), 7.37 (2H, d, J 8.1, tosyl-H), 7.08-6.92 (14H, m, 
ArH), 3.96-3.88 (2H, m), 3.29-3.25 (2H, bm), 3.17-3.12 (1H, m), 3.05-3.01 (1H, m), 2.97-2.86 (3H, m), 2.73-2.67 
(1H, m), 2.31 (6H, s, 2 x CH3), 1.82 (2H, bs).  
9.7. Alkyne-tagged chemical probe 
3-(4-Ethynylbenzenesulfonyl)acrylonitrile 192  
 
To a solution of TMS-acetylene 203 (5.7 mg, 0.020 mmol, 1.0 eq.) in THF (1 mL) at 0 °C was added TBAF (1.0 M in 
THF):AcOH, 1:1 (40 µL, 0.020 mmol (TBAF), 1 eq.) and the colourless solution stirred at 0 °C for 5 min and at rt for 
a further 90 min. The reaction mixture was partitioned between EtOAc and H2O and the layers separated. The aqueous 
layer was further washed with EtOAc (x 1) and the combined organics were dried over Na2SO4, filtered and the 
solvent removed in vacuo. The crude white solid was purified on silica (EtOAc/n-hex, 1:4) and the isolated product 
re-purified on silica (EtOAc/n-hex, 1:9). The solvent was partially removed from fractions and left for 16 h to allow 
the desired product to crystallise. The remaining solvent was removed via pipette and the crystals dried under high 
vacuum to yield the desired terminal acetylene 192 (2.1 mg, 48 %) as a white crystalline solid, mp = 182-185 °C; Rf  = 
O
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0.63 (n-hex/EtOAc, 7:3); νmax /cm-1 3254, 1330, 1151, 828; δH (400 MHz, CDCl3) 7.86 (2H, d, J 8.5, ArH2’), 7.71 
(2H, d, J 8.5, ArH3’), 7.21 (1H, d, J 15.7, SO2CH), 6.57 (1H, d, J 15.7, HCCN), 3.36 (1H, s, acetylene-H); δC (101 
MHz, CDCl3) 148.8, 137.1, 133.6, 129.6, 128.6, 113.3, 111.3, 82.7, 81.6; m/z (EI) 217 [MH]+; found [MH]+ 217.0184 
C11H7NO2S requires 217.0198 , Δ 6.5 ppm.    
4,4'-dibromo-diphenyl sulfone 195 
 
To a solution of bromobenzene (1.00 mL, 9.4 mmol, 1.0 eq.) in anhydrous CHCl3 (10 mL) at 0 °C was added 
chlorosulfonic acid (0.94 mL, 14.1 mmol, 1.5 eq.) and the reaction mixture stirred at 0 °C for 30 min and at rt for 30 
min. The reaction mixture was then added dropwise to ice and extracted with CH2Cl2 (x 1). The organic layer was 
dried over MgSO4, filtered and the solvent removed in vacuo. The crude white solid was purified on silica (EtOAc/n-
hex, 1:9) to yield biaryl sulfone 195 (167.1 mg, 9 %) as a white solid, mp = 169-171 °C. Rf  = 0.54 (EtOAc/n-hex, 
3:7); νmax /cm-1 1573, 1467, 1388, 1327, 1279, 1157, 1100, 1064, 1006, 819, 754, 728; δH (400 MHz, CDCl3) 7.79-
7.76 (4H, m), 7.65-7.61 (4H, m); δC (101 MHz, CDCl3) 140.2, 132.8, 129.2, 128.9; m/z (EI) 376 [M]+. Data in 
agreement with literature values.[300, 301] 
p-Bromophenylsulfonyl hydrazide 197  
 
To hydrazine hydrate (4.0 mL, 62.4 mmol, 3.2 eq.) at 0 °C was added p-bromobenzenesulfonyl chloride (5.0 g, 19.6 
mmol, 1.0 eq.) with vigorous stirring. The solution was stirred at 0 °C for 30 min, diluted with saturated NaCl and 
extracted with ether (x 1). The solvent was removed from the organic layer in vacuo to yield the desired sulfonyl 
hydrazide 197 (4.4 g, 91 %) as a white powder, mp = 119-122 °C; νmax /cm-1 3284 (NH), 1324, 1155 (SO2); δH (400 
MHz, DMSO-d6)  8.49 (1H, s, NH), 7.82 (2H, d, J 8.5, ArH), 7.72 (2H, J 8.5, ArH), 4.21 (2H, bs, NH2); δC (101 MHz, 
MeOD) 138.3, 133.5, 131.0, 128.9. Data in agreement with literature values.[302]  
Phenylselenenyl p-bromobenzenesulfonate 198 
 
To a solution of benzene seleninic acid (1.62 g, 8.56 mmol, 1.0 eq.) in anhydrous CH2Cl2 (20 mL) at 0 °C was added 
sulfonylhydrazine 197 (2.14 g, 8.56 mmol, 1.0 eq.) in anhydrous CH2Cl2 (20 mL) dropwise, and the resulting yellow 
solution stirred at 0 °C for 1 hour. The solvent was removed in vacuo and the resulting crude orange residue 
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recrystallised from methanol to yield the desired selenylsulfonate 198 (2.38g, 74 %) as a light yellow crystalline solid, 
mp = 84-87 °C; νmax /cm-1 1568, 1475, 1465, 1439, 1386, 1318 (SO2), 1274, 1130 (SO2), 1067, 1009, 837, 815, 743, 
733, 697, 685; δH (400 MHz, CDCl3) 7.53-7.45 (5H, m, C6H5Se), 7.37-7.31 (4H, m, SO2ArH); δC (101 MHz, CDCl3) 
144.4, 137.4, 132.2, 131.4, 130.0, 128.9, 128.6, 127.9; m/z (CI) 394 [MNH4]+; found: [MNH4]+, 393.9017 
C12H13NO2SBrSe requires 393.9016, Δ 0.3 ppm.       
3-(4-Bromo-benzenesulfonyl)-acrylonitrile 200 
 
Sodium aryl sulfinate (64 %) 202 (1.22 g, 5.56 mmol, 3.0 eq.) and 2,3-dibromopropanenitrile (0.18 mL, 1.85 mmol, 
1.0 eq.) in DMF (2.6 mL) were heated at 80 °C for 1 h. After cooling to rt the reaction mixture was treated with H2O 
and extracted with EtOAc (x 2). The EtOAc layers were combined and washed with brine (x 6), dried over Na2SO4, 
filtered and concentrated in vacuo. The crude solid was purified on silica (EtOAc/n-hex, 1:5) to yield the desired vinyl 
sulfone 200 (195.7 mg, 44 %) as a white solid, mp = 177-178 °C ; Rf = 0.56 (n-hex/EtOAc, 2:1); νmax /cm-1 3077, 
1577, 1390, 1327, 1274, 1147, 1084, 1068, 1009, 945, 820, 809, 746, 623, 562; δH (400 MHz, CDCl3) 7.72-7.77 (4H, 
m, ArH), 7.19 (1H, d, J 15.8, ArSO2CH), 6.54 (1H, d, J 15.8, ArSO2CHCHCN); δC (101 MHz, CDCl3) 148.7, 136.4, 
133.6, 131.1, 130.2, 113.4, 111.4; m/z (ESI) 219/220 [BrPhSO2]-, 271/272 [M]- ; found [M]- 270.9298 C9H6NO2SBr 
requires: 270.9303, Δ 1.8 ppm.             
Sodium 4-bromo-benzenesulfinate 202 
 
A mixture of anhydrous sodium sulfite (1.98 g, 15.7 mmol, 2.0 eq.), sodium bicarbonate (1.32 g, 15.7 mmol, 2.0 eq.) 
and H2O (8 mL) was heated at 60-70 °C. To this mixture, p-bromobenzenesulfonyl chloride (2.00 g, 7.8 mmol, 1.0 
eq.) was added gradually over a 10 minute interval. After 2 h the reaction was allowed to cool and the thick white 
precipitate was collected by filtration under reduced pressure. The resulting white solid was dried under a high 
vacuum to yield the desired sulfinate 202 as a mixture with inorganic salts (2.05 g, 70 % sulfinate using 1,3,5-
trimethoxybenzene as an internal NMR standard), mp > 235 °C; Rf = 0 (EtOAc/n-hex, 1:1); νmax /cm-1 3500 (b), 3250 
(b), 1125 (b), 1063, 999, 971, 825, 725, 607, 575; δH (400 MHz, D2O) 7.59-7.56 (2H, m, ArH), 7.43-7.40 (2H, m, 
ArH); δC (101 MHz, D2O) 152.6, 131.9, 125.3, 124.1; m/z (ESI) 219 [M(79Br)]-, 221 [M(80Br)]-; found [M]-, 218.9107 
C6H4O2S79Br requires 218.9115, Δ 3.7 ppm.         
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3-(4-Trimethylsilanylethynylbenzenesulfonyl)acrylonitrile 203 
Method One: Oxidation and elimination of α-selenide 218 
 
Meta-chloroperoxybenzoic acid (76 mg, 0.35 mmol, 1 eq.) was added portionwise to a solution of selenide 218 (157.8 
mg, 0.35 mmol, 1 eq.) in CH2Cl2 (5 mL) at 0 °C. After 1 h the reaction was allowed to warm to rt and stirred for a 
further 3 h before dilution with CH2Cl2 and addition of Na2SO3 (sat. aq.). The layers were separated and the organic 
layer washed with H2O, dried over Na2SO4, filtered and the solvent removed in vacuo. The crude residue was purified 
on silica (9:1, n-hex/EtOAc) to yield the desired acrylonitrile 203 (36.8 mg, 36 %) as a white solid, mp = 92-93 °C. Rf  
= 0.56 (4:1, n-hex/EtOAc); νmax /cm-1 3057, 2161, 1588, 1330, 1249, 1147, 1082, 837, 809, 760; δH (400 MHz, 
CDCl3) 7.82 (2H, d, J 8.6, ArH2’), 7.65 (2H, d, J 8.6, ArH3’), 7.21 (1H, d, J 15.7, SO2CH), 6.55 (1H, d, J 15.6, 
HCCN), 0.26 (9H, s, TMS); δC (101 MHz, CDCl3) 148.8, 136.4, 133.2, 130.6, 128.5, 113.4, 111.1, 102.5, 101.0, -0.2; 
m/z (CI) 307 [MNH4]+; found [MNH4]+ 307.0945 C14H19N2O2SSi requires 307.0937, Δ 2.6 ppm.    
Method Two: Addition of lithium sulfinate salt 212 to 2-chloropropenenitrile 
 
To a solution of sulfinate salt 212 (213.0 mg, 0.51 mmol, 1.0 eq.) in H2O (0.75 mL) and acetic acid (0.75 mL) was 
added 2-chloropropenenitrile (41.1 µL, 0.51 mmol, 1.0 eq.) and MeOH (0.75 mL) and the yellow solution stirred at rt 
for 15 min, warmed to 100 °C for 15 min and allowed to cool to rt. The resulting precipitate was collected by filtration 
to yield the 3-sulfonyl acrylonitrile 203 (17.6 mg, 16 %) as an off-white powder. Data in agreement with that reported 
above.   
2-Fluoro-4-[(trimethylsilyl)ethynyl]benzonitrile 205 
 
An adaption of a literature procedure was used.[260] A flame dried 2-neck flask was charged with 4-bromo-2-
fluorobenzonitrile (110.0 mg, 0.55 mmol, 1.0 eq.), PdCl2(PPh3)2 (20 mg, 0.03 mmol, 5 mol %) and CuI (13 mg, 0.07 
mmol, 12.5 mol %) and subjected to 10 sucessive vacuum-argon cycles. Anhydrous THF (2 mL), sparged with argon 
was added to the mixture under argon, followed by TMS acetylene (0.16 mL, 1.10 mmol, 2.0 eq.) and anhydrous, 
sparged Et3N (2.5 mL). Upon addition of the Et3N, the reaction mixture turned rapidly from orange to black to 
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indicate the generation of Pd(0). The black reaction mixture was stirred at rt for 24 h and filtered through celite to 
remove the catalyst. The solvent was removed in vacuo and the black residue diluted with EtOAc and washed with 
brine (x 1), 10 % NH4Cl (x 1), brine (x 1), dried over MgSO4, filtered and the solvent removed in vacuo. The crude 
residue was purified on silica (EtOAc/n-hex, 1:19) and the resulting mixture of product and TMS-acetylene dimer 
separated on silica (gradient elution 100 % n-hex to 100 % EtOAc) to yield the desired TMS-acetylene 205 (85.5 mg, 
72 %) as a brown solid, mp = 110-112 °C; Rf  = 0.57 (EtOAc/n-hex, 1:19); νmax /cm-1 2242, 1615, 1557, 1493, 1411, 
1247, 1159, 1113, 959, 840, 764, 726, 707; δH (400 MHz, CDCl3) 7.56-7.52 (1H, m, ArH), 7.32-7.25 (2H, m, ArH), 
0.25 (9H, s, SiMe3); δC (101 MHz, CDCl3) 164.0, 161.5, 133.3, 130.5, 130.4, 128.4, 128.4, 119.7, 119.5, 113.7, 101.8, 
101.8, 101.4, 101.3, 101.3, 0.27; m/z (CI) 235 [MNH4]+; found [MNH4]+ 235.1075 C12H16N2SiF requires 235.1067, Δ 
3.4 ppm. Data in agreement with literature values.[260] 
Racemic trans-N,N'-dimethyl-1,2-cyclohexanediamine 207 
 
The method of Klapars et al. was used with small modifications.[261] Racemic trans-1,2-cyclohexanediamine (5 mL, 
41.6 mmol, 1.0 equiv.) in ethyl formate (20 mL, 250 mmol) was heated at 50 °C for 6 h. The resulting thick white 
suspension was allowed to warm to rt and filtered. The filter cake was washed with EtOAc (30 mL) and the solid was 
dried under high vacuum to yield the trans-N,N'-diformyl-1,2-cyclohexanediamine (4.91 g, 70 %) as a white powder 
which was carried directly on to the next step.  
 
A flame dried 2-neck flask was charged with trans-N,N'-diformyl-1,2-cyclohexanediamine (3.02 g, 17.7 mmol, 1.0 
equiv.), fitted with a reflux condenser and purged with argon. Anhydrous THF (20 mL) was added and the resulting 
suspension cooled to 0 °C. A 1.0 M solution of LiAlH4 in THF (Aldrich Sure/Seal, freshly purchased, 60 mL, 60 
mmol) was added dropwise and the slightly cloudy reaction mixture heated at 65 °C for 24 h under argon. The 
resulting thick white suspension was cooled to 0 °C and carefully quenched by dropwise addition of H2O (2 mL) 
followed by 20 % aqueous NaOH solution (20 mL). The resulting suspension was stirred at rt for 1 h and filtered 
through celite eluting with THF (100 mL). The solvent was removed from the filtrate and the residue acidifed with 10 
% HCl (30 mL) in water (50 mL) and extracted with CH2Cl2 (3 x 100 mL). The aqueous phase was then basified with 
20 % aqueous NaOH (30 mL) and extracted with CH2Cl2 (3 x 50 mL). The organics from the basic extraction were 
combined, dried over Na2SO4, filtered and concentrated in vacuo to give the desired 1,2-trans diamine 207 (1.92 g, 76 
%) as a clear oil. δH (400 MHz, CDCl3) 2.35 (6H, s, CH3), 2.08-2.04 (2H, m, CH(NHMe)), 2.00-1.93 (2H, m, CH2), 
1.72-1.63 (2H, m, CH2), 1.55 (2H, bs, NH), 1.24-1.12 (2H, m, CH2), 0.95-0.86 (2H, m, CH2); δC (101 MHz, CDCl3) 
63.5, 33.9, 31.1, 25.2; m/z (ESI) 143 [MH]+; found [MH]+ 143.1539 C8H19N2 requires 143.1548, Δ 6.3 ppm.  
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(4-Bromophenylethynyl)trimethylsilane 211 
 
A flame-dried 2-neck flask was charged with 1-bromo-4-iodobenzene (283 mg, 1 mmol, 1 eq.), Pd(PPh3)2Cl2 (35.1 
mg, 0.05 mmol, 5 mol %) and CuI (23.8 mg, 0.125 mmol, 12.5 mol%) and subjected to 10 x successive vacuum-argon 
cycles. Sparged anhydrous THF (4 mL), trimethylsilyl acetylene (0.16 mL, 1.1 eq., 1.1 mmol) and sparged anhydrous 
Et3N (5 mL) were added via syringe to the flask under argon, and the reaction mixture stirred for 18 h under argon. 
The black slurry was filtered through celite and the solvent removed from the filtrate in vacuo. The brown residue was 
dissolved in EtOAc, washed with brine (x 1), 10 % NH4Cl (x 2), brine (x 1), dried over MgSO4, filtered and the 
solvent removed in vacuo. The crude brown solid was purified on silica (100 % n-hexane) to yield the desired 
acetylene 211 (243.8 mg, 96 %) as a white solid, mp = 58-59 °C. Rf = 0.6 (100 % n-hexane); νmax /cm-1 2956, 2157, 
1483, 1469, 1246, 1009, 840, 816, 755, 663; δH (400 MHz, CDCl3) 7.43 (2H, d, J 8.5, ArH), 7.32 (2H, d, J 8.5, ArH), 
0.25 (9H, s, Si(CH3)3); δC (101 MHz, CDCl3) 133.5, 131.6, 122.9, 122.2, 104.0, 95.7, 0.03; m/z (CI) 253 [MH]+; found 
[MH]+ 253.0034 C11H14BrSi requires 253.0048, Δ 5.5 ppm. Data in agreement with literature values.[303]  
4-Trimethylsilanylethynylbenzenesulfinic acid lithium salt  212  
 
To a colourless solution of 4-bromoarene 211 (1.00 g, 3.9 mmol, 1.0 eq.) in anhydrous THF (50 mL) under argon at -
80 °C was added nBuLi (2.5 M in hexanes) (1.7 mL, 4.3 mmol, 1.1 eq.) dropwise and the light yellow solution stirred 
at -80 °C for 15 min. Gaseous SO2 was bubbled through the reaction mixture for 20 min using the reaction setup 
indicated in Figure 118, generating a black solution which lightened to yellow after 5 min.  The light yellow solution 
was allowed to warm to rt and the solvent removed in vacuo. To the bright yellow residue was added n-hexane and 
the precipitate collected by filtration. The filter cake was washed thoroughly with n-hexane to generate the desired 
lithium sulfinate salt 212 (573.2 mg, 59 % sulfinate using 1,3,5-trimethoxybenzene as an internal 1H NMR standard, 
35 % yield), as a bright yellow powder, mp > 245 °C. νmax /cm-1 3351 (b), 2158, 1643, 1248, 967, 946, 834, 757; δH 
(400 MHz, DMSO-d6) 7.45 (2H, d, J 8.1, ArH), 7.39 (2H, d, J 8.1, ArH), 0.22 (9H, s, TMS); δC (101 MHz, DMSO-d6) 
160.9, 131.0, 124.7, 121.1, 105.7, 93.7, 0.0; m/z (EI) 237 [M]-; found [M]- 237.0389 C11H13O2SSi requires 237.0406, 
Δ 7.2 ppm.    
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Figure 118 
3-(4-Bromobenzenesulfonyl)propionitrile 213 
 
To a suspension of 4-bromophenylsulfinate salt 202 (1.83 g, 5.3 mmol, 1.0 eq.) in H2O (6 mL) was added acrylonitrile 
(0.73 mL, 10.6 mmol, 2 eq.) and acetic acid (0.6 mL, 10.6 mmol, 2 eq.). The reaction was stirred rapidly for 1.5 h at 
100 °C and subsequently cooled to rt. The resultant precipitate was filtered, washed thoroughly with H2O and dried 
under high vacuum to yield the desired nitrile 213 (1.29 g, 87 %) as a white solid, mp = 113-114 °C; Rf = 0.29 
(EtOAc/n-hex, 2:3); νmax /cm-1 2248 (CN), 1576, 1466, 1408, 1386, 1317, 1260, 1137, 1080, 1067, 1007, 821, 744, 
743; δH (400 MHz, CDCl3) 7.79 (2H, d, J 8.8, Ph), 7.76 (2H, d, J 8.8, Ph), 3.38 (2H, t, J 7.5, SO2CH2), 2.82 (2H, t, J 
7.5, CH2CN); δC (101 MHz, CDCl3) 136.7, 133.3, 130.4, 129.9, 116.0, 51.2, 12.0; m/z (CI) 291 [MNH4(79Br)]+, 293 
[MNH4(81Br)]+; found [MNH4(79Br)]+, 290.9802 C9H12N2O2S79Br requires 290.9803, Δ 0.3 ppm. 
3-(4-Trimethylsilanylethynyl benzenesulfonyl)propionitrile 214 
  
A flame-dried, 2-neck flask was charged with sulfonyl-nitrile 213 (200 mg, 0.73 mmol, 1 eq.), Pd(PPh3)2Cl2 (26 mg, 
0.04 mmol, 5 mol%) and CuI (17 mg, 0.09 mmol, 12.5 mol%) and subjected to 10 x vacuum-argon cycles. Argon-
sparged THF (2.6 mL), TMS-acetylene (0.11 mL, 0.80 mmol, 1.1 eq.) and Et3N (3.3 mL) were added and the mixture 
heated to 40 °C for 24 h. The reaction mixture was allowed to cool to rt, filtered through celite and the solvent 
removed from the filtrate in vacuo. The crude brown residue was purified on silica (n-hex/EtOAc, 7:3) to yield the 
desired acetylene 214 (140.2 mg, 66 %) as an off-white solid, mp = 99-102 °C; Rf = 0.48 (EtOAc/n-hex, 2:3); νmax 
/cm-1 2259, 2158, 1592, 1315, 1298, 1282, 1249, 1168, 1134, 1087, 842, 759, 742; δH (400 MHz, CDCl3) 7.85 (2H, d, 
J 8.4, ArH2’), 7.66 (2H, d, J 8.4, ArH3’), 3.38 (2H, t, J 7.6, SO2CH2), 2.81 (2H, t, J 7.6, CH2CN), 0.26 (9H, s, 
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Si(CH3)3); δC (101 MHz, CDCl3) 136.8, 133.1, 130.2, 128.3, 116.0, 102.6, 100.5, 51.2, 12.0, -0.2; m/z (CI) 291 [MH]+, 
309 [MNH4]+; found [MNH4]+ 309.1095 C14H21N2O2SiS requires 309.1093, Δ 0.6 ppm. 
2-iodoxybenzoic acid 215 and 1-hydroxy-1,2-benziodoxol-3(1H)-one 216  
 
A procedure reported by Santagostino et al. was used.[268] 2-iodobenzoic acid (5.0 g, 20 mmol, 1 eq.) was added to a 
solution of oxone (37.2 g, 61 mmol, 3 eq.) in distilled H2O (200 mL) and the mixture heated to 70 °C for 3 h. The 
cloudy suspension was cooled to 0 °C for 30 min and the fine precipitate filtered. The filter cake washed with water (x 
6) and acetone (x 2) and the solid dried under high vacuum to yield 2-iodoxybenzoic acid 215 (4.24 g, 76 %) as a fine 
white powder. The filtrate was left at rt for 12 h to allow the crystallisation of a solid which was filtered, washed with 
H2O (x 6) and acetone (x 2) and dried under high vacuum to yield 1-hydroxy-1,2-benziodoxol-3(1H)-one 216 (434.4 
mg, 8 %) as long fine white needles.  
2-iodoxybenzoic acid 215 
 νmax /cm-1 1633, 1331, 1295, 774, 749; δH (400 MHz, DMSO-d6) 8.14 (1H, d, J 7.9, ArH), 8.04-7.98 (2H, m, ArH), 
7.84 (1H, t, J 7.3, ArH), 3.43 (1H, bs, OH); δC (101 MHz, DMSO-d6) 167.5, 146.6, 133.4, 133.0, 131.5, 130.1, 125.0. 
Data in agreement with literature values.[304]  
1-hydroxy-1,2-benziodoxol-3(1H)-one 216 
νmax /cm-1 1585, 1556, 1439, 1337, 1300, 1148, 819, 737, 693; δH (400 MHz, DMSO-d6) 8.04 (1H, bs, OH), 8.01 (1H, 
dd, J 7.5, J 1.2, ArH), 7.96 (1H, td, J 7.6, J 1.4, ArH), 7.84 (1H, d, J 7.9, ArH), 7.7 (1H, td, J 7.3, J 0.6, ArH); m/z 
(CI) 264 [MH]+; found [MH]+ 264.9341 C7H6O3I requires 264.9362, Δ 7.9 ppm. Data in agreement with literature 
values.[305]   
Trimethyl-(4-phenylselanylphenylethynyl)silane 217 
 
nBuLi (2.5 M in hexane, 0.13 mL, 0.33 mmol, 0.95 eq.) was added dropwise to a stirred solution of diisopropylamine 
(47.7 µL, 0.34 mmol, 1.0 eq.) in dry THF (3 mL) at -78 °C and the colourless solution stirred at -78 °C for 45 min. A 
solution of sulfonylnitrile 214 (100 mg, 0.34 mmol, 1.0 eq.) in THF (1 mL) was added dropwise and the brown 
solution stirred at -78 °C for 1 hour. A solution of PhSeCl (52.1 mg, 0.27 mmol, 0.8 eq.) in THF (1 mL) was added 
rapidly in one portion, leading to evolution of a white gas. The resulting yellow solution was stirred at -78 °C for 1.5 h 
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and the mixture quenched with 1 M HCl (0.23 mL), warmed to rt and stirred for 15 min. Water (5.7 mL) was added 
and the reaction extracted with EtOAc (x 3). The organics were combined, dried over MgSO4, filtered and the solvent 
removed in vacuo. The crude residue was purified on silica (1:9, EtOAc/n-hex) to yield selenide 218 (14.7 mg, 17 %) 
as an off-white solid. Rf  = 0.65 (7:3 n-hex/EtOAc); δH (400 MHz, CDCl3) 7.51-7.33 (9H, m, ArH), 0.26 (9H, s, 
Si(CH3)3); δC (101 MHz, CDCl3) 144.5, 137.4, 132.2, 131.2, 129.8, 128.7, 127.9, 127.0, 103.1, 99.5, -0.12; m/z (EI) 
330 [M(80Se)]+, 328 [M(78Se)]+, 314 [M-CH4(80Se)]+, 312 [M-(78Se)]+, 157 [SePh(80Se)]+, 155 [SePh(78Se)]+. 
(±)-3-Phenylselanyl-3-(4-trimethylsilanylethynylbenzenesulfonyl)propionitrile 218 
 
 To a solution of N-(phenylseleno)phthalimide (443 mg, 1.47 mmol, 1 eq.) in anhydrous CH2Cl2 (6 mL) under argon 
at – 78 °C was added LiHMDS (1.0 M in THF, SigmaAldrich SureSeal) (1.47 mL, 1.47 mmol, 1 eq.) and sulfone 214 
(427 mg, 1.47 mmol, 1 eq.) as a solution in anhydrous CH2Cl2 (6 mL) and the thick yellow precipitate stirred at -78 
°C for 30 min and then removed from the cold bath and allowed to warm to rt. Stirrring was continued at rt for 15 min 
before addition of H2O and extraction with CH2Cl2 (x 2). Combined organics were dried over Na2SO4, filtered and the 
solvent removed in vacuo. The crude residue was purified on silica (gradient elution, 9:1 to 4:1, n-hex/EtOAc) to yield 
the desired selenide 218 (143.9 mg, 22 %) as a yellow oil. Rf = 0.36 (4:1, n-hex/EtOAc); νmax /cm-1 2960, 2165, 1590, 
1317, 1148, 862, 844; δH (400 MHz, CDCl3) 7.88 (2H, d, J 8.6, SO2ArH2’), 7.65 (2H, d, J 8.6, SO2ArH3’), 7.54 (2H, 
dd, J 8.1, J 1.1, SePhH2’), 7.41 (1H, tt, J 7.5, J 1.1, SePhH4’), 7.32-7.28 (2H, m, SePhH3’), 4.21 (1H, dd, J 10.9, J 
4.0, CH2CN), 3.36 (1H, dd, J 17.2, J 4.0, CH2CN), 2.90 (1H, dd, J 17.2, J 10.9, SO2CH(SePh)), 0.30 (9H, s, TMS); δC 
(101 MHz, CDCl3) 136.6, 135.1, 132.7, 130.2, 130.1, 129.8, 129.7, 125.6, 115.7, 102.7, 100.6, 60.9, 20.0, -0.15; m/z 
(EI) 447 [M(80Se)]+, 445 [M(78Se)]+, 432 [M(80Se)-CH3]+, 430 [M(78Se)-CH3]+, 378 [M(80Se)-(2(CH3)+CH2CN)], 376 
[M(78Se)-(2(CH3)+CH2CN)], 210 [M(80Se)-(SO2Ar)]+, 208 [M(78Se)-(SO2Ar)]+; found [M(80Se)]+ 447.0236 
C20H21NO2SSi80Se requires 447.0227, Δ 2.0 ppm.       
Cis-3-phenylselanyl acrylonitrile 219 and Trans-3-phenylselanyl acrylonitrile 220 
 
Selenide 218 (18.0 mg, 0.04 mmol, 1 eq.) was stirred at rt with K2CO3 (5.6 mg, 0.04 mmol, 1 eq.) in MeOH (1 mL) 
for 1 h. The solvent was removed in vacuo  and the yellow residue redissolved in CH2Cl2, washed with brine (x 2), 
dried over Na2SO4, filtered and the solvent removed in vacuo. The crude residue (9.3 mg) was purified on silica (n-
hex/EtOAc, 9:1) to yield the cis olefin 219 (1.2 mg, 14 %) as a clear oil and the trans olefin 220 (0.9 mg, 11 %) as a 
clear oil.  
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Cis-3-phenylselanyl acrylonitrile 219 
 
Rf = 0.20 (n-hex/EtOAc, 9:1); νmax /cm-1 2923, 2212, 1553, 1477, 1439, 1316, 1022, 741, 688; δH (400 MHz, CDCl3) 
7.70 (1H, d, J 10.4, PhSeCH), 7.59-7.57 (2H, m, Ph), 7.40-7.35 (3H, m, Ph), 5.82 (1H, d, J 10.4, HCCN); m/z (EI) 
209 [M(80Se)]+, 207 [M(78Se)]+, 182 [M(80Se)-HCN]+, 180 [M(78Se)-HCN]+, 157 [Ph80Se]+, 155 [Ph78Se]+, 77 [Ph]+; 
found [M(80Se)]+ 208.9754 C9H7NSe requires 208.9744, Δ 4.8 ppm. 
Trans-3-phenylselanyl acrylonitrile 220 
 
Rf = 0.29 (n-hex:EtOAc, 9:1); νmax /cm-1 2214, 1565, 738; δH (400 MHz, CDCl3) 7.89 (1H, d, J 16.1, PhSeCH), 7.58-
7.56 (2H, m, Ph), 7.46-7.7.40 (3H, m, Ph), 5.22 (1H, d, J 16.1, HCCN); m/z (EI) 209 [M(80Se)]+, 207 [M(78Se)]+, 182 
[M(80Se)-HCN]+, 180 [M(78Se)-HCN]+, 157 [Ph80Se]+, 155 [Ph78Se]+, 77 [Ph]+; found [M(80Se)]+ 208.9757 C9H7NSe 
requires 208.9744, Δ 6.2 ppm. 
3-(4-Ethynylbenzenesulfonyl)propionitrile 221 
 
To a solution of sulfone 214 (23.1 mg, 0.08 mmol, 1 eq.) in THF (1 mL) at 0 °C was added TBAF (1.0 M solution in 
THF, 0.08 mL, 0.08 mmol, 1 eq.) dropwise and the reaction stirred at 0 °C for 5 min. The reaction mixture was diluted 
with EtOAc and washed with H2O (x 1). The aqueous layer was further extracted with EtOAc (x 1) and the combined 
organics dried over MgSO4, filtered and the solvent removed in vacuo. The crude residue was purified on silica (100 
% EtOAc) to yield the desired terminal acetylene 221 (9.7 mg, 55 %) as an off-white solid, mp = 121-124 °C. Rf = 
0.28 (n-hexane/EtOAc, 7:3); νmax /cm-1 3257, 2932, 2113, 1593, 1313, 1290, 1278, 1135, 1081, 954, 839, 730, 701; δH 
(400 MHz, CDCl3) 7.89 (2H, d, J 8.4, ArH2’), 7.71 (2H, d, J 8.4, ArH3’), 3.39 (2H, t, J 7.7, SO2CH2), 3.34 (1H, s, 
acetylene-H), 2.83 (2H, t, J 7.7, CH2CN); δC (101 MHz, CDCl3) 137.4, 133.4, 129.2, 128.4, 115.9, 82.3, 81.6, 51.3, 
12.1; m/z (EI) 219 [M]+; found [M]+ 219.0344 C11H9NO2S requires 219.0354, Δ 4.6 ppm.    
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10. Appendices 
Appendix I HPLC irreversibility results  
Separation of mercaptosuccinic acid adducts from the reacting acrylamides 
 
 
Figure 119 Conjugate addition of mercaptosuccinic acid to acrylamides gave products which were easily separable by HPLC. 
 
Acrylamide irreversibility at pH 8 
 
Figure 120 (Left hand side) Black and blue traces show formation of a conjugate addition product over 12 h by addition of GSH to 
acrylamide 55. 20 h after addition of a second acrylamide 46, no formation of a second conjugate addition product was observed, pink 
trace. (Right hand side) Black trace shows the formation of a conjugate addition product by addition of GSH to acrylamide 46 after 13 h. 
16h after addition of a second acrylamide 55 no formation of a second conjugate addition product was onbserved, cyan coloured trace.   
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Figure 121 (Left hand side) Pink traces show formation of a conjugate addition product over 16 h by addition of GSH to acrylamide 46. 
21 h after addition of a second acrylamide 49, there was no observed formation of a second conjugate addition product, black trace. 
(Right hand side) Pink trace shows the formation of a conjugate addition product by addition of GSH to acrylamide 49 after 15 h. 16 h 
after addition of a second acrylamide 46, there was still no formation of a second conjugate addition product, black trace.   
 
Acrylamide irreversibility pH 11  
 
Figure 122 (Left hand side) Blue trace shows the formation of a conjugate addition product on addition of GSH to acrylamide 46. On 
addition of a second acrylamide 51, to this mixture no second conjugate addition product is formed as measured over a 10 h time course. 
(Right hand side) The same experiment was carried out in the reverse manner. Again, no second conjugate addition product was formed 
over a 12 h period.  
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Figure 123 (Left hand side) The blue traces show a time course over 12 h for the addition of N-acetyl L-cysteine to acrylamide 51. 12 h 
after the addition of a second acrylamide 46, no formation of a second conjugate addition product was observed, pink trace. (Right hand 
side) Blue traces show a time course over 12 h for the addition of N-acetyl L-cysteine to acrylamide 46. 12 h after the addition of the 
second conjugate addition product 51, no formation of a second conjugate addition product was observed, pink trace. 
 
Vinyl sulfonamide irreversibility at pH 11 
 
Figure 124 (Top left) Overlay of HPLC traces for addition of 41 to N-acetyl L-cysteine. (Top right) Overlay of HPLC traces for addition 
of vinyl sulfonamide 39 to N-acetyl L-cysteine. (Bottom left) Overlay of HPLC traces after addition of sulfonamide 39 to the mixture of 
sulfonamide 41 and the 41-cys conjugate addition product. Irreversibility confirmed by the absence of a further peak due to conjugate 
addition to sulfonamide 39. (Bottom right) Overlay of HPLC traces after addition of sulfonamide 41 to the mixture of sulfonamide 39 
and the 39-cys conjugate addition product. Irreversibility confirmed by the absence of a further peak due to conjugate addition to 
sulfonamide 41. 
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Figure 125 Overlay of 4 different HPLC traces. Dark and light blue traces are to assign the peaks to the different compounds. Black and 
pink traces show a time course for addition of vinyl sulfonamide 39 to conjugate addition product 59 (pH 11) at 3 and 6 hours 
respectively. 
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Appendix II cdc25 MALDI 
 
 
 
 Figure 126 MALDI MS analysis of the crude peptide mixture resulting from cdc25A trypsin digestion. (Top) Spectrum from 500-2400 
Da. (Bottom) Zoom of region highlighted within the red dotted line on the top spectrum. Coloured spheres represent the presence of the 
indicated peptide.  
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Appendix III Mass spectrometry results 
TS with positive control 67 and acrylamide 47 at equimolar concentrations (400 µM) 
Sample recipe: 24 μL thymidylate synthase (10 μM) in ammonium bicarbonate (10 mM) and DTT (1 mM) at  pH 8, 
1 μL ligand stock solution (positive control acrylamide 67 and acrylamide 47, each at 10 mM) in methanol. Sample 
was allowed to react for 30 minutes at rt before addition of 0.5 % aq. formic acid (50 μL) and methanol (50 μL) and 
analysis by ESI mass spectrometry.  
 
Figure 127 Deconvoluted mass spectrum for TS incubated with acrylamides 47 and 67 (both at 400 µM). An adduct to acrylamide 67 is 
observed to form as labelled on the spectrum. However, no peak is seen due to the formation of an adduct with acrylamide 47.  
 
TS with acrylamide 47 under more forcing conditions 
Sample recipe: 24 μL thymidylate synthase (10 μM) in ammonium bicarbonate (10 mM), DTT (1 mM) at pH 8, 1 μL 
acrylamide 47 from 60 mM stock solution in methanol to give a final concentration of 2.4 mM. The sample was 
allowed to react for 4 hours at rt before addition of 0.5 % aq. formic acid (50 μL) and methanol (50 μL) and analysis 
by ESI mass spectrometry.  
 
Figure 128 Formation of a TS-47 adduct under more forcing conditions.  
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TS with bound sulfate ions 
If TS is subjected to only a 6 h dialysis into ammonium bicarbonate from the TRIS-HCl/ammonium sulfate pellet, the 
sulfate ions are not removed, as observed by ESI-MS (see spectra below).  
 
Figure 129 Crystal structure of TS (PDB code 1F4B) with bound sufate ions highlighted as sticks. 
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DTT concentration 
Initial preparations of TS utilised DTT (5 mM) as a reducing agent to prevent oxidation of the active site cysteine 
thiol over time. However, it was unexpectedly found that over a one month period at 4 °C, TS formed an adduct with 
DTT as identified by ESI MS. Spectrophotometric analysis of the same sample of enzyme immediately after 
purification and after a one month period at 4 °C indicated that less of the enzyme was active, Figure 130. Li et al. 
reported the formation of a DTT adduct with a cysteine residue of adenylate kinase upon aging of the enzyme.[306] To 
prevent the significant formation of a DTT adduct, the concentration of DTT in the buffer was reduced to 1 mM. 
Under these conditions, purified TS was stable at 4 °C for 2 weeks, as observed by the spectrophotometric assay and 
ESI mass spectrometry.     
 
Figure 130 Spectrophotometric assay using the same enzyme sample immediately after purification (purple diamonds) and after 1 month 
at 4 °C (blue diamonds). Conditions for the assay: dUMP (48 µM), THF (167 µM), TS (8.0 nM), TRIS-HCl (40 mM), MgCl2 (20 mM), 
βME (100 mM), formaldehyde (12 mM), EDTA (750 µM).   
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Appendix IV Plasmid sequences 
1. pGEM-TS 
…gacctgcaggcggccgcactagtgattcatATGAAACAGTATTTAGAACTGATGCAAAAAGTGCTCGACGAAGGCACA
CAGAAAAACGACCGTACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTTTAACCTGCAG
GATGGATTCCCGCTGGTGACAACTAAACGTTGCCACCTGCGTTCCATCATCCACGAACTGCTGTGGTTCC
TGCAGGGCGACACTAACATTGCTTATCTACACGAAAACAATGTCACCATCTGGGACGAATGGGCCGATG
AAAACGGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCCTGGCCAACGCCAGATGGTCGTCAT
ATTGACCAGATCACTACGGTACTGAACCAGCTGAAAAACGACCCGGATTCGCGCCGCATTATTGTTTCA
GCGTGGAACGTAGGCGAACTGGATAAAATGGCGCTGGCACCGTGCCATGCATTCTTCCAGTTCTATGTG
GCAGACGGCAAACTCTCTTGCCAGCTTTATCAGCGCTCCTGTGACGTCTTCCTCGGCCTGCCGTTCAACA
TTGCCAGCTACGCGTTACTGGTGCATATGATGGCGCAGCAGTGCGATCTGGAAGTGGGTGATTTTGTCT
GGACCGGTGGCGATACGCACCTGTACAGCAATCATATGGATCAAACTCATCTGCAATTAAGCCGCGAA
CCGCGTCCGCTGCCGAAGTTGATTATCAAACGTAAACCCGAATCCATCTTCGACTACAGTTTCGAAGAC
TTTGAGATTGAAGGCTACGATCCGCATCCGGGCATTAAAGCGCCGGTGGCTATCTGAattcaatcccgcggccatg
gcggccgggagcatgcgacgtcgggcccaattcgccc… 
Figure 131 Text in capitals is coding, text in lower case is vector sequence. Underlined ATG and TGA represent the start and stop codons 
respectively. NdeI, AscI and EcoRI sites shown in red, blue and purple respectively.  
 
2. pET21a-TSNdeI 
…aattcccctctagaaataattttgtttaactttaagaaggagatatacatATGAAACAGTATTTAGAACTGATGCAAAAAGTGCTCGA
CGAAGGCACACAGAAAAACGACCGTACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTT
TAACCTGCAGGATGGATTCCCGCTGGTGACAACTAAACGTTGCCACCTGCGTTCCATCATCCACGAACT
GCTGTGGTTCCTGCAGGGCGACACTAACATTGCTTATCTACACGAAAACAATGTCACCATCTGGGACGA
ATGGGCCGATGAAAACGGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCCTGGCCAACGCCA
GATGGTCGTCATATTGACCAGATCACTACGGTACTGAACCAGCTGAAAAACGACCCGGATTCGCGCCGC
ATTATTGTTTCAGCGTGGAACGTAGGCGAACTGGATAAAATGGCGCTGGCACCGTGCCATGCATTCTTC
CAGTTCTATGTGGCAGACGGCAAACTCTCTTGCCAGCTTTATCAGCGCTCCTGTGACGTCTTCCTCGGCC
TGCCGTTCAACATTGCCAGCTACGCGTTACTGGTGCATatggctagcatgactggtggacagcaaatgggtcgcggatccgaattcg
agctccgtcgacaagcttgcggccgcactcgagcaccaccac… 
Figure 132 Text in capitals is coding, text in lower case is vector sequence. Underlined ATG represents the start codon. NdeI, AscI and 
EcoRI sites shown in red, blue and purple respectively.  
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3. Plasmid pET21a-TS 
…tctagaaataattttgtttaactttaagaaggagatatacatATGAAACAGTATTTAGAACTGATGCAAAAAGTGCTCGACGAAG
GCACACAGAAAAACGACCGTACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTTTAACC
TGCAGGATGGATTCCCGCTGGTGACAACTAAACGTTGCCACCTGCGTTCCATCATCCACGAACTGCTGT
GGTTCCTGCAGGGCGACACTAACATTGCTTATCTACACGAAAACAATGTCACCATCTGGGACGAATGGG
CCGATGAAAACGGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCCTGGCCAACGCCAGATGGT
CGTCATATTGACCAGATCACTACGGTACTGAACCAGCTGAAAAACGACCCGGATTCGCGCCGCATTATT
GTTTCAGCGTGGAACGTAGGCGAACTGGATAAAATGGCGCTGGCACCGTGCCATGCATTCTTCCAGTTC
TATGTGGCAGACGGCAAACTCTCTTGCCAGCTTTATCAGCGCTCCTGTGACGTCTTCCTCGGCCTGCCGT
TCAACATTGCCAGCTACGCGTTACTGGTGCATATGATGGCGCAGCAGTGCGATCTGGAAGTGGGTGATT
TTGTCTGGACCGGTGGCGATACGCACCTGTACAGCAATCATATGGATCAAACTCATCTGCAATTAAGCC
GCGAACCGCGTCCGCTGCCGAAGTTGATTATCAAACGTAAACCCGAATCCATCTTCGACTACAGTTTCG
AAGACTTTGAGATTGAAGGCTACGATCCGCATCCGGGCATTAAAGCGCCGGTGGCTATCTGAattcgagctcc
gtcgacaagcttgcggccgcactcgagcaccacca… 
Figure 133 Text in capitals is coding, text in lower case is vector sequence. Underlined ATG and TGA represent the start and stop codons 
respectively. NdeI, AscI and EcoRI sites shown in red, blue and purple respectively. 
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Appendix V Vector maps 
1. pGEM-T 
 
 
2. pET21a 
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Appendix VI Raw Mass Spectrometry Data I 
Figure 
number File reference 
Figure 60 LCT26206 
Figure 62 LCT26355 (back trace) 
Figure 63 LCT21186 (100 µM), LCT21187 (200 µM), LCT21188 (400 µM) 
Figure 65 LCT26209 (30 min), LCT26212 (60 min), LCT26215 (90 min) 
Figure 66 MMX11313 (TS), MMX11315 (TS + positive control acrylamide 67) 
Figure 67 LCT26356 (30 min), LCT26358 (45 min), LCT26360 (60 min), LCT26362 (90 min) 
Figure 68 LCT27638 (pH 8.1), LCT27639 (pH 7.9), LCT27640 (pH 7.6), LCT27641 (pH 7.4), LCT27642 (pH 7.3), LCT27643 (pH 7.2)  
Figure 69 LCT27675 (pH 8.1), LCT27676 (pH 7.9), LCT27677 (pH 7.6), LCT27678 (pH 7.4), LCT27679 (pH 7.3), LCT27680 (pH 7.2).  
Figure 70 LCT27645 (2 min), LCT27647 (30 min), LCT27649 (60 min), LCT27651 (120 min)  
Figure 75 LCT27793 
Figure 76 LCT27984 (270 min) 
Figure 87 LCT26577, LCT26578, LCT26581, LCT26582 
Figure 88 LCT26503 (2 min), LCT26504 (10 min), LCT26505 (30 min), LCT26514 (120 min) 
Figure 98 LCT27373 (1 h), LCT27377 (2 h), LCT27387 (5 h), LCT27403 (9 h) 
Figure 99 LCT27431 
Figure 106 LCT28408 (10 min), LCT28415 (1020 min) 
Figure 127 LCT21191 
Figure 128 LCT26176 
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Raw data for Figure 60 
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Raw data for Figure 62 
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Raw data for Figure 63: 100 µM 
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Raw data for Figure 63: 200 µM 
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Raw data for Figure 63: 400 µM 
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Raw data for Figure 65: 30 min 
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Raw data for Figure 65: 60 min 
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Raw data for Figure 65: 90 min 
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Raw data for Figure 66: 
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Raw data for Figure 67: 30 min 
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Raw data for Figure 67: 45 min 
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Raw data for Figure 67: 60 min 
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Raw data for Figure 67: 90 min 
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Raw data for Figure 68: pH 8.1 
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Raw data for Figure 68: pH 7.9 
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Raw data for Figure 68: pH 7.6   
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Raw data for Figure 68: pH 7.4  
 
 
 
 Chapter Ten Appendix VI 
  244 
Raw data for Figure 68: pH 7.3  
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Raw data for Figure 68: pH 7.2 
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Raw data for Figure 69: pH 8.1 
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Raw data for Figure 69: pH 7.9  
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Raw data for Figure 69: pH 7.6  
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Raw data for Figure 69: pH 7.4  
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Raw data for Figure 69: pH 7.3  
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Raw data for Figure 69: pH 7.2  
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Raw data for Figure 70: 2 min 
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Raw data for Figure 70: 30 min 
 
 
 
 Chapter Ten Appendix VI 
  254 
Raw data for Figure 70: 60 min 
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Raw data for Figure 70: 120 min 
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Raw data for Figure 75 
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Raw data for Figure 76: 270 min 
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Irreversibility test for acrylamide reaction with TS 
Method 
Sample ‘A’: 192 µL TS (10 µM in ammonium bicarbonate (10 mM), DTT (1 mM)) + 8 µL acrylamide 54 (from 
250 µM stock in MeOH).  
 
Sample ‘B’: 192 µL TS (10 µM in ammonium bicarbonate (10 mM), DTT (1 mM)) + 8 µL acrylamide 67 (from 
250 µM stock in MeOH).  
 
Both samples A and B were left to equilibrate at room temperature for 3.5 h. A 25 µL aliquot was then taken 
from both A and B and analysed by ESI MS (Sample A: LCT26577, Sample B: LCT26578).  
 
A 100 µL aliquot was then taken from Sample A and from Sample B, and to each was added 4 µL of the 250 
µΜ stock solution for acrylamides 67 or 54 respectively. Both were subsequently analysed after 60 min (Sample 
A + 67: LCT26581, Sample B + 54: LCT26582). 
 
Raw data for Figure 87: LCT26577 
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Raw data for Figure 87: LCT26578 
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Raw data for Figure 87: LCT27581 
 
 
 
 Chapter Ten Appendix VI 
  262 
Raw data for Figure 87: LCT26582 
 
 
 
 Chapter Ten Appendix VI 
  263 
Raw data for Figure 88: 2 min 
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Raw data for Figure 88: 10 min 
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Raw data for Figure 88: 30 min 
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Raw data for Figure 88: 120 min 
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Raw data for Figure 98: 1 h 
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Raw data for Figure 98: 2 h 
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Raw data for Figure 98: 5 h 
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Raw data for Figure 98: 9 h 
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Raw data for Figure 99 
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Raw data for Figure 106: 10 min 
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Raw data for Figure 106: 1020 min 
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Raw data for Figure 127 
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Raw data for Figure 128 
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Appendix VII Raw Mass Spectrometry Data II 
 
Experiment File numbers 
Papain LCT26205 
Papain and acrylamides (120 min) LCT27920 
Papain and iodoacetamide (10 min) LCT26353 
P97 LCT26352 
P97 and acrylamides (45 and 90 min) LCT26366 (45 min), LCT26368 (90 min) 
Cdc25 LCT28287 
Cdc25 and acrylamides (180 min) LCT287290 
Cdc25 and iodoacetamide (10 and 60 min) LCT287292 (10 min), LCT287293 (60 min) 
TS and benzyl piperidine acrylamide 54 over pH range 
LCT27681 (pH 8.1), LCT27682 (pH 7.9), LCT27683 
(pH 7.6), LCT27684 (pH 7.4), LCT27684 (pH 7.3), 
LCT27685 (pH 7.2) 
Vinyl sulfonamide irreversibility using vinyl 
sulfonamides 44 and 70 
LCT26571, LCT26572, LCT26579, LCT26580 
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Papain   
Papain (10 µM) and DTT (1 mM) in ammonium bicarbonate (10 mM) at pH 8.  
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Papain and Acrylamides at 120 min 
Papain (10 µM) and DTT (1 mM) with acrylamides 55, 48, 47, 50, 49, 54, 67, 68, 119	  	  each at 96 µM in ammonium 
bicarbonate (10 mM), pH 8, after a 120 min incubation time.   
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Papain and Iodoacetamide at 10 min 
Papain (10 µM), DTT (1mM) and iodoacetamide (4 mM) in ammonium bicarbonate (10 mM), pH 8 after a 10 minute 
incubation period.  
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P97  
P97 (10 µM) and DTT (1 mM) in ammonium bicarbonate (10 mM), pH 8.  
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P97 + Acrylamides at 45 min 
P97 (10 mM), DTT (1 mM) and acrylamides 55, 48, 47, 50, 49, 67, 68 each at 343 µM in ammonium bicarbonate (10 
mM), pH 8, after a 45 min incubation period. 
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P97 and Acrylamides at 90 min 
P97 (10 mM), DTT (1 mM) and acrylamides 55, 48, 47, 50, 49, 67, 68 each at 343 µM in ammonium bicarbonate (10 
mM), pH 8, after a 90 min incubation period.  
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Cdc25A 
Cdc25A (10 µM) and DTT (1 mM) in ammonium bicarbonate (10 mM), pH 8.  
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Cdc25A and Acrylamides at 180 min 
Cdc25A (10 µM), DTT (1 mM) and acrylamides 47, 48, 49, 50, 54, 55, 67, 119 each at 100 µM in ammonium 
bicarbonate (10 mM), pH 8, after 180 min incubation time.  
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Cdc25A and Iodoacetamide at 10 min 
Cdc25A (10 µM), DTT (1 mM) and iodoacetamide (4 mM) in ammonium bicarbonate (10 mM), pH 8 after a 10 min 
incubation period.  
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Cdc25A and Iodoacetamide at 60 min 
Cdc25A (10 µM), DTT (1 mM) and iodoacetamide (4 mM) in ammonium bicarbonate (10 mM), pH 8 after a 60 min 
incubation period.  
 
 
 Chapter Ten Appendix VII 
  287 
TS and N-benzyl piperidine acrylamide 54 at different pH values 
TS (10 µM), DTT (1 mM) and N-benzyl piperidine acrylamide 54 (400 µM) in ammonium bicarbonate (10 mM). 
Addition of 0.5 % formic acid to adjust the pH to the indicated value.  
pH 8.1 
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pH 7.9 
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pH 7.6 
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pH 7.4 
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pH 7.3 
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pH 7.2 
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Irreversibility test for vinyl sulfonamide reaction with TS 
Method 
Sample ‘A’: 192 µL TS (10 µM in ammonium bicarbonate (10 mM), DTT (1 mM)) + 8 µL vinyl sulfonamide 44 
(from 250 µM stock in MeOH).  
 
Sample ‘B’: 192 µL TS (10 µM in ammonium bicarbonate (10 mM), DTT (1 mM)) + 8 µL vinyl sulfonamide 70 
(from 250 µM stock in MeOH).  
 
Both samples A and B were left to equilibrate at room temperature for 2 h. A 25 µL aliquot was then taken from 
both A and B and analysed by ESI MS (Sample A: LCT26571, Sample B: LCT26572).  
 
A 100 µL aliquot was then taken from Sample A and from Sample B, and to each was added 4 µL of the 250 
µΜ stock solution for vinyl sulfonamides 70 or 44 respectively. Both were subsequently analysed after 120 min 
(Sample A + 70: LCT26579, Sample B + 44: LCT26580).  
 
 
LCT26571 
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LCT26571 after deconvolution 
 
 
LCT26572 
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LCT26572 after deconvolution 
 
 
LCT26579 
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LCT26579 after deconvolution 
 
LCT26580 
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LCT26580 after deconvolution 
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Appendix VIII Original SDS PAGE images 
The MW Marker for all SDS PAGE images is composed of proteins with molecular weights as indicated:  
 
Images from Figure 32 
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Images from Figure 50 
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Images from Figure 51 
 
 
 
Images from Figure 59 
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Appendix IX Correlation between olefinic acrylamide 1H NMR shifts and acrylamide reactivity towards 1,4-
conjugate addition  
1H NMR shifts and J values for the olefinic protons from a selection of acrylamides are shown in the table below.  
 
Compound No.  Proton 1 Proton 2 Proton 3 J (trans) J (cis) J (gem) 
47 6.15 6.35 5.69 17.0 10.3 1.3 
48 6.09 6.32 5.66 17.1 10.3 1.3 
49 6.64 6.36 5.76 16.7 10.8 1.7 
51 6.91 6.68 6.01 17.2 10.0 1.4 
52 6.32 6.48 5.82 16.0 10.0 1.0 
53 6.10 6.25 5.61 17.0 10.2 1.5 
54 6.10 6.30 5.65 17.0 10.2 1.4 
55 6.12 6.27 5.63 17.1 10.3 1.7 
67 6.21 6.33 5.69 17.3 9.7 1.6 
85 6.15 6.27 5.63 16.7 10.0 1.7 
86 6.27 6.09 5.59 17.5 10.0 - 
91 6.15 6.26 5.62 17.1 9.5 1.9 
119 6.03 6.26 5.56 17.0 10.3 1.2 
132 6.07 6.16 5.49 17.1 10.0 2.4 
134 6.15 6.26 5.57 17.3 10.0 1.8 
160 6.05 6.26 5.62 17.0 10.3 1.6 
161 6.07 6.26 5.50 16.5 9.9 1.1 
162 6.04 6.19 5.54 16.9 10.3 1.7 
163 6.03 6.23 5.58 16.9 10.3 1.5 
164 6.15 6.24 5.54 17.0 9.8 2.1 
165 6.29 6.10 5.62 15.9 9.4 2.4 
173 6.11 6.20 5.58 17.0 9.8 2.1 
 
It is interesting to note that the sum of the shifts for the three olefinic protons may give an indication of acrylamide 
reactivity towards conjugate addition. This may be expected as proton shift by 1H NMR gives an indication of 
electron shielding, and an electron deficient centre is more susceptible to nucleophilic attack. As shown in the chart 
below, acrylamide 51 is seen to have the highest olefinic proton shift sum, and this acrylamide was indeed the most 
reactive acrylamide encountered during HPLC studies. Acrylamide 51 was excluded from tethering studies with 
protein on the basis of its very high intrinsic reactivity as seen by HPLC. Acrylamide 49 is seen in the chart below to 
have the second highest olefinic proton shift sum, and this acrylamide was observed by HPLC studies to be the most 
reactive of those used for tethering studies. If 1H NMR shifts can indeed be used to predict acrylamide reactivity, this 
would provide a highly useful and quick measure of the suitability of an acrylamide for tethering, overcoming the 
need for time consuming HPLC studies with a model thiol.   
N
O
H1
H2
H3
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